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ABSTRACT 
 
The aim of this thesis was to develop biodegradable devices loaded with chemotherapy drug. 
The system is targeted for advanced ovarian cancer treatment through the intraperitoneal (IP) 
route of administration. Polylactide-co-glycolide (PLGA) was selected as the model 
biodegradable polymer to produce drug-loaded microsphere, hollow and solid fibres. 
Copolymer PLGA with three different lactic:glycolic acids ratios; 50:50, 65:35 and 75:25 
were used in order to compare their drug loading capacities and in vitro drug release profiles. 
Cisplatin, a cytotoxic drug with proven activity against ovarian cancer was selected as the 
model chemotherapy drug. Intraperitoneal administration is often associated with abdominal 
pain therefore a local anaesthetic; lidocaine, was selected for the purpose of pain relief. 
 
Solvent evaporation with a single emulsion method (oil/water) was used to produce the drug-
loaded PLGA microspheres. This method was selected due to the feasibility and robustness of 
the procedure and material involved. A number of double emulsion procedures were carried 
out but results show low robustness and no distinct advantage in the final products. Hollow 
and solid fibres were spun using a dry/wet-spinning method based on the phase inversion 
technique. The phase inversion process produces hollow fibre with unique finger-like 
microcavities and skin layer that offers high mass transfer resistance, which are useful 
features to prolong the drug release. Solid fibre was found to have similar characteristic but 
without a lumen.  
 
The degradation profiles of PLGA microspheres, hollow and solid fibres before and after 
incubation in phosphate buffer saline solution were studied by means of SEM imaging and 
weight loss analysis. SEM images evidently show that these PLGA devices underwent bulk 
degradation based on their morphological changes during degradation. Autocatalytic 
degradation also occurred in hollow and solid fibres due to the accumulation of degraded 
acidic byproducts. A lag phase in mass loss of approximately two weeks was observed in 
50:50 PLGA samples while it was few days longer in the cases of 65:35 and 75:25 PLGA.  
 
Devices made of 50:50 PLGA exhibited the fastest degradation rate due to its highest 
glycolide acid content which is more prone to hydrolytic degradation. In contrast, devices 
made of 75:25 PLGA exhibited the highest degradation resistance, thought to be due to cause 
by a steric hindrance offered by the extra chiral methyl group in the lactide unit. This feature 
improves its chemical stability against hydrolytic attack.  
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The distribution of entrapped agent in 75:25 PLGA microspheres assessed by confocal laser 
scanning microscopy showed a heterogeneous distribution of the entrapped agent. Pulse field 
gradient-NMR was used to study pore evolution in the PLGA microspheres and results show 
that they underwent pore swelling and shrinking. During swelling, the system shifts from 
glassy state to rubbery state. Medium diffusion is faster in the latter state and therefore, 
swelling in PLGA microsphere was anticipated to increase drug diffusion. 50:50 PLGA 
microsphere was found to be most prone to swelling due to its higher amorphous region.  
 
NMR-cryoporometry experiments permitted the studies of freezing of imbibed water in 
microsphere pores. It is suggested that the pores in the PLGA microspheres have “ink-bottle” 
geometry and the freezing of water confined in these pore occurs via solid ingress though the 
neck.  Results show that 75:25 PLGA microsphere was inherited with biomodal necks system. 
It is thought that these necks also undergo similar swelling and shrinking mechanisms.  
 
Cisplatin (CPt)-loaded PLGA solid fibres and microspheres were successfully produced with 
maximum drug loadings of approximately 15% and 10% respectively. CPt-loaded 
microsphere exhibited faster in vitro drug release compared to CPt-loaded solid fibre mainly 
due to its higher surface area:volume ratio which increased drug diffusion rate. Solid fibre 
exhibited slower drug release due to its smaller surface area and its unique fibre wall 
structure. In vitro CPt release results show promising potentials in mimicking an IP or IV 
doses of chemotherapy regimens.  
 
Lidocaine (LID)-loaded PLGA microspheres and hollow fibre were successfully produced 
with maximum drug loadings of approximately 15% and 5% respectively. The lumen of the 
hollow fibre offers additional drug loading. In the case of drug solution-filled lumen, the drug 
release was faster due to the enhanced diffusion by the drug solution across the fibre wall. 
LID loaded-microsphere was also loaded into the fibre lumen. The combination of this duo 
reduced the drug release rate. This is because of the “retardant” effects of the fibre skin layers.  
 
A number of basic empirical models were used to study the in vitro drug release profiles. 
Results show that these models are inadequate to characterise the overall drug release profiles 
possibly due to the degrading nature of these devices. However, a Higuchi-diffusional release 
model provides good fit to drug release during the first day for both LID- and CPt-loaded 
PLGA devices. A biexponential model with two fractions of drug present in the releasing-
depot was derived and show reasonable fits to the in vitro CPt and LID release profiles.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Background Information 
 
This thesis partly supports a project funded by the Department of Health, UK under the 
program of New and Emerging Application of Technology (NEAT, FSC020), and is in 
collaboration with the Royal United Hospital (RUH), Bath. In parallel to the aim of the 
NEAT project, the purpose of this thesis was to develop cisplatin-loaded microspheres for 
the treatment of advanced ovarian cancer. Details of objectives are defined in Section 1.2.  
 
Approximately 6,600 women are diagnosed with ovarian cancer in the UK annually. It is the 
fourth commonest cancer in woman after breast, bowel and lung cancer. Statistics show that 
5 out of every 100 women diagnosed with cancers suffer from ovarian cancer and the UK has 
one of the highest incidence of ovarian cancer in northern Europe (Cancer Research UK, 
2008; WHO, International Agency for Research on Cancer, 2001). In the United States, 
ovarian cancer causes more deaths than other cancer of the female reproductive system. It is 
the seventh most common and the fifth leading cause of cancer death in women after lung 
and bronchus, breast, colorectal, and pancreatic cancers. In 2002, more than 19,000 women 
in the US were diagnosed with the disease and death rate was > 73% (US Dept. of Health & 
Human Services, National Cancer Institute, 2005). 
 
The survival prospects greatly depend on prompt diagnosis, the effectiveness of 
cytoreductive surgery, the development of responsive chemotherapy regimens and novel 
drugs. In the 1960s, the 5-year survival rate for ovarian cancer was 30%, whereas recent 
statistics indicate an increase to 44% (Jemal et al., 2005). The increase in survival rate in the 
last 30 years is a result of improved management in chemotherapy treatment for the disease. 
Since 1990’s, cytoreductive surgery and systemic combination chemotherapy with platinum 
and taxane compounds have become the standard treatment for this disease (McGuire and 
Markman, 2003). The route of administration of chemotherapy is usually intravenous (IV) in 
which the drug is delivered to the tumour site through the blood circulation.  
 
Advanced ovarian cancer has an unusual pattern of spread and is usually confined to the 
abdominal cavity. This offers an opportunity to expose the tumour to cytotoxic agents by 
administration directly into the peritoneal cavity (Willemse and Vries, 2003). While 
intraperitoneal (IP) chemotherapy is unlikely to be beneficial in bulky disease because drug 
penetration into larger tumour nodules is limited, ovarian cancer often produces small 
seedlings or cellular dissemination invisible at surgery. Ovarian cancer is therefore an 
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attractive malignancy for IP chemotherapy (Dedrick et al., 1978; Kirmani et al., 1994 and, 
Willemse and Vries, 2003). The addition of IP chemotherapy to the management of ovarian 
cancer has demonstrated to be beneficial over IV chemotherapy (Hofstra et al., 2000 and 
Markman, 2004). In fact, in the early 1950s, the very first introduction of cytotoxic drugs 
into clinical practice was examined in IP delivery (Markman, 1986).  
 
Studies from Markman et al. (1992) and Alberts et al. (1996) reported an improvement in 
overall survival rate after IP administered cisplatin compared to IV administered cisplatin. 
The direct IP administration not only provides a longer systemic drug exposure locally, but 
also lowers the cytotoxic effects of nephro- and neurotoxicities suffered from IV treatment. 
Occasionally, the site of injection can cause problems such as inflammation or patient 
discomfort. On the other hand, IP chemotherapy administration is associated with 
complications with the catheter instillation. Further evaluations on these subjects will be 
discussed in Chapter Two.  
 
The on-going improvement of IP chemotherapy treatment for ovarian cancer and its 
shortcomings have provided the aspiration for this thesis. The ultimate aim of this thesis is 
thus to develop an improved system with the potential to address the problems encountered 
in the IP chemotherapy treatment. Today, new methods of drug administrations are available; 
the desired drug can be delivered directly to the target site by using rate-controlling and/or 
biodegradable devices containing the medication. Commonly reported in the literature, these 
controlled drug delivery systems can reduce the complications in conventional administration 
and provide a sustained release of the therapeutic agent in a predictable profile. This will 
improve localised effects and reduce systemic toxicities. Controlled drug delivery system 
will be further studied in Chapter Three.  
 
In conjunction to the aim of this thesis, devices made of biodegradable polymer 
encapsulating medications have been developed and studied. First, a control delivery system 
in the form of microsphere was explored due to its capability for: (1) providing a controlled 
release of the therapeutic agent, (2) localising the therapeutic agents thus lowering their 
systemic toxicities, (3) these submicron spherical devices could improve in situ distribution 
and thus help to increase the exposure of tumour to drug, (4) the use of biodegradable system 
can also reduce clinic visits thereby improves patients compliance. Furthermore, the 
microspheres could also serve as protective coatings against in vivo enzyme biodegradation. 
Second, hollow and solid fibres were also developed with similar objectives. The 
characteristics of these drug-loaded microspheres and hollow/solid fibres were studied and 
compared.  
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1.2 Aims and Objectives 
 
The aim of this thesis is to develop a controlled drug delivery system suitable for 
intraperitoneal (IP) treatment of advanced ovarian cancer. The proposed systems will take the 
forms of microsphere, hollow and solid fibres made of poly(lactide-co-glycolide) (PLGA). 
PLGA was selected because of its well-established biocompatibility and versatility. Cisplatin 
and lidocaine were selected as the encapsulation targets. Cisplatin is a common cytotoxic 
drug used to treat ovarian cancer. Patient receiving IP treatment often experience abdominal 
pain and local anaesthetic is used to suppress the pain. Thus, lidocaine was also used in this 
work. The development objectives are two-fold: 
i. To develop a microsphere system encapsulating the selected drugs.  
Solvent evaporation technique with a single emulsion, water-in-oil (o/w) method was 
used to produce PLGA microspheres loaded with cisplatin and lidocaine. 
ii. To develop hollow and solid fibres systems encapsulating the selected drugs.  
Phase inversion technique with a wet-spinning method was used to spin PLGA 
hollow and solid fibres loaded with lidocaine and cisplatin respectively. 
 
The following objectives are aimed to gain better understandings of the developed systems: 
iii. Characterisation of microspheres, hollow and solid fibres 
The developed PLGA devices were examined using scanning electron microscopy 
(SEM) for their morphologies. Confocal laser scanning microscopy (CLSM) was 
used to study the distribution of entrapped agent within a microsphere. Laser 
diffraction analysis was used to determine the size distribution of microsphere. Gas 
permeation analysis was conducted on hollow fibre to study its porosity. 
iv. Monitoring of PLGA Degradation 
The morphology of the three PLGA devices before and during degradation was 
monitored using SEM and mass loss analysis. 
v. Pore Evaluation using Pulse Field Gradient (PFG) and Cryoporometry  NMR 
The pore information of microspheres was explored by measuring the diffusion of 
confined water using PFG NMR. NMR cryoporometry was used to study the pore 
structural information by following the freezing of confined water. 
vi. In Vitro Drug Release Profiles 
In vitro drug release of cisplatin and lidocaine were measured based on their 
concentrations in buffer using atomic absorption spectroscopy for cisplatin, and uv-
spectroscopy for lidocaine.  
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1.3 Thesis Outline 
 
Chapter Two provides an introduction to ovarian cancer and emphasis is placed on 
conventional chemotherapy treatment (i.e. IV vs. IP administrations). The pharmacology 
profile of the model drug, cisplatin is also discussed. Chapter Three discusses the 
suitability of a biodegradable-controlled release system and its potential for improving IP 
chemotherapy. Both the model forms developed in the thesis, namely the microsphere and 
hollow fibre are also discussed in this chapter.  
 
Chapter Four details the methodology used to conduct investigations presented thereafter. 
Chapter Five presents the development of a microsphere system using the solvent 
evaporation technique, followed by the development of hollow and solid fibres using the 
phase inversion technique. This chapter concludes the final and optimum production 
conditions for the subsequent experiments. 
 
Chapter Six presents the morphological characterisations of the developed PLGA devices 
before and after degradation by means of SEM imaging, mass loss and pH profiles. This 
chapter closely studies the degradation behaviour of the developed systems and findings 
were correlated to in vitro drug release. Chapter Seven further studies the pore structural 
evolution of PLGA microspheres using PFG and cryoporometry NMR. The swelling 
mechanism in polymeric microsphere was proposed.  
 
Chapter Eight investigates the cisplatin loadings in both PLGA microspheres and solid 
fibres. In vitro drug release profiles were studied in relation to PLGA degradation. Chapter 
Eight investigates the effects of both PLGA and lidocaine concentrations on drug loading. 
Following the production of lidocaine-loaded PLGA devices, the in vitro drug release 
profiles from these devices were studied.  
 
Chapter Ten provides a summary of the thesis objectives and followed by an overall 
conclusion. This chapter ends with suggestions for further work.  
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CHAPTER 2: INTRODUCTION  TO  OVARIAN  CANCER 
 
Following the statistics information on the incidence of ovarian cancer presented in Section 
1.0, this chapter studies the diagnosis and the treatment principles for the disease. Emphasis 
is placed on the conventional treatments for the disease; by intravenous and the less common 
intraperitoneal route chemotherapy. This chapter will also address the shortcomings of 
conventional treatments and, the rationale of developing a controlled release system for 
intraperitoneal administration. Cisplatin, a cytotoxic drug with proven activity in ovarian 
cancer is studied in order to understand its mode of action.  
 
 
2.1 Overview of Ovarian Cancer  
 
Cancer is a collection of diseases with a common feature of uncontrolled cell growth, 
which develops to produce a tumour. This unregulated growth can be:  
i. benign – will not spread (i.e. only grows locally); 
ii. malignant – will or can spread by direct invasion via metastasis. Metastasis is a 
complex process when cancer cells leaving the primary site, penetrating into either 
lymphatic or blood vessels or both and circulating through them to grow in normal 
tissues elsewhere in the body. 
It is the disruption of normal tissues and organs that makes a cancer fatal. When cancer cells 
spread to form a secondary or metastatic tumour, it carries similar characteristic from its 
original tumour (McKinnell, 1998). Ovarian cancer (OC) occurs when malignant epithelial 
cells develop in the ovary. The primary site of this disease is within the abdominal cavity of 
the patient (Cannistra, 2004 and Thigpen, 2004). Spread of this disease is often by local 
extension, by intra-abdominal dissemination to other sites within the peritoneal cavity, or less 
commonly by lymphatic spread to pelvic and para-aortic nodes in the retroperitoneum 
(Bristow et al., 2003 and Fung et al., 2007).  
 
The symptoms experienced by ovarian cancer patient can include back or leg pain, shortness 
of breath, loss of appetite and general abdominal discomfort such as swelling, pain, bloating, 
indigestion or cramps (Eltabbakh et al., 1999 and Donovan et al., 2005). One of the reasons 
contributing to OC having the highest death rate among gynaecologic malignancies is the 
non-specific nature of recognisable early symptoms, which also relates to the inadequacy of 
most OC screening tests. Thus, patients are often diagnosed at an advanced stage when the 
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cancer has spread beyond the ovary; i.e. beyond Stage II according to the International 
Federation of Gynecology and Obstetrics (FIGO) system (Landrum et al., 2008). Table 2.1 
describes the different stages of OC according to the FIGO system.  
 
Table 2.1: Different stages used to diagnose ovarian carcinoma (Eltabbakh et al., 1999). 
Staging Condition of Disease 
Stage I Tumour is found in one or both of the ovaries and has not spread 
           I A  Tumour limited one ovary  
           I B  Tumour limited to both ovaries 
          I C  Both ovaries and with capsule rupture or ascites 
 
Stage  II  Tumour is found in one or both ovaries and has spread into other areas of  
the pelvis within the peritoneal cavity 
           II A  Tumour extension to the uterus and/or tubes 
II B  Tumour extension to other pelvic tissues/organ  
II C  Tumour other pelvic tissues or with ascites 
 
Stage  III  Cancer is found in one or both ovaries and has spread to other parts of the abdomen 
within the peritoneal cavity. 
           III A Microscopic peritoneal metastasis beyond the pelvis 
III B Macroscopic peritoneal metastasis beyond the pelvis  
III C Peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or  
regional lymph nodes metastasis 
Stage  IV  Distant metastasis beyond the peritoneal cavity  
 
 
2.2 Conventional Ovarian Cancer Treatment 
 
In a case of suspected ovarian cancer (OC), conventional diagnosis these days always 
involves a computed tomography scan (Gilby, 2008). After that, common primary processes 
are such as primary surgery for diagnosis and staging, laparotomy is carried out to order to 
identify the stage of the disease. Consequently, surgical removal of the cancerous materials is 
performed (Fung et al., 2007). These processes are illustrated in Figure 2.1. Staging (Table 
2.1) is a process to describe the progression of ovarian cancer based on the tumour size, 
spread to the lymph nodes and metastasis to distant sites, or known as the TNM system.  
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Figure 2.1: A conventional process of ovarian cancer treatment. 
 
After staging is established, a strategy for treatment (cytoreduction) can be formulated. The 
main treatment options are surgery, chemotherapy and radiotherapy. Different treatments are 
required for cancers of different stages. Surgery is usually sufficient only for early stage 
ovarian cancer where the tumour is localised at Stage I to IB. Surgical therapy for women 
with advanced stage disease would include total abdominal hysterectomy (removal of 
uterus), and bilateral salpingo-oophorectomy (removal of ovary with Fallopian tube) and 
omentectomy (removal of the omentum); aiming to achieve the best cytoreductive effect. 
Unfortunately, surgery alone fails to cure majority of the patients (Gilby, 2008).  
 
The majority of the patients will experience recurrence of the disease and the site of 
recurrence is still confined within the abdominal cavity (Landrum et al., 2008). 
Improvements in survival have been achieved through aggressive cytoreductive surgery 
followed by combination of chemotherapy (Ozols et al., 2003). In the late 1980’s and early 
1990's, standard combined regimens used for ovarian cancer chemotherapy were such as 
cisplatin with cyclophosphamide or doxorubicin. In the 1990’s, the chemotherapy regimen 
after debulking is generally a combination of platinum and taxane drugs (McGuire et al., 
1996). Examples of chemotherapy regimen are given in Table 2.2. The conventional 
administration routes for chemotherapy are discussed in the following section.  
 
 
2.2.1 Chemotherapy Treatment: Intravenous and Intraperitoneal Administrations  
The course of chemotherapy treatment is commonly given through intravenous (IV) 
administration by inserting a needle (through which medication is transported) into a vein, 
usually in the arm. The drug is then delivered to the disease site through blood circulation. 
The major setback of this administration is the systemic blood circulation which increases the 
risk of toxicities. Other problems with injection are such as patients discomfort and 
Diagnosis  
Low-Risk High-Risk 
Primary surgery 
& Staging 
 
 
 
Cytoreduction 
Chemotherapy 
IV    IP 
Debulking 
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inflammation at the injection site. Since chemotherapy is usually given after debulking to 
either kill residual tumour or later, recurrent tumours, various regimens are used for diseases 
of different stages. IV chemotherapy is often given in a combination of more than one 
chemotherapy drugs.  
 
Owing to the localisation of the disease, regional delivery of chemotherapy directly into the 
peritoneal cavity is permitted and is termed intraperitoneal (IP) administration. This is done 
by surgical implantation of a catheter (Figure 2.2). The catheter is a hollow flexible tube used 
to deliver fluid into the abdominal cavity. IP administration requires the drugs to be dissolved 
in saline or dextrose solution (for adequate fluid distribution), prewarmed to body 
temperature (to avoid peritoneal irritation) before the drug solution is infused into the body 
via the catheter. Following IP administration, patients are also encouraged to frequently 
change their position to help drug distribution (Kirmani et al., 1994). 
 
 
 
 
 
 
 
 
Figure 2.2:  An ensemble of impaired peritoneal access system using a Port-A-Cath type catheter kit 
manufactured by Pharmacia Deltec Inc., US (adapted from McClay and Howell, 1990). 
 
In cases where a patient is unable to tolerate the planned IV administration due to problems 
such as ineffective infusion or low tumour response rate, then the IP therapy offers an 
alternative. Conversely, if the patient is unable to receive IP administration due problems 
such as catheter-related complication, then conventional IV therapy will be assumed. 
Common IV and IP regimens and duration of course used to treat patients with advanced 
stages OC and residual tumour after debulking are given in Table 2.2. These studies are 
carried out in order to compare the effectiveness of IV and IP administrations.  
 
The drug dosages are based on the body surface area of the patient. For example, IV cisplatin 
is given at 100 mg/m2 per cycle once every 3 weeks. At a dose of 100 mg/m2, for a patient of 
height 170 cm, weighing 70 kg with a surface area of 1.7 m2 (Dearnaley et al., 2002 and 
Syringe 
 
 
          Huber point needle            Self sealing septum 
 
    Suture      Sleeve 
 
      Skin layer              Cuffs 
 
      Muscle 
             
Tenckhoff       
catheter      
Peritoneum 
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Gilby, 2008), the dose for the patient will be 170 mg. The duration of IV infusion in each 
cycle ranged from 1-2 hours. Factors such as the health condition of the patient, the response 
rate of the tumour and, the time allowance for the body’s normal tissue to recover, will all 
influence the regimen and course of chemotherapy.  
 
Table 2.2: Different regimens used to treat patients with advanced ovarian cancer. 
Authors Stages Control Regimen (C)  Experimental Regimen (E) Duration of course 
Kirmani 
et al., 1994 
IIC-IV 
IV cisplatin, 100 mg/m
2
 
IV cyclophosphamide, 
600 mg/m
2
 
IP cisplatin, 200 mg/m
2
 
IP etoposide, 350 mg/m
2
 
C: cycle/3 wk × 6 
E: cycle/4 wk × 6 
Alberts 
et al., 1996 
III, 
≤ 2 cm 
residual 
IV cisplatin, 100 mg/m
2
 
IV cyclophosphamide, 
600 mg/m
2
 
IP cisplatin, 200 mg/m
2
 
IV cyclophosphamide, 
600 mg/m
2
 
C: cycle/3 wk × 6 
E: cycle/3 wk × 6 
Markman 
et al., 2001 
III, 
≤ 1 cm 
residual 
IV cisplatin, 75 mg/m
2
 
IV paclitaxel, 135 mg/m
2
 
IP cisplatin, 100 mg/m
2
 
IV paclitaxel, 135 mg/m
2
 
C: cycle/3 wk × 6 
E: cycle/3 wk × 6 
Yen 
et al., 2001 
III, 
≤ 1 cm 
residual 
IV cisplatin, 50 mg/m
2 
IV cyclophosphamide, 
50 mg/m
2 
IV Epidoxorubicin/ 
Doxorubicin, 50  mg/m
2 
IP cisplatin, 100 mg/m
2
 
IV cyclophosphamide, 
50 mg/m
2 
IV Epidoxorubicin/ 
Doxorubicin, 50  mg/m
2
 
C: cycle/3 wk × 6 
E: cycle/3 wk × 6 
Armstrong 
et al., 2006 
III, 
≤ 1 cm 
residual 
IV cisplatin, 75 mg/m
2 
IV paclitaxel, 135 mg/m
2
 
IP cisplatin, 100 mg/m
2
 
IP paclitaxel, 60 mg/m
2
  
IV paclitaxel, 135 mg/m
2
 
C: cycle/3 wk × 6 
E: cycle/3 wk × 6 
 
IV cisplatin = cisplatin given intravenously; IP cisplatin = cisplatin given intraperitoneally; wk = week. 
 
The classic rationale of IP administration was first published by Dedrick et al. (1978). This 
philosophy has since encouraged studies exploring both the safety and pharmacokinetic 
advantage of IP administration. Figure 2.3 shows the early findings from Dedrick et al. 
(1978). 
 
   
 
 
 
 
 
 
 
Figure 2.3: Model simulations of concentrations of (A) Methotrexate, MTX and (B) Cytosine arabinose, 
Ara-C in peritoneal cavity and plasma (adapted from Dedrick et al., 1978). 
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Figure 2.3 (A) and (B) are the model simulations of plasma and peritoneal fluid 
concentrations of methotrexate (MTX) and cytosine arabinose (Ara-C) respectively, based on 
known physiologic and anatomic characteristics of the peritoneal cavity. Continuous infusion 
produces the “saw-tooth” profiles due to drug absorptions by the peritoneum, liver, kidney, 
skin and muscle. MTX is an antimetabolite used in cancer treatment such as leukemia. Ara-C 
is an agent used in intraperitoneal disease such as hematological malignancies. Figure 2.3 
shows that both concentrations of MTX and Ara-C in peritoneal cavity are a few orders 
higher than those in blood plasma. Their results showed that the peritoneal route has a lower 
clearance of chemotherapeutic agents than the plasma.  
 
Since the principle site of OC is confined to the peritoneal cavity, IP administration could be 
expected to result in a significant drug concentration difference between the peritoneal cavity 
and blood plasma. This confinement provides pharmacologic advantages whereby the tumour 
(1) can be exposed to a more sustained and higher concentration of chemotherapeutic agents 
while; (2) the drugs remains active in the IP cavity longer compared to those of IV 
administration (Kirmani et al., 1994 and, Willemse and de Vries, 2003). A study by 
Markman (1996) collected evidence that IP cisplatin was able to increase the exposure of 
peritoneal cavity to the drug by a factor of 10- to 20-fold compared with IV cisplatin. This IP 
route was also able to overcome some degree of drug resistance and partial sensitivity 
towards cytotoxic agent associated with tumours, which could not be achieved with an IV 
cisplatin. Owing to the drug slowly leaving the peritoneal cavity to enter the bloodstream, 
there is lower systemic toxicity than with IV drug administration. Meanwhile, normal tissues 
such as the bone marrow are relatively spared (Armstrong et al., 2006). 
 
From the clinical studies tabulated in Table 2.2, the number of patients included in the 
clinical trials by Alberts et al. (1996) was 546 patients. They reported a median overall 
survival of 49 months for advanced stage patients treated with IP cisplatin compared to 41 
months for those treated with IV cyclophosphamide. This translated to a higher survival rate 
for the patients group receiving IP chemotherapy compared to the IV patients group.  
 
In a study involving a total of 118 patients carried out by Yen et al. (2001), the patients 
group receiving IP chemotherapy had a median overall survival rate of 48 months compared 
to 43 months for the IV chemotherapy patients group. The percentages of patients 
completing the course were rather low; i.e. 32% from the IP patients group and 25% for the 
IV patients group. Armstrong et al. (2006) formulated two regimens; (i) IV [paclitaxel + 
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cisplatin] and, (ii) IV paclitaxel and IP [paclitaxel + cisplatin] to treat patients with optimally 
debulked Stage III OC. The IV alone regimen produced an overall survival of 49.7 months 
and the combined IV + IP regimen produced an overall survival rate of 65.6 months. The 
total number of patients was 415 while 83% of the IP patients group had completed the 
course of IP treatment and 42% for the IV patients group. 
 
In a large clinical study carried out by Markman et al. (1992), 600 patients with small-
volume residual Stage III OC (largest diameter disease after debulking ≤ 2cm) were 
randomised to receive either IV or IP cisplatin, both at 100 mg/m2. With a median of 
approximately four years from study entry, patients receiving IP cisplatin showed a 
significant improvement in survival (median: 49 months) compared to IV cisplatin (median: 
41 months). Patients with IP cisplatin also experienced less neutropenia and hearing loss. 
These were due to the lower systemic toxicity in IP cisplatin compared to IV cisplatin. This 
study suggested that IP cisplatin can increase the effectiveness of chemotherapy on small-
volume residual OC.  
 
Rothenberg et al. (2003) used IP cisplatin and IV paclitaxel as primary treatments in 68 
patients with optimally debulked Stage III OC. The median survival time using IV 
chemotherapy was 41-52 months and the 2-year survival rate was 65-70%. Whilst for IP 
chemotherapy, the median survival time was 49-63 months and the 2-year survival rate was 
70-80%. Based on the survival rates information from the studies presented above, it can be 
concluded that IP administration of chemotherapeutic agents are capable of producing higher 
survival rate compared to IV administration.  
 
There are many reasons for patients being unable to complete the treatment of either IV or IP 
course but these factors will not be discussed here. However, in particular, Walker et al. 
(2006) investigated the reasons for IP failures and reported that up to two-third of the patients 
suffered from problems caused by the catheter. Half of them suffered complications related 
to the indwelling catheter devices and the rest experienced abdominal pain causing the 
patients to refuse the treatment. Further examples are given below (Markman, 1992; 
Willemse and Vries, 2003): 
i. Subcutaneous installation of a catheter leads to higher risk of infection and fever. 
ii. IP therapy involved delivering large volume of medication solution into the 
peritoneum of the patient. This causes abdominal pain, nausea and vomiting. 
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iii. The development of intra-abdominal adhesions, may be promoted by IP therapy 
which increase the risk of subsequent abdominal surgery. 
iv. Other incidents included inflow obstruction and bowel injury.  
 
IP administration can also lead to peritonitis (inflammation of the peritoneum), which 
prevents the use of higher drug doses. A number of authors have improved the problem by 
pretreating the patient with local anaesthetics before IP treatment; e.g. Use of lidocaine to 
lessen the pain during IP course (Zylberberg et al., 1996). Table 2.3 provides a summary of 
the advantage and disadvantages of IP administration. 
 
Table 2.3: Advantages and disadvantages of IP chemotherapy (Willemse and Vries, 2003). 
Advantage   Disadvantage 
i. Higher therapeutic effect  i. Complications of IP catheter: 
ii. Lower systemic toxicity:    - Infection 
- Renal     - Perforation 
- Neural    - Bleeding 
- Bone marrow - Pain; fibrous adhesions causing insufficient IP fluid and 
drug distribution or, local pain or irritation due to cytotoxic 
agents. 
 
Other non-clinical related problems associated with IP treatment include the cost of 
performing the operation and clinicians are lack of familiarity with the technique. The 
instillation and replacement of a catheter requires skill and expertise (Armstrong et al., 2006 
and, Markman and Walker, 2006). However, the beneficial pharmacology of IP therapy 
encourages promising outcomes and is increasingly been used. Evidence are demonstrated by 
the literatures cited above. The underpinning concepts of IP therapy is the direct delivery of 
medication to the disease site where ovarian cancer is confined to the peritoneal cavity. This 
criterion suits a microsphere delivery system which could offer a localised effect.  
 
The drug-loaded microspheres can be directly delivered to the peritoneal cavity by a single 
injection. Over time, as the biodegradable microspheres degrade they are resorbed by the 
body and further releasing their drug content. No surgical removal is required and no 
complicated installation is required such as the instillation of a catheter system. These 
microspheres could also help to increase the exposure of tumour surface to cytotoxic drug via 
(1) their small and free flow spherical nature which helps in situ distribution and (2) the 
microspheres offer a high surface area for drug diffusion. Further elaboration on the 
microsphere drug delivery system will be discussed in Chapter Three.  
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Studies have been reported in the literature regarding the efficiency of cisplatin-loaded 
microsphere delivery system. Tamura et al. (2002) formulated three different cisplatin-
loaded microspheres using PLGA and two PLA with different molecular weights. The 
platinum profile in plasma shown on Figure 2.4 is the concentration of cisplatin measured 
based on its platinum content after subcutaneous (s. c.) administration of the PLGA/PLA 
microspheres in male Donryu rats.  
 
        
 
 
 
Figure 2.4: The plasma platinum concentration after s.c. administration of cisplatin-loaded microspheres of 
different formulations (close symbols) and cisplatin solution (open symbol) (adapted from Tamura et al., 
2002).  
 
For comparison, Tamura et al. (2002) also dissolved cisplatin in saline solution and followed 
the same microspheres administration into the rats at a dose of 5 mg/kg rat. Tamura et al. 
(2002) claimed that their results using IP administration exhibited the same concentration 
profile as the s. c. administration. It can be seen in Figure 2.4 that the cisplatin microspheres 
formulations exhibited the typical sustained drug release for two to four weeks as appose to 
one week from cisplatin solution.  
 
A pilot study in 1993 was carried out with 13 patients receiving cisplatin-loaded 
microspheres (Hagiwara et al., 1993). Nine of these patients were suffering from gastric 
cancer, two with colon cancer and two with pancreatic cancer. The route of administration 
was IP injection of cisplatin-loaded microspheres; twelve patients received 100 mg of the 
formulation and one received 200 mg. At different time, ascites fluid and blood samples were 
collected from each patients. Figure 2.5 shows the corresponding cisplatin concentrations, 
measured based on its platinum content. In all cases, the cisplatin concentrations in ascites 
fluid were higher than those present in blood plasma. Their final observation noted that eight 
(62%) patients responded completely, four (31%) partially and one (8%) did not respond to 
the treatment. This resulted in a response rate of 92% towards IP administration of cisplatin.  
10 
 
 
 
1 
 
 
0.1 
 
 
 
 
0.01 
0              7            14          21           28            35 
 
Time (Day) 
PLGA : PLA (0.4 : 0.55) 
 
PLGA : PLA (0.1 : 0.85) 
 
PLA : PLA 
Cisplatin microspheres: 
  CHAPTER 2: INTRODUCTION TO OVARIAN CANCER   
THE DEVELOPMENT OF CONTROLLED-CHEMOTHERAPY DRUG DELIVERY SYSTEM  14 
 
     
 
 
 
Figure 2.5: Platinum concentrations in ascites fluid (close symbols) and blood plasma (open symbols). 
Each symbol represents a patient (adapted from Hagiwara et al., 1993). 
 
Results from Hagiwara et al. (1993) showed that the absorption of cisplatin into the blood 
plasma was low and this translated to a reduced systemic toxicity. The concentration 
remained high in the peritoneal cavity and this improved the therapeutic effect of IP therapy. 
Further example of involving clinical studies was reported by Fujiyama et al. (2003). The 
authors developed biodegradable microspheres loaded with cisplatin for local therapy in 
patients with thyroid carcinoma with poor diagnosis. Results showed that the treatment 
demonstrated antitumour effects without side effects during the treatment period, and a 
survival period of ≥ 1 year. Fujiyama et al. (2003) also found that the cisplatin-microsphere 
system demonstrated effectiveness in local injection therapy in patients with cancerous 
peritonitis or who were intolerable to surgery. After establishing the rational for developing a 
microsphere drug delivery system for IP chemotherapy, the following section studies the 
pharmacology profile of the model chemotherapy drug, cisplatin.  
 
 
2.3 Single Agent Therapy – Cisplatin 
 
Early clinical trials using cisplatin at standard dose (50 – 150 mg/m
2
) have demonstrated 
the safety and efficacy of IP therapy. Cisplatin is one of the most active agents used for 
the treatment of OC (Rothenberg et al., 2003 and Markman 2006). After IP 
administration, the large molecular weight of cisplatin produces a peritoneal-to-plasma 
concentration ratio of 20 which result in a high level of intrinsic activity against OC (Howell 
et al., 1982 and Markman et al., 2004). Meanwhile, the therapeutic index of IP cisplatin 
can be further increased through the use of concurrent IV sodium thiosulfate, which 
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protects the kidneys from the cytotoxic effect of the drug. This circumvention enables the 
body to tolerate with a higher dose of IP cisplatin and thus dose escalation is permitted 
(Howell et al., 1982). From the principle of IP therapy, one can improve cancer response 
rate if the delivery of the anticancer drug to the cancer can be increased. With such a 
profile, cisplatin has been commonly used as a single agent to treat OC and because its 
profound availability for dose escalation which may increase cancer response rate 
(Bristow et al., 2002 and Gildy, 2008). These criteria make cisplatin a suitable model 
drug for this work. 
 
2.3.1 Pharmacology Profile 
Cisplatin (cis-diaminedichloroplatinum), with a molecular formula of PtCl2H6N2, is a heavy 
metal complex containing a platinum atom at the centre of the molecule. It is surrounded by 
two chloride atoms and two ammonia molecules in the cis position, as indicated in Figure 
2.6. The molecular weight of cisplatin is 300.05 and it has a water or saline solubility of 2 
mg/ml.  
 
      
 
 
The clinical benefits of cisplatin as an anticancer agent have now been recognised for over 30 
years. To his surprise, Rosenberg discovered cisplatin in 1965 while investigating the effect 
of electric currents on bacteria (Rosenberg et al., 1965). A few years later cisplatin quickly 
reestablished itself as a chemotherapeutic agent after it was found to inhibit the growth in 
Eschericia coli (Rosenberg et al., 1969). Early clinical studies by Higby et al. (1974) found 
that cisplatin exhibited anti-tumour activity in testicular teratoma, while Wiltshaw and 
Kroner (1976) found similar behaviour in relapsed ovarian cancer.  
 
The cisplatin concentration in plasma decays monoexponentially with a half-life of about 30 
minutes following a two, six or seven hours infusion of 100 mg/m2 dose. The total body 
clearance and volume of distribution at steady-state for cisplatin are about 15-16 l/h/m2 and 
11-12 l/m2 respectively. About a quarter of the IV dose is excreted through the kidneys in the 
first 24 h. Total cisplatin (free and bound) has a prolonged half-life of 2 to 3 days. Cisplatin 
does not bind to protein but the platinum within its molecule can remain bound to protein in 
tissues for a long time (Rixe et al., 1996 and, van Zutphen and Reedjik 2005). The key 
H3N            Cl 
  Pt 
H3N            Cl 
Figure 2.6: Molecular structure of cisplatin. It has two ammonia groups (NH3) 
and chloride atoms (Cl) joining to the centre platinum atom in the cis-position.  
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elements in the effects of cisplatin on DNA are (1) its controlled hydrolysis within a cell, (2) 
specific binding at adjacent guanine bases in DNA which leads to; (3) specific distortion of 
DNA, changing its interactions with proteins, leading to either repair of the damage, or cell 
killing by apoptosis. 
 
The mode of action of platinum agents is through irreversible binding to DNA. Upon 
entering a cell, they will become aquated. In the case of cisplatin, it loses chloride or oxalate 
ions, gains two water molecules and becomes positively charged. This subsequently enables 
them to interact with nucleophilic molecules within the cell, including DNA, RNA, and 
proteins. Due to its unique chemical structure, the chlorine atoms of cisplatin are more 
subject to chemical displacement reactions by nucleophiles, such as water or sulfhydryl 
groups, than to enzyme-catalysed metabolism. When binding to DNA, the aquated platinum 
species binds preferentially to the highly nucleophilic N-7 position of the purine bases 
guanine and adenine in a DNA molecule (Reedijk, 2003). Three different types of binding 
can form on purine bases of DNA: monoadducts, intrastrand crosslinks, and interstrand 
crosslinks as illustrated in Figure 2.7. All crosslinks result in distortion of the DNA which 
then interferes with the cell multiplication (Rabik and Dolan, 2007). 
 
 
 
Figure 2.7: Platinating agent adducts on DNA. Platinating agents are able to react with DNA to form 
monoadducts, intrastrand crosslinks (1,2-d(GpG), 1,2-d(ApG), 1,3- d(GpXpGp)), interstrand crosslinks (G-
G), and DNA–protein crosslinks (adapted from Rabik and Dolan, 2007). 
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CHAPTER  3: CONTROLLED  RELEASE  SYSTEM   
 
In Chapter Two we discussed the condition of ovarian cancer and due to its confinement in 
the peritoneal cavity; a local and direct delivery of cytotoxic drugs to the site can be 
introduced. This chapter discusses the suitability of a controlled release system with an 
emphasis on the model forms of the developed systems. The techniques used to develop the 
controlled release systems for this thesis are also discussed. 
 
 
3.1 Controlled Release System 
  
The key challenge with drug administration is that the plasma drug level should remain at the 
desired therapeutic level; above which may represent a toxic level, below which the 
therapeutic is no longer effective (Illum, 1987). A controlled release occurs when a carrier 
successfully captures a bioactive agent in such a way that the active agent is released from 
the carrier in a predesigned manner. The release of the agent may be constant or cyclic over a 
period, or it may be triggered by the environment or other external events.  
 
Depending on the application, this system can be tailor-made to perform within hours to 
months or up to years. These systems can take the form of either soluble polymers, implants 
(to which the drug may be attached by some form of suitable biodegradable linkages) or 
biodegradable micro/nano-particles (in which the drug is entrapped). An impeccable reality 
of which a controlled release system is an ideal candidate system to be explored for this 
thesis is the Special Programme for Vaccine Development initiated by the WHO in the 1980s 
(Bloom, 1989). In parallel to improving conventional drug delivery, increasing attention is 
being paid to developing polymeric carriers for controlled delivery. Reason being that most 
principles developed for this strategy are versatile and adaptable.  
 
The most indispensable attribute of a biodegradable material is its biocompatibility (i.e. no 
part of the polymer induces inflammatory responses in blood or tissues), and its degradation 
products can be metabolised and excreted by natural pathways (Shive and Anderson, 1997). 
Hence, biodegradable polymers have since been stemming in the biomedical application. In 
recent years, controlled drug delivery formulations and the polymers used in these systems 
have become much more sophisticated and materials have been developed to be target-
specific; i.e. specific cell, tissue, or site (Gupte and Ciftci, 2004).  
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3.2 Use of Biodegradable Polymers  
 
The primary criteria for a polymer to be used for controlled drug delivery formulation are 
such that the material has an appropriate physical structure, good stability and be readily 
processable (Yeo and Park, 2004). There is a broad range of biodegradable polymers 
available and the most widely studied belong to the polyester family. For example, 
polylactide acids (PLA) polyglycolide acids (PGA) and their copolymers, which in fact are 
approved by the US Food and Drug Administration (FDA). These polymers are particularly 
attractive due to their versatile degradation kinetics which can be preprogrammed. Clinically, 
for at least 20 years PGA and PLA have been applied for orthopaedic fixation, reconstruction 
and allogenic/autogenic bone surgery (Winet et al., 1995 and 1997). Not only because they 
are absorbed and revision surgery is unnecessary, but they are also non-proteinaceous and 
thus antigenic response is avoided.  
 
3.2.1 Polylactide and Polyglycolide  
Polylactide (PLA) and polyglycolide (PGA) are aliphatic polyesters of poly(α-hydroxy 
acids). These polymers and their associated copolymers are perhaps one of the most common 
biodegradable polymers known and have been used in drug delivery, bone osteosynthesis and 
tissue engineering (Middleton and Tipton, 2000). Compared to PGA, PLA has an extra chiral 
methyl group which gives rise to L or D-PLA (levorotary or dexorotary), or a racemix of DL-
PLA.   
 
 
 
 
Figure 3.1: Molecular structure of lactic acid and PLA (adapted from Lakeshore Biomaterials, 2005). 
 
The extra methyl group also makes PLA more hydrophobic than PGA due to steric hindrance 
of the methyl group. Consequently, the ester bond of PLA is less accessible for hydrolysis 
compared to PGA, making PLA has greater degradation resistance than PGA. The 
crystallinity of PLA usually governs their end uses. L-PLA is semi-crystalline as they have 
regular repeating units that enable the chains to fold into dense regions called crystallites. 
These act as cross-links giving the polymer higher tensile strength, low elongation and higher 
modulus, as well as higher resistance to degradation. These features make L-PLA suitable for 
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load-bearing applications such as orthopaedic fixations and sutures. On the other hand, D-
PLA is an amorphous polymer having a random distribution of both isomeric forms of lactic 
acid and is unable to arrange into an organised crystalline structure (Hasirci et al., 2001). 
Therefore D-PLA is more suitable to be use in drug delivery applications that require a fast 
degradation rate. 
 
 
 
 
 
 
Figure 3.2: Molecular structure of glycolic acid and PGA (adapted from Lakeshore Biomaterials, 2005). 
 
PGA is a highly crystalline polymer due to its relatively short chain length and polar 
properties which also give rise to a high melting point and low solubility in organic solvents. 
PGA is commonly used as biodegradable suture material in the 1970s and it continued to 
evolve in the biomedical polymer applications such as being synthesised with PLA to form 
polylactide-co-glycolide. 
 
Both PLA and PGA degrade by hydrolysis of the ester bond linkage to yield their original 
monomers, L- or D-lactic acid from PLA and glycolic acid from PGA, which are common 
by-products of various metabolic pathways in the body (Jalil and Nixon, 1990). This cycle is 
the second stage of three major stages in carbohydrate catabolism, between the process of 
glycolysis and oxidative phosphorylation; a breakdown process of glucose to carbon dioxide. 
 
3.2.2 Polylactide-co-glycolide (PLGA) 
 
 
 
 
 
Figure 3.3: Molecular structure of PLGA; x = PLA, y = PGA (Freiberg and Zhu, 2004). 
 
The molecular structure of PLGA is shown in Figure 3.3. Polylactide-co-glycolide (PLGA) 
are synthesised via random ring opening copolymerisation of monomers PLA and PGA. The 
polymerisation process usually requires a catalyst such as tin(II) 2-ethylhexanoate. During 
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this copolymerisation, successive monomeric units of lactic and glycolic acids are linked 
together by ester linkages, yielding a linear aliphatic polyester. The ratio of lactic/glycolic 
acids can be altered and for instance, 50:50 PLGA. The first number indicates the molar 
percentage of lactic and the second for glycolic acids.  
 
The copolymer of PLGA extended their properties from their monomers PLA and PGA. 
Table 3.1 is the physical properties of PLA, PGA and PLGA. PLGA with different 
copolymer ratios have varying glass transition temperatures and degradation rates. Since 
PLGA have longer chains, they generally have lower crystallinity and are more amorphous 
than PGA or PLA. Copolymer PLGA is more susceptible to hydrolysis and degrades faster 
than their monomers, due to the disruption of the regularity of the polymer chain by the 
glycolide monomer (Park, 1995). Figure 3.4 is adapted from Middleton and Tipton (2000) in 
order to illustrate the relation between copolymer ratio and degradation rate. 
 
Table 3.1: Physical properties of PLA, PGA and PLGA (Middleton and Tipton, 2000). 
         Glass Transition      Complete Resorption 
Polymer   Morphology       Temperature, Tg (
oC)              (months) 
 
 
PGA   Semi-crystalline           35 - 40   6 to 12 
L-PLA   Semi-crystalline           60 - 65    >24 
DL-PLA   Amorphous  55 - 60   12-16 
75:25 DL-PLGA  Amorphous  50 - 55   4 to 5 
65:35 DL-PLGA  Amorphous  45 - 55   3 to 4 
50:50 DL-PLGA  Amorphous  45 - 55   1 to 2  
 
 
 
 
Figure 3.4: Half-life of PLA, PGA and PLGA copolymers (Middleton and Tipton, 2000). 
 
PLGA undergoes random scission degradation (Cha and Pitt, 1990 and, Jalil and Nixon, 
1990). PLGA is an attractive material for drug delivery systems because of its potential to 
offer different degradation rates by varying the lactide/glycolide acids ratio (Walter et al., 
2001). This feature is advantageous for applications requiring specific degradation kinetics 
ranging from weeks to months. Similar to PLA and PGA, PLGA is also biocompatible and is 
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hydrolytically degraded into natural metabolites: lactic and glycolic acids which are 
eliminated from the body through the Kreb’s cycle (Gunatillake and Adhikari, 2003).  
 
Degradation of a polymer can occur via mechanisms known as unzipping or random 
hydrolytic scission (Kiss and Vargha-Butler, 1999). In this case, aliphatic polyester PLGA 
undergoes hydrolytic degradation via random chain scission at ester linkages (Spenlehauer et 
al., 1989), such as illustrated in Figure 3.4. Random scission of the polyester backbone leads 
to the initial production of insoluble oligomeric fragments of carboxylic acid end groups, 
which can further catalyse the degradation. As degradation proceeds, soluble oligomers and 
monomers are formed and released. At later stage, mass loss of the polymer will occur (Loo 
et al., 2005). Figure 3.5 shows the degradation of PLGA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: The degradation of PLGA occurs through hydrolytic scission at the ester linkage of the main 
chain. The final degradation products are their monomer; the lactic and glycolic acids. 
 
 
3.3 Biocompatibility of PLA and PLGA 
 
The importance of biocompatibility in determining the therapeutic usefulness of 
biomaterials is well recognised to ensure the safety and efficacy of the devices (Park, 1995 
and Anderson, 1994). In controlled delivery, implantation of biodegradable polymeric 
products circumvents the need for surgical removal after complete release of the active agent. 
The circumvention potentially reduces pain, cost and risk of infection (Hasirci et al., 2001). 
Sandstrap et al. (1999) demonstrated that it was possible to obtain reasonable accordance 
between in vitro and in vivo results using PLGA microsphere systems in rats for the release 
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of nifedipine, while PLGA polymer has already been well characterised and approved for 
application in humans by the FDA (Waeckerle-Men and Groettrup, 2005).  
 
Other credible studies have also proven the biocompatibility of PLGA in the brain (Kou et 
al., 1997) and central nervous system (Menei et al., 1999). Jackson et al. (2004) formulated 
paclitaxel-loaded PLGA films and characterised them for potential application as 
perivascular “wraps” to prevent restenosis. In vivo analyses on Wistar rats with no adverse 
reaction were reported in their work. Ogura and Kimura (1995) used biodegradable 
microspheres for targeted drug delivery to the retinal pigment epithelium. Both 50:50 and 
75:25 PLGA were used for subretinal delivery in rabbits. Retinal pigment epithelium was 
demonstrated to phagocytose the biodegradable microspheres. No adverse cellular or tissues 
reactions were noted in these studies. 
 
Massey et al. (2004) conducted investigations into the resorption rates and biocompatibility 
characteristics of PLA and 50:50 PLGA tympanostomy tubes in a guinea pig. Tympanic 
membranes of all animals following tube degradation were intact with minimal scarring and 
no signs of persistent foreign body response. The histological analysis showed that 
implantation of resorbable tubes was not accompanied neither by secondary infection, 
otorrhea, permanent perforation, nor followed by excess tympanosclerosis or localised or 
diffuse membrane atrophy. They concluded that these tubes were substantially equivalent to 
other FDA-approved tympanostomy devices with regard to safety and biocompatibility in the 
guinea pig model examined. They further suggested that by combining this approach with 
controlled release technology, an improved clinical performance can be expected. 
 
An important consideration when evaluating biocompatibility in terms of tissue response to 
biodegradable implants is the biologic activity of the loaded drug or therapeutic agent, 
especially if it has cytotoxic, anti-inflammatory or wound healing characteristics. Moreover, 
the variation in inflammatory and foreign body giant cell responses can be affected by the 
implant form, different routes of administration of the implant as well as different implant 
sites in tissues or organs (Spenlehauer et al., 1989).  
 
A study carried out on a controlled release system containing gentamycin exhibited a 
significant increase in the Phase I inflammatory response due to the cellular cytotoxicity of 
gentamycin when present at high concentrations (Anderson and Shive, 1997). Cisplatin 
loaded PLGA microspheres in rats also caused an increase in inflammatory reaction 
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compared to cisplatin-free microspheres. These are examples of the localised response to the 
released drug. However, the benefits gained from using this system far outweighed the slight 
increase in the localised inflammatory reaction (Ike et al., 1992 and Itoi et al., 1996).   
 
These studies signified the importance in considering the inherent cytotoxicity of the drug or 
therapeutic agent when evaluating the biocompatibility of biodegradable systems. Otherwise, 
the histological observation of enhanced or prolonged acute and chronic inflammatory and 
foreign body reactions may be mistakenly attributed to the polymer or contaminants in the 
polymer. Sections 3.1 to 3.4 have justified the suitability of PLGA as the model polymer for 
this thesis. Preliminarily work also showed that this polymer is easily processable. Examples 
of commercially available products listed in Table 3.2 further confirm the biocompatibility 
profiles of PLA, PGA and PLGA and their versatile applications.  
 
Table 3.2: Examples of the various forms of PLA, PGA and PLGA used in biomedical applications. 
 Product name & Manufacturer  Material & Form Medication Application 
 Nutropin® Depot PLGA, microspheres       Somatropin          Growth failure 
 Genentech Inc.  
  
 Zolade®          PLA, rod implant        Goserelin        Prostate cancer, 
 Astra Zeneca Pharmaceuticals, LP                     acetate        endometriosis 
 
 Trelsta® Depot          PLGA, microspheres          Triptorelin             Prostate cancer  
 Pharmacia & Upjohn Company           pamoate 
 
 BVS           PLA, stent         Everolimus           Coronary artery  
 BVS, Abbot               disease 
 
 CYPHER®           PLA, stent         Sirolimus        Coronary artery     
 Cordis, Johnson & Johnson              disease 
 
 TAXUS®           PLA, stent         Paclitaxel        Coronary artery 
 Boston Scientific                             disease 
 
 Tissue Fixation Screw             P-L-LA, screw/pin            -                    Orthopaedics 
 DePuy Orthopaedic Inc.                            fixations 
 
 Interference Screw         85:15 PLGA, screw               -        Orthopaedics 
 Instrument Makar              fixations 
 
 SD Sorb Suture Anchor         82:18 PGA, screw            -        Orthopaedics      
 Dynamics                             fixations  
 
 Dexon® PGA, suture             -        Surgical suture 
 Davis and Geck 
 
 Vicryl® PLGA, suture            -        Surgical suture 
 Ethicon 
 
A number of PLGA or PLA microsphere systems are clinically available. Example is such as 
Lupron Depot®, manufactured by TAP Pharmaceutical Products Inc., which can be 
subcutaneously or intramuscularly administered. Lupron-PLA microsphere was reported to 
have an approximately 10 % of drug loading, and releases leuprolide, an GnRH analogue at 
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for treating prostate cancer. The following section will discuss the model forms of the 
devices developed for this thesis. 
 
 
3.4 Microspheres for Controlled Delivery 
 
Polymeric microparticle for drug delivery can be classified as colloidal carriers (Illum, 
1987), which includes not only micro- and nano-spheres, but also liposomes, emulsions and 
materials of biological origin such as low density lipoproteins. Small spherical devices, made 
of biodegradable polymers could potentially accommodate reasonable drug loadings can be 
used to deliver drug in a continuous and controlled fashion (Freitas et al., 2005). Owing to 
their micron sizes, they can be ingested or injected. These devices practically act as a 
reservoir releasing their content at a relatively slow rate over a prolonged time allow less 
frequent administrations, thereby increasing patient compliance and reducing discomfort, 
protection of the therapeutic compound within the body, and maintaining a more-constant 
drug level in the blood (Freiberg and Zhu, 2004).  
 
In some cases, particulate carriers have been devised for protecting the active molecules 
against the host; e.g. blood, lymph and digestive juice (Niwa et al., 1993). By controlling 
drug input with a modified release dosage form, it is possible to maintain the plasma drug 
concentration at the desired level with minimal fluctuations, meanwhile, providing a 
prolonged therapeutics effect with a reduced incidence of side effects. An efficient delivery 
strategy will also lead to cost efficiency (Akhtar and Agrawal 1997). Various parenteral 
microparticles drug delivery systems have been developed based on biodegradable polyesters 
polymers (Johansen et al., 2000; Birnbaum and Brannon-Peppas, 2003).  
 
The delivery of chemotherapeutic agents using polymeric microspheres has become one of 
the most popular areas of research because of the possibilities of reducing toxicities and 
localising the drug delivery (Liggins et al., 2000 and Wang et al., 2005). Site-specific 
delivery offered by microparticulate system can also improve the biological effects of poorly 
water-soluble drugs with low bioavailability and short lives (Akhtar and Agrawal, 1997 and 
Hussain et al., 2002). The above examples have demonstrated the advantageous features of 
microsphere systems. To summarise, employing a microsphere delivery system could 
potentially offer to accomplish the purposes listed below: 
i. A prolonged controlled release (i.e. controlled release of the therapeutic agents) 
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ii. Offers protection (i.e. host the entrapped drugs to increase their bioavailability) 
iii. Localised effect (i.e. direct delivery to a target/specific site by injection etc.) 
iv. Amplification of adjuvant effect (i.e. spherical depots offer high surface areas for 
drug diffusions therefore increase the contact between the drugs and target site.) 
 
There are various methods for preparing microspheres and for examples, solvent evaporation, 
organic phase separation, spray-drying or supercritical fluid technology amongst which has 
been widely applied to tailor made the targeted systems. Spray-drying method is widely 
employed in the pharmaceutical industry and has been investigated by several researchers as 
a method for formulating biodegradable microparticles (Freitas and Muller, 1998 and Yoo et 
al., 1999). Considering the laboratory condition and availability of facility, a traditional 
single emulsion method based on the solvent evaporation was employed in this thesis to 
produce the drug-loaded microsphere system.  
 
3.4.1 Production of Microspheres 
Solvent evaporation and phase separation are probably the commonest techniques used to 
prepare microspheres due to the simplicity of its preparation mode. A range of  mechanisms 
involved in the preparation process are subjects of investigations by a number of authors 
such as Rafati et al. (1997), Yang et al. (2001), Freitas et al. (2005), Mainardes and 
Evangelista, (2005). From preliminary experiments, it was decided that solvent evaporation 
technique will be used as the main technique for this thesis. The reasons are:  
i. This technique permits small working volumes, which is cost effective for multiples 
trials and experiments. 
ii. The procedures involved in this technique are easy to manipulate therefore allowing 
different production conditions to be investigated. 
iii. This technique is rapid and the whole production process is not lengthy.   
 
The two main methods of the solvent evaporation technique are single and double emulsions 
methods. The element that distinguishes between single and double or multiple emulsions is 
the hydrophobicity of the drugs used. For single emulsion, because the method involves an 
aqueous emulsion, the drug being encapsulated in the microspheres are limited to those that 
have low water solubility. A simple definition of an emulsion is the dispersion and 
stabilisation of one liquid within another to which it is immiscible.  
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3. Solvent Evaporation 4. Microspheres Harvest 
3.4.2 Solvent Evaporation – Single Emulsion Method 
Sansdrap and Moës (1993), and Freitas et al. (2005) have presented the microencapsulation 
technique using this method. The process involves emulsification of a polymer solution-
containing drug (either dissolved or in suspension) into a second, immiscible liquid phase 
containing an emulsifier to form a dispersion of drug-polymer-solvent droplets. The solvent 
is removed from the dispersed droplets by applications of heat, vacuum, or by evaporation as 
the drug-loaded microsphere solidifies. They can then be separated by filtration or 
centrifugation, washed, and dried. The process can be basically divided into four stages:  
i. Dissolution or dispersion of the drug often in an organic solvent containing the 
matrix forming polymer.  
ii. Emulsification of this organic phase in a second continuous (frequently aqueous) 
phase immiscible with the first one.  
iii. Extraction of the solvent from the dispersed phase by the continuous phase, which is 
accompanied by solvent evaporation, transforming the droplets into solid spheres.  
iv. Harvesting and drying of the solid spheres. 
 
3.4.3 Solvent Evaporation – Double Emulsions  
A typical procedure for a double emulsion method is illustrated in Figure 3.6. This system is 
suitable for hydrophilic compound and compound with low solubility in the organic solvent 
(used to dissolve the polymer).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Schematic diagram of a w/o/w emulsion process. The primary w/o is formed by homogenising 
a polymer solution and a drug solution (usually aqueous). This emulsion is then added to a larger aqueous 
volume containing emulsifier to form the w/o/w emulsion.  
 
The drug is first dissolved in water and emulsified in an organic phase containing the 
polymer and an emulsifier; forming the primary w/o emulsion. This emulsion is then 
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dispersed in another aqueous phase containing more emulsifier. Complication with this type 
of emulsion could occur when the primary emulsion is not sufficiently stabilised and the 
droplets containing the dissolved drug are lost to the aqueous phase in the secondary 
emulsion. 
 
Primarily, the solvent of choice must be immiscible or only slightly soluble in the continuous 
phase (i.e. water). Most importantly, the solvent must has a lower boiling point than that of 
the water phase. If dissolution of the drug in the polymer solution is desired, then the ability 
of the solvent to dissolve the polymer and drug needs to be considered. Table 3.3 describes 
the basic criteria for selecting the working solvent. 
 
Table 3.3: Important criteria for dispersed and continuous phase solvents (Watts et al., 1990). 
Dispersed Phase Solvent   Continuous Phase 
Ability to dissolve chosen polymer   Immiscibility with the continuous phase solvent. 
 
Ideally, the solvent should be able to  Inability to dissolve polymer. 
dissolve the drug.  
 
Immiscibility with the continuous  Low solubility toward drug. 
phase solvent.  
 
Lower boiling point than continuous  Higher boiling point than dispersed phase  
solvent phase. solvent. 
 
Allows easy recovery and clean-up of microsphere 
 
Preliminary work involving microspheres production was carried out using solvent ethyl 
acetate. Ethyl acetate is classified as a Class 3 solvent by the International Conference on 
Harmonisation (ICH Q3C (R3), 2005). It is less toxic than the commonly used 
dichloromethane (DCM) in PLGA microsphere production. Ethyl acetate has a high boiling 
point, i.e. 77oC, and preliminary work showed that the nascent droplets required more than 
four hours to solidify. Collection before this resulted in non-uniform and misshapen 
microspheres. DCM was replaced as the working solvent for this work for its lower boiling 
point; i.e. 40 °C which would aid solvent removal during solvent evaporation stage in 
microsphere production. DCM is a class 2 solvent according to ICH Q3 (R3). 
 
 
3.5 Hollow Fibres for Controlled Delivery 
 
The development of hollow fibres started in the 1970’s. Pitt and Schindler (1979) developed 
subdermal delivery system based on tubular implant made of poly(ε-caprolactone). Different 
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post-treatments were performed on the tubular implant in order to modify the porosity and 
the connectivity of the interior pores. Pitt et al. (1979) found that the dense structure of the 
implant required further adjustment to offer a better drug release kinetic. Few years later, 
Eenink et al. (1987) produced PLA hollow fibre with porous structure using a dry-wet 
spinning process based on the phase separation technique.  
 
By applying different spinning conditions, Eenink et al. (1987) found that the property of the 
fibre can be modified to favour better drug release rates. The drug release rate appeared to be 
dependent on the fibre wall structure, and a porous structure was concluded by Eenink et al. 
(1987) to be necessary for better control in drug release. Since then, various drugs-loaded 
fibre systems have shown promising results including a predictable first order release kinetic 
(Dunn et al., 1982 and 1987; Eenink et al. 1987). 
 
Zilberman (2007) developed bioresorbable PLGA fibres loaded with paclitaxel and the 
product demonstrated good mechanical properties. With a desired drug release profile, 
Zilberman (2007) concluded that they are ideal for scaffolds for tissue regeneration 
applications and other basic medical implants. PLGA hollow fibres have been developed as 
scaffolds for tissues engineering for their unique structures (Morgan et al., 2007 and Ellis 
and Chaudhuri, 2007).  
 
Similar to microsphere production, the fibre production parameter can be altered to 
predetermine their final property for specific application. Tailor-made hollow fibre 
membranes with controllable structures improve their biomedical applications based on their 
mass transfer property, which controls the transport of permeate species (Perepechkin and 
Perepechkina, 1999). 
 
The hollowness of the hollow fibre offers an opportunity to load additional drug dosage into 
the device. While drug can be encapsulated within the wall of the hollow fibre, in this case, it 
is intended that drug solution and drug-loaded microsphere to be loaded into the lumen of the 
fibre. This requires investigation into the behaviour of the new combined system. The studies 
of drug release from these systems are presented in Chapter Nine.  
 
Preliminary work has been carried out to produce hollow fibre-patch and the final product is 
shown in Figure 3.7. The ultimate purpose of developing this drug-loaded fibre patch is that 
the device can act as a self-releasing device. For instance, after surgical removal of a tumour, 
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a chemotherapy drug-loaded fibre patch can be attached to the peritoneum in order to kill 
residual cancerous materials (Gilby, 2008). Different drugs loadings in the fibre wall and 
lumen can also be formulated for a co-delivery system. For the objective of this thesis, the 
development of hollow fibres and their drug release characteristics require an understanding 
of the membrane structure formation. This set the purpose for the next section and the 
concept will be applied to the production of PLGA hollow fibre.   
 
  
  
 
3.5.1 Production of Hollow Fibre 
The hollow fibres developed in this thesis take the characteristic of a porous-asymmetric 
membrane. Synthetic membranes with asymmetric structures have very thin (0.1 to 1 µm) 
skin layer on a highly porous sublayer of 100-200 µm (Bungay et al., 1986). The phase 
inversion technique is a common method employed to produce asymmetric membranes. 
Phase inversion is a process whereby a polymer is transformed in a controlled manner from a 
liquid to a solid state (Mulder, 2000). The phase inversion of polymer to form a membrane 
can be achieved in a number of ways and by convention, Drioli and Nakagaki (1997) 
summarised three main methods as following: 
i. Thermogelation of a two-component mixture - a process in which the cooling of a 
two component mixture from a temperature where both components form a 
homogenous phase, to a temperature where two phases will form, one phase will be 
the solid forming porous system. 
ii. Evaporation of a nonsolvent from a three component mixture - a mixture of polymer, 
a solvent and nonsolvent will have: (1) a region where there will be homogenous 
phase and (2) a region of composition where two distinct phases will form. By 
starting from a composition in the homogenous region and evaporating the solvent, 
the system moves into the two phase region forming a liquid and a solid phase. This 
results in the formation of a solid phase with porous structure. The two-phase region 
is known as the miscibility gap in a ternary phase diagram (Figure 3.8). 
Figure 3.7: A “woven” 75:25 PLGA hollow fibre patch. 
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iii. The third method is the mechanism through which the addition of non-solvent to a 
two mixture system causes precipitation. This method is known as the immersion 
precipitation and it is the method employed in this thesis.  
 
Immersion precipitation achieves the phase inversion by immersing a solvent/polymer 
mixture cast in the desired shape into a nonsolvent coagulation bath. The behaviours of these 
three components can be related using a ternary phase diagram (Figure 3.8). One of the 
liquids will be rich in polymer the other lean in polymer. The addition of the nonsolvent to 
the two component mixture (a polymer and a solvent) rapidly moves the mixture from a 
homogenous phase to the miscibility gap. This is because of the exchange between solvent 
and nonsolvent. At the point where the miscibility gap is reached, a polymer rich phase and a 
polymer lean phase are formed. As the solvent/non-solvent exchange continues, the polymer 
rich phase reaches a point where it can be considered as solid.  
 
  
       
Figure 3.8: Ternary phase diagram relating the three components; polymer, solvent and nonsolvent to the 
structure formation of hollow fibre membrane (adapted from Chung, 1997). 
 
The immersion precipitation can be characterised using thermodynamics principle because 
the process begins with a demixing process. The initial procedure for hollow fibre formation 
is to prepare a homogeneous (thermodynamically stable) polymer solution. This will often 
correspond to a point on the polymer-solvent axis. The demixing process is the addition of a 
nonsolvent into the polymer solution that causes the solution to become thermodynamically 
unstable. During the demixing, if the solvent/nonsolvent exchange is very rapid, the 
composition path will enter the miscibility gap almost immediately after immersion. When 
the miscibility gap is entered at compositions above the critical point, nucleation of the 
polymer-lean phase occurs. Phase separation is thus initiated via the nucleation and growth 
of a polymer-lean phase.  
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In a slow or delayed demixing, the composition of the solution remains in the homogeneous 
region for a certain period of time. During this the composition in the polymer solution 
gradually shifts to higher nonsolvent concentration until finally the miscibility gap is entered. 
The solvent/nonsolvent exchange continues as the demixing process continues. Eventually, 
both the compositions of the polymer-rich -lean phases will move towards the polymer-
nonsolvent axis.  
 
The rapid and delay demixing result into two different types of membrane structures. Rapid 
demixing usually produces thin and less dense skin layer but with open structure in the 
sublayer. Delay or slow demixing usually produces thick and denser skin layer with less open 
or interconnect sublayer (Bungay et al., 1996). The lower porosity in the skin layer compared 
to the porosity of the sublayer can be related to the high polymer concentration in the 
interfacial layer between the polymer solution and the nonsolvent at the instant of demixing.  
 
For semi-crystalline polymer or amorphous polymers, gelation is a common phenomenon for 
solidification process (Mulder, 2000). When gelation occurs, a dilute or more viscous 
polymer solution is converted into a system of infinite viscosity. In semi-crystalline 
polymers, gelation is often initiated by the formation of microcrystallites. For amorphous 
polymers, it often involves a sol-gel transition. A sol-gel transition occurs where the solution 
gels. The addition of a nonsolvent induces the formation of polymer-polymer bonds and 
gelation occurs at a lower polymer concentration.  
 
A work by Kong and Li (2001) investigated a range of effects in the production of hollow 
fibre membranes. They found that water permeation rate increases and solute rejection 
decreases as the polymer concentration is reduced. This is translated to a condition of higher 
flux and porosity. Barth et al. (2000) suggested that the following parameters could affect the 
final performance of the hollow fibre:  
i. Composition of polymer solution (polymer, solvent, additives etc) 
ii. The non-solvent or the mixture of non-solvents,  
iii. The temperature of the polymer solution, the coagulation bath or the environment,  
iv. The amount of dry phase inversion before wet phase inversion and the humidity, and 
among others.  
 
Barth et al. (2000) conducted their investigations using polysulfone (PSF) polymer, N-
methyl-pyrrolidone (NMP) as solvent, and water or acetone as nonsolvent. Their studies 
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concluded that the phase inversion process leads to the development of long finger-like 
cavities beneath the surface of the membrane. These became smaller when the concentration 
of PSF was increased in the casting solution. In another work by Deshmukh and Li (1998) 
revealed that the coagulation rate in hollow fibre has a great effect on the structure of the 
membrane produced. Rapid coagulation results in large finger-like cavities whereas slow 
coagulation results in a porous sponger like structure.  
 
For this thesis, the hollow fibre is developed for its structural characteristic which may be 
beneficial to drug release kinetic. An example of the cross sectional structure of a hollow 
fibre is shown in Figure 3.9. These structural characteristics are associated with high mass 
transfer resistance (Zhang and Cussler, 1985; Yang et al., 2001b and Tai, 2007) and could act 
as a barrier to rapid drug release. The dense “finger-like” structures adjacent to the skin 
layers were anticipated to provide additional control in drug release thereby prolonging the 
drug release period. More detailed morphology characterisation of PLGA hollow fibre will 
be presented in Sections 5.3 and 6.4.  
 
   
Figure 3.9: Cross section of a 72:25 PLGA hollow fibre prepared using the phase inversion technique. (A) 
Detailed fibre wall structure and (B) Cross sections of the hollow fibre. 
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CHAPTER 4: MATERIALS  AND  METHODS     
 
This chapter describes the methodology applied to develop the drug-loaded PLGA 
microspheres (Section 4.1), hollow and solid fibres (Section 4.2). Sections 4.3 and 4.4 
describe the methods used to determine drug concentration, drug loading and encapsulation 
efficiency. Section 4.5 describes the in vitro drug release analysis while Section 4.6 describes 
characterisation of PLGA microspheres followed by characterisation of PLGA hollow and 
solid fibres in Section 4.7.  
 
4.1 The Development of Drug-Loaded Microspheres 
4.1.1 Materials 
HPLC grade dichloromethane (DCM) used as solvent and polyvinyl alcohol (PVA) used as 
emulsifier were purchased from Fisher Scientific, UK. 
 
Table 4.1: Biodegradable polymers purchased from Lakeshore Biomaterials, Inc., USA. 
Polymer Grade 
Molecular Weight & 
Inherent Viscosity 
Abbreviation 
50:50 Poly(DL)lactide-co-glycolide GMP 51 k Da, 0.57 dL/g 50:50 PLGA 
65:35 Poly(DL)lactide-co-glycolide GMP 118 k Da, 0.79 dL/g 65:35 PLGA 
75:25 Poly(DL)lactide-co-glycolide  GMP 113 k Da, 0.75 dL/g 75:25 PLGA 
* All PLGA are with carboxylic acid end-capped to improve degradability. 
  
Table 4.2: Anaesthetic and chemotherapy drugs used for the production of drug-loaded PLGA devices. 
Model Drug Grade Supplier Abbreviation 
Lidocaine (anaesthetic) GMP Spodefell Ltd., UK LID 
Cisplatin (chemotherapy) USP 27 
Lianyungang Unionrun Foreign 
Trade Co. Ltd., China. 
CPt 
 
4.1.2 Equipment  
Table 4.3: List of equipment used in microspheres production. 
Equipment/Instrument Manufacturer Functions 
Homogeniser 
(IKA-Ultra-Turrax® T25) 
Janke & Kunkel GMBH & 
Co. KG., Germany 
Creation of single or double emulsions for 
microspheres production 
Centrifuge 
(IEC CL10) 
Thermo Electron 
Corporation, UK 
Harvest of microspheres 
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4.1.3 Production of Microspheres – Single Emulsion Method 
The desired concentrations of drug and polymer were prepared into DCM and left mixing on 
a roller mixer for at least three days to ensure thorough mixing. Typically, 10 g of the 
drug/polymer solution was injected into 100 ml of PVA solution and homogenised in order 
to produce a uniform w/o emulsion (Figure 4.1A and B). After that, the nascent microspheres 
were transferred to magnetic-stirring for solvent evaporation for 3 h at 750 rpm as the 
microspheres solidify (Figure 4.1C). Examples of working concentrations are such as 10 % 
(w/w) polymer, drug-to-polymer ratio of 1:2 and 0.5 % (w/w) PVA. Investigations into the 
effects of these parameters are presented in Section 5.1. 
 
    
         
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: The production of microsphere: (A) Drug/polymer mixture is injected into PVA solution using 
a syringe with 17G needle and (B) undergoes homogenisation. (C) The nascent microspheres are 
transferred to magnetic stirring. (D) The harvesting step involves a vacuum filtration system. 
 
 
 
Air 
Microspheres 
 PVA stabilising emulsion 
Polymer matrix entrapping 
model drug 
A & B. Droplet Formation 
Drug/Polymer 
Solution  
D. Microsphere Harvest 
Evaporation 
C. Solvent Removal 
Figure 4.2: The filtered microspheres are placed in a sintered glass funnel in 
which a mild current of air is passed through to dry the microspheres. 
  CHAPTER 4: MATERIALS AND METHODS 
THE DEVELOPMENT OF CONTROLLED-CHEMOTHERAPY DRUG DELIVERY SYSTEM  35 
After the magnetic stirring, the resulting microspheres (as suspension in PVA solution) were 
transferred to 50 ml centrifuge tubes for centrifugation at 1000 rpm for 3 min. The 
supernatant (i.e. PVA solution) was replaced with 50 ml fresh distilled water and underwent 
centrifugation again. Lastly, for harvesting step; the microspheres were filtered (Figure 4.1D) 
and washed once with distilled water, collected and air dried (Figure 4.2).  
 
 
4.2 The Development of Drug-Loaded Hollow and Solid Fibres  
4.2.1 Materials 
Polymers and drugs used for manufacturing drug loaded hollow and solid fibres were as 
listed in Tables 4.1, 4.2 and 4.3 respectively. Solvent used in this case was HPLC grade 1-
methyl-2-pyrrolidone (NMP), purchased from Sigma-Aldrich, UK. NMP is highly miscible 
with water and this criterion is necessary to achieve the phase inversion effect. 
 
4.2.2 Equipment  
Table 4.4: List of equipment used in hollow and solid fibres production. 
Equipment/Instrument Manufacturer Functions 
Syringe Pump 
(KDS 100) 
KD Scientific Inc., USA 
Delivery of polymer/drug solution during 
spinning process.  
Micropump 
(REGLO-Z) 
ISMATEC SA, Labortechnik, 
Switzerland 
Delivery of internal coagulant during 
spinning process. 
Motorised Roller 
(AEG AM63NT4) 
Spaggiari Trasmissioni S.P.A., 
Italy 
Collection of nascent fibres during 
spinning process. 
  
4.2.3 Spinning of Hollow and Solid Fibres – Phase Inversion Technique 
The desired concentrations of drug and polymer were prepared into NMP and left mixing on 
a roller mixer for at least three days. Distilled and tap water were used as the internal and 
external coagulants respectively. Prior to spinning, the drug/polymer dope was degassed in a 
desiccator for 1-2 h using a vacuum pump to remove gas bubbles. Figure 4.3A shows the 
spinning apparatus used to spin PLGA hollow fibre and Figure 4.3B shows the solid fibre 
spinning system. All spinning work was carried out at room condition. 
 
For spinning of hollow fibre, 100 ml of drug/polymer dope was collected into a syringe and 
mounted onto a syringe pump. The dope was then extruded into a tube-in-orifice spinneret, 
with a simultaneous flow of the internal coagulant through the central tube in the spinneret. 
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This produces a lumen in the centre of the nascent hollow fibre. The extruded nascent hollow 
fibre from the spinneret then passed through a water bath (external coagulant) in which NMP 
diffused into the aqueous phase and the nascent hollow fibre continue to solidify. The air gap 
between the spinneret and water level was fixed at 10 cm. The nascent hollow fibre was 
gently driven into a washing tank by a motorised roller, at a typical speed of 5 rpm. A 
suitable rotation rate is important to prevent mechanical dragging of the fibre. The fibre was 
immersed in the washing tank for at least 24 h as the nascent fibre solidified before they were 
collected for drying.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Schematic diagrams (A) Hollow fibre spinning system. The internal coagulant or bore liquid 
flow rate was usually maintained at 1 - 2 ml/min.  (B) Solid fibre spinning system. The spinneret was 
replaced with a needle (17G) to extrude polymer/drug solution with a rate of 2-3 ml/min. 
 
For spinning of solid fibre, a spinneret was not used and the polymer/drug solution in this 
case, was extruded through a syringe needle (17G) directly into the water bath such that the 
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needle tip was just reaching the surface of the water bath as illustrated in Figure 4.3B. The 
collection and washing of solid fibres remained the same as in hollow fibre production.  
 
 
4.3 Determination of Drugs Concentrations in PLGA Devices 
 
4.3.1 Anaesthetic Drug Concentration Determination 
Lidocaine concentration was determined using a Cecil 3000 Series uv spectrophotometer 
(Cecil Instrument, UK) with wavelengths, λ = 262.5 nm. Drug solutions with desired 
concentrations were prepared by dissolving the drug crystals in phosphate buffer saline and 
subsequent dilution with the buffer. The calibration curve of known drug concentrations with 
corresponding absorbances for lidocaine is shown in Figure 4.4. 
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Figure 4.4: Calibration curve with lidocaine concentration ranged from 0.05 to 1.0 mg/ml. 
 
4.3.2 Chemotherapy Drug Concentration Determination 
Cisplatin concentration was measured based on the platinum content in the drug molecule 
using a Model 3110 atomic absorption spectrometer (AAS) (Perkin Elmer Ltd., UK), 
equipped with a platinum cathode lamp set at a λ = 265.9 nm. The platinum content in the 
sample was measured directly by aspirating the sample solution into the AAS at a rate of 1.0 
± 0.2 ml/min for 20 sec. The cisplatin content was determined using the calibration curve 
shown in Figure 4.5 constructed using standard platinum solution. Platinum standard solution 
(1 g/l) in 2M HCl was purchased from Sigma-Aldrich, UK. 
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Figure 4.5: Calibration curve with cisplatin concentration ranged from 0.05 to 1.0 mg/ml. 
 
 
4.4 Drug Loading and Encapsulation Efficiency 
Typically, 5 ml of DCM was used to dissolve a 0.20 g of lidocaine-loaded sample and the 
mixture was left for complete dissolution overnight. After that, 5 or 10 ml of 0.1M H2SO4 
solution was added to extract the drug and left overnight. The aqueous phase was then 
collected and measured according to the method described in Section 4.3.1. 0.1M H2SO4 
solution was used to normalise absorbance readings while all the drug loaded samples were 
measured against blank samples. The drug loading (DL) and encapsulation efficiency (EE) 
were estimated using Equations 4.1 and 4.2 respectively. 
 
DL (%)  = Total Drug Encapsulated (mg)  x 100%     
      Total Sample Used (mg)                                    (4.1)                       
EE (%)  =           Total Drug Encapsulated (mg) x     100% 
                    Total Drug Used in Preparation (mg)         (4.2)                                  
 
Acid digestion was used to process cisplatin-loaded samples. Nitric acid (HNO3) and 
hydrochloric acid (HCl), used as aqua regia were purchased from Fisher Scientific, UK. A 
0.20 g of cisplatin-loaded sample was digested with 4 ml of aqua regia (1:3, HNO3:HCl) and 
dried at 85oC for 45 min to just dryness. The drying duration and temperature were altered in 
order to produce solution-least residue for further processing. Depending on the sample, this 
procedure was repeated once or twice in order to achieve complete sample digestion to yield 
an absolute platinum content. 5 or 10 ml of 2M HCl were then added and the solution was 
aspirated to the AAS for the determination of cisplatin concentration (Section 4.3.2). The DL 
and EE were estimated using Equations 4.1 and 4.2 respectively. 
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4.5 In vitro Incubation of PLGA Devices 
For both in vitro drug release and degradation analyses, all samples were incubated in a 
shaking water bath (Grant Instrument, UK) maintained at 37.0 ± 0.5 oC, with a back-forth 
shaking of 150 rpm for up to thirty days. 0.1 M phosphate buffered saline solution (PBS) was 
prepared from ready-made tablets purchased from Oxoid Ltd., UK. 
 
4.5.1 In vitro Drug Release Analysis 
Approximately 0.20 g of sample was immersed in 10 ml of PBS (pH 7.4) and incubated in 
the condition described above. For hollow or solid fibres, each sample constituted fifteen 8 
cm fibres were immersed in 15 ml of PBS. The total weight of twenty fibres was 
approximately 0.20 g. Control samples were prepared in a similar way but using blank 
microspheres or hollow/solid fibres. The frequencies of absorbance measurements and PBS 
refreshing may vary during the first day depending on the released drug concentration. 
Typically, initial measurements were taken hourly for the first six hours and later at twelve 
hour intervals or daily. Drugs concentrations were determined using methods described in 
Section 4.3 and normalised against the blanks accordingly.  
 
4.5.2 In vitro Degradation Analysis 
Sample preparation for PLGA microspheres, hollow and solid fibres were the same as in 
Section 4.5.1. In order to monitor the degradation of PLGA samples, samples were collected 
at tenth, twentieth and thirtieth days for SEM imaging (Section 4.6.2) and mass loss analysis 
using Equation 4.3: 
Percentage mass loss due to degradation, % MLoss = [(Mo - Mn ) / Mo ] x 100 %                (4.3) 
Mo and Mn are the weights of the sample before and after degradation respectively.  
 
 
4.6 Characterisation of PLGA Microspheres 
4.6.1 Particle Size Analysis 
Particle size was measured using a Mastersizer X (Malvern Instruments, UK) with a laser 
diffraction with range lens of 300 mm, a laser obscurity between 12 and 25%. Briefly, in a 
laser diffraction particle analyser, a beam of laser light is projected through an aperture to the 
sample particles and as a result, the incident light is diffracted and scattered onto a lens. This 
lens focuses the scattered light onto a detector array and using Mie theory (which solves 
Maxwell’s equations for the boundary conditions of a spherical particle), the particle size 
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distribution is inferred from the collected diffracted light data. Each sample was analysed a 
total of 2000 times by the system to give a mean particle size. 
 
The measurement system for PLGA microspheres was based on the wet dispersion in which 
the sample is suspended in a compatible solvent that is also transparent to the laser beam. A 
sample (~0.1 g) was prepared into a glass vial containing 2 ml of cyclohaxane and lechitin (1 
mg/ml) and sonicated for 5 min in order to produce a homogeneous suspension. After that, a 
few drops of this suspension were added to the sample chamber equipped with a magnetic 
stirring bead. The latter feature prevents the suspension from precipitating whereas lechitin 
helps to stabilise the suspension.  
 
 
4.6.2 Scanning Electron Microscopy (SEM) 
In order to examine the surface morphologies of PLGA devices, small amount of sample was 
evenly sprinkled (for microspheres) or placed (for fibres) onto a carbon adhesive disc 
mounted onto an aluminium stub. Samples were coated with a thin layer of gold for 5 min in 
an Edwards Sputter-coater S150B and viewed using a JEOL JSM 6310 electron microscope 
operating at a typical 10k V accelerating voltage, 20oC and 10-5 Torr. For assessing the 
internal structure of PLGA microspheres, a cryo-fractioning technique was used. A basic 
protocol for cryo-fractioning sample preparation is illustrated in Figure 4.6.  
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Sample preparation involves in cryo-fractioning of microspheres prior to SEM imaging. 
 
A cup-shaped sample holder was filled with a suspension of microspheres in distilled water 
and covered by a thin rectangular sheet of scratched aluminium (Figure 4.6A). The sample 
holder aperture was sealed by anchoring each end of the aluminium rectangle to a piece of 
sticky carbon adhesive disc. The whole apparatus was inverted to prevent the sinking of 
N2 
Cryo-preparation 
chamber 
(A)                                                                  (C) 
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microspheres, and then plunged into liquid N2, “plunge freezing” (Figure 4.6B). In quick 
repetition, the sample holder was introduced into the cryo-preparation chamber which was 
maintained under vacuum and -165oC (Figure 4.6C). The scratched aluminium rectangle was 
then removed with a cold blade causing fracturing of the ice crystal at the specimen surface. 
The specimen was then transferred into the SEM chamber and mounted onto a stage at -
170oC. The stage temperature was then raised to -80oC in order to sublime the ice slowly 
hence revealing the fractured microspheres. After that, the specimen was transferred back 
into the preparation chamber, for gold-coating and ready for imaging. 
 
 
4.6.3 Confocal Laser Scanning Microscopy (CLSM) 
In order to examine the distribution of drug within the microsphere, CLSM was used. PLGA 
microspheres were prepared according to method described in Section 4.1.3, but with 
trifluoromethyl umbelliferone (4-TFMU) premixed to the polymer solution. PLGA-to-
4TFMU of ratio of 1:1 was used. A small amount of sample was placed between two glass 
slides with minimal mineral oil added to hold the cover slides in place. The sample 
containing-slides were then mounted onto the microscope sample stage. The distribution of 
entrapped 4-TFMU in PLGA microspheres were observed using a Carl Zeiss LSM 510 
(Germany) microscope equipped with Argon photon laser (laser power, 10-75%) with 
excitation wavelength, λ = 488 nm. The pinhole size was varied from 169 to 1000 µm. Image 
viewing and processing were performed using LSM 510 software. 3 dimensional (3D) 
projection is generated using a series of 2 dimensional (2D) micrographs.  
 
 
4.6.4 Disc Making 
This experiment was conducted in order to assess microspheres swelling due to hydration 
using a hydraulic press (Specac Ltd., UK). Stainless steel evacuable pellet die was used to 
compact PLGA microspheres into a disc under a hydraulic pressure of 1-3 tonnes.  The 
resulting disc; 7 mm in diameter and approximately 3 mm in thickness was then treated in 
PBS and incubated in the condition described in Section 4.5.  
 
 
4.7 Characterisation of PLGA Hollow and Solid Fibres 
4.7.2 Scanning Electron Microscopy (SEM) 
The morphology of both hollow and solid fibres were observed using SEM. The specimen 
preparation and imaging conditions were similar those described in Section 4.6.2.  
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4.7.3 Gas Permeation Analysis 
Gas permeation analyses were conducted on hollow fibres in order to assess the permeability 
of the PLGA hollow fibres. The analysis generates information on mean pore size and 
effective surface porosity. The apparatus set up is illustrated in Figure 4.7A. A bubble metre 
was used to measure the volumetric flow rate of permeate gas through the fibre module.  
 
 
 
 
 
 
 
 
Figure 4.7: (A) The apparatus set up for gas permeation analysis on PLGA hollow fibres. The N2 is fed 
into the bottom of the hollow fibre (HF) module and the permeate gas is connected to a bubble meter. (B) 
Configuration of HF module. 
 
The module containing the hollow fibres was prepared by sealing one the end of the hollow 
fibre using Epoxy® resin while the other end remained open. The open end fibre was fixed to 
the top of the module, as illustrated in Figure 4.7B. This configuration allows the gas to 
permeate through the fibre wall into the lumen and the permeate gas from the lumen 
subsequently travels into a vertical bubble meter from its bottom.  
 
Measurements were carried out under operating pressure ranged from 1 to 2 M Pa. Time 
measurements were recorded for the bubbles created by the permeate gas to travel along a 
predetermined distance along the bubble meter. The time was then used to calculate the gas 
permeation flux. The gas permeation flux was calculated using the Equation 4.4 and plotted 
against mean pressure. The gradient and intercept from the plot equal to Po and Ko 
respectively in Equation 4.5. The mean pore diameter can thus be calculated. Equation 4.6 
was to calculate the effective surface porosity. 
Gas permeation flux, J = NA / Pin           (4.4) 
Mean pore diameter, 
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Where N is the molar flow rate of N2 (mol/s), A is the membrane surface area (m
2), Pin is the 
pressure inside hollow fibre (2.01 M Pa), Po is the gradient of plot (mol/s.Pa
2.m2), Ko is the 
intercept of plot (mol/s.Pa2.m2). R is the universal gas constant (8.31 kJ/k/mol.K), M is the 
molecular weight of N2 (2.7 x 10
-2 kg/mol), µN2 is the viscosity of N2 (1.78 x 10
-5 Pa.s), and T 
equals 298 K. 
 
 
4.8 Data Analysis 
For comparison between two means, independent t-test, two tailed with p < 0.05 was used to 
test the significant in the differences. Where more than two means were involved, analysis of 
variance (ANOVA-single factor, p < 0.05) was used instead. Single or non-linear 
regressions, and model fittings were done using software R and Solver from the Microsoft’s 
Excel with least squares method. Graph/plot representation shows the means from n = 3 or 5 
with standard deviations.   
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CHAPTER 5: THE  DEVELOPMENT  OF  PLGA  DEVICES  
 
This chapter reports the development of PLGA devices. The objectives were to establish the 
production conditions for producing PLGA microspheres and hollow/solid fibres. Section 5.1 
presents the results and findings for PLGA microspheres production. The investigation into 
the production of PLGA hollow and solid fibres is presented in Section 5.2. More details of 
each development work are described in each section.  
 
 
5.1 The Development and Production of PLGA Microspheres 
 
This section is divided into two subsections. Section 5.1.1 studies the effects of 
homogenisation conditions, PVA and PLGA concentrations on microsphere size based on the 
single emulsion-solvent evaporation method. Section 5.1.2 presents the work involving the 
double emulsion-solvent evaporation method. For ease, 50:50 PLGA microsphere will be 
abbreviated as 50:50MS henceforth, similarly for 65:35 and 75:25 PLGA microspheres.   
 
5.1.1 Single Emulsion Method - Effects of the Homogenisation Conditions, PVA and 
PLGA Concentrations on Microsphere Size 
 
For each experiment, 10 g of polymer solution was homogenised in 100 ml of PVA solution. 
After that, the nascent spheres were transferred to magnetic stirring. Lastly, the resultant 
spheres were filtered, washed and air-dried. Detailed procedure for single emulsion method 
is previously described in Section 4.1.3. Table 5.1 tabulates the experimental condition for 
each investigation. Different homogenisations time and speed, concentrations of PVA and 
50:50 PLGA were employed to produce 50:50MS. Five batches of microspheres for each 
experiment were produced and analysed for their sizes using laser diffraction method 
(Sections 4.6.1) and their morphologies using SEM imaging (Section 4.6.2). 
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Table 5.1: Experimental conditions employed in the studies of the effects of homogenisation conditions, 
PLGA and PVA concentrations on the size of 50:50 PLGA microspheres. 
50:50 PLGA 
(% w/w) 
PVA concentration  
(% w/w) 
Homogenisation Time 
(min) 
Homogenisation Speed 
(rpm) 
1 
3 
5 
15 
10 
15 6500 
5 
10 
15 
15 0.5 
20 
6500 
6500 
9500 15 0.5 15 
13500 
5 
8 
10 
15 
0.5 15 6500 
 
 
5.1.1.1 Results and Discussion 
The formation of PLGA microspheres is illustrated in Figure 5.1. During the single emulsion 
method, the PLGA containing-DCM solution was homogenised into a PVA containing-water 
phase. An emulsion is thus formed because of the semi-immiscibility of the organic solution. 
The aqueous phase now contains multiple oil droplets or nascent microspheres. Possible 
coalescence between the droplets of emulsion is prevented by the presence of an emulsifier 
such as PVA. As the solvent diffuses out from these droplets, these nascent spheres solidify 
to form solid spheres. The latter process is described as solidification due to solvent 
diffusion. The dissolved solvent eventually evaporates at the air-liquid interface.  
 
 
 
 
 
 
 
Figure 5.1: The mechanism of sphere formation from an oil-droplet to nascent sphere to polymeric sphere. 
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aqueous phase. 
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Classically, emulsifiers are amphiphilic compounds that have a hydrophilic (i.e. head group) 
and a lipophilic end (i.e. tail) and Figure 5.2 illustrates the functioning of an emulsifier. The 
emulsifier molecules organised themselves such that their tails adjoin in the organic droplet 
and their head in the opposite direction. Thus, a stabilised emulsion is formed and the 
coalescences between droplets are prevented. In this case, the PVA molecules are thought to 
absorb onto the surfaces of the oil/polymer droplets, and serving the same purpose as an 
emulsifier. Increase in emulsifier concentration will increase the stability of the emulsion 
(Cui et al., 2005). In the single emulsion method, a higher emulsifier concentration will 
result in a larger excess of emulsifier that adsorbs on the surface of the organic droplets. The 
end result is a decrease in the microsphere sizes (Sansdrap and Moës, 1993 and Boisdron-
Celle et al., 1995).   
 
 
 
 
 
 
 
 
 
Figure 5.3: 50:50MS produced using (A) 1; (B) 3; (C) 5 and (D) 10 % (w/w) PVA. 
 
Figure 5.3 shows the 50:50MS produced using different PVA concentrations. By visual 
comparison, 50:50MS produced using 10 % (w/w) PVA is probably the smallest amongst the 
others whereas 1 % (w/w) PVA produced the largest 50:50MS. The size distributions tend to 
be smaller for 50:50MS produced using 5 and 10 % (w/w) PVA. While SEM images show 
the surface morphology the microspheres, laser diffraction technique (Section 4.6.1) was 
used to estimate the particle size distribution. With particle size analysis, three diameter 
percentiles or percentage (%) undersize were produced for each sample. They are referred as 
the majority fraction (90%), minority fraction (10%) and, the 50% fraction which is also the 
median of the particle size. It is commonly referred to as the 50th percentile, D50 or D[v, 
0.5]. The “v” denotes a volume distribution. The three percentiles or undersizes will be 
described as the D[v, 0.9], median size and the D[v, 0.1] henceforth. 
A 1 % (w/w) PVA               B 3 % (w/w) PVA    C 5 % (w/w) PVA               D 10 % (w/w)  PVA 
100 µm              100 µm             100 µm       10 µm 
Figure 5.2: 
The figure shows the functioning of an emulsifier 
stabilising an oil droplet in an aqueous phase.  
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Figure 5.4: Results showing the effect of PVA concentration on the size distribution of 50:50MS. 
 
Figure 5.4 shows the effect of PVA concentration on the size distribution of 50:50MS. D[v, 
0.9] size of the 50:50MS produced using 1 % (w/w) PVA was ≤69.89 µm. The median size 
was ≤32.05 µm and the D[v, 0.1] size was ≤4.01 µm. As previously concluded by Freiberg 
and Zhu (2004), the amount of emulsifier is a primary factor to control sphere size. From 
Figure 5.4, the smallest diameter percentile of the four 50:50MS produced using four 
different PVA concentrations were statistically similar (t-test, p<0.05). These sizes ranged 
from 4.01 to 4.53 µm. The D[v, 0.9] sizes of the four 50:50MS demonstrated a decreasing 
trend with increasing PVA concentration. The same can be observed on their median sizes. 
The lower PVA concentration was found to produce larger particle sizes and distribution. 
Table 5.2 shows the variations in each data set. The decrement in the D[v, 0.9] size was the 
most pronounced between 50:50MS produced using 1 % (w/w) and 3 % (w/w) PVA. 
 
Table 5.2: The size distribution of 50:50MS produced using PVA concentrations of 1, 3, 5 and 10 % (w/w).  
Diameter Percentile PVA concentration 
(% w/w) D [v, 0.9] D [v, 0.5] D [v, 0.1] 
1 69.89 ± 19.53 µm 32.05 ± 13.38 µm 4.01 ± 2.57 µm 
3 54.84 ± 18.51 µm 21.95 ± 11.89 µm 4.42 ± 2.87 µm 
5 38.25 ± 12.74 µm 16.31 ± 7.49 µm 4.30 ± 1.86 µm 
10 30.92 ± 8.95 µm 15.47 ± 7.92 µm 4.53 ± 1.26 µm 
 
Similar trend was observed in a work by Jalil and Nixon (1990) where there was a sharp drop 
in diameter when the emulsifier was increased from 1 to 2 %. Beyond this concentration 
there was little change in sphere size due to no emulsifier could be adsorbed at the sphere 
surface. Scholes et al. (1993) found that a PVA concentration of above 10 % had no effect on 
sphere sizes. Görner et al. (1999) also reached to the same conclusion and they also found 
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that polymer concentration (at constant surfactant concentration) is more dominant in 
governing the microsphere sizes. Through the understanding of the principle of an emulsifier, 
there exists an optimum concentration where above this point no more emulsifier could be 
adsorbed at the sphere surface. Further increase in the emulsifier concentration will not affect 
the sphere sizes. This could help to explain the decreasing size distribution with the increased 
PVA concentration as seen on Figure 5.4 and Table 5.2. In contrast, a lower PVA 
concentration probably led to insufficient surface adsorbing emulsifier and allowed a higher 
degree of coalesces between oil droplets. As a result, these nascent droplets/spheres 
solidified to yield larger spheres. 
 
Regarding the residual PVA in the final product, a work conducted by Zambaux et al. (1998) 
showed that by using a 5 % (w/v) PVA solution, a single washing procedure led to particles 
containing ~20 % (w/w) PVA whereas three washing decreased the PVA content to ~10 % 
(w/w). Although increasing washing repetition could improve the situation but when drug 
encapsulation is involved, it could lead to higher tendency of drug loss. Furthermore, when ≥ 
5 % (w/w) PVA was used, much smaller spheres were produced (Table 5.2) and caused 
problems during filtration in the microsphere harvesting stage. The filter membrane was 
sometimes damaged, causing fibres to remain within the final product. 
 
 
Figure 5.5: 50:50MS produced with homogenisation time of (A) 5, (B) 10, (C) 15, and (D) 20 minutes. 
 
Figure 5.5 shows the 50:50MS produced with different homogenisation times. The 50:50MS 
produced with homogenisation times of 5 and 10 minutes resulted in none uniform spheres. 
Polymeric aggregates and strands are also present in the final products (Figures 5.5A and B). 
Increasing the homogenisation time to 15 minutes improved the sphericity of the resultant 
spheres, as shown in Figure 5.5C. Figure 5.5D shows that 20 minutes of homogenisation 
time produces much smaller 50:50MS. Based on the SEM images, it can be deduced that 
there exists a minimum time required to thoroughly homogenise the organic volume in the 
aqueous phase. It is often been predicted that increasing the time of homogenisation helps to 
produce a more stable microsphere system. This is because the more thorough shear force 
A 5 min                B 10 min`  C 15 min  D 20 min  
100 µm                   100 µm    100 µm         10 µm 
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created by the homogenisation to form the emulsion. This subsequently leads to an improved 
spheres uniformity and symmetry from the stabilised emulsion.  
 
           
Figure 5.6: 50:50MS produced with homogenisation speed of (A) 6500; (B) 9500 and (C) 13500 rpm’s. 
 
Figure 5.6 shows the SEM images of 50:50MS produced using different homogenisation 
speeds. Figure 5.6A shows that a 6500 rpm homogenisation speed produced large 50:50MS 
with a wide size distribution. Further increase in homogenisation speed to 13500 rpm 
produced 50:50MS of approximately 20 µm in diameter (Figure 5.6C). Studies have shown 
that microsphere size decrease with increasing stirring rate since increase in stirring rate 
produces finer emulsions through stronger shear forces and increased turbulence (Jalil and 
Nixon, 1990). Ruan et al. (2002) also demonstrated that stronger emulsification strength 
resulted in smaller particles.  
 
           
Figure 5.7: The resultant 15 % (w/w) of (A) 50:50MS; (B) 65:35MS and (C) 75:25MS. 
 
In addition to the 50:50MS produced using different polymer concentrations, 65:35 and 
75:25 PLGA were also used to repeat the experiment under the same condition. Examples of 
15 % (w/w) of 50:50MS, 65:35MS and 75:25MS are shown in Figure 5.7. 75:25MS tend to 
have the largest spheres, followed by 65:35MS and 50:50MS, probably due to the higher 
inherent viscosities of 75:25 and 65:35 PLGA (Table 4.1). This suggests that the higher 
lactide acid ratio is, the larger spheres could be produced (Yan et al., 1994). Figure 5.8 
further compares the size distributions of 15 % (w/w) 50:50MS, 65:35MS and 75:25MS.  
 
 
 
A – 6500 rpm              B – 9500 rpm              C – 13500 rpm 
 
 
 
 
     
  
      100µm       20µm                    20µm 
 
A – 50:50MS               B – 65:35MS            C – 75:25MS 
 
 
 
 
          
 
            100 µm               100 µm               100 µm 
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Figure 5.8: The size distributions of (A) 50:50MS, (B) 65:35MS and (C) 75:25MS produced using 5, 8, 10 
and 15 % (w/w) polymer concentrations. 
 
As seen in Figure 5.8A, 50:50MS of lowest polymer concentration (5 % w/w) yields the 
smallest spheres; with D[v, 0.9] being ≤30.78 µm, median size being ≤10.60 µm and D[v, 
0.1] size being ≤1.06 µm. There is an increasing trend in D [v, 0.9] size of 50:50MS when 
the polymer concentration was increased from 5 to 15 % (w/w). Only the median sizes of 8 
% (w/w) and 5 % (w/w) 50:50MS were found statistically different (t-test, p < 0.05). 
(A) 50:50MS 
(B) 65:35MS 
(C) 75:25MS 
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From Figure 5.8B, by comparing the D[v, 0.9] size, 5 % (w/w) 65:35MS has the smallest size 
of ≤ 54.02 while 15 % (w/w) 65:35MS has the largest spheres of ≤ 90.43 µm. Similar to 
50:50MS, the D[v, 0.1] of 65:35MS did not show any relationships to its polymer 
concentration. Both the D[v, 0.9] and median sizes of 65:35MS demonstrated an increasing 
trend with increased in polymer concentration.  
 
Figure 5.8C shows the 75:25MS size distribution with different polymer concentrations. As 
expected, the lowest polymer concentration generally produced the smallest spheres while 
the opposite was observed for higher polymer concentration. 15 % (w/w) 75:25MS has the 
largest spheres compared to 65:35MS and 50:50MS. This may be attributed to the higher 
lactic acid ratio in the PLGA which has a higher as-reported inherent viscosity in Table 4.1 
(Section 4.1). This condition produces a system with higher viscosity while at constant 
homogenisation effect, the shear force generated by the homogenisation is not sufficient to 
break the more viscous phase into smaller droplets. Therefore, they remained in larger sizes, 
forming larger nascent spheres and finally larger solid spheres. However, there seemed to be 
no clear trend for the D[v, 0.1] fraction in any case. Further comparisons on the sizes of 
PLGA microspheres are studied and results are tabulated in Tables 5.3 to 5.5.  
 
Table 5.3 compares the sizes for the D[v, 0.1] sizes of the three PLGA microspheres. 
There is lack of a clear trend across different PLGA and polymer concentration. In some 
cases, the size distributions are similar. These size ranges are not within the targeted range 
therefore will not be further discussed. The very large variation in sizes may have caused by 
the imperfection in homogenisation effect. During the production process, different regions 
of the vessel may have varied mixing dynamics and affected the movement of the droplets. 
Stagnant region would promote the coalescence of the droplets. It was also found that the 
products occasionally attached to the vessel walls. Attempts to recover these microspheres 
for analysis may have contributed to the problem.  
 
Table 5.3: The sizes of the D[v, 0.1] fraction of 50:50MS, 65:35MS and 75:25MS. 
D [v, 0.1] Concentration 
(% w/w) 50:50 PLGA 65:35 PLGA 75:25 PLGA 
5 1.06 ± 0.83 µm 6.15 ± 1.10 µm 5.55 ± 2.43 µm 
8 4.31 ± 1.14 µm 4.94 ± 1.81 µm 6.67 ± 1.70 µm 
10 5.02 ± 1.85 µm 4.66 ± 2.26 µm 9.28 ± 3.58 µm 
15 5.95 ± 1.92 µm 8.00 ± 3.69 µm 4.59 ± 1.34 µm 
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Table 5.4: The median sizes of 50:50MS, 65:35MS and 75:25MS. 
D [v, 0.5] Concentration 
(% w/w) 50:50 PLGA 65:35 PLGA 75:25 PLGA 
5 10.60 ± 3.92 µm 21.55 ± 5.88 µm 20.30 ± 9.11 µm 
8 19.41 ± 4.63 µm 24.83 ± 6.68 µm 34.26 ± 6.91 µm 
10 22.53 ± 3.99 µm 34.14 ± 9.35 µm 42.40 ± 12.06 µm 
15 26.01 ± 3.74 µm 44.98 ± 10.98 µm 53.51 ± 11.54 µm 
  
Table 5.5: The sizes of the D[v, 0.9] fraction of 50:50MS, 65:35MS and 75:25MS. 
D [v, 0.9] Concentration 
(% w/w) 50:50 PLGA 65:35 PLGA 75:25 PLGA 
5 30.78 ± 9.01 54.02 ± 10.89 67.33 ± 25.67 
8 53.73 ± 16.29 74.57 ± 18.28 78.34 ± 15.62 
10 58.07 ± 14.19 86.43 ± 26.57 95.99 ± 12.63 
15 84.21 ± 28.16 90.43 ± 12.68 107.13 ± 29.83 
  
Table 5.4 shows the median sizes 50:50MS, 65:35MS and 75:25MS. In some cases, 
overlapping deviations of samples indicate the insignificant differences in the size. Table 5.5 
shows that there are increasing trends across the PLGA in the D[v, 0.9] sizes. At a same 
concentration, 50:50 PLGA has the lowest viscosity as apposed to 65:35 and 75:25 PLGA 
which offers lower resistance for homogenisation. Hence, finer droplets was formed and 
yielded smaller spheres. This trend is common in the literatures (Yan et al., 1994 and 
Ghaderi et al., 1996).  
 
The same could be used to explain when the polymer concentration is increased. The higher 
polymer concentration forms more volumes of “droplets” and this higher volume increases 
the frequency of collisions between these droplets. Thus, a higher concentration results in 
more fusions of these semi-formed particles and produces larger particles. Also, higher 
polymer concentration will yield higher viscosity and it requires a higher shear force to 
“break” these viscous droplets. Boisdron-Celle et al. (1995) obtained an almost linear trend 
between sphere size with 50:50 PLGA concentrations while keeping other parameters 
constant. In their studies, 13.5% (w/v) polymer yielded spheres of ~90 µm and 5.5% (w/v) 
yielded spheres of ~20 µm. In general, Figure 5.8 concurred with these authors where 
spheres sizes tended to increase with polymer concentration. 
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5.1.2 Investigation of Double-Emulsion Solvent Evaporation  
The objective of this section was to establish a double-emulsion method to produce drug-
loaded PLGA microspheres. Extensive efforts have been shown by numerous authors to 
improve the microsphere delivery system for both lipophilic and hydrophilic drugs and these 
works served as a foundation for the development work herein. The selection criteria 
comprised:  
i. The similarity in materials (e.g. drugs and polymer) – this similarity provides 
guidance in developing a method to encapsulate hydrophilic drugs in PLGA 
microspheres. In retrospect, insights into alternative production recipes such as 
different emulsifiers or solvents could be gained.  
ii. The different procedures – numerous authors have formulated production procedures 
in order to accomplish their objectives and each was proclaimed advantageous. With 
a collection of procedures, their feasibilities are studied and developed to an optimum 
method. 
iii. The selected works were collected over in the past twenty years. This indicates how 
the technique has evolved throughout the years including newly developed 
techniques used to characterise the microspheres. 
 
The various adapted methods are detailed in Table 5.6. Modifications were made accordingly 
in order to suit the production process. After preliminary trials, each experiment was repeated 
twice and drug loading were determined using the method described in Section 4.4. The 
concentration of fluorouracil was determined using uv-spectrophotometer (λ = 262 nm). 
Each method was compared on the basic of drug loading, quality of resultant spheres and the 
feasibility to perform the procedures. The structure of the following Result and Discussion 
section is organised such that a text of discussion is presented prior to SEM results. A 
summary of major studies findings are presented in Table 5.7. 
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Final Stage 
Mixture transferred for  
MG-S at 500 rpm, 2h, 30
o
C 
Mixture transferred for  
MG-S at 800 rpm, 4h 
Second emulsion mixed into [100 ml 
4% PVA + 0.9% NaCl] by MG-S at 
500 rpm, 3h 
Mixture mixed into [150 ml 0.1% 
PVA] by MG-S at 500 rpm, 2h 
Second Emulsion 
First emulsion HG into [400 ml 0.5% PVA]  
at 6500 rpm, 15 min 
First emulsion mixed into[50 ml mineral oil with 8% 
SPAN 80] by MG-S at 1500 rpm, 15min 
First emulsion mixed into [250 ml 0.25% PVA]  
by MG-S at 500 rpm, 3h 
First emulsion mixed into [250 ml 0.25% PVA]  
by MG-S at  1200 rpm, 5 min 
First emulsion mixed into [100 ml 4% PVA]  
by MG-S at 500 rpm, 3.5h 
First emulsion HG into [0.5 g 75:25 PLGA in 5 ml DCM] at 13500 rpm, 5 min  
MG-S [160 ml 4% PVA + 0.9% NaCl] at 1000 rpm, 3h 
First emulsion HG into [2 ml 5Fu & PVA + 3 ml 8% 
75:25 PLGA] at 13500 rpm, 15 min. 
First emulsion HG into [8 ml 4% PVA] at 13500 
rpm, 5 min 
First emulsion HG into [1g 75:25 PLGA] at 6500 rpm, 10 min  
Transferred to [250 ml 4% PVA + 0.9% NaCl] MG-S at 250 rpm, 4h 
First emulsion mixed into [100 ml 5% isopropanol in 20 ml 1% PVA]  
by MG-S at 500 rpm, 30 min 
Experimental Condition 
First Emulsion 
[1g 5-FU in 10% (w/v) gelatin] homogenised in 
[4 g 75:25 PLGA in 7.5 ml DCM] at 6500 rpm, 5 min 
[1 g 5Fu] homogenised in 
[0.5 g 50:50 PLGA in 6.5 ml acetone] at 13500 rpm, 5 min 
o/w method: 
[1 g 5Fu and 0.8 g 75:25 PLGA] in [10 ml DCM] 
mixed with magnetic stirring at1500 rpm, 10 min 
w/o/w method: 
[1 ml 0.05 mg/ml 5Fu and 0.8 g 75:25 PLGA] 
sonicated in [10 ml DCM] mixed for 30 sec 
[0.2 g 50:50 PLGA and 0.1 g 5Fu] homogenised in 
[0.5 ml DCM + 25 ml acetone + 5 ml methanol] 
at 13500 rpm, 10 min 
[0.5 ml 0.05 g/ml 5Fu] sonicated in 
[0.05 ml 4% PVA] for 10 min 
[0.01 g PVA] homogenised in [2 ml 5Fu (0.05g/ml)] 
at 13500 rpm, 1 min 
[1 ml 0.05 g/ml 5Fu] homogenised in 
[4 ml 8% 75:25 PLGA] at 13500 rpm, 10 min 
[0.5 g 5Fu] sonicated in [8.4 ml DCM] for 10 min 
[1 ml 0.05 mg/ml 5Fu] mixed into [0.2 g 75:25 PLGA in 10ml 
DCM] using homogenisation (13500 rpm, 2 min), 
or vortexing (5 min), or sonication (5 min) 
Table 5.6: Experimental double-emulsion methods adapted from the literatures. HG = Homogenised; MG-S = Magnetic stirring 
Authors 
Ogawa et al. 
(1988) 
Chen and Lu 
(1999) 
Perez et al. 
(2000) 
Niwa et al. 
(1993) 
Hussain et al. 
(2002) 
Messaritaki et 
al. (2005) 
Zambaux et 
al. (1998) 
Spenlehauer 
et al. (1989) 
Yan et al. 
(1994) 
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5.1.2.1 Results and Discussion 
Ogawa et al. (1988) devised a method to encapsulate hydrophilic drug in PLA or PLGA 
microspheres using gelatin as the emulsifier in the inner water phase based on a water-in-oil-
in-water (w/o/w) emulsion method. 10% (w/v) of gelatine, as opposed to 20% (w/v) quoted 
in the literature was used herein because it was found very problematic to dissolve the high 
concentration gelatine. Ogawa et al. (1988) also cooled the working solution to 15oC during 
the production process but this was found to cause instant gelling. For this reason, gelatin 
partially retained its “gel” form and is visible in the final product (Figure 5.9). This 
procedure was found to be problematic especially during the product recovery. Figure 5.9 
shows that the sizes of the resultant microspheres ranged between 1 to 10 µm. This small size 
is thought to cause by the concentrated gelatine. Residual gelatine also formed “linkages” 
between microspheres as can be seen in Figure 5.9.  
 
Chen and Lu (1999) optimised an o/w method to encapsulate carboplatin in 50:50 PLGA 
microsphere. The mineral oil used in this experiment was found troublesome (e.g. highly 
viscous) for processing from preparation to cleaning. During the production process, the 
nascent spheres constantly attached to the vessel wall which caused problems to product 
recovery. The harvesting procedures involved triplicate washing with heptane and a further 
stirring in cold heptane before they were collected. The product recovery from this procedure 
was low and aggregates of polymer are present in the final product (Figure 5.10). This 
procedure was found not to be robust and drug loading determination was problematic due to 
the interference by undesirable residual materials. 
 
Perez et al. (2000) produced poly-ε-caprolactone microspheres containing both lipophilic and 
lydrophilic. This single emulsion (o/w) procedure produced microspheres with varied degree 
of sphericity and a small amount of larger particles (Figure 5.11A). Polymeric aggregates 
were observed to be present in the final product produced using the w/o/w method (Figure 
5.11B). In comparison, the o/w method produced microspheres with better morphology and 
results show no significant difference in drug loading (t-test, p < 0.05). 
 
According to Niwa et al. (1993), methanol is admixed to the organic phase to dissolve 5Fu 
and the addition of acetone would lead to drastic decrease in sphere size. The higher the 
acetone to DCM ratio, the more rapidly acetone diffuses into the aqueous phase, causing 
rapid polymer deposition on the outer surface of droplets. Preliminary trials showed low 
productivity. Modifications were made such that sequential addition of solvent to the 
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polymer and drug solutions was incorporated into the procedure. The final procedure yielded 
large amount of polymer remnants (Figure 5.12).  
 
Hussain et al. (2002) intended to formulate a co-delivery of antisense oligonucleotide and 
fluorouracil (5Fu) using PLGA microspheres. Useful remarks from this literature are such 
that the morphology of microspheres was not affected by either separate or simultaneous 
encapsulation of two drugs. This was also the case for encapsulation efficiencies. From 
Figure 5.13, the microspheres produced have smooth surface and good sphericity but are 
highly porous. The low PLGA concentration may have contributed to the formation of small 
particles. The high speed magnetic stirring (1000 rpm) may have promoted increased rate of 
solvent removal thereby yielding these porous spheres. 
 
A work by Messaritaki et al. (2005) was intended for NMR and confocal microscopy studies 
of the burst release mechanism from PLGA microspheres loaded with 5Fu. This w/o/w 
procedure roduced highly porous spheres and with varied degree of sphericity while polymer 
aggregates are also present in the final product. Figure 5.14 shows that the surface pores are 
clearly visible on the sphere and are as large as 1 µm. The resultant microspheres produced 
using the method adapted from Zambaux et al. (1998) have similar characteristics to the 
microspheres shown in Figure 5.14. This similarity indicates that a w/o/w method will 
produce porous microspheres.  
  
Spenlehauer et al. (1989) achieved the w/o emulsion by continuously stirring the suspension 
at 250 rpm for 4 h before harvesting the product. This was unusual compared to other work. 
Normally, an emulsion is first formed, then the nascent microspheres are transferred to 
magnetic stirring for a much longer period. Figure 5.16 shows that this procedure produced 
microspheres with a large size distribution and partially deformed spheres/capsules. The 
large size distribution was expected because of the low speed of stirring (i.e. 250 rpm). The 
formation of very small spheres may due to the high PVA concentration (i.e. 4%).  
 
Yan et al. (1994) conducted studies to study the effects of different mixing methods on the 
morphology of protein-loaded PLGA microspheres using by w/o/w emulsions. Their work 
showed that different mixing techniques (e.g. sonication, homogenisation, vortex mixing) 
produced microspheres with different structures. In this experiment, it was found that the 
vortex mixer was not efficient to form a stable emulsion. Figure 5.17 shows the highly 
A 
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porous microspheres produced from this procedure. It is attributed that the high porosity was 
a result of addition of isopropanol which increased the rate solvent removal.  
 
     
     
    
    
    
    
      
Figure 5.9: Resulting microspheres 
produced using method adapted from 
Ogawa et al. (1988). 
 
Figure 5.13: Resultant microspheres 
produced using method adapted from 
Hussain et al. (2002). 
 
Figure 5.10: Resulting microspheres 
produced using method adapted from 
Chen and Lu (1999). 
Figure 5.11: Resulting microspheres 
produced using (A) o/w emulsion 
and (B) w/o/w methods adapted from 
Perez et al. (2000). 
Figure 5.12: Resultant microspheres 
produced using w/o/w emulsion 
method adapted from Niwa et al. 
(1993). 
Figure 5.14: Resultant microspheres 
produced using method adapted from 
Messaritaki et al. (2005). 
 
Figure 5.15: Resultant microspheres 
produced using method adapted from 
Zambaux et al. (1998). 
 
(A) o/w method        (B) w/o/w method 
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Figure 5.17: Resultant micro spheres produced based on procedures adapted from Yan et al. (1994). 
 
The above findings demonstrated the advantages and disadvantages of each adapted 
procedure. For this work, it was observed that a single emulsion method tended to produce 
PLGA microspheres with a smooth surface, whereas a double emulsion method tended to 
produce PLGA microspheres with a porous surface. The latter was especially true when 
additional solvent was added to the system to promote faster solvent removal. The robustness 
of these procedures were assessed and it was found that a double emulsion method of this 
sort required detailed consideration to ensure good productivity.  
 
In general, it was found much easier to carry out the procedures for single emulsion and the 
whole production period was also shorter. Most of the works adapted from the literature they 
were conducted on small scales. In this regard, most of the experiments reported herein were 
scaled up with a factor of five or ten. This has in turn altered the fluid dynamic of the system. 
Therefore result deviations from the adapted literature were anticipated. In vitro drug releases 
from these microspheres were measured and results are shown in Appendix III. Findings 
show that these drug releases were rapid, probably due to their low drug loading or high 
surface porosity. Table 5.7 summarises the concluding remarks for experiments in this 
section.  
 
The major advantage offered by the model drugs used in this thesis is their dried-powder 
form. This enables a larger amount of working concentration in comparison to drug solution. 
Preliminary experiments with a single emulsion method using cisplatin and lidocaine 
demonstrated good reproducibility. Since the starting drug concentration can be processed in 
grams, as apposed to milli-grams in commercially available drug solution, a better drug 
Figure 5.16: Resulting microspheres 
produced using method adapted from 
Spenlehauer et al. (1989). 
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loading can be achieved compared to those reported in Table 5.7. For these reasons, the 
double emulsion method will not be employed for further development work.   
 
Table 5.7: A summary of the findings from Section 5.1.2 and concluding remarks. The figures in bracket 
are calculated drug loading from the final product. Data represent mean ± standard deviation, n = 3. 
 
Method by 
Author 
Size range & 
Consistency 
Morphology of 
Product 
Remarks 
Drug 
Loading 
Ogawa et al. 
(1998) 
1-10 µm 
Consistent 
 Spherical 
 Reasonably 
uniform 
 
 Gelatin is problematic for 
processing and, 
 Difficult to be removed, 
remained in samples forming 
linkages. 
 
4.33 ±  
2.31 % 
 
Chen and Lu  
(1999) 
50-300 µm 
Poor 
 Spherical but 
hardly uniform 
 Presence of 
large amount of 
polymer 
remnants 
 
 Mineral oil and Span 80 are 
problematic; forming viscous 
solution and difficult for 
processing and cleaning.  
 Viscous solution hinders 
effective homogenisation.  
 
6.21 ± 
3.56 % 
Perez et al. 
(2000) 
10-200 µm 
Moderate 
 Capsules & 
spherical 
 Reasonably 
uniform 
 
 Reasonable good microspheres 
& microcapsules produced. 
 w/o/w method produced 
spheres with a small number of 
visible but small and pores. 
 
5.02 ± 
3.51 % 
Niwa et al. 
(1993) 
10-20 µm 
Moderate 
 
 
 Microcapsules & 
spherical 
 Moderate 
uniformity 
 
 
 Microspheres and irregular 
particles produced. 
 Polymer aggregates largely 
present in final product. 
 
3.44 ± 
2.01 % 
Hussain et al. 
(2002) 
50-200 µm 
Low 
consistency 
 Microcapsules & 
spherical 
 Moderate 
uniformity 
 
 Low uniformity microspheres & 
microcapsules produced. 
 Very visible porous surface, 
pores bigger than 2 µm. 
 
5.18 ± 
2.44 % 
 
Messaritake 
et al. (2005) 
10-50 µm 
Moderate 
 Mostly 
microcapsules 
 Not uniform 
 
 Reasonable good 
microcapsules produced. 
 Very visible porous surface. 
 
4.37 ± 
2.14 % 
Zambaux et 
al. (1998) 
10-50 µm 
Poor 
 
 Microcapsules & 
spherical 
 Low uniformity 
 
 
 Microcapsules produced. 
 Very visible porous surface. 
 
2.21 ± 
1.03 % 
Spenlehauer 
et al. (1989) 
10-150 µm 
Moderate 
 
 Spherical and 
smooth 
 Uniform 
 
 Reasonably good microspheres 
produced. 
 Smooth surface 
 
7.02 ± 
4.20 % 
 
Yan et al. 
(1994) 
50-100 µm 
Poor 
 Microcapsules 
 Not uniform 
 
 Very large particle with highest 
visible porous structure. 
 Presence of polymer 
aggregates. 
 
7.25 ± 
 2.55 % 
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5.2 The Development and Production of PLGA Hollow and Solid Fibres 
 
This section presents the production of PLGA hollow and solid fibres using a wet spinning 
method based on the phase inversion technique. The large amount of PLGA required to spin 
each batch of hollow fibre is a concern to cost of production. Therefore, the investigation 
work was carefully devised based on the works by previous researchers in the Department, 
namely; Ellis, (2005), Tai (2007) and Shearer (2008). The spinning work and apparatus were 
fundamentally similar to the previous system. However, the spinning conditions were tested 
accordingly to accomplish the aim of this thesis. See Table 5.8 for details. Since the viscosity 
and polymer concentration of the PLGA dope used in this work were in general, lower than 
those to make commercial membrane, a syringe pump was used to deliver the polymer dope. 
This extrusion method provides better control of the flowrate of the dope. Meanwhile, in 
order to aid the solvent diffusion process and decrease the immersion time, the desired 
fractions of nascent fibres were cut into 20 cm in length during the immersion stage. 
Decreasing the aqueous immersion period would help to reduce drug leakage and loss. For 
ease, 50:50 PLGA hollow fibre will be abbreviated as 50:50HF, and 50:50 PLGA solid fibre 
as 50:50SF. Similar abbreviation will also be used for fibres made of 65:35 and 75:25 PLGA.  
 
 
5.2.1 Method 
50:50, 65:35 and 75:25 PLGA were used to spin both hollow and solid fibres according to 
the method and conditions described in Section 4.2. The spinning apparatus is shown 
previously in Figures 4.3 and 4.4 respectively. Prior to spinning, the polymer dope was 
degassed for 1-2 h. Table 5.8 describes the spinning conditions for hollow and solid fibres. 
Occasionally, the flowrates of both the bore liquid and polymer dope required slight 
adjustments in the beginning of the process when the system was approaching equilibrium.  
 
Table 5.8: The spinning conditions for 50:50, 65:35 and 75:25 PLGA hollow and solid fibres. 
Spinning Condition Hollow Fibre Solid Fibre 
Polymer used 20 % (w/w) 50:50, 65:35 and 75:25 PLGA 
Solvent used 1-methyl-N-pyrrolidone (NMP) 
Polymer extrusion rate (ml/min) 2.5 ± 0.5 4.0 ± 1.0 
Spinneret  Yes No 
Bore liquid flow rate (ml/min) 2.0 ± 0.5 No bore liquid used 
Air gap (cm) 10.0 ± 0.5 No air gap 
Speed of collection motor (rpm) 7 ± 2  10 ± 2  
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The PLGA hollow fibre ‘membrane’ developed in this work were characterised using gas 
permeation (Section 4.7.3) to obtain mean pore size and effective surface porosity, as well as 
by SEM imaging for morphology. Because these membranes were intended to be 
encapsulating drugs or loaded with drug solution for the purpose of drug delivery, as opposed 
to a traditional separation application, further membrane characterisation, i.e. flux or 
rejection analysis, were not applicable and therefore not carried out. These analyses will not 
realistically characterise the transport and spaces occupied by the entrapped drug.  
 
 
5.2.2 Results and Discussion 
The shape of the hollow fibre is determined by pushing the polymer dope under pressure 
through a spinneret. A spinneret is a device which two or more fluids can be fed with one 
central flowing fluid and the other flowing concentrically around the central flow. In this 
work, a tube shaped stream of viscous polymer solution flows from the nozzle of the 
spinneret, and within this stream the bore liquid flows. Figure 5.18 is the cross sectional view 
of the tube-in-orifice used in this work. The bore liquid, also termed as the internal coagulant 
facilitates the phase inversion process at the lumen of the hollow fibre. The external 
coagulation bath facilitates phase inversion of the outer surface of the fibre.  
 
 
 
 
Figure 5.18: Cross sectional view of the spinneret with a tube-in-orifice used in this work. 
 
Prior to the spinning of hollow fibres using PLGA, practice runs were carried out using 
polysulfone and a set of spinning condition was devised for preliminary PLGA experiments. 
A number of process variables of the spinning condition were tested, such as the air gap, 
polymer concentration, polymer solution and bore liquid flowrates were varied and examples 
of results from these investigations are shown in Table 5.9. The conditions used to spin these 
PLGA hollow fibres are given in the table. Table 5.9 also summarises the defects observed 
on the relevant hollow fibres and their causes. The distinctive structures of the fibre wall 
produced by the different spinning conditions are clearly visible in the SEM images. These 
structural characteristics are closely associated to the physical property of hollow fibre 
membranes such as molecular weight cut off (MWCO) and porosity.  
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Cause of Defects: 
 High polymer 
concentration. 
 Small air gap.  
 Low bore liquid 
flowrate. 
 Large air gap. 
 High polymer 
concentration. 
 Inadequate bore liquid 
flowrate. 
 High polymer 
concentration. 
 Low bore liquid 
flowrate. 
Defects  on Hollow Fibres: 
 Irregular macrovoids.  
 Very dense structure. 
 Very dense inner skin 
layer. 
 Regular and consistent 
macrovoids.  
 Visible finger structures.  
 Rather thin fibre wall. 
 Very large macrovoids. 
 Dense structure. 
 Thick skin layer. 
 Dense structure. 
 Limited macrovoids. 
 Longer finger structure. 
Spinning condition 
 Air gap: 15 cm 
 Polymer solution flowrate: 5 ml /min 
 Bore liquid flow rate: 0.5 ml/min 
 Polymer concentration: 25 % (w/w) 
 Air gap: 15 cm 
 Polymer solution flowrate: 2 ml /min 
 Bore liquid flow rate: 2 ml/min 
 Polymer concentration: 20 % (w/w) 
 Air gap: 10 cm 
 Polymer solution flowrate: 3 ml /min 
 Bore liquid flow rate: 1 ml/min 
 Polymer concentration: 25 % (w/w) 
 Air gap: 10 cm 
 Polymer solution flowrate: 2 ml /min 
 Bore liquid flow rate: 5 ml/min 
 Polymer concentration: 30 % (w/w) 
Table 5.9: Results of hollow fibres spun using different spinning conditions. HFM = Hollow Fibre Membrane 
Cross Section SEM images of Hollow Fibre 
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Previously, a work by Wen and Tresco (2006) showed that a reduction in MWCO of the 
membrane was caused by an increase in the flowrates of polymer solution and bore liquid. 
This was attributed to increased shear stresses within the spinneret, and between the bore 
liquid and the fibre lumen. The increased stress aligns the polymer molecules which allows 
for tighter packing within the polymer molecules on the surface, and leads to formation of a 
dense skin layer (Chung and Hu, 1997). This effect is reflected in the SEM images of HFM1 
and HFM4 fibres presented in Table 5.9. 
 
The effect of increasing polymer concentration will decrease the MWCO of the membrane. 
This is due to an increased viscosity which leads to an increase in shear stress in the 
spinneret. The higher polymer concentration also means that more space will be taken up by 
the polymer in the fibre structure, and this leads to a formation of denser structure with 
reduced porosity (Wen and Tresco, 2006). This explains the dense structures of HFM1, 
HFM3 and HFM4 where 25 and 30 % (w/w) were used to produce these hollow fibres.  
 
Denser structure formed by higher polymer concentration also caused by a condition where 
the molecules are more tightly packed in the spinneret before the molecules can relax once 
they leave the spinneret (Qin et al., 2001). The higher air gap tended to reduce the wall 
thickness of the hollow fibre. This effect could be seen by comparing hollow fibres spun 
using 15 cm air gap (i.e. HFM1 and HFM2) and 10 cm air gap (i.e. HFM3 and HFM4). This 
is because the air gap increases longitudinal stress which acts to pull apart adjacent polymer 
chains (Chung and Hu, 1997).  
 
The findings and the spinning condition of HFM2 presented in Table 5.9 enabled a final 
spinning condition to be established and is tabulated in Table 5.8. Typically, a polymer and 
bore liquid flowrates of approximately 2 ml/min with an air gap of 10 cm were used to spin a 
20 % (w/w) PLGA hollow fibre. A “preset” stage was required to adjust both the flowrates of 
the bore liquid and polymer solution when the nascent hollow fibre was first emerging from 
the orifice of the spinneret. This stage usually takes 5-10 minutes before an equilibrium 
condition is reached and then the speed of the collection motor can be set. In all cases, only 
hollow fibre formed during the equilibrium stage was used for subsequent studies in order to 
obtain fibre of consistent quality.  
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Figure 5.19: (A) The morphology of the fibre wall of 20 % (w/w) 75:25 PLGA hollow fibre. (B) A cross 
section of the 20 % (w/w) 75:25HF. O = Fibre outer surface, L = Inner surface at the fibre lumen 
 
Figure 5.19 shows the morphology of the fibre wall of 75:25HF. There are two skin layers; 
one at the outer surface and another at the lumen of the hollow fibre (Figure 5.19A). These 
skin layers are the result of the instantaneous demixing during the phase inversion process. 
The skin layers surrounding the hollow fibre and its lumen are instantly formed at the 
solvent/nonsolvent interface due to a rapid solvent exchange. The skin layers enveloped a 
layer with finger-like structure and adjacent to this structure, large cavities or macrovoids 
forming a sublayer in the fibre core. The formations of these structures are discussed below. 
 
Two types of membranes structures are discussed by Drioli and Nakagaki (1986); namely, 
the “sponge-like” and the “finger-like” structures. They are formed during the rapid phase 
inversion in a coagulation bath and subsequent solidification form the membrane structure. 
During phase inversion, the mixed solution of rapidly changing composition forms the two 
separate phases. At a particular point (when its composition crosses into the miscibility gap), 
the solvent leaches out from the solution. A microporous structure within the polymer-rich 
phase is formed with the cavities formed by the influx of nonsolvent. The former phase 
eventually reverts to being entirely solid as the solvent migrates out.   
 
Bungay et al. (1986) suggested that a fast precipitation tends to give larger finger structures 
whilst slow precipitation will results in a more sponge like structure. The type of solvent can 
affect the rate of precipitation. A non-compatible solvent will take longer to exchange with 
nonsolvent and will thus spend more time within the structure. Hence, the finger structure 
will be fewer and smaller because precipitation is slower. A compatible solvent will 
exchange with nonsolvent more rapidly and finger-like structures will be numerous and large 
as precipitation is fast.  
 
Macrovoids 
Finger structure 
Skin 
layer 
Skin 
layer 
L O 
A Cross Section of 75:25HF 
Lumen 
B 
CHAPTER 5: THE DEVELOPMENT OF PLGA DEVICES 
THE DEVELOPMENT OF CONTROLLED-CHEMOTHERAPY DRUG DELIVERY SYSTEM                                                                                    65 
The finger structure propagates rapidly with a thin (skin) precipitated layer of polymer 
preventing direct contact with the nonsolvent. Increasing the initial polymer concentration 
will lead to a higher polymer concentration at the skin/polymer interface. This implies a 
higher volume fraction of polymer and consequently, a denser skin layer will be formed with 
a lower porosity. This is due to a lower solvent exchange flux.  
 
The macrovoid formation originates from the demixing effect. The formation of macrovoids 
takes place through two stages: (1) initiation, (2) propagation or growth. Most of the 
macrovoids start to develop just beneath the skin layer, initiated by some of the nuclei which 
are formed directly underneath this layer. Initially, the dispersed droplets formed between the 
polymer-rich phase and the interface of the solution/nonsolvent interface consist of a mixture 
of solvent and nonsolvent with very little polymer. These droplets then develop further until 
the surrounding continuous phase solidifies. Figure 5.20 illustrates the formation of 
macrovoids. 
 
 
 
 
 
 
 
 
Figure 5.20: Schematic representation of the growth of macrovoids during instantaneous demixing and as 
the solvent exchange proceeds.  
 
The diffusional flow of solvent from the surrounding polymer solution initiated the growth of 
the nuclei in the polymer-lean phase. The first droplet of the polymer-lean phase being 
formed at time; say t = 1, the polymer solution in front of the droplets is still homogenous 
and remains stable, i.e. no new nuclei is formed. At the same time, diffusion of solvent and 
nonsolvent occur into the first nuclei. In this way the growth of a macrovoid occurs and this 
growth continues until the polymer concentration in the macrovoid at the solution interface 
becomes so high that solidification occurs. The coalescence of the droplets before 
solidification is responsible for the formation of large cavities and porous structures. 
 
The porosity of the hollow fibre governs its permeability and for control drug release, the 
diffusion of medium across the fibre is important. Specifically, the permeability of a 
Macrovoid
Nuclei is formed after t = 1 and its growth 
leads to the formation of macrovoids.  
Solution/nonsolvent 
interface 
Solution/nuclei 
interface 
Nonsolvent Phase 
Solution (polymer) Phase 
Droplets 
Time, t =1 
Growth 
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membrane is determined by the morphology of the skin layer; including pore size, pore 
density and/or distribution, the thickness of the skin layers, and among others (Mulder, 
2000). For membrane application, pore size usually determines the selectivity (i.e. MWCO) 
and the pore density and thickness of skin layers determine the flux of mass transfer (Drioli 
and Nakagaki, 1986). 
 
In general, the influential factors in spinning condition discussed in Section 3.5.1 also apply 
as factors influencing the membrane permeability. For instance, a decrease in permeability 
can be caused by increases in polymer concentration and polymer solution flowrate. This is 
due to the increase of polymer volume fraction at the interface thereby creating a higher 
resistance for the solvent/nonsolvent exchange. This is similar to a delay in demixing 
resulting in a denser structure. Decrease in air gap also leads to decrease in permeability 
(Mulder, 2000). On the other hand, the increase in the flowrate of the bore liquid will 
increase the permeability of a membrane because of the enhanced solvent/nonsolvent 
exchange rate at the interface of between the lumen surface and the bore liquid. This parallels 
to the effect of rapid demixing forming a porous structure (Wen and Tresco, 2006).  
 
The results from gas permeability analysis (Section 4.7.3) conducted on 20 % (w/w) 
50:50HF, 65:35HF and 75:25HF are shown in Figure 5.21.  The plot indicates that the 
effective surface porosity tends to increase as the lactide acid in the PLGA increases. In term 
of mean pore diameter, 65:35HF tends to have the larger size. Statistic analysis (ANOVA, p 
< 0.05) suggests that there were no significant differences in both the mean pore diameter 
and effective surface porosity between 50:50HF, 65:35HF and 75:25HF. This is reflected on 
the overlapping deviations in each result.  
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Figure 5.21: Gas permeation analyses showing the mean pore diameter and effective surface porosity of 20 
% (w/w) 50:50HF, 65:35HF and 75:25HF.  
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The similarity in results observed in the plot is not unexpected because of the constant 
spinning conditions and the same polymer concentration used. It should not be mistaken that 
the effective surface porosity is a function of mean pore size. This is because the varied 
structure across the fibre wall and the core structure could be the dominant factor in 
governing the effective porosity instead of the overall mean pore size (Kong and Li, 2000 
and Tai, 2007). The overall structure across the fibre wall comprises the skin layers, 
macrovoids of various sizes, a sponge-like sublayer of various thicknesses and porosities, all 
can affect the effective porosity (Drioli and Nagakagi, 1986).  
 
Based on the optimum condition established for spinning hollow fibre, the final spinning 
condition of solid fibres was developed. In this case, there were less spinning parameters 
involved. Attempts to maintain a constant polymer concentration at 20 % (w/w) was 
plausible leaving only the flowrate of the polymer solution and the speed of the collection 
motor required adjustment accordingly. The successful PLGA solid fibre formed with 
structure of consistent quality is shown in Figure 5.22. The finger-like microcavities in the 
fibre wall are visible in Figure 5.22A. Figure 5.22B shows the skin layer and structure near 
the outer surface of the solid fibre. Since a spinneret was not used and with no bore liquid, 
the characteristic of hollowness is not seen in a solid fibre. The formations of the skin layer 
and finger structure from the phase inversion are similar to those in hollow fibre.  
 
     
Figure 5.22: SEM images of 20 % (w/w) 75:25 PLGA solid fibre. (A) Cross section showing the finger 
structure and (B) skin layer at the outer surface.     
 
More detailed morphological characterisation of PLGA hollow and solid fibres will be 
presented in Sections 6.3 and 6.5 respectively.  The estimated internal (ID) and outer (OD) 
diameters of 50:50HF, 65:35HF and 75:25HF are tabulated in Table 5.10. The OD of 
50:50SF, 65:35SF and 75:25SF were also measured. These results further suggest that under 
the same spinning condition, the physical property of the hollow fibres is very similar.  
 
 
A                         B 
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Table 5.10: The measured ID and OD of 50:50, 65:35, and 75:25 PLGA hollow and solid fibres. 
PLGA 
Hollow/Solid Fibre 
Outer Diameter  
(Average ± Standard Deviation) µm 
Internal Diameter 
(Average ± Standard Deviation) µm 
50:50HF 688 ± 83  477 ± 66 
65:35HF 751 ± 95  524 ± 75 
75:25HF 852 ± 84 630 ± 88 
50:50SF 676 ± 73 - 
65:35SF 715 ± 63 - 
75:25SF 764 ± 78 - 
 
 
5.3 Conclusion 
 
1. The objective in Section 5.1 was to establish a standard procedure to produce PLGA 
microspheres for this work. A typical requirement is to process a 10 g of polymer 
solution in 100 ml of PVA solution. Adequate residence time and speed during the 
homogenisation stage are required in order to thoroughly homogenise the total 
volume of organic phase and form a suitable size emulsion. The organic droplets-
emulsion solidifies to produce microsphere of desire sizes. The required PVA 
concentration is such as to produce a stable emulsion containing the nascent 
microsphere of desirable sizes and good sphericity upon solidification. 
 
2. The main parameters in the single emulsion, oil-in-water (o/w) were investigated and 
the final optimum condition is such as: 15 min of homogenisation time, 0.5 % (w/w) 
PVA concentration, and 6500 rpm of homogenisation speed for processing a typical 
15 % (w/w) polymer solution.  
 
3. Results from the investigation into double emulsion methods demonstrated that the 
procedures involved were laborious and associated with low productivity. Since the 
model drugs are available in solid form, this enables a higher starting drug 
concentration which is necessary to ensure better drug loading. For this reason, a 
double emulsion method will not be developed in this work. All drug-loaded 
microspheres will be produced using single emulsion with the condition determined 
in (2) above.  
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4. The principle of phase inversion technique (Section 3.5) was studied closely and 
applied to spinning of both hollow and solid fibres. Preliminary experiments preset a 
condition for the spinning of PLGA hollow fibre and further adjustments were tested 
before a final spinning condition was established. The final spinning condition for the 
production of PLGA hollow fibre are such as: 10 cm as the air gap, 2 ml/min as the 
starting bore liquid flowrate, 3 ml/min as the starting polymer solution extrusion rate 
and 5 rpm as the starting speed for collection motor. Once the spinning system has 
reached equilibrium, the latter three rates required adjustment accordingly.  
 
5. Using the established spinning condition determined in (4) above, results show good 
quality hollow fibres were produced. Hollow fibres made of PLGA with different 
copolymer ratios exhibited consistent fibre wall structures. Cross section examination 
of hollow fibres reveals the unique finger-like structure across the fibre wall. 
Uniform and thin skin layers, macrovoids with consistent geometry were also 
obtained.  
 
6. Based on the spinning condition of PLGA hollow fibre, the spinning of PLGA solid 
fibre was established. Solid fibres made of PLGA with different copolymer ratios 
were successfully produced with consistent fibre wall structure. The elongated finger 
structure is observed across the solid fibre wall.  
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CHAPTER  6 
MORPHOLOGICAL  CHARACTERISATION  OF   PLGA  DEVICES 
 
This chapter studies the morphology of PLGA devices before and after in vitro degradation 
by means of SEM imaging and mass loss measurement. Section 6.1 presents the 
morphological characterisation of PLGA microsphere and Section 6.2 follows their in vitro 
degradation by means of SEM imaging. Similarly, Sections 6.3 and 6.4 study the 
morphologies of PLGA hollow fibre before and after degradation respectively. The 
morphological characterisations of PLGA solid fibre before and after degradation are 
presented in Sections 6.5 and 6.6 respectively.  
 
 
6.1 Morphological Characterisation of PLGA Microspheres 
 
50:50, 65:35 and 75:25 PLGA were used to produce blank microspheres based on the single 
emulsion method described in Section 4.1.3. Briefly, 10 g of 15 % (w/w) polymer solution 
was homogenised at 6500 rpm in 100 ml of 0.5 % (w/w) PVA for 15 min. After that, the 
nascent microspheres were transferred to magnetic stirring for 3 h. Finally, they were 
washed, filtered and air dried. Five batches of each PLGA microsphere were prepared for 
this and subsequent degradation studies. For ease, 50:50 PLGA microsphere will be 
abbreviated as 50:50MS henceforth, similarly for 65:35 and 75:25 PLGA microspheres. 
 
6.1.1 Morphology of PLGA microspheres 
The surface morphologies of 50:50MS, 65:35MS and 75:25MS produced using the single 
emulsion method are shown in Figures 6.1 (A1), (A2) and (A3) respectively. Their overall 
smooth surfaces are seen on the images obtained with higher magnifications (Figures 6.1-A2, 
B2 and C2). The smooth condition is thought to be a result of rapid solvent diffusion and 
polymer deposition during the phase inversion process. This scenario is very similar to the 
rapid demixing between solvent and nonsolvent previously described in Section 3.5. 
 
The formation of microsphere will be illustrated in Figure 6.3 later. Sometimes, imperfect 
effects from homogenisation or unstable emulsion can cause the nascent spheres to coalesce. 
As a result, deformations to the sphericity of the final product are observed, as indicated in 
Figures 6.1 (A1) and (C1).  
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Figure 6.1: SEM images of 50:50MS (A1 & A2), 65:35MS (B1 & B2) and 75:25MS (C1 & C2) produced 
using the single emulsion method at polymer concentration of 15 % (w/w). 
 
Attempts to magnify the PLGA specimen was found problematic due to the heat sensitivity 
of PLGA. When the magnification is increased, the heat generated by the electrons projected 
onto the PLGA specimen tends to destroy the specimen. Likewise, magnification could not 
be repeated on the same area. Figure 6.2 shows the heat-damage 75:25MS specimen. Due to 
these circumstances, the typical acceleration voltage used for SEM imaging on PLGA 
specimen was maintained at 10-15 kV. The bright regions/bands observed on the SEM 
images are caused by the electron charging of residual moisture.  
 
               
Figure 6.2: SEM images showing heat sensitivity of 75:25MS during magnification. 
 
 
6.1.2 SEM Cryo-Fractioning 
This section presents the results that reveal the interior of PLGA microsphere. The basic 
cryo-fractioning protocol is given in Section 4.6.2. Understanding the internal structures of 
biodegradable microspheres will aid the understanding of their drug release kinetics (Yang et 
al., 2001 and, Kim and Park, 2004).  
 
As aforementioned, the smooth outer surface of the microsphere is a result of rapid solvent 
deposition. During the emulsion process, the organic droplets or nascent spheres experience 
A                         B            C 
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solidifying effect as a result of solvent diffusion. This initial rapid solvent diffusion is driven 
by the largest concentration gradient present at the interface between the organic droplets and 
the aqueous phase. At this instant, the outermost layer of the droplet will solidify first 
forming a layer enveloping the nascent interior (Crotts and Park, 1995). Consequently, the 
nascent spheres will solidify from the periphery towards the centre. A higher polymer 
concentration will produce a denser outermost layer due to a more rapid solvent diffusion 
(Yang et al., 2000). Figure 6.3 illustrates a possible scenario of the formation of nascent 
microsphere during the phase inversion process. 
 
 
 
 
 
 
 
 
Figure 6.3: A simplified initial solvent diffusion events during the formation of a skin layer enveloping the 
nascent interior, which contains multiple water droplets. 
 
The diffusion of the remaining solvent out from the nascent microspheres to the aqueous 
phase may give rise to a porous interior. This is because of the partial water immiscibility of 
DCM which permits the influx of water into the nascent spheres, and the presence of a PVA-
stabilised water emulsion. An increase in concentration of the aqueous phase will increase 
the volume of water droplets-emulsion, forming more water pockets. Upon solidification, 
these pockets will form particles with interior of higher porosity. Since the nascent sphere 
solidifies inwards from its periphery, there is a tendency that the water-emulsion will be 
driven towards the centre of the microspheres. This situation can form microspheres with 
larger cavities at their centres. The above mechanisms are used to explain the porous interior 
of 75:25MS shown in Figure 6.4.  
 
               
Figure 6.4: SEM images of cryo-fractured 75:25MS. 
PVA stabilises water droplets          Nascent microsphere                Solvent diffusion 
Multiples water droplets may present inside the   
nascent microsphere which eventually form the 
porous interior.  
Initial high solvent gradient gives rise to a rapid 
solvent diffusion from the organic droplet forming 
a skin layer enveloping the nascent interior.  
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Figure 6.4A shows a 75:25MS of ~35 µm in size whereas Figure 6.4B shows a 75:25MS of 
~110 µm in size. The microcavities in the porous interiors of these 75:25MS are 
approximately ~1 nm in size. Figure 6.4A indicates a “skin” layer enveloping the sphere 
while a flat region is observed in Figure 6.4C. During contact with N2 freezing, it is possible 
that the rather weak porous structure expanded due to ice crystallisation. As this expansion 
takes place, the adjacent structure shrinks. If this occurs across a local region, it could form a 
flat region. Figure 6.4 (B) and (C) also show the present of a small number of macrocavities. 
These may be a result of the formation of random size water droplets-emulsion. With a less 
viscous 65:35 and 50:50 PLGA polymer solutions, higher interior porosity can be expected 
because of the higher influx of water into the nascent spheres during phase inversion. 
 
While a number of 75:25MS were successfully fractured, little fractured 50:50MS and 
65:35MS were obtained. Figure 6.5 illustrates a possible scenario during the cryo-fractioning 
of specimen. The initial assumption was that a larger sphere would aid the fracturing process. 
This is because of the larger surface of the larger sphere would be strongly held by the 
surrounding ice crystal. 
  
 
 
 
 
   
 
Figure 6.5: Possible scenario during sample preparation for cryo-fracturing. Larger sphere offers a larger 
surface area to be held by the ice crystal while the opposite applied for a smaller sphere.  
 
               
Figure 6.6: SEM images showing the “impression” resulted from the removal of a sphere.   
 
Owing to the minute sizes of the specimen, it is impossible to distribute the spheres between 
the fracture plane, while the fracture plane is a random position due to the nature of the 
procedure. For these reasons, the whole sphere was removed leaving an empty space (Figure 
6.6). To attempt to improve the fracturing effect, further modification was made to the basic 
protocol procedure and details are included in Appendix IV. Figure 6.7 shows the fractured 
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75:25MS using the modified procedure. These specimens were first freeze-dried, and then 
fixed onto Araldite® resin followed by sectioning using a microtome. The freeze drying may 
have altered the internal structure of the 75:25MS because their exposed interiors seen in 
Figure 6.7 are different from those in Figure 6.4. Close-up images of 75:25MS (Figure 6.7B) 
indicate that their internal morphology were dense with no visible cavities.  
 
             
Figure 6.7: SEM images of fractured 75:25MS using a modified cryo-fractioning procedure.  
 
All the microspheres used in this section were produced using the same condition therefore it 
was anticipated that they would have similar characteristic. Based on the results in Figures 
6.4 and 6.7, two critical conditions must be distinguished: 
i. In the basic protocol, the spheres were prepared based on the condition described in 
Section 4.6.2. They did not undergo any overnight freeze-drying.  
ii. In the modified procedure, the specimen was freeze-dried overnight prior to cryo-
fractioning.  
 
Freeze drying can affect molecular mobility of PLGA by altering the excess structural energy 
in the glassy particle. Glassy materials, including amorphous or semi-crystalline polymer at 
temperatures below their glass transition (Tg) are thermodynamically unstable. These 
materials are to be regarded as solidified supercooled liquids, whose properties such as free 
volume, enthalpy and entropy are greater than they would be in the equilibrium state 
(Allison, 2008a). In the metastable glassy state, the physical and mechanical properties of 
such materials change with time as the glass attempts to achieve equilibrium by slow changes 
in molecular configurations. Molecular mobility in the glassy state allows the glass to relax 
toward the equilibrium liquid state in a process referred as structural relaxation. 
 
Molecular mobility in PLGA may lead to structural changes, such as the closure of surface 
pore and structural relaxation in glassy PLGA microparticles is characterised by volume 
reduction (density increase) and can affect the dynamic behaviour of the amorphous PLGA 
microspheres (Allison, 2008a). PLGA microparticle can exhibit pore closure in increased 
Spheres engulfed  
in Araldite® 
A              B            C 
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humidity environment (Bouissou et al., 2006) and incubation in solution (Ali et al., 1993). 
Messaritaki et al. (2005) discovered that the freeze drying had detrimental effect on the 
permeability of PLGA microsphere. A non-freeze-dried PLGA microsphere has much larger 
pore density than the freeze-dried sphere.  
 
Owing to the structural instability of glassy-PLGA microspheres, all the PLGA microspheres 
used in this thesis were standardised to undergo air drying according to the method described 
in Section 4.1.3 and they were freshly prepared prior to each experiment. Unconditioned 
storage of PLGA microspheres may lead to irreversible aggregation of the microspheres. 
Bouissou et al. (2006) reported that at high humidity and temperature higher than the 
polymer’s Tg, interparticulate bridges were formed due to high degree of molecular mobility 
of the PLGA chains. For the shortcomings encountered in the cryo-fracturing process, it is 
suggested that: 
i. Figure 6.4 is more suitable to be used to predict the internal morphology of the single 
emulsion-PLGA microspheres produced in this thesis.  
ii. Subsequent freeze-drying of 75:25MS can alter the internal structure of 75:25MS due 
to polymer aging or structural relaxation. 
 
 
6.1.3 Distribution Of Entrapped Agent in PLGA Microsphere 
This section studies the distribution of entrapped agent in microsphere which can mimic the 
distribution of the entrapped drug in PLGA microspheres. This information can be related to 
the drug release pattern of PLGA microsphere (Rigby et al., 2004 and Messaritaki et al., 
2005). The objective was achieved by using a fluorescent compound, 4-trifluoromethyl 
umbelliferone (4-TFMU) as the entrapment agent and observation under confocal laser 
scanning microscopy (CLSM). 75:25MS entrapped with 4-TFMU were produced using the 
method described in Section 4.6.3. Confocal micrographs showing 75:25MS entrapped 
with 4-TFMU are shown in Figure 6.8. 
 
                                        
Figure 6.8: Confocal micrographs focused at equatorial plane showing (A) multiple 75:25MS and (B) to 
(D) singular 75:25MS entrapped with 4-TFMU. 
B          C               D 
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Figure 6.8A shows multiples 75:25MS while singular 75:25MS are shown in Figure 6.8 
(B) to (D). Figures 6.8 (B) and (C) indicate a heterogeneous distribution pattern of the 
entrapped 4-TFMU based on the varied fluorescence intensities. By “stacking” sequential 
2D micrographs collected at different planes depth through the specimen, the spatial 
distribution of entrapped 4-TFMU in 75:25MS can be studied.  
 
The 3D projections of 75:25MS entrapped with 4-TFMU are shown in Figures 6.9 and 6.10; 
with orthogonal views of the sphere and sequential 2D micrographs focused at different 
depth planes. The depth of the image plane is indicated on the top left corner of the 
micrograph; i.e., 0 µm indicates the image plane was at the periphery of the sphere; 1 µm 
indicates the image plane was 1 µm into the sphere from its periphery. 
 
          
Figure 6.9: Confocal micrographs showing the cross sections of a 75:25MS entrapped with 4-TFMU, (A) 
at equatorial plane, (B) orthogonal views and (C) cross sections at different plane depth.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10: Confocal micrographs showing the cross sections of a 75:25MS entrapped with 4-TFMU, (A) 
at equatorial plane, (B) orthogonal views and (C) cross sections at different plane depth.  
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Figure 6.9 shows a 75:25MS of size ~20 µm. From Figure 6.9C, it can be seen that the spatial 
distribution of 4-TFMU varied across the sphere. For instance, with the increasing intensity 
from plane distance of 0 µm to 4-5 µm, this indicates an increase in concentration of 
entrapped agent across these planes. Figure 6.10 shows a number of smaller spheres are 
located at top left quadrant of the main sphere. Referring to the equatorial plane of the 
sphere, the 4-TFMU at this plane is highly concentrated (i.e. high intensities). 
 
The distribution of 4-TFMU in sphere shown in Figure 6.10 indicates similarity to the one 
shown in Figure 6.9. Findings in Section 6.1.1 indicated that the 75:25MS has porous interior 
and this may permit water transport. Hence, regions filled with 4-TFMU could vary in 
intensity over time due to probable water transport within the porous the interior. 
                                                                                    
Figures 6.9 and 6.10 show that the spatial heterogeneous distribution of 4-TFMU in 
75:25MS. The amorphous regions in PLGA are thought to hinder a homogeneous 
distribution of the entrapped agent (Sastre et al., 2004). An imperfect entrapment can 
arise from an unstable emulsion during the production process. This instability leads to 
the coalescence of droplets and cause the drug to heterogeneously distribute in the 
microsphere (Perez et al., 2000). Emulsion instability is also seen previously in Figure 
6.4 where macrocavities are observed in the interior matrix.  
 
 
6.2 Degradation of PLGA Microspheres 
 
This section studies the in vitro degradation of 50:50MS, 65:35MS and 75:25MS in PBS. 
The same samples produced in Section 6.1.1 were used in this study. In vitro degradation 
was carried out by incubating the samples in a shaking water bath with a back-forth shaking 
(150 rpm) maintained at 37oC. Details of degradation analysis can be found in Section 4.5. 
At ten, twenty and thirty days intervals, samples were collected for SEM imaging.  
 
Hydrolysis has been widely accepted as the main degradation pathway for PLGA polymers 
(Metha et al., 1994; Hauesberger and DeLuca, 1995 and Lu et al., 1999). Typically, the term 
degradation refers to a chemical process resulting in the reduction of the average molecular 
weight. As the incubation progresses, erosion will take place and it is a physical process 
whereby mass is lost from the sample by solubilisation of polymer chains and their removal 
from the vicinity. It will be shown that the PLGA microspheres produced in this thesis 
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underwent bulk degradation pathway and their mass loss profiles are associated with lag 
phases. The degradation states of 50:50MS, 65:35MS and 75:25MS over a period of thirty 
days are shown in Figure 6.11. 
 
         
 
         
 
         
Figures 6.11: SEM images showing the morphological changes experienced by 50:50MS, 65:35MS and 
75:25MS after 10, 20 and 30 days of incubation in PBS. 
 
After ten days in PBS, 50:50MS had deformed and swelling/shrinking can be observed. After 
twenty days, the surface of 50:50MS had collapsed with small fractions of polymeric debris 
formed at its surface. After thirty days, it was increasingly difficult to distinguish a degraded 
50:50MS from polymer debris. The degradation of 65:35MS after ten days exhibited a small 
degree of deformation and it could also be a result of hydration that caused 65:35MS to 
swell. After twenty days, pores can be partially observed on 65:35MS. The formation of 
these surface pores on 65:35MS is thought to be caused by degradation effect on the 
polymer. Unlike 50:50MS, 65:35MS did not degrade to substantial matrix disintegration and 
its morphology is retained after thirty days.  
 
As the degradation process is hydrolytic, water uptake into the polymer has an important 
effect on the rate of polymer degradation. Amorphous PLGA permits water influx and 
initially, water diffuses into the microspheres and attacks the chemical bonds in the 
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amorphous region, cleaving the long PLGA chain (Zweers et al., 2004). As this progresses, 
polymer remnants will formed such as those seen in the twenty days degraded 50:50MS. Kiss 
and Vargha-Butler (1999) concluded that the glycolide content can significantly increase the 
hydrolysis rate of PLGA. Lactide with its pendant methyl group tends to sterically hinder 
water and makes it more hydrophobic than glycolide. Hence, 50:50MS is observed to 
degrade faster due to its highest glycolide ratio, which is more prone to hydrolytic attack.  
 
Throughout the incubation period, 75:25MS demonstrated better resistance to degradation 
and retained its spherical form the best comparing to 50:50MS and 65:35MS. After ten days, 
no distinct effect of degradation is observed on 75:25MS. After twenty days, 75:25MS 
partially show small degree of roughness on its surface. Attempts to magnify on these areas 
were inconclusive because of the heat-sensitivity of the PLGA specimen. After thirty days, 
75:25MS is still intact but with increased microscopic swelling across its surface. 
 
PLGA undergoes bulk erosion due to faster water diffusion into the polymer matrix is than 
polymer degradation (Lu et al., 1999). Since the diffusion of water into the matrix is faster 
than polymer degradation, the whole matrix undergoes degradation and eventually erosion. 
The two principle mechanisms of polymer degradation are illustrated in Figure 6.12. The 
distinct differences between the two mechanisms is that surface erosion causes the sample to 
reduce in size while for bulk degradation, the sample experience less size reduction but 
undergoes more pronounced morphological changes. Surface erosion of polymers occurs 
with a constant rate while in bulk degradation; such as PLGA, it involves more complicated 
events because they do not show constant erosion velocity (Göpferich and Langer, 1995; 
Park, 1995 and Göpferich, 1996).  
 
 
 
 
 
 
 
 
Figure 6.12: The mechanisms of surface and bulk erosions. The colour intensity symbolises the degree of 
erosion; with the darkest as undegraded and lightest as most eroded.   
 
Based on Figure 6.11, it is evident that 50:50MS and 65:35MS exhibit the characteristics of 
bulk erosion. Initially, Spenlehauer et al. (1989) suggested that PLGA microspheres undergo 
Surface erosion 
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homogenous degradation with both equal rates of degradation in core and surface. Later it is 
discovered that PLGA microspheres can proceed heterogeneously throughout the device (Li 
et al., 1990 and Therin et al., 1992). This is caused by an autocatalysis situation. The 
degradation of PLGA will produce byproducts with carboxylic acid chain ends in the system. 
Figure 6.13 shows the formation of acidic products as a result of hydrolysis at the ester 
linkages in the PLGA chain. 
 
 
 
Figure 6.13: Hydrolysis of ester bonds in biodegradable polyesters (Loo et al., 2005). 
 
The acidic byproducts could autocatalyse the ester hydrolysis. For those that are formed in 
the interior and are insoluble oligomers, they remained relatively trapped (de Jong et al., 
2001). This results in a decrease in local pH which could promote interior degradation of the 
matrix. The soluble oligomers and those located near to the surface can leach out from the 
matrix through the diffusing medium. Meanwhile, the hydroxyl ions from the buffer provide 
a neutralisation effect on the carboxylic end groups located at the surface (Dong et al., 2005). 
Hence, the surface undergoes a relatively slower degradation compared to the interior. 
 
 
                    
 
Figure 6.14: Theoretical molecular weight decrease and mass loss of PLGA during degradation 
(Hausberger and DeLuca, 1995). 
                         
A theoretical molecular weight decrease and mass loss during bulk degradation of PLGA is 
adapted from Hausberger and DeLuca (1995) and shown in Figure 6.14. During degradation, 
an almost immediate and rapid decrease in molecular weight can be observed as susceptible 
bonds in the PLGA chains are cleaved. This leads to the formation of chains of small 
fragments as the degradation products. The onset of mass loss corresponds to a point when a 
critical molecular weight is reached due to the continual bond cleavage. Appreciable mass 
loss will only begin when the degraded small fragments begin to obtain a critical molecular 
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weight (Hausberger and DeLuca, 1995 and Metha et al., 1994). After this only will the 
solubilisation of low molecular weight degradation products begun. Hence, a lag phase is 
present on the mass loss profile as indicated in Figure 6.14.  
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Figure 6.15: The degradation profiles of 50:50MS, 65:35MS and 75:25MS. 
 
The pH and mass loss profiles of 50:50MS, 65:35MS and 75:25MS during the incubation in 
buffer were measured and are shown in Figure 6.15. The decrease in pH suggests the release 
of acidic products from degradation of PLGA samples. The buffer pH of 50:50MS was the 
lowest after thirty days of degradation. This suggests the greater susceptibility of glycolide to 
hydrolytic degradation. The removal of glycolic acid has been reported to be as twice as fast 
as that of lactic acid from 50:50 PLGA sample (Göpferich, 1996). Meanwhile, Siepmann et 
al. (2004) reported that the sizes of microspheres did not strongly affect the degradation of 
the matrix. However, the buffer pH’s of the three PLGA samples at Day 30 were not 
significantly different from each other (ANOVA, p < 0.05).   
 
The initial more prominent decrease in buffer pH of 50:50MS and 65:35MS may due to the 
initial release of degradation products near the microsphere surface. Meanwhile, the buffer 
influx may have given rise to a neutralisation effect. Time also required for the degraded 
byproducts formed in the interior to leach out. Combination of these conditions minimise the 
decrease in buffer pH at later stage.  
 
Appreciable mass loss of 50:50MS was only noticeable after approximately a week, and two 
weeks for 65:35MS and 75:25MS. This may be because the degraded mono/oligomers had 
not reached critical molecular weights and the soluble byproducts were only formed at later 
Buffer pH profile : 
Mass loss profile :  
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stage. These two conditions might have delayed the onset of mass loss. The lag phase may 
also due to the time required by the polymeric microspheres to become hydrated (Metha et 
al., 1994). The degraded products formed in the interior also depend on the presence of a 
medium for transport or to leach out into the buffer. The lag phase in mass loss of 50:50 
PLGA microspheres could be as long as two weeks (Dunne et al., 2000).  
 
At the end of thirty days, the changes in both the buffer pH and mass loss of 75:25MS and 
65:35MS were not as extensive as for 50:50MS. Only the mass loss of 50:50MS was 
significantly different from that of 75:25MS (ANOVA, p < 0.05).  This is attributable to the 
greater degradation resistance of 75:25 PLGA. During degradation of PLGA in buffer, the 
matrix shifts from glassy state to a rubbery state and is independent of the microsphere size 
(Siepmann et al., 2004). The increasing mass loss in 50:50MS is attributable to the continual 
attack in its amorphous region as the polymer state rapidly shifts to a rubbery state. The 
rubbery state permits higher water diffusion through the matrix and further promotes the 
hydrolytic attack on the PLGA chain, causing further mass loss. 
 
 
6.3 Morphological Characterisation of PLGA Hollow Fibres 
 
This section presents the morphology of PLGA hollow fibre produced based on the phase 
inversion method described in Section 4.2.3. For ease, 50:50 PLGA hollow fibre will be 
abbreviated as 50:50HF henceforth; similarly for 65:35 and 75:25 PLGA hollow fibres. The 
outer surfaces of 50:50HF, 65:35HF and 75:25HF are shown in Figure 6.16. They are 
relatively smooth with no visible pores. These pore-less surfaces are a result of the rapid 
polymer precipitation during the phase inversion. A small degree of unevenness on the 
surface of 50:50HF may be caused by the amorphous property of 50:50 PLGA as apposed to 
the more crystalline 75:25 PLGA, which show a denser and smoother outer surface. 
Mechanical dragging or friction between the orifice and the nascent hollow fibre can also 
cause uneven polymer deposition during the spinning process. 
 
   
Figure 6.16: The outer surfaces of 20 % (w/w) (A) 50:50HF, (B) 65:35HF and (C) 75:25HF. 
(A) 50:50HF                (B) 65:35HF               (C) 75:25HF 
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Figure 6.17: Detailed cross sectional views of the fibre wall structure of 20 % (w/w) 75:25HF. 
 
Figure 6.17 shows the cross section details of 75:25HF. The overall “honey-comb” structure 
can be seen across the fibre wall as indicated in Figure 6.16B. Both the outer and inner skin 
layers with adjacent finger-like microcavities can be seen (Figure 6.16A and D, respectively). 
Throughout the phase inversion process, air pockets were formed initially and upon 
solidification, transformed to the finger-like microcavities and macrovoids structures. The 
long and elliptical finger cavities are due to diffusion of solvent into the aqueous phase. 
These different sublayers form the asymmetrical property of the hollow fibre membrane, 
which also give the fibre its mechanical support. 
 
     
Figure 6.18: Detailed cross sectional views of the fibre wall structure of 20 % (w/w) 65:35HF. 
 
     
Figure 6.19: Detailed cross sectional views of the fibre wall structure of 20 % (w/w) 50:50HF. 
  
The cross sections of 65:35HF and 50:50HF are shown on Figures 6.18 and 6.19 
respectively. In all cases, the finger-like microcavities are visible across the fibre walls 
between the skin layers. The skin layers are formed during the contact between the polymer 
solution and water. The diffusion of solvent is rapid and this produces layers with denser 
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structures compared to the centre of the fibre. The slower diffusion of the remaining solvent 
from the nascent hollow fibre gives rise to the macrovoids at the fibre core.  
 
 
6.4 Degradation of PLGA Hollow Fibres 
 
This section studies the in vitro degradation of 50:50HF, 65:35HF and 75:25HF. The same 
batches of PLGA hollow fibres produced in Section 6.3 were used in this study. In vitro 
degradation was carried out by incubating the samples in a shaking water bath with a back-
forth shaking (150 rpm) maintained at 37oC. More details of degradation analysis can be 
found in Section 4.5. At ten, twenty and thirty days intervals, fibres were randomly collected, 
sectioned and prepared for SEM imaging. The degradation conditions of 50:50HF, 65:35HF 
and 75:25HF are shown in Figures 6.20 to 6.22. Figure 6.20 shows the degradation of 
50:50HF incubated in PBS for ten, twenty and thirty days.  
 
      
 
    
 
      
Figure 6.20: SEM images of degrading 50:50HF after 10, 20 and 30 days of incubation in PBS. 
 
The honeycomb structure across the fibre wall of 50:50HF at Day 10 was still intact but its 
macrocavities had markedly increased in size. Numerous pores can be observed on its outer 
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surface. These conditions show that degradation effect will lead to an increase in the fibre 
porosity. Figure 6.20 shows that 50:50HF with the most glycolide content is highly 
susceptible to hydrolytic degradation. The glycolic acid in the PLGA chain was suggested by 
Göpferich (1996) could be more susceptible to hydrolytic attack. At Day 30, 50:50HF had 
disintegrated into polymeric debris. The thirty days degraded 50:50HF showed the 
entanglements of polymer chain most likely constituted by the remaining polylactide. 
 
             
 
              
 
             
Figure 6.21: SEM images of degrading 65:35HF after 10, 20 and 30 days of incubation in PBS. 
 
Figure 6.21 shows the degradation conditions of 65:35HF incubated in PBS for ten, twenty 
and thirty days. The fibre wall at Day 10 still retains the honeycomb structure but is highly 
porous. Pores formation had also begun on the outer surface of 65:35HF at Day 10. 
Degradation effect becomes noticeable by comparing the lumen surfaces of 65:25HF at Days 
10 and 20. At Day 20, the degraded 65:35HF lost its honeycomb structure in the fibre wall. 
Similar approach from 50:50HF is applied here where the amorphous regions in the PLGA 
permitted hydrolytic attack and the breakage of mono- or oligo-mers disrupted the polymer 
chain. As a result, disintegration to the physical state of the thirty days degraded 65:35HF is 
clearly visible.  
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The thirty days degraded 65:35HF confirms the occurrence of autocatalytic effect where its 
outer surface condition is better than its disrupted interior. As previously discussed, the fast 
water diffusion leads to hydrolytic attack in the fibre interior. With the formation of insoluble 
byproducts and the skin layers that restrict mass transfer, minimises medium transport. 
Hence, the accumulation of acidic products might have promoted autocatalytic degradation. 
Meanwhile, the formation of degradation products at/near the fibre surface are likely to be 
neutralised by the bulk fluid and thus, degradation is suppressed. 
 
             
 
             
 
              
Figure 6.22: SEM images of degrading 75:25HF after 10, 20 and 30 days of incubation in PBS. 
 
Figure 6.22 shows the degradation conditions of 75:25HF incubated in PBS for ten, twenty 
and thirty days. At Days 10 and 20, the fibre wall structure of 75:25HF did not undergo any 
distinct degradation but pores are visible on their lumen surfaces. After Day 30, 75:25HF still 
retain its fibre integrity but its honeycomb structure had started to collapse. As previously 
discussed, the presence of an extra chiral methyl group on the lactide unit reduces the 
chemical reactivity of the ester groups through steric hindrance (Göpferich, 1996). The 
removal of mono- or oligo-mers from the PLGA main chain also increases the mobility of 
the remaining molecules. Polymer backbone movements may have produced the structural 
changes observed in the thirty days degraded 75:25HF. 
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In general, the degradation states of PLGA hollow fibres demonstrated the expected trend; 
where 50:50HF with the highest glycolic acid ratio experienced the fastest degradation rate. 
In contrast, 75:25HF demonstrated high degradation resistance. This trend concurred with the 
previous results from PLGA microspheres. By studying the degradation states of PLGA 
hollow fibres, it is confirmed that PLGA hollow fibres undergo bulk degradation erosion. 
  
In terms of the structure of the devices, hollow fibres have a more open structure for contact 
with water compared to microspheres, i.e. the lumen of the hollow fibre and its open end 
fibre wall structure. These conditions allow for higher water influx into the fibre. However, 
as aforementioned, the denser structures at the skin layers of the hollow fibres are associated 
with high mass transfer resistance. This effect is reflected on the thirty days degraded 
65:35HF where polymeric disruption was less severe at the surface compared to the interior.  
 
The initial formation of insoluble degradation products and the restricted mass transfer at the 
skin layers, promoted autocatalytic effect at the fibre interior. Since hollow fibre is a larger 
and thicker structure compared to microsphere, the degree of heterogeneous or bimodal 
degradation in hollow fibre would be greater (Grizzi et al., 1993). 
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Figure 6.23: The degradation profiles of 50:50HF, 65:35HF and 75:25HF. 
 
The mass loss and buffer pH profiles of 50:50HF, 65:35HF and 75:25HF were measured 
over a period of four weeks and results are shown in Figure 6.23. From statistic analyses 
(ANOVA, p < 0.05), only the buffer pH and mass loss of 50:50HF were significantly 
different from 75:25MS. There were significant differences between 65:35HF from 50:50HF 
and 75:25HF. The lag phase for 50:50HF is observed to be approximately two weeks and 
 pH profile :  
Mass loss profile :  
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after this, the mass loss tends to increase linearly. The mass losses of 63:35HF and 75:35HF 
are lower in comparison. Figure 6.20 shows that 50:50HF underwent severe degradation 
effect and the porosity of its structure was increased. The increased porosity may have eased 
the release of degradation byproducts and this is reflected by the decreasing buffer pH of 
50:50HF seen in Figure 6.23. The increased porosity also promoted buffer penetration and 
diffusion. As a result, degradation continued causing the mass loss to increase further.  
 
The decrease in buffer pH of 65:35HF and 75:25HF was not as great as for 50:50HF. The 
small changes in buffer pH may due to the less degradation effects occurring in the former 
two. Since 65:35HF and 75:25HF have higher lactic acid compositions in their polymers, 
they would have higher degradation resistances.  
 
 
6.5 Morphological Characterisation of PLGA Solid Fibres 
 
This section presents the morphology of PLGA solid fibres produced using the phase 
inversion technique described in Section 4.2.3. 20 % (w/w) 50:50, 65:35 and 75:25 PLGA 
were used to produce blank solid fibres. For ease, 50:50 PLGA solid fibre will be abbreviated 
as 50:50SF henceforth; similarly for 65:35 and 75:25 PLGA solid fibres. The surface 
conditions of 50:50SF, 65:35SF and 75:25SF are shown in Figure 6.24. Similar to PLGA 
hollow fibres, these solid fibres have smooth and rigid surfaces. The rapid polymer 
deposition during the phase inversion produces these properties.  
 
             
Figure 6.24: The surface conditions of 20 % (w/w) (A) 50:50SF, (B) 65:35SF and (C) 75:25SF. 
 
The morphology of the cross sections of 75:25SF, 65:35SF and 50:50SF are shown in Figure 
6.25. The cross sectional structures of 50:50SF, 65:35SF and 75:25SF show the typical 
finger-like microcavities structures enveloping by skin layers. Unlike hollow fibre, solid fibre 
has no lumen. The longer solvent diffusion path from the fibre core contributes to the 
extended finger structure during the phase inversion process.  
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Figure 6.25: The cross sectional views of 20 % (w/w) (A) 75:25SF, (B) 65:35SF and (C) 50:50SF. 
 
 
6.6 Degradation of PLGA Solid Fibres 
 
This section studies the in vitro degradation of 50:50SF, 65:35SF and 75:25SF. The same 
batches of PLGA solid fibres produced in Section 6.5 were used in this study. In vitro 
degradation was carried out by incubating the samples in a shaking water bath with a back-
forth shaking (150 rpm) maintained at 37oC. Details of degradation analysis can be found in 
Section 4.5. At ten, twenty and thirty days intervals, fibres were randomly collected, 
sectioned and prepared for SEM imaging.  
 
The degradation states of 50:50SF after ten, twenty and thirty days of incubation in PBS are 
shown in Figure 6.26. As incubation progresses, the degree of unevenness and swelling on 
the surface of 50:50SF developed over time. Swelling effect on 50:50SF is clearly visible at 
Day 10. Meanwhile, the fast degrading 50:50SF lost the finger structure of its fibre wall. The 
development of surface pore is visible from Day 20 to Day 30 as 50:50SF. Cavities are 
observed to be developing at the core of 50:50SF at Day 10. As degradation progressed, 
these cavities continued to grow in size and depth, after twenty and thirty days in PBS.  
 
 
 
Wall structure    Cross section             Core structure 
(A) 75:25SF                75:25SF                75:25SF 
(B) 65:35SF   65:35SF                 65:35SF 
(C) 50:50SF   50:50SF                 50:50SF 
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Figure 6.26: 20 % (w/w) 50:50SF after 10, 20 and 30 days of incubation in PBS. 
 
The presence of interior autocatalysis is thought to contribute to the hollowness of the 
cavities. Unlike hollow fibre, solid fibre without lumen offers no passage to transport any 
degraded byproducts. Findings in Section 6.4 showed that PLGA can undergo heterogeneous 
degradation where the inner matrix experience different rates of degradation compared to the 
matrix surface. The 50:50SF sample was incubated at 37oC and subjected to constant shaking 
while immersion in buffer led to hydrolytic degradation. Under these conditions, the 
unevenness on the fibre surface may also caused by the distortion to the polymer chain as a 
result of degradation, heat or motion effects from the incubation.  
Day 10    Day 10                 Day 10 
 
 
 
 
 
 
 
 
 
Day 20    Day 20     Day 20 
 
 
 
 
 
 
 
 
 
Day 30    Day 30    Day 30 
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Figure 6.27: 20 % (w/w) 65:35SF after 10, 20 and 30 days of incubation in PBS. 
 
Figure 6.27 shows the ten, twenty and thirty days degraded 65:35SF. The finger structure is 
partially visible at Day 10 and the swelling on the fibre can also be observed. The swelling 
confirms the uptake of water by polymeric solid fibre. Among the finger structure, larger 
cavities had also started to develop at the core of 65:35SF on Day 10. At Day 20, the cavities 
at the core continued to develop and the polymeric disintegration due to degradation is 
becoming more evident. Degradation continued and at Day 30, these cavities had grown in 
size and depth.  
 
With the swelling effect, the interior of the fibre becomes more hydrated as the polymer 
shifts to a rubbery state. This hydration subsequently may have promoted interior hydrolytic 
degradation. The accumulation of the degraded byproducts in the fibre core matrix can 
produce a local acidic environment which autocatalyse the degradation. The degraded 
polymer remnants at the core matrix can be seen at Day 30.  
 
 Day 10    Day 10                 Day 10 
 
 
 
 
 
 
 
 
 
Day 20    Day 20    Day 20 
 
 
 
 
 
 
 
 
 
Day 30    Day 30    Day 30 
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Figure 6.28: 20 % (w/w) 75:25SF after 10 and 20 days of incubation in PBS. 
 
Figure 6.28 shows the ten, twenty and thirty days degraded 75:25SF. In general, the 
structural changes in 75:25SF was minimal compared to 50:50SF and 65:35SF. The finger 
structure of 75:25SF can be clearly identified throughout the incubation period. This scenario 
is attributable to its higher lactide content which have high resistance against hydrolytic 
attack.  
 
    
                                                                          
 
 
 
 
Figure 6.29: A simplified illustration of the swelling-expansion events in a porous fibre matrix. Bold 
arrows indicate hydrolytic attack.  
 
The polymer swelling/shrinking in solid fibre is thought to be similar to those observed in 
microspheres. A hypothetical pore expansion is illustrated in Figure 6.29 to envisage the 
different swelling degrees experienced by PLGA solid fibre. Considering a single void or 
 Day 10    Day 10    Day 10 
 
 
 
 
 
 
 
 
 
Day 20    Day 20    Day 20 
 
 
 
 
 
 
 
 
 
Day 30    Day 30    Day 30 
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Water diffuses into fibre 
Water fills up a pore 
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Swelling effect 
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pore is gradually becoming hydrated, the pore/void will expand. This expansion takes place 
in all direction and continues towards the outer layer of the fibre. The fibre porous structure 
comprises non-uniform cavities of various sizes and dimensions. Therefore these 
pores/cavities will expand at different rates. These conditions are suggested to be the cause of 
the unevenness of the fibre surface. 
 
Regions with different water permeability; i.e. glycolic vs. lactic acids regions, may also 
evolve over time as degradation takes places. This could further alter the structural expansion 
in the fibre. At the swollen surface, the surface tension at the hemispheres stresses the 
polymer chain and with the breakage of oligomers, monomers or glycolide from the region, 
polymeric disintegration leads to the formation of surface pores.  
 
The degraded PLGA solid fibres at the end of thirty days are observed to retain better 
structural integrity compared to PLGA microspheres, especially in the case for 50:50 
PLGA. The much larger structure of solid (and hollow) fibre offers smaller surface area 
for contact with buffer compared to the submicron microsphere. This factor reduces the 
degradation effect on solid fibre. Similar to hollow fibre, the dense structure at the skin 
layer of solid fibre restricts medium transport. Therefore buffer influx is minimised and 
degradation is also reduced in the interior. This condition may also minimise the 
transport of degradation products, and interior autocatalytic degradation would be more 
severe in solid fibre compared to hollow fibre. As result, large cavities were developed at 
the core of the fibre due to more severe autocatalysed degradation. 
 
The mass loss and changes in buffer pH during the degradation of 50:50SF, 65:35SF and 
75:25SF were measured and results are shown in Figure 6.30. The development of large 
cavities at the core of 50:50SF from Day 10 onwards (Figure 6.26) can be validated by the 
continual decrement in its buffer pH which was caused by the release of degradation acidic 
products. The lag phase in mass loss of 50:50SF is approximately two weeks. Prior to the 
onset of mass loss, the interior autocatalysis reaction gradually increased the interior 
porosity. After two weeks, the degradation products leached out into the buffer as the 
formation of surface pore took place. At this stage, it is thought that 50:50SF had degraded to 
a critical degree where a network of pores within the polymeric matrix has formed, which 
allows the release of monomers and oligomers (Burkersvoda et al., 2002). This caused 
appreciate mass loss and drop in buffer pH. The increased porosity permitted higher 
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hydration rate and medium transport therefore degradation rate also increased. As a result, 
the mass loss of 50:50SF continued to increase.   
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Figure 6.30: The degradation profiles of 50:50SF, 65:35SF and 75:25SF. Fill symbols = pH profile. Open 
symbols = mass loss profile. 
 
Figure 6.27 shows that 65:35SF experienced greater erosion than 75:25SF. This is 
reflected in the decrease in buffer pH of 65:35SF compared to the buffer pH of 75:25SF. 
While the surface degradation of 65:35SF and 75:25SF were experiencing neutralisation 
effect from the buffer, the degradation effect was reduced. Coupled with the delay in 
pore formation, less acidic products were formed and released into the buffer. Thus, 
decrease in buffer pH was not as prominent as in 50:50SF. This concurs with the 
relatively small mass loss experienced by 65:35SF and 75:25SF. Statistic analyses 
(ANOVA, p < 0.05) suggested that only the buffer pH and mass loss of 50:50SF were 
significantly different from those of 75:25SF. 
 
 
6.7 Conclusion 
 
1. Degradation of PLGA devices is thought to be initiated by hydration during the 
immersion in buffer. The amorphous property of PLGA permits buffer influx into the 
polymer matrix. 
 
2. For PLGA polymer, the mechanism of degradation is assumed to be hydrolysis. The 
mode of action of hydrolytic attack is through the random scission at the ester linkage 
pH profile :  
Mass loss profile :  
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in the polymer main chain. The final degradation product is the monomers of the 
copolymer; namely lactic and glycolic acids.  
 
3. For PLGA microspheres, hollow and solid fibres, the degradation pathway on these 
devices assume the bulk degradation characteristic. This is evident in the degradation 
studies where the degrading PLGA devices underwent obvious morphological 
changes.  
 
4. Devices made of 75:25 PLGA experienced the least effect of degradation because of 
its highest lactide content compared to 65:35 and 50:50 PLGA. This is thought to 
benefit from the extra chiral methyl group in the lactic unit which enhances its 
chemical stability towards hydrolytic attack. 50:50 PLGA which has the least lactide 
ratio demonstrated the opposite characteristic. 50:50 PLGA experienced the fastest 
degradation rate due to its higher glycolide ratio. 
 
5. Autocatalytic degradation is observed to occur in PLGA devices. This is attributable 
to the accumulation of the degradation products with carboxylic end groups. 
Degraded product at the surface of the device can be removed from the vicinity by 
buffer. For those that trapped deeper in the matrix or interior of the devices, their 
accumulation would result in a decrease in local pH and hence, autocatalyse the 
degradation. This is evident for the case of PLGA hollow and solid fibres where their 
core or fibre wall structures experienced higher degree of polymeric disintegration 
compared to their outer surfaces. 
 
6. Comparing the degradation rates between microsphere, hollow and solid fibres, 
microsphere degrade the fastest. This is because the submicron particles have higher 
surface area therefore offer greater medium influx rate. Thus, a higher hydration rate 
and faster degradation are observed. For hollow fibre, its lumen provided extra 
surface area for medium transport compared to solid fibre. This leads to better release 
of degradation products and thus autocatalysis was not as severe as those observed in 
solid fibre. The degrading solid fibre show core disruption and larger cavities were 
developing at the core as degradation progressed.  
 
7. The unique finger structures formed during the phase inversion technique of hollow 
and solid fibres are also thought to indirectly resist hydrolytic degradation. This is 
because of the denser structures near the skin layers are associated with high mass 
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transfer resistance. This minimises buffer influx and hydration that cause hydrolytic 
degradation.  
   
8. From the literature, the swelling of polymeric matrix shifts the system from glassy 
state to rubbery state. Medium diffusion is assumed to be faster in the rubbery state. 
Thus, swelling of PLGA devices is thought to have promoted hydration and swollen 
devices undergo faster degradation. The morphological conditions of the three PLGA 
devices shown in SEM images evidently demonstrate that these devices experienced 
swelling. 
 
9. In terms of mass loss, devices made of 50:50 PLGA exhibit the highest and fastest 
mass loss. This is attributed to its higher glycolide ratio, which is more prone to 
degradation. A lag phase of approximately two weeks is observed in the mass loss 
profile of 50:50 PLGA hollow and solid fibres. In the case of 50:50MS, the lag phase 
was observed to be approximately a week.  
 
10. The mass loss of 50:50 devices at the end of four weeks varied between 20 to 30%. 
For devices made of 65:35 PLGA, the mass loss is approximately 10% and 5% for 
devices made of 75:25 PLGA at the end of four weeks. The onsets of mass loss of the 
latter two were delayed for more than two weeks.  
 
11. The decrease in buffer pH is the highest for devices made of 50:50 PLGA due to 
their greater susceptibilities to hydrolytic degradation. This led to the formation 
of more acidic degradation products and once leached into the buffer, the buffer 
pH is subsequently lowered. 
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CHAPTER  7  
STUDIES  OF  CONFINED  WATER  IN  PLGA  MICROSPHERES 
   
This chapter studies the transport of free water imbibed within pores of PLGA microspheres 
using nuclear magnetic resonance (NMR). The approach is to follow the movement of free 
water to probe structural information of the sample. Quantitative analyses such as mean pore 
size, pore size distribution and volume can be obtained from available techniques such as 
mercury porosimetry and gas adsorption. The former uses a mercury intrusion-extrusion 
mechanism while the latter uses nitrogen adsorption-desorption.  
 
Mercury porosimetry also requires absolutely dry sample and this technique forces mercury 
into the pores or voids by applying pressure (Strange et al., 1993 and Strange, 1994). 
Mercury will not replace any liquid already in the pores or voids, unless additional pressure 
is applied to displace the liquid (Ek et al., 1995). Since the analysis usually undergoes two 
pressure levels (one lower and one higher), concern is then raised where high pressure might 
possibly deform a pore (Landry, 2005). Difficulty also encountered in discriminating 
between interior pores and voids between small porous cellulose beads (Ek et al., 1994). In 
addition, for solids which are susceptible to swelling, pore structures may be different in dry 
and wet states.  
 
Gas adsorption subjects the sample to in situ heating (i.e. ≥ 100oC) or degassing for long 
periods (i.e. ≥ 12h) in order to produce an absolutely dry sample. Subsequent analyses utilise 
weight measurements and, ad- and desorption isotherms to generate pores information. 
Heating to ≥100oC is beyond the Tg of PLGA and it has been a major problem to obtain 
absolutely dry PLGA microsphere. PLGA microspheres were found to be extremely light and 
encourage static; thus accurate weight measurements, as required by these methods could be 
problematic. Transferring PLGA microsphere into a specific sample chamber also hinders 
accurate measurements.  
 
The samples used for this work were incubated in water and that means predrying is required 
for the above analyses. This may affect the pore structure due to redeposition of dissolved 
compound present in the fluid within pores structure (Collins et al., 2007). In this case, 
possibly the degradation byproducts. PLGA was selected for this work because of its 
hydrolytic-degradation and an aqueous environment is ideal to mimic an in vivo condition. 
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From the issues associated with sample handling and the fragility of PLGA microspheres, a 
non-invasive method and a method which can deal with “wet” samples is sought. NMR 
enables the determination of diffusion coefficients for mobile species that can be related to 
pore information. This method requires the sample to be saturated with a probe liquid; water 
in this case, which makes it a good simulation system to explore the pore structural evolution 
of degrading PLGA microspheres in aqueous environment. 
  
 
7.1 Pulse Field Gradient (PFG) NMR 
 
NMR is sensitive to the chemical and physical environments of a molecule and, for this 
reason this technique can characterise motion in liquid phase system (Hollewand and 
Gladden, 1995). Pulsed field gradient (PFG) NMR is a method used to study the self-
diffusion of liquids by facilitating the measurement of root mean square (r.m.s.) displacement 
of the self-diffusing molecules (Callaghan, 1991). This measurement is responsive to the 
structure of over a scale comparable to r.m.s. displacement of molecules during the 
measurement duration ranged from milliseconds to seconds. In this case, the mobile species; 
1H nucleus within the self-diffusing water is used to monitor the movement of free water.  
 
Free water molecules are always in Brownian motion (Hansen et al., 2005). While self-
diffusing water in bulk has a free diffusion, the diffusion of imbibed or confined liquid is 
restricted by the wall of the pore. The relationship for the molecular mean square 
displacement, 
2r  and the molecular self-diffusion coefficient, Do is given by the Einstein 
equation:  
∆= oDr 6
2
      (7.1) 
with ∆ as the diffusion time (Veith et al., 2004). By varying the diffusion time, the diffusing 
molecules can indicate the connectivity of the pore space. This connectivity is characterised 
by a geometrical quantity termed as tortuosity (Hürlimann et al. 1994). The tortuosity will be 
defined shortly below. 
 
Since the 1960’s, Stejskal and Tanner (1965) had used PFG NMR experiments to measure 
molecular self-diffusion using the attenuated spin echo under the influence of a magnetic 
gradient. Spin echo refers to the refocusing of a precessing nuclear spin magnetisation by a 
180o pulse of a resonant radio frequency. The pulse sequence used for this work is the pulsed 
CHAPTER 7: STUDIES OF CONFINED WATER IN PLGA MICROSPHERES 
THE DEVELOPMENT OF CONTROLLED-CHEMOTHERAPY DRUG DELIVERY SYSTEM 99 
field gradient spin echo (PFGSE), such as illustrated in Figure 7.1. Consider that a radio 
frequency (r. f.) pulse has been applied to a nucleus, the nucleus will be excited and 
undergoes relaxation by emitting an echo. The signal generated from the pulse decays with 
time due to spin-spin relaxation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1: A pulsed field gradient spin echo (PFGSE) NMR sequence with a gradient, g used and the 
attenuated echo signal emitted after a 180
o
 dephasing-pulse is applied (Hollewand and Gladden, 1995). 
 
For a group of nuclei present, inhomogeneity in the magnetic field gradients causes different 
spins to precess at different frequencies and as a result, these spins will be out of phase with 
each other. This inhomogeneity led-to-dephasing can be re-phased by applying a 180o pulse. 
If a r. f. pulse is applied for a τ period of dephasing, an echo of the r. f. pulse will be emitted 
at time 2τ. With a magnetic field gradient applied after the initial r. f. pulse, the relaxation of 
a nucleus will then be dependent on its position in the magnetic field. If the nucleus is 
diffusing during the measure period, then the 180o will not be able to position the nucleus 
back in phase with the others because of its different precessing frequency. The echo signal 
is therefore reduced or attenuated.  
 
PFG NMR utilises the above features to measure the diffusion coefficient of a molecule. 
After a defined time, diffusion coefficient; D, of the measuring species can be obtained by 
observing the positions of the molecule before and after its random diffusion, each labelled 
with a field gradient respectively. The echo attenuation, R is defined as the ratio of the echo 
intensity in the presence of the gradient to the echo intensity obtained in the absence of a 
gradient; i.e. I/Io (Hollewand and Gladden, 1995). For free Brownian self-diffusion, where 
the random motion of the molecules is assumed to follow Gaussian behaviour, the echo 
attenuation has the functional form given by:  
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where γ is the gyromagnetic ratio of the observed nucleus; g is the applied PFG strength; δ is 
the time of the applied PFG; ∆ is the diffusion time; τ is the correction time for the phasing 
and dephasing between bipolar gradients and D is the diffusion coefficient (Kerssebaum, 
2002).  For simplicity, the term γ2 δ2 g2 [∆ - (δ/3) - (τ/2)] will be abbreviated as θ.  
 
A single diffusing system will give rise to a linear log-attenuation plot of ln (I/I0) vs. θ, with 
a gradient that equals the diffusion coefficient, D of the diffusing species. Deviations from 
this linearity can arise from regions of the sample possessing different diffusion coefficients; 
i.e. multi-component diffusion environment (Hollewand and Gladden, 1995). For the 
microsphere experiment herein, it was anticipated that there would be two water components; 
free water in bulk and water imbibed in microsphere (Messaritaki et al., 2005). Hence, 
considering a two separate diffusion components present, the model now becomes: 
]).1(.[ 210
DD
epepII
θθ −− −+=      (7.3) 
where D1 is the diffusion coefficient of free water in bulk and D2 is the diffusion coefficient 
of water imbibed within pores. p is the fraction of free water while (1 – p) is the fraction of 
imbibed water.  
 
For water that is imbibed within pores or cavities, their diffusion are restricted by the size of 
the pores/cavities (Callaghan et al., 1983). The restricted diffusion in cavities can be related 
to the radius of the cavity: 
 




 −∆=
3
5
δ
DR       (7.4) 
where R is the cavity radius, D is the diffusion coefficient, ∆ is the diffusion time and δ is the 
length of the gradient pulse. Pore diameter, d is 2R. For Equation 7.3 to valid, ∆ had to 
satisfy the conditions in relation to pore size and diffusion time (Callaghan et al, 1983).   
 
For all diffusion to be restricted, ∆ must be sufficiently large compared to the pore size. 
Reason being that a long diffusion time allows the water molecules to reach to the restriction 
bounded by the pore surface. Hence, they are under restricted diffusion and from Einstein 
equation (Equation 7.1); ∆ » Dr 6/2 . Contrarily, if ∆ is too short; i.e. ∆ « Dr 6/2 , the diffusion 
time is insufficient for the molecule to diffuse across the pore, then the measured diffusion 
coefficient represents the free diffusion because the molecules will not reach to the boundary 
of the pore (Ek et al., 1994 and Hürlimann et al., 1994).   
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The effective diffusion of the imbibed water in a porous solid is related to its molecular self-
diffusion coefficient by: 
κ
εo
eff
D
D =        (7.5) 
Deff is the effective diffusion coefficient; Do is the molecular self-diffusion coefficient; κ  is 
the tortuosity and ε is the voidage of the solid (Hürlimann et al., 1994). Equation 7.5 shows 
that the higher the tortuosity is, the lower the Deff is, due to lower r.m.s. displacement. Since 
the NMR signal measurement is observed based on the intensity that is proportional to 
volume, which in turn comprises the voidages density. Therefore, the diffusion coefficient 
measured by PFG NMR, DPFG can be related to Deff by: 
Deff = ε.DPFG       (7.6) 
By equating Equation 7.5 and Equation 7.6,  
2
1
D
D
D
D
PFG
o ==κ       (7.7) 
Where Do = D1 = diffusion coefficient of free water and, DPFG = D2 = diffusion of imbibed 
water (Hollewand and Gladden, 1995). The tortuosity or the connectivity of the porous 
network can thus be studied. A high κ  value usually indicates a complex network system. 
 
7.1.1 Method 
Blank PLGA microspheres were prepared using a single emulsion method described in 
Section 4.1.3. Approximately 0.3 g of sample was immersed in 2 ml of distilled water and 
then transferred into a 5 mm ID NMR tube. 1H NMR with PFGSE sequence experiments 
were conducted using a 400 MHz Bruker spectrometer at probe temperature 298 K. The 
measurement of diffusion coefficient of water was conducted using diffusion ordered 
spectroscopy (DOSY) program. DOSY follows the intensity of the spin echo signal based on 
the movement or displacement of a species from one point to another; this movement alters 
the intensity of the signal. 1H DOSY NMR data was obtained for 1H2O alone in order to 
determine the 1H2O peak position and diffusion coefficient for free water.  
 
The values of ∆, δ and τ used were 0.05 s, 0.002 s, and 0.001 s, respectively. For each 
measurement, eight datum points (16 scans / datum) were collected at different PFG 
strengths ranged from 67.40 to 3203.0 Gaussian per meter (G/m). Each measurement yielded 
a set of eight intensities (Ireal); each corresponded to the eight different PFG strengths. Icalc 
was generated by fitting these Ireal to Equation 7.4 using solver from Microsoft Excel with 
least-squares method. The echo attenuation; R = I / Io is a relative parameter. 
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Linear Fit 
X   R
2
 = 0.9953 
O    R
2
 = 0.9939 
         Polynomial Fit 
X   ln (Ireal / Io)     R
2 
= 0.9999 
O   ln (Icalc / Io)    R
2
 = 0.9999 
Findings in Section 6.1.2 showed that 75:25MS tends to have porous interior and their 
interior pores were in the order to 1 nm. As aforementioned, in order to obtain a restricted 
diffusion, the diffusion time, ∆ has to be sufficiently large. Based on Equation 7.1 and a ∆ 
value of 0.05 s, the corresponding r.m.s. displacement was ~26 µm. This value exceeds the 
pore size but not larger than the microspheres used in this experiment. 
 
7.1.2 Results and Discussion 
Figures 7.2 (A) and (B) show the goodness of fit for Equation 7.4 used to estimate the 
diffusion coefficient of imbibed water, D2 and fraction of free water, p. The calculated 
intensities (Icalc) are in good correlation to the Ireal where R
2 are very close to unity.  
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Figure 7.2: (A) Plot of calculated intensities, Icalc against real intensities, Ireal. (B) Comparison of the 
calculated intensity (Icalc) and real intensity (Ireal) against different PFG strengths.  
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Figure 7.3: (A) Example of a log-attenuated intensity plot based on the two D’s component model 
Equation 7.4. (B) Log-attenuated intensity plot used to estimate the diffusion coefficient of free water. 
 
Figure 7.3A is an example of log-attenuated plot based on the data measured using PLGA 
microsphere sample. The polynomial trendline yielded higher values of R2 and thus 
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8
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-2
) θ (x10
8
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) 
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A B 
X   lcalc, R
2
 = 0.9996 
O    Ireal, R
2
 = 0.9998 
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indicating that the system contained more than one diffusion component as suggested earlier. 
By using water and one D component model (Equation 7.3), the diffusion coefficient of free 
water, D1 can be determined from the gradient of the log attenuated plot shown in Figure 
7.3B. The D1 for free water was found to be 2.22 m
2/s. Mitra et al. (1995) reported a value of 
2.3 x 10-9 m2/s while the Bruker Biospin Handbook suggested a value of 2.299 x 10-9 m2/s at 
298K (Wolff, 2005). 
 
Swelling of the device is common for PLGA microspheres (Matsumoto et al., 2006), and 
PLGA rod implants (Witt et al., 2000). Figure 7.4A shows the 65:35MS-discs produced 
using method described in Section 4.6.4. These images prove that 65:35MS underwent 
hydration and the disc had swollen after ten and twenty days immersion in water. Figure 7.4 
(B) and (C) show the fragility of PLGA microsphere towards high pressure disc-pressing. 
The partially deformed 65:35MS could lead to a hydration gradient across the disc.  
 
         
Figure 7.4: (A) 65:35MS-disc before and, after 10 days and 20 days immersion in water. (B) and (C) SEM 
images of 65:35MS-disc. 
 
The effects of water uptake (i.e. hydration) by PLGA microspheres are proposed below: 
i. Hydration occurs via two phases, water diffusion through amorphous region of the 
polymeric microsphere and water penetration through surface micropores. This 
hydration process will increase the fraction of imbibed water (1 – p). Prior to this, the 
microspheres may be partially filled with residual water from the production process.  
ii. Increase in imbibed water (1 – p) would result in an increase in D2. 
iii. When a cavity or pore undergoes hydration, it expands and leads to swelling. As a 
result, the microsphere can increase in size (Figure 7.4A). 
iv. Through interconnecting channels, water can travel from one pore to another. 
Different regions within a microsphere can experience different hydration rate due to 
water transport. 
 
With repeated experiments using different batches of microspheres, it was found that PLGA 
microspheres are associated with both intra- and inter-variations within production batches. 
A    B                         C 
 
 
       10 day      20 day 
Before  After  
Immersion immersion 
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In order to minimise these variations, the sample remained in the same tube was used 
throughout the experiment. The result presented herein is batch-specific and PFG-NMR was 
used to explore the pore swelling mechanism. Occasionally, unobtainable data were due to 
faulty DOSY measurements. The diffusion coefficient of imbibed water, D2 estimated from 
two D’s component model measured over a period of one hundred days is shown in Figure 
7.5. These results were obtained from a same batch of microspheres and will be denoted as 
Batch 1 (B1). The corresponding fraction of imbibed water (1 – p) is shown in Figure 7.6. 
The hourly measurements during the first ten hours are shown in Appendix V.F. 
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Figure 7.5: The diffusion coefficient of imbibed water, D2 of 50:50MS (  ), 65:35MS (  ) and 75:25MS (  ). 
 
Figure 7.5 shows the measured D2’s were smaller than the free water diffusion; D1 of ~2.2 
x10-9 m2/s, and this suggests restricted water diffusion. The very low values of D2 of 
65:35MS during the initial hourly measurement suggested a low volume of imbibed water, 
and is reflected on its low (1 – p) shown in Figure 6.7. With an assumption that the D2 of 
65:35MS on the fifth day is an outlier, there is an increasing trend until the twenty-first day. 
Thereafter a decrease in D2 for about fifteen days before it increases again on the forty-fifth 
day. From the fiftieth day onwards, D2 of 65:35 remain relatively constant. The increasing 
trend in D2 of 65:35MS in the first twenty five days could be attributed to the increasing 
hydration rate which leads to swelling. This can be validated by an increasing trend in its 
fraction of imbibed water seen in Figure 7.6.  
 
There is a clear increase in D2 of 50:50MS over the first twenty days and thereafter the 
values tend to fluctuate at a magnitude of 0.8 x 10-9 m2/s. The D2 measured on the thirty-fifth 
Hourly measurements 
Incubation Time (Days) 
× 
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day has a value of 1.09 x 10-9 m2/s and its corresponding fraction of imbibed water has the 
value of unity (result not shown on Figure 7.8). This is attributed to a faulty measurement 
thereby generating this outlier. Unlike its D2 trend, the fraction of imbibed water of 50:50MS 
is observed to decrease after the first day and then increases again until the thirtieth day. 
After that, the (1 – p) tend to fluctuate at a magnitude of 0.4. This fluctuation may due to (1) 
intermittent swelling and shrinking, (2) different rates of hydration in empty pores and, (3) 
the commencement of interior degradation that altered the structural volume. 
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Figure 7.6: The fraction of imbibed water (1 – p) in 50:50MS (   ), 65:35MS (   ) and 75:25MS (   ). 
 
During the initial hourly measurements, the D2’s and fractions of imbibed water of 50:50MS 
and 75:25MS shown on Figure 7.5 are well above those of 65:35MS, suggesting the former 
two experienced higher rates of hydration. The D2 of 50:50MS begun with a lower value than 
of 75:25MS but after four days, it surpasses the D2 of 75:25MS. A possible scenario is that; 
initially, the pores in 50:50MS were the smallest and then water started to diffuse into these 
pores. This is highly possible due to the more amorphous regions in 50:50 PLGA. As a 
result, pore expansion and swelling increased the fraction of imbibed water.  
 
50:50MS has the most amorphous region which permits higher water diffusion and thus 
higher hydration rate. In this sense, the glycolide acid content decreases the hydrophobicity 
of PLGA. Here, it is suggested that the least hydrophobic and degradation resistance 
50:50MS give rise to a higher water diffusion compared to 65:35MS and 75:25MS. As a 
result, 50:50MS is more prone to swelling. Hence, D2 increases with (1 – p) because of the 
higher hydration rate experienced by 50:50MS.  
Incubation Time (Days) 
× 
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The rather constant values of D2 of 75:25MS indicate that the internal structure of 75:25MS 
was highly intact. The fraction of imbibed water in 75:25MS is also observed to be relatively 
constant. These conditions would agree with the less hydrophilic 75:25 PLGA which 
minimises hydration due to its extra chiral group.  
 
Figures 7.5 and 7.6 were reproduced and presented in Figure 7.7 in order to show the initial 
results of twenty days. The very low D2 values of 65:35MS during the first ten hours of 
measurement corresponded with less than 10% of imbibed water; i.e. (1 – p) < 0.1, as shown 
in Figure 7.7B. There was an increment in D2 of 50:50MS after the first ten hours and this 
suggests that the water diffusion increases during this period of time. This is attributed to the 
higher hydration rate of 50:50MS which leads to swelling and thus, the imbibed water was 
able to move more freely in enlarging pores. The relatively constant D2’s of 75:25MS 
indicates minimal pore swelling. 
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Figure 7.7: Reproduction of Figures 7.6 and 7.7 on the first twenty days of measurement. (A) The 
diffusion coefficient of imbibed water, D2 of 50:50MS, 65:35MS and 75:25MS. (B) The fraction of 
imbibed water, (1 - p) in 50:50MS, 65:35MS and 75:25MS. 
 
The experiment was repeated with two different batches of PLGA microspheres; denoted as 
Batch 2 (B2) and Batch 3 (B3) produced using the same method and condition as B1. Results 
were plotted on the same graphs in order to study the repeatability of the work. Measurement 
was planned for thirty days in conjunction with the degradation experiment reported in 
Section 6.2. Random measurements were still carried out in order to confirm the behaviour 
of the system at later stages.  
 
Figure 7.8 shows the diffusion coefficients of imbibed water in 50:50MS, 65:35MS and 
75:25MS from B2 and B3. The corresponding fractions of imbibed water in 50:50MS, 
A B 
Incubation Time (Days) Incubation Time (Days) 
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65:35MS and 75:25MS from B2 and B3 are shown in Figure 7.9. Occasionally, the estimated 
p had the values of unity, resulting D2 of zero values. On the other hand, when D2 approaches 
D1 (i.e. 2.22 x 10
-9 m2/s), their corresponding (1 – p) values were unity. These values were 
not shown in Figure 7.9 because majority of the results concentrated at low values and the y-
axis was focused to reflect them.  
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Figure 7.8: The diffusion coefficient of imbibed water, D2 of 50:50MS (   ,   ), 65:35MS (   ,   ) and 
75:25MS (    ,    ) from Batch 2 (B2, open symbols) and Batch 3 (B3, close symbols) microspheres. 
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Figure 7.9: The fraction of imbibed water, (1 – p) of 50:50MS (   ,   ), 65:35MS (   ,   ) and 75:25MS (   ,   ) 
from Batch 2 (B2, open symbols) and Batch 3 (B3, close symbols) microspheres. 
 
From Figure 7.8, the measured D2 values from B2 and B3 microspheres were approximately 
halved of those of D2 from B1 microspheres, with the exception for the 50:50MS. The D2 
B2 : 
B3 : 
B2 : 
B3 : 
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results from B2 and B3 microspheres seemed logical because their corresponding fractions of 
imbibed water are also much smaller than those observed in B1 microspheres.  
 
50:50MS from B3 demonstrated an increasing trend in D2 during the first ten days. Due to 
faulty NMR data acquisition, no data could be processed thereafter. It corresponding fraction 
of imbibed water did not concurred with this trend. The fraction of imbibed waters measured 
on the third, fifth and eighth days had the value of unity (data points not shown) and this 
could be explained by the increasing D2 from the fifth day to the eight day. The highest D2 
value during this period is 2.42 x 10-9 m2/s, which matches the value of free water and 
therefore the measured D2 is no longer under restricted diffusion.  
 
65:35MS from both B2 and B3 show a decreasing trend in D2 values during the first ten day 
and their corresponding (1 – p) in Figure 7.9 indicate agreement. This trend is opposing the 
trend exhibited by 65:35MS from Batch 1. 75:25MS from B2 and B3 also demonstrate 
decreasing trends in both their D2 and (1 – p). The very low D2 detected could be the 
diffusion within the polymer matrix. By comparing the results of (1 – p) shown on Figures 
7.9 and 7.6, microspheres from B2 and B3 had much less imbibed water with fractions of ≤ 
0.15. B1 microspheres had almost doubled this amount. This explains the smaller D2 values 
from B2 and B3 microspheres than those from B1.  
 
Overall the results from the three different batches PLGA microspheres suggest the presence 
of inter-batch variations. Very often the D2 results tend to exhibit “sinusoidal” pattern and 
this is interpreted as the intermittent swelling and shrinking of the pores within these 
microspheres. This is a common characteristic of polymeric microspheres which are capable 
of hydration. Fujiyama et al. (2003) presented cross sectional SEM images of degrading 
PLGA/PLA microspheres. Interior structural collapse is shown by these authors and at 
different degradation time, this structure alternated between dense and porous natures. 
Swelling is thought to have caused local cavities or pores expansion and minimises the 
spaces between the adjacent cavities. The pore sizes of swollen cellulose beads after 
immersion in water could sometimes doubled its initial sizes (Ek et al., 1995).  
 
In the event of water diffusing from one pore to another, i.e. from bigger pores to smaller 
pores or vice versa. While the water in a bigger pore leaves to fill a smaller pore, the 
“swollen” bigger pore decreases in size while the smaller pore expands as water gradually 
fills up. These lead to temporary changes in pore sizes where pore expands and shrinks due 
CHAPTER 7: STUDIES OF CONFINED WATER IN PLGA MICROSPHERES 
THE DEVELOPMENT OF CONTROLLED-CHEMOTHERAPY DRUG DELIVERY SYSTEM 109 
to water migration between pores. So far results indicate these events are random. It could 
also be that initially, the pores nearest to the microsphere surface experience a more frequent 
hydration/swelling effect. As immersion proceeded, the inner part of the spheres becomes 
increasingly hydrated. The presence of interconnecting channels of different sizes can affect 
the mobility of water. Section 7.2 will show that these interconnecting channels also swell 
and shrink over time. This could further affect the hydration rates in the main pores. The 
different crystalline and amorphous regions of polymeric PLGA microsphere would also 
affect water diffusion within the polymer matrix.  
 
The PFG-NMR measurement could be indeterminately detecting water molecules located 
near the wall of the pores or diffusing near the surface of the pore wall. Callaghan et al. 
(1979) had observed a reduction in the diffusion coefficient of water and concluded it is 
caused by the occasional binding of water at the pore surface layers. There could be a nano-
sized layer water surrounding the interior pore surface (Callaghan et al., 1983). The 
Brownian motions of these water molecules persisted within this layer and showed higher 
r.m.s. displacement. This layer of water exists only nearest to the pore surface due the OH-
bond interactions between the water and pore wall that leads to a fraction of the water next to 
the pore wall no longer fully free. Section 7.2 will further discuss the nano-sized water layer 
located at the pore surface. 
 
In addition, the tortuosity effect also arises from the changes in local dimensionality. 
Structural heterogeneities have been shown to influence both steady-state and transient 
diffusion (Hollewand and Gladden, 1993, and Rigby et al., 1996). Callaghan et al.  (1979) 
suggested a two-third reduction in diffusion coefficient for lamellar or slit-shaped and, a-
third reduction for cylindrical or capillary geometry pores. While monitoring the adsorbed 
liquids in porous glasses with pore sizes ranged 0.8-50 nm, Kärger et al. (1983) found that 
stabilisation of liquid molecules by the pore wall might be responsible for the reduction in 
diffusivity in small pores. Fukuda et al. (1989) also agreed to the same conclusion where 
decreased in diffusivity was observed from the effects of smaller pores (4 - 45 nm) samples. 
In conjunction to these studies, findings in Section 6.1.3 showed that microcavities in 
75:25MS are ~1 nm in size.  
 
By obtaining the diffusion coefficient of the imbibed water (D2) from Equation 7.3, the r.m.s. 
displacement of water and the pore diameter, d can be estimated using Equations 7.1 and 7.4 
respectively. The results of 50:50MS, 65:25MS and 75:25MS from Batches 1, 2 and 3, 
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plotted against incubation time are shown in Appendix V.A. A summary of the overall trends 
observed on the pore size evolutions of the PLGA microspheres over the period of twenty 
days is presented in Table 7.1. The tortuosity results estimated using Equations 7.3 and 7.7 
are also shown in Appendix V.B. Only results up to twenty days are shown because changes 
were more prominent during this period. The tortuosity in PLGA microspheres vary 
randomly over time but 75:25MS tend to show the smallest fluctuation in its tortuosity factor.  
 
Table 7.1: Summary of the overall trends observed for the pore size evolutions exhibited by 50:50MS, 
65:35MS and 75:25MS from different batches.  
Overall trends observed for Pore sizes Evolutions PLGA 
microspheres Batch 1 Batch 2 Batch 3 
50:50MS 
Increase – constant  
Small increase on  
Day 1 to 2; constant 
thereafter.  
Sinusoidal 
Decreases on Day 1, 
thereafter gradual 
increase. 
Sinusoidal 
Increases within Day 1, 
decreases after Day 1, 
increases thereafter. 
65:35MS 
Increase – constant 
Gradual increase over 6 
days; constant thereafter.  
Increase – constant 
Increases after Day 1; 
constant thereafter 
Sinusoidal 
Slight increase on Day 1; 
decreases thereafter. 
75:25MS 
Constant 
Small degree of 
fluctuation. 
Sinusoidal 
Decreases from Day 1 to 
5, increases thereafter. 
Constant 
Slight decrease. 
 
The pore evolution in PLGA microspheres often exhibit intermittent swelling and shrinking. 
The expansion of one pore, or a few pores in a region may “push” the surrounding pores and 
cause them to shrink. If the overall shrinkage is dominant, then a reduction in fraction of 
imbibed water was observed. This effect will also be reflected in a decrease in water 
displacement or pore size. Comparing the overall trends exhibited by 75:25MS to 50:50MS 
and 65:35MS, 75:25MS of all batches demonstrated the least fluctuation in results.  
 
For comparison purposes, the pore sizes from PLGA microspheres are collected to assess the 
degree of pore swelling. Figure 7.10 shows the swollen pore diameters calculated using 
Equation 7.4 for 50:50MS, 65:35MS and 75:25MS from B1, B2 and B3. The swollen pore 
was taken as the largest pore observable from each sample and is not time-specific The initial 
pore size is the pore size measured at the first time point. Comparing the initial pore sizes of 
50:50MS, 65:35MS and 75:25MS, their sizes are not significantly different from each other 
(t-test, p < 0.05). This indicates that the single emulsion method employed in this thesis 
produces microspheres with interior pores of similar magnitudes and is independent of the 
different copolymer ratios.  
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Figure 7.10: The average pore sizes of 50:50MS, 65:35MS and 75:25MS from B1, B2 and B3. Fill 
symbols = initial pore size measured at the first time point; open symbols = largest (swollen) pores.  
 
The pore swelling in 50:50MS is the greatest and its swollen pore is significantly larger than 
its initial pore size (t-test, p < 0.05). 65:35MS and 75:25MS did not experience significant 
pore swellings. Comparing the swollen pore sizes, only the swollen pore of 50:50MS is 
significantly larger than the swollen pore of 75:25MS (ANOVA, p < 0.05). 75:25MS of all 
batches experienced the least swelling effect. This is contributed to its structural integrity of 
75:25 PLGA. In contrast, 50:50MS experienced the most swelling effect. This is due to its 
highest glycolide acid ratio which provides more amorphous region for water diffusion. Thus 
hydration and swelling is greater in 50:50MS.  
 
 
7.2 NMR Cryoporometry 
 
NMR cryoporometry is a technique used to determine pore size distribution in a porous 
media by studying the melting point depression of a confined liquid (Mitchell et al., 2008). It 
will be explained shortly that the pore size and melting point have a reciprocal relationship. 
Similar to PFG NMR, NMR cryoporometry measures the signal from the 1H within the liquid 
molecule. The property of a confined liquid will deviate from its bulk state because the 
confinement has introduced new liquid molecules-solid wall interactions and surface-to-
volume ratios (Sv). While Sv is affected by the size of a pore, the spin–spin relaxation time of 
the NMR signal is long for a liquid and short for a solid (Strange et al., 1993 and Hansen et 
al. 1996). This enables differentiation between a molten liquid and a frozen liquid as a 
function of temperature during freezing.  
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Gas adsorption and mercury porosimetry characterise porous media based on studies of the 
equilibrium conditions between liquid and gas phases arise from capillary effects. These 
methods transform volume/pressure data into volume/pore size data. Cryoporometry 
generates the same sort of data but based on heat/temperature data from the studies of 
solid/liquid equilibrium. Similar to capillary phenomena, hysteresis is also observed for 
freezing and melting transitions in cryoporometry experiments (Denoyel and Pellenq, 2002, 
and Denoyel et al., 2004).  
 
The development of NMR cryoporometry is fuelled by the theories from J. W. Gibbs, J. 
Thomson, W. Thomson (later Lord Kelvin) and J. J. Thomson, whom among the pioneers to 
realise the different mechanisms involved in a non-equilibrium phase transitions 
experiencing by a confined material. Their experimental findings showed that variables such 
as geometry can affect the basic property of the matter such as its vapour pressure. In 
particular, they established that the bulk melting point varies inversely with crystal size. A 
pore of size x will melt at a temperature Tm(x) lower than the bulk melting point Tm, which is 
inversely proportional to x. As expressed in Mitchell et al. (2008), the Gibbs-Thomson 
equation that relates the melting point depression, ∆Tm for a small crystal of size x is:  
sf
msl
mmm
Hx
T
xTTT
ρ
σ
∆
=−=∆
4
)(     (7.8) 
where Tm is the normal bulk melting point, Tm(x) is the melting point of pore of size x, σsl is 
the surface energy of the solid-liquid interface, ∆Hf is the enthalpy of fusion, ρs is the density 
of the solid. Assuming all parameters in the equation to be independent of temperature and 
pore dimension (Hansen et al., 1996), then Equation 7.8 can be simplified to: 
x
k
Tm =∆        (7.9) 
where k is the melting point depression constant associated to the absorbate’s thermodynamic 
property (Strange, 1993).  
 
The numerical constant “4” in Equation 7.8 is derived for cylindrical pores. Equation 7.8 is a 
basic model that assumes the pore structure has the same geometry throughout the sample. 
Micro- and mesoporous materials can have pores or voids of different geometry; i.e. slit-
shaped, cylindrical or spherical etc. In real samples, the influence of pore geometry must be 
taken into account because the geometry is often not perfect. For instance, the pores may be 
interconnected or of mixed geometry. The model then requires new approach taking into 
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account the confinement’s structure and properties. Webber et al. (2008) further formulated k 
into multiples of constants such that;  
k = kg . ks . ki        (7.10)  
kg is a geometric constant dependent on the interfacial shape, ks is a constant involving 
parameters specific to the crystalline solid of solid-liquid system and ki is an interfacial 
energy term. The calibration of these constants is beyond the scope of this thesis and an 
appropriate value for PLGA-water system will be adapted from a selected literature.  
 
A temperature gradient was anticipated to be present along and across the measuring sample. 
This temperature gradient is minimised by using a set of susceptibility plugs. The plugs 
raised the sample to within the receiver coil and at the same time, reduced the sample length. 
Not only these plugs help to provide insulation for the sample, they also permit liquid 
expansion and prevent the NMR tube from rupturing during freezing. Figure 7.11 shows the 
ensemble of a sample tube. The NMR experimental condition herein is developed by Perkins 
et al. (2008) and they suggested a temperature deviation of 0.2 K to be expected. 
 
 
 
 
 
 
 
7.2.1 Method 
Blank PLGA microspheres were prepared according to the method described in Section 
4.1.3. Approximately 1 g of microspheres “stock” sample was immersed in 5 ml of distilled 
water and incubated at 37oC in a shaking water bath (Section 4.5). At specific time interval, a 
small amount of microspheres was collected using a tip. The top part of the tip was trimmed 
in order to fit into a NMR tube. The trimmed tip was then inserted into a NMR tube and 
positioned between a set of susceptibility plugs. A thermocouple used to assess temperature 
was inserted through the top susceptibility plug to the depth of just reaching the sample 
(Figure 7.11). Fresh sample was prepared from the “stock” for each measurement. 
Cryoporometry analysis was conducted using the same NMR system described in Section 7.1 
but with liquid nitrogen as a mean to control the temperature ranged between 225 K and 273 
K. The temperature was varied step-wise (0.5 or 1 K/step) with a 10 minutes equilibration 
Figure 7.11: An ensemble of a sample prepared using 
susceptibility plugs and thermocouple for NMR 
cryoporometry analysis.  
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time in between changes. The small step change was necessary to ensure temperature 
stability. The sample was subjected to consecutive cycles of freezing, melting and refreezing, 
abbreviated as F/M/rF cycles. E.g. The temperature was reduced step-wise from room 
temperature (c.a. 298 K) to 225 K, then raised to 273 K and reduced again to 225 K.  
 
The variation of NMR signal intensity (I) during the F/M/rF cycles was measured as a 
function of temperature (T) was plotted as the IT curve. The reasons for using water as a 
probe fluid are that the water molecules are small enough to enter the minute cavities within 
the sample and no part of the sample is soluble in water. Allen et al. (1998) found that 
repeated freezing-thawing often changes the structure of porous materials while the growth 
of ice crystal can cause deterioration to the sample. For these reasons, each analysis was done 
on fresh sample.  
 
7.2.2 Results and Discussion 
The principle of cryoporometry requires the understanding of the mechanism of freezing and 
melting transitions. In order for a new phase to appear; i.e. from liquid to solid, an interface 
must exist. For most real cases, suspended impurities or imperfectly wetted surfaces provide 
an interface on which the growth of a new phase is initiated. These elements enable 
heterogeneous nucleated-freezing (Scherer, 1998). In the absence of these elements, a new 
phase is developed from a small, localised embryo formed within the bulk metastable liquid. 
This is known as homogeneous nucleation, and it is only activated when a free energy barrier 
to form the embryo of critical size is overcome, beyond which the new phase grows 
spontaneously (Debenedetti, 1996).  
 
In the case of suspended solids, such as PLGA spheres, they present as a small degree of 
distribution that provide additional nucleation sites (Chellaiah and Viskanta, 1989). Two 
common freezing mechanisms in porous media are: freezing initiated by nucleation in pores, 
or by solid-front penetration through pores which are in contact with the frozen bulk 
(Swainson and Schulson, 2001 and Beurroies et al., 2004). The former is associated with 
homogeneous nucleation while the latter occurs via heterogeneous nucleation. Here, the 
freezing in pores is thought to be heterogeneously nucleated by the presence of bulk ice 
surrounding the microspheres, and penetration of ice front into the interior of the 
microspheres (Hansen et al., 2005 and Petrov et al., 2006). Figure 7.12 depicts a scenario for 
the PLGA microspheres used herein. 
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The interior pores are connected through “necks” which are smaller in size and they 
ensemble the typical ink-bottle pores. Brun et al. (1977) proposed that the ingress of solid 
front (ice) from frozen bulk into the pores is the mechanism responsible for pore freezing. 
This mechanism will be illustrated later with the F/M/rF cycles obtained from PLGA 
microspheres. With excess liquid saturating the microsphere, once the bulk liquid is frozen, 
further freezing in the pores occurs by ice ingress through pores which are in contact with the 
frozen bulk. For example, pore a is in direct contact with the frozen bulk, ice front ingresses 
into the microsphere through the necks from a to b to c. 
 
In order to overcome nucleation barrier that may delay freezing, Brun et al. (1977) suggested 
to freeze the system with excess liquid and at a low enough temperature to obtain a frozen 
bulk. Following that, the temperature is increased to a point just below the bulk melting 
temperature to study melting in pores. Subsequently, freezing cycle is initiated again. By 
doing so, the solid phase will always exists at the entrance of the pores and can act as nuclei 
for freezing inside pores, which can eliminates the nucleation barrier as assumed earlier. 
Thus, for the experiment herein, after the first cooling cycle (Freezing 1), the Melting cycle 
was aimed to melt only the confined ice while the bulk remained frozen. After that, the 
temperature was decreased again (Refreezing); these constituted the F/M/rF cycles.  
 
The resulting F/M/rF cycles show that the signal intensities of the latter two cycles were very 
close to the signals of the background noise and were unable to clearly indicate any phase 
changes. This scenario may due to a very low volume of confined water which failed to 
produce significant signal during the melting cycle. It is also possible that 75:25MS used 
herein has pores of magnitudes such that their corresponding melting points are very close to 
the bulk melting temperature. For these reasons mentioned, only the freezing curves will be 
used to explore the pore characteristic in 75:25MS.  
The measured NMR intensity is temperature dependent due to Boltzman’s effect. The 
Maxwell–Boltzmann statistics shows that the ratio of NMR proton spins, with upper- and 
lower-energy states are temperature dependent (Mitchell et al., 2008). The measured 
PLGA  
sphere                 Pore 
         at surface 
 
      
   
 
          Frozen Bulk 
Pores     Necks 
 
a 
 b 
 
c 
 Figure 7.12: A depicted PLGA-sphere with a porous 
network. Pores are interconnected through necks, both varied 
in size but the latter is assumed to be smaller than the main 
pores. 
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intensity, SI (TK) at absolute temperature, TK can be corrected relative to the signal intensity, 
SI (273 K) at 273 K based on the Curie Law using Equation 7.11: 
K
K
TKSI
TSI 273
)273(
)(
=        (7.11) 
The measured intensities of cryoporometry experiments were corrected using Equation 7.11 
and the results show that the temperature effect was minimal to the measured intensities. 
Therefore Equation 7.11 was not crucially required to correct the intensity data.  
 
For comparison purposes, the F-cycle for 75:25MS immersed in water for various days are 
shown on the same plot (Figure 7.13). Individual IT curve for the F/M/rF cycles will be 
shown from Figures 7.14 to 7.17. In some cases, the values of I/Io are observed to be higher 
than unity. This is attributed to the varying Io. Since I was detected based on the presence of 
molten water in molten phase and indicative to its volume in bulk, over time, the bulk water 
diffuses into the microspheres and thus reduces the prior measured Io. 
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Figure 7.13: IT curves for the F-cycles of 75:25MS after immersion in water for 5, 10, 20 and 30 days. 
Inset: A refocus on the lower scale of I/Io. 
 
Referring to the significance decrease in signal intensities shown on Figure 7.13, the bulk 
liquid was frozen at 266-267 K (denoted as TFo). The F-cycle of five days immersion 
75:25MS exhibits a diminutive step just after 260 K and at another at ~240 K. The F-cycle 
from ten days 75:25MS exhibits a clear step close to TFo and another at ~241 K. The F-cycle 
from twenty days 75:25MS exhibits a gradual decrease in I/Io below TFo and a step at ~240 
K. The thirty days 75:25MS exhibits the most distinct pattern where a clear and prominent 
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step close to TFo can be seen followed by another at ~240 K. The secondary freezing 
temperatures seen in Figure 7.13 suggest an “ink-bottle” geometry pores are present in 
75:25MNS. These F-cycles indicate similarity to results from Khokhlov et al. (2007) using 
samples with ink-bottle pore geometry. 
 
Since the measured intensity is proportional to the volume of water present, the decrease in 
intensity shown on the refocus IT curve suggests that bulk water constituted almost 90% of 
the total volume detected and ~10% water were imbibed in 75:25MS. After the bulk freezing 
point, the occurrence of second or third freezing points is attributed to the solid (ice) front 
penetration into the subsets of pores within the partially frozen microspheres.  
 
Owing to their high Sv, liquid confined in pores crystallises (or freezes) and melts at 
temperatures well below their bulk melting points (Christenson, 2001). Compared to bulk, 
this high Sv ratio introduces excess energy for the solid. Thereby, shifts the liquid-solid 
equilibrium towards the liquid state (Petrov and Furó, 2006). Hence, molten liquid is still 
present in the porous microspheres even below the normal freezing point of water. As 
aforementioned, the freezing of water in pores occurs via the ingress of ice crystals from the 
frozen bulk into the interior pores (Khokhlov et al., 2007 and Perkins et al., 2008) and this 
causes the delay in complete freezing of water present in the system, as seen on Figure 7.13.  
 
Figure 7.14 shows the F/M/rF cycles subjected on 75:25MS after five days of immersion in 
water. The plot focused on the lower scale of I/Io in order to show the small variations in I/Io 
with temperature. After Freezing 1, the frozen sample was subjected to subsequent Melting 
but the temperature was raised only to the point below the bulk melting (i.e. ≤ 273K) while 
the bulk remained frozen. Following that, Refreezing was initiated. Following the Freezing 1 
curve, the bulk liquid was first frozen at ~267 K. Second and third freezing transitions 
occurred at ~258.5K (TN1) and ~239K (TN2) respectively. For convenience, the notations 
such as ‘N1’ and ‘N2’ are used to describe the relative temperatures to TFo; i.e. TN1 is closer 
to TFo while TN2 is further away from TFo. With both the F/M cycles, it shows that the 
confined water in 75:25MS underwent supercooling.  
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Figure 7.14: IT curves for F/M/F cycles of 75:25MS after 5 days immersion in water. 
 
It is also evident that the F/M cycles shown in Figure 7.14 did not retrace one another 
thereby suggesting the presence of hysteresis. This is largely due to the delayed in freezing 
nucleation (Janssen et al., 2004). By referring to Figure 7.14, the mechanism whereby the 
freezing of water confined in pores occurs by ice ingress from the frozen bulk through the 
interconnecting channels can be demonstrated.  
 
After the bulk liquid freezes at TFo, from the intensity detected, it indicates that molten and 
confined liquid are still present in the system. While the microspheres are surrounded by a 
frozen bulk, ice crystals started to ingress into the microspheres via the pores at the surface. 
The ice front will first freeze the water in the connecting channels. The ice front in the 
channels then ingress into the pores and consequently freezes the liquid confined in the main 
pore. The presence of confined liquid leads to supercooling and shifted the actual freezing 
point. The pore size is more reliably determined using the melting temperature by raising the 
temperature after the primary freezing cycle. The F-cycle is therefore used to predict the size 
of the neck through which the ice front ingresses through.  
 
For porous media, the hysteresis is thought to have originated from the pores of varying cross 
sections and networks. It is the connection through a smaller channel to a bigger main cavity 
that gives rise to pore blocking effect, or known as the ink-bottle mechanism. This 
mechanism occurs when a narrow channel is preventing the further ingress of the solid phase. 
After reaching TFo, the ice front will not be able to ingress into smaller pores until the 
TN2              TN1            TFo 
x                                                          x                        x 
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thermodynamical condition favouring this penetration is achieved. Consequently, a second or 
third freezing point is detected at a much lower temperature. The following are suggested by 
Petrov and Furó (2006) to explain the freezing/melting hysteresis;  
i. As far as bulk liquid is concerned, homogenous nucleation causes uncontrollable 
delay on cooling. The bulk liquid becomes supercooled until homogeneous 
nucleation initiates freezing.  
ii. Freezing by solid ingress within the interior pores may be heterogeneously nucleated 
by the surrounding bulk ice but this solid ingress is delayed by pore-blocking effect. 
iii. There present a free-energy barrier for solid ingress which separates metastable states 
of a confined material from stable ones. 
 
This sort of analysis is advanced from the studies of capillary condensation and vaporisation 
which are parallel to those of melting and solidification/freezing respectively (Beurroies et 
al., 2004 and Denoyel et al., 2004). With the delayed in freezing, Figure 7.14 shows that the 
75:25MS used herein are indeed: 
i. Porous and hydration enables water to be imbibed in these pores. 
ii. The presence of hysteresis suggested these pores are made of ink-bottle geometry. 
The ink bottle effect is thought to delay the freezing of confined water. 
iii. Since melting curves could not be explored, the freezing curves can only used to 
estimate the size of the neck. The presence of second and third freezing points 
indicated a bimodal system; 75:25MS used herein was potentially inherited with 
necks of one or two different sizes.    
 
Referring to Figure 7.14, when the temperature reaches TN1; this point corresponds to the 
freezing of the water in the interconnecting necks of size, xN1. Further cooling to TN2 freezes 
the water in the neck of size xN2. From the Gibbs-Thomson equation (Equation 7.9), the neck 
with size xN1 is bigger than the neck with size xN2 because the latter occurs at a lower 
temperature. Further F/M/rF cycles obtained from 75:25MS after ten, twenty and thirty days 
of immersion in water are shown in Appendix V.C. These cycles exhibit great likeliness to 
Figure 7.14, with secondary freezing temperatures suggesting the presence of smaller necks.  
 
The same mechanism observed in liquid freezing can be expected for melting of liquid in 
porous media inherited with ink-bottle pores (Beurroies et al., 2004). Since the water 
confined in pores will not freeze before the water in its connecting necks, likewise, the 
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melting will also begin in the neck before the frozen confined water. For melting transition in 
small pores, in most cases, nuclei of the liquid phase are present at all relevant temperature.  
 
Booth and Strange (1998) studied the freezing and melting cycles of cyclohexane in silicas 
using NMR. They observed a melting point below the bulk’s melting point but in the 
confined ice crystal, there were two distinct components of the transverse relaxation time. 
The short relaxation time (comparable to the crystal phase in the bulk) was attributed to the 
ice crystal in the inner core of the pore and the long relaxation time was attributed to the 
liquid-like layer between this crystal and pore wall, the so-called “bound-layer”. It is thought 
that melting begins from this liquid-like phase layer. Denoyel and Pellenq (2002) also agreed 
to this phenomenon suggesting that surface melting occurs at the end of the metastable range 
and the only condition is that the pore wall is preferentially wetted by the liquid rather than 
by the solid phase (ice).  
 
Overloop and van Gerven (1993), Morishige and Kawano (1999) among others also observed 
the presence of a bound layer located adjacent to the pore wall which remained liquid-like 
structure when the inner fluid had frozen, such as illustrated in Figure 7.15. This 
phenomenon is observed regardless the geometry and size of the pores. Based on these 
studies, the melting mechanism in pores or necks is thought to begin from the surrounding 
wall inwards to the core of the ice crystal. Morishige and co-workers repeatedly found that 
the freezing of this bound layer was a continuous process and it persisted over a range of 
temperature (Morishige and Nobuoko, 1997 and, Morishige and Kawano, 1999).  
 
 
 
Since the early 1980s, Buttet et al. (1982) and Myles (1982) have shown that the decrease in 
freezing temperature for water in the inner region of the pore is consistent with the Gibbs-
Thompson equation but the pore diameter, x is replaced by (x-xbw) where xbw is the thickness 
of the bound water. Webber et al. (2001) also reached to the same conclusion. Hansen et al. 
(1996) found that this thickness was within experimental error and its variation with material 
type was only marginal. Thus, xbw can be treated as a constant but this assumption only valid 
Figure 7.15: Within frozen liquid confined in a pore, 
there exits of a ‘bound layer’ located between the 
frozen inner core and pore wall.  The ice crystal formed 
at the inner core is thus enveloped by a layer of 
unfrozen water adjacent to the pore surface.  
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for pore with dimension bigger than xbw. This layer also appears to be temperature dependent 
(Petrov et al., 2007). This bound layer can cause problem when it produces signal extending 
to low temperature which can be misinterpreted as very small pores (Aksnes et al., 2001).  
 
Results from experiments conducted on 50:50MS were presented below where the results of 
65:35MS are included in Appendix V.C. The F-cycles subjected on 50:50MS after 
immersion in water for various days are shown on Figure 7.16. The sampling time point of 
50:50MS was based on hourly basis in view to a more rigid sample before degradation had 
altered its internal structure which might complicate results interpretation. The F-cycle from 
50:50MS after two hours immersion in water did not exhibit any clear step below TFo (266 
K) but close observation suggests that there may be a small step present at ~260 K. Based on 
the enlarged plot (shown in inset), the F-cycle of six hours water-immersed 50:50MS 
exhibits a step at ~258 K. The F-cycle from 50:50MS after fifteen hours immersion in water 
exhibits a clear step at ~255 K. Thereafter fluctuation occurred at a magnitude close to the 
background signal and no further interpretation will be derived. For the thirty hours 
immersed 50:50MS, a step tends to appear at ~266 K and another at ~236 K.  
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Figure 7.16: IT curves for freezing cycles of 50:50MS after 2, 6, 15 and 30 hours immersion in water. 
Inset: A refocus on the lower scale of I/Io. 
 
The F-cycles shown in Figure 7.16 demonstrate the difficulty of interpreting precise 
information purely based on the IT-curve. The information of interest, in this case, the pore 
size distribution can be quantitatively determined by studying the distribution of these 
freezing of temperatures.  From the Gibbs-Thompson equation, the measurement of melting 
or freezing of confined liquid produces a temperature distribution that depends on the pore 
size distribution. Since the liquid volume is related to the measured intensity, the IT curves 
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represented the pore volume as a function of temperature (Strange et al, 1993). The pore 
volume, V(x) is a function of pore diameter x and the volume of pores with diameter between 
(x + ∆x) is (dv/dx)∆x. If the pores are filled with liquid, the melting temperature of the liquid 
Tm(x) is related to the pore size distribution by; 
With 
dT
dV
x
k
dx
dV
2
=          (7.12) 
From Equation 7.9; x = k / ∆Tm, and substituting into Equation 7.12; 
dT
dV
Tk
k
dx
dV
m
2)/( ∆
=
dT
dV
k
T 2∆
=        (7.13) 
From the gradient of the IT curves; 
21
21
TT
II
dT
dV
dT
dI TT
−
−
=≈       (7.14) 
Substituting 7.13 into Equation 7.13; 
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2
21
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2
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TT
II
k
TT
dx
dV TT
−
−
×



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


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
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
 +−
=       (7.15) 
 
Note that 237.15 K is used herein as the normal freezing temperature for water and not the 
freezing point measured on melting curve obtained from specific sample. Reason being the 
presence of supercooling which shifted the actual freezing point. The pore size distribution 
can then be determined using the measurement dV/dx provided k is known for the liquid use. 
A range of k values for water as probe liquid measured using different silica beads are 
available in the literatures; i.e. 52 K nm (Hansen et al., 1996; Morishige and Kawano, 1999) 
and 58 K nm (Webber et al., 2001). Hansen et al. (2005) used particles made of polystyrene 
crosslinked with divinylbenzene for cryoporometry and found a k value of 42 K nm. In work 
involving PLGA microspheres by Petrov et al. (2006), they assumed a k value of 50 K nm.  
 
In cryoporometry, the problems with polymeric microspheres are the influences of swelling 
and degradation, both which will alter the physical structure and property of the measured 
sample. The influence of these variations needed to be accounted for in the k calibration. For 
this thesis, a k value of 50 K nm will be used to estimate the magnitude of the neck sizes 
based on the freezing curves. The measurements of dV/dx as a function of pore size 
distribution are presented in Figures 7.17 and 7.18. A summary of the estimated neck sizes 
and their corresponding freezing temperature are presented in Tables 7.2 and 7.3. 
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Figure 7.17: The measurement of dV/dx as a function of pore size distribution for 75:25MS immersed in 
water for 5, 10, 20 and 30 days. Inset: Refocus on the lower scale of pore size distribution. 
 
0
100
200
300
400
500
600
700
800
900
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
Size (nm)
R
e
la
ti
v
e
 P
o
re
 V
o
lu
m
e
 (
d
V
/d
x
)
2 hours 6 hours 15 hours 30 hours
0
10
20
30
40
0.02 0.04 0.06 0.08
 
Figure 7.18: The measurement of dV/dx as a function of pore size distribution for 50:50MS immersed in 
water for 2, 6, 15 and 30 hours. Inset: Refocus on the lower scale of pore size distribution. 
 
Table 7.2: The estimated freezing temperatures and necks sizes of 75:25MS after immersion in water. 
First Freezing Transition Second Freezing Transition 
Immersion in 
water (Day) Temperature, TN1 
(K) 
Neck size,  
xN1 (nm) 
Temperature, TN2 
(K) 
Neck size,  
xN2 (nm) 
5 261.4 0.36  239.5 0.05 
10 - 0.05 240.3 0.05 
20 - 0.05 239.2 0.05 
30 265.6 1.24 238.2 0.043 
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Table 7.3: The estimated freezing temperatures and necks sizes of 50:50MS after immersion in water. 
Estimated Temperature (K) Estimated Neck size (nm) Immersion in water 
(Hour) TN1 xN1 
2 265.1 1.05 
6 267.3 1.62 
15 265.5 1.28 
30 238.9 0.05 
 
As been anticipated, necks with bigger sizes have higher freezing temperatures. This is 
because a liquid confined in smaller pore requires a lower temperature to freeze, according to 
the Gibbs-Thompson equation. For the necks present in 75:25MS, only the five and thirty 
days samples show a bimodal necks system. The appearance and disappearance of the 
smaller necks in 75:25MS could have caused by the swelling and shrinking effects. Hansen 
et al. (2005) discovered a complicating situation in which changes could appear in the porous 
network upon the addition of water. During their sample preparation, the drying process 
caused the pores to partially shrink, and in extreme cases, collapsed. In subsequent 
measurement, some of the larger pores that collapse during the earlier drying reappeared 
after water immersion.  
 
The evolutionary of swelling-shrinking are seen in PFG-NMR experiments. In 75:25MS, 
although pores of size xN1 were not detected on the tenth and twentieth days, they may 
reappear at different stages. The expansion of smaller space within the polymeric matrix 
could also be forming new necks, while the swollen necks transforming into larger 
cavities/pores and disappeared from the detection. 
 
For 50:50MS, they are observed to have unimodal necks pore system. Again, the intermittent 
polymer swelling and shrinkage may have give rise to the increase and decrease in their neck 
size. Due to the amorphous nature of 50:50 PLGA, 50:50MS undergoes high rate of 
hydration and this leads to greater effect of swelling. After fifteen hours immersion in water, 
a much smaller neck size; i.e. 0.05 nm was detected. This neck could be a newly expanded 
space due to polymeric swelling, or a neck that is experiencing shrinking effect. Results from 
PFG-NMR experiment show that 50:50MS can be experiencing more prominent swelling 
effect between the first and second days (Batch 1 50:50MS, Figure 7.7A). Thereafter pore 
swelling becomes more random. These characteristics provide reasoning to suggest the 
appearance of second necks in 50:50MS at much later stage. 
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7.3 Conclusion 
 
1. Findings from Chapter Six and Figure 7.4 are used to confirm that PLGA 
microspheres undergo swelling. Swelling is initiated by water uptake of 
microspheres; i.e. hydration.  
 
2. Following are the proposed swelling effects on PLGA microspheres:   
i. Swelling causes the pore to expand and increase in size. As a result, the 
microsphere will eventually increase in size. 
ii. The hydrated and swollen pores would offer more paths for water displacement 
and this promotes self-diffusion of water. Consequently, an increase in the 
diffusion coefficient of imbibed water can be expected.  
iii. Within a sphere, pores are thought to be interconnected. Since these connecting 
channels are still part of the polymeric matrix, they will also experience 
swelling. The expansions in these channels ease the migration of water from 
one pore to another. 
 
3. By measuring the diffusion coefficients of imbibed water in PLGA microspheres 
using PFG NMR, the estimated pore sizes increased and decreased over time. This 
phenomenon is attributable to the evolution pores swelling and shrinkage. 50:50MS 
with the highest glycolide acid ratio is most hydrophilic and easily wetted and so 
more susceptible to swelling.  
 
4. It is predicted that solvent evaporation with single emulsion produces microspheres 
with interior pores of similar sizes regardless the different ratio of lactide to glycolide 
ratios. This could be validated by the similar initial pore sizes of 50:50MS, 65:35MS 
and 75:25MS. It was found that 50:50MS experienced significant pore swelling while 
65:35MS and 75:25MS did not.  The significant pore swelling observed in 50:50MS 
could be a result of interior autocatalytic. 
 
5. NMR cryoporometry experiments subjected 75:25MS and 50:50MS to a series of 
freezing, melting and refreezing cycles. The results from freezing curves led to the 
following findings: 
i. Homogenous nucleation initiates freezing in the bulk liquid. This produces a 
frozen bulk surrounding the suspended microspheres. 
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ii. The surrounding bulk provides nucleation site for heterogeneous freezing in 
microspheres where the confined liquid freezes via ice ingress through the 
pores at the surface of the microspheres which are in contact with the frozen 
bulk.  
iii. The inheritance of pores with ink-bottle geometry causes a delay in freezing 
due to pore-blocking effect. The liquid confined in a pore will not freeze before 
the liquid filling the connecting necks. Pore blocking effect also leads to 
hysteresis. 
iv. The same behaviour was expected for the melting transition of liquid in 
microspheres. Melting begins in the frozen liquid in the connecting necks 
before the frozen liquid confined in pores.   
 
6. The Gibbs-Thompson equation shows that for a pore size of x, its melting 
temperature, Tm(x) is inversely proportional to the size of the pore. NMR 
cryoporometry is expected to show a decrease in Tm(x) due to increase in pore size 
resulted from pore swelling. From the Melting and Refreezing cycles obtained from 
75:25MS, the I/Io values in all cases were very low and occasionally close to the 
background noise signal. This scenario was thought to cause by the insufficient 
melting of frozen water to produce a significant change in signal intensity in addition 
to the low fraction of confined water. Therefore, the melting curves could not be 
explored to predict the pore size. Instead, the freezing curves were used to predict the 
neck size through which ice front ingress deeper into the microspheres. 
 
7. The freezing curves measured as a function of temperature shows that the 75:25MS 
used was inherited with pores of ink-bottle geometry and bimodal neck system. The 
dV/dx vs. size distribution plots show that the neck sizes shifted over time possibly 
due to swelling mechanism. Evolutionary swelling and shrinkage causes the necks of 
bigger sizes to disappear from been detected on the freezing curve but reappeared at 
later stages.   
 
8. It is possible that 50:50MS will only develop to a bimodal neck system after two 
days of immersion in water. The F-cycles shown in Section 7.2 indicate that 
50:50MS were inherited with unimodal neck system but further experiment (shown 
in Appendix V.C) show that a second neck was detected on the F-cycle after longer 
period of immersion. Apart from suggesting that these necks were capable of 
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extensive shrinkage, it is also possible that new necks may be forming; i.e. swelling 
continued to expand spaces between polymer matrixes forming new necks while the 
initial necks expand to becoming a pore.   
 
9. With their amorphous nature and susceptibility to hydrolytic degradation, the above 
strongly suggested that PLGA microspheres used in this thesis undergo swelling. 
Polymer swelling is caused by hydration, since it is almost impossible to control the 
water transport inside a microsphere, pore swelling so far is considered as a random 
rate process, as well as pore shrinking. Other factor contributing to this random effect 
is the varied amorphous and crystalline regions in the polymeric PLGA 
microspheres.  
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CHAPTER 8: IN  VITRO  CISPLATIN  RELEASE  PROFILES 
 
8.1 Cisplatin-Loaded PLGA Microspheres and Solid Fibres 
 
The ultimate application of the developed system is for the intraperitoneal treatment of 
advanced ovarian cancer. Cisplatin (CPt) was selected as the model drug for this work 
because it has a proven activity in ovarian cancer. The objective of this chapter was to study 
the in vitro drug release profiles of CPt-loaded microspheres and solid fibres. Their drug 
release profiles were studied by using simple rate release kinetic models.  
 
According to Lao et al. (2008), modelling of drug release from surface degrading systems 
would be easier because the drug is release concurrently with the layer-by-layer degradation 
starting from the outermost surface. In contrast, complication arises from bulk degrading 
PLGA which does not progress at a constant velocity across the sample. Faisant et al. (2002) 
conveniently categorised the mathematical modelling approaches for degradable devices 
into two groups: (1) empirical models that assume first or zero order process controlling the 
overall drug release; (2) models considering specific physicochemical phenomena, such as 
diffusional, mass transfer or chemical reaction such as degradation and autocatalytic effects.  
 
For this work, two empirical models, first and zero order kinetics, and a simplified Higuchi 
model were used to fundamentally characterise the CPt release profiles of PLGA samples. 
The models adapted from Koester et al. (2004) are shown below:  
Higuchi Model:  Qt = kH.t
0.5                 (8.1) 
First order kinetic:  ln Qt = ln Qi + kF.t           (8.2) 
Zero order kinetic:  Qt = Qi + kz.t           (8.3) 
Qi and Qt and are the amounts of drug at time, t = 0 and t = t respectively. kH is the Higuchi 
dissolution constant, kF and kz are the first and zero orders rate constants respectively. The 
conditions and assumptions associated with Equations 8.1 to 8.3 are described in Table 8.1. 
 
For zero order kinetic, the equation is commonly used to describe drug dissolution from 
several types of modified release pharmaceutical dosage forms such as those that involved 
an osmotic system (Costa and Lobo, 2001). A zero order kinetic model is useful for system 
that requires prolong pharmacological action. For first order kinetic, it can be used in porous 
matrices system that contains water soluble drug maintained in a sink condition (Mulye and 
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Turco, 1995). The pioneering model first proposed by Higuchi was to describe the 
dissolution of drug in suspension from ointment and it is valid throughout the measurement 
period except when the total depletion of the drug is reached.  
 
The Higuchi model can be further developed for drug release from spherical homogenous 
matrix systems and planar or spherical system having a granular (heterogeneous) matrix 
(Higuchi, 1962 and 1963). The model can be used to study the release of water soluble and 
low soluble drugs incorporated in semi-solid and/or solid matrixes. This model is expressed 
in Equation 8.4:  
tCCC
D
Q sst )2( ε
τ
ε
−=           (8.4) 
Where Qt is the amount of drug release in time t by surface unit, C is the initial 
concentration of the drug, ε is the matrix porosity, τ is the tortuosity factor, Cs is the drug 
solubility in the matrix/exipient media and D is the diffusion constant of the drug molecules 
in that liquid. Equation 8.4 can be simplified and written as Equation 8.1 to characterise the 
drug release using a single integral value, which is essentially the effective diffusion 
coefficient of the dissolution component. The simplicity of Equation 8.1 can offer a good 
description for drug release profiles but sometimes conflicts with the more complex 
conditions.  
 
Table 8.1: Conditions and assumptions of the Higuchi, first and zero order kinetics models. 
MODEL CONDITIONS ASSUMPTIONS Note 
Zero 
Order 
 
 Same amount of drug is 
released by unit time. 
 
 Drug dissolution from matrix that does 
not disaggregate. 
 Area of matrix remains constant. 
 No equilibrium condition is achieved. 
 
 
 
(i) 
(ii) 
(iii) 
First  
Order 
 
 The amount drug released is 
proportional to the amount of 
drug remaining in its interior. 
 The amount drug released by 
unit of time is diminishing. 
 
 
 The matrix is inert, insoluble, 
nonswellable towards the drug and 
medium. 
 Area of matrix remains constant. 
 Medium influx and drug dissolution in 
the medium rapidly occur when come 
into contact. 
 
 
 
 
(iv) 
(ii) 
 
 
(v) 
Higuchi 
Model 
 
 Drug release is a diffusion 
process based on Fick’s first 
law. 
 Drug released is square root 
time dependent. 
 
 
 System is not surface coated. 
 Matrix does not undergo significant 
alteration in the presence of water. 
 Dissolution of drug is instantaneous. 
 Drug release rate is controlled by the 
rate of drugs diffusion and solubility 
within the device. 
 
 
(vi) 
 
(ii) 
(v) 
 
 
 
 
Notes no. (i) to (vi), see text for discussion. 
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The degradation studies in Chapter Six provide reasoning for the applicability of Equations 
8.1 to 8.3. Notes no. (i) to (vi) are discussed below: 
(i) The degradation effect of 75:25 PLGA was not as extensive as for 50:50 PLGA and 
65:35 PLGA. Therefore, the zero order kinetic could be applied on 75:25 PLGA. For 
faster degrading 50:50 and 65:35 PLGA, zero order kinetic may be applicable during 
the initial period before prominent degradation effect sets in. 
(ii) Similar to (i). It is assumed that initially the morphology and sizes of the PLGA 
devices do not alter significantly before prominent degradation. 50:50 PLGA devices 
are likely to experience morphological changes during the first week and a few days 
later, follow by 65:35 PLGA devices. 
(iii) Drug diffusion is continual because buffer refreshment maintains a concentration 
gradient between the device and dissolution medium, i.e. sink condition. 
(iv) So far little or no literature information has suggested the presence of any chemical 
interaction between cisplatin/lidocaine and PLGA. Therefore, the developed PLGA 
devices are assumed to be inert towards the model drugs.  
(v) PLGA is amorphous therefore medium influx can take place and leads to drug 
transport. Cisplatin has a water solubility of 2 mg/ml therefore drug dissolution 
buffer can occur which leads to drug release.  
(vi) No coatings were incorporated into the developed systems in this work. 
 
Results show that Equations 8.1 to 8.3 are inadequate to provide good fit to CPt release 
profiles and a three compartmental model was further developed in order to improve model 
fitting. This model will be evaluated in the discussion section. For ease, CPt-loaded 50:50 
PLGA microspheres will be abbreviated as CPt-50:50MS and CPt-loaded 50:50 PLGA solid 
fibres as CPt-50:50SF. Similarly for the microspheres and solid fibres made of 65:35 and 
75:25 PLGA. 
 
 
8.2 Production of CPt-Loaded PLGA Microspheres and Solid Fibres 
CPt-loaded 50:50, 65:35 and 75:25 PLGA microspheres were produced using the method 
described in Section 4.1.3. A polymer concentration of 15 % (w/w) and a drug-to-polymer 
ratio of 1:2 were used. Briefly, 10 g of polymer/drug solution was homogenised in 100 ml 
PVA solution (0.5 % w/w) at 6500 rpm for 15 min. Then the nascent microspheres were 
transferred to magnetic stirring before they were harvested. CPt-loaded 50:50, 65:35 and 
75:25 PLGA solid fibres were spun using the method described in Section 4.2.3 with a drug-
to-polymer ratio of 1:2 and a 20 % (w/w) polymer concentration.  
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The resulting CPt-loaded microspheres were sieved into three different size fractions; 
between 90-75 µm, 75-53 µm, and 53-38 µm, in order to compare their drug release rates.  
 
Five preweighed samples were prepared from each PLGA microsphere and solid fibre for in 
vitro drug release analyses. CPt concentration and drug loading were determined using 
methods described in Sections 4.3.2 and 4.4 respectively. In vitro drug release analysis was 
carried out by incubating the sample in a shaking water bath maintained at 37oC. More 
details of the incubation conditions can be found in Section 4.5. 
 
 
8.3 Results & Discussion 
The drug loadings for CPt-loaded solid fibres and microspheres of different size fractions 
are shown in Figure 8.1. The drug loadings of PLGA solid fibres are in general higher than 
those of microspheres and this is thought to be because of the higher water miscibility of 
NMP. The faster solvent diffusion into the aqueous phase leads to a rapid phase inversion of 
the nascent solid fibre compared to the case of DCM with microsphere. A faster rate of 
solidification would decrease the residence time of drugs leakage and loss. Figure 8.1 shows 
that 75:25 PLGA tends to have higher drug loading compared to 50:50 and 65:35 PLGA. 
This trend is attributable to the higher lactic acid ratio in 75:25 PLGA which produces a 
more viscous solution and thereby exhibits a faster rate of solidification. PLGA with higher 
glycolic acid ratio would be more hydrophilic which permits higher diffusion of 
medium. Therefore drug leakage and loss are higher.  
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Figure 8.1: Drug loadings of PLGA solid fibres (SF) and PLGA microspheres of sizes 53-38 µm, 75-53 
µm and 90-75 µm and solid fibres. Data represent mean ± standard deviation (n = 5). 
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CHAPTER 8: IN VITRO CISPLATIN RELEASE PROFILES 
THE DEVELOPMENT OF CONTROLLED-CHEMOTHERAPY DRUG DELIVERY SYSTEM 132 
Table 8.2: Statistical analyses comparing the drug loadings between PLGA solid fibres and microspheres. 
PLGA Sample 
Significant Difference 
ANOVA – one factor (p < 0.05) 
75:25SF vs. 65:35SF   
75:25SF vs. 50:50SF   SF 
50:50SF vs. 65:35SF   
50:50MS (38-53 µm) vs. 50:50SF   
50:50MS (53-75 µm) and (75-90 µm) vs. 50:50SF   
65:35MS (38-53 µm) vs. 65:35SF   
65:35MS (53-75 µm) and (75-90 µm) vs. 65:35SF   
75:25MS (38-53 µm) vs. 75:25SF   
75:25MS (53-75 µm) vs. 75:25SF   
MS vs. SF  
75:25MS (75-90 µm) vs. 75:25SF   
  
Table 8.2 summarises the comparisons of drug loading between PLGA solid fibres and 
microspheres. Siepmann et al. (2004) suggested that drug loading increases with particle 
size due to a condition where bigger spheres offer bigger structure to accommodate more 
drugs. In terms of total surface area, smaller microspheres would have higher surface for 
drug leakage compared to bigger microspheres during the rapid phase inversion process. 
However, considering the volume of a small and a large nascent microspheres, the 
bigger the nascent sphere, higher the volume of solvent it contains. This would require 
longer residence time for solvent diffusion and solidification. In contrast, a smaller 
sphere with lesser solvent volume will solidify faster. The combinations of the above 
mechanisms may have contributed to the deviation in drug loading trend with regard to 
microsphere size, as seen in Figure 8.1.  
 
Section 6.1.3 showed the spatial heterogeneous distribution of the entrapped agent in 
75:25MS, due to reasons such as imperfect emulsification. This also indicates that for 
microspheres of similar sizes, the amount of entrapped drug could be different. As a 
result, the inhomogeneity of entrapment ratio of microspheres in a size fraction could be 
producing an “average” effect on the final drug loading and thus, affected the trend in 
overall drug loading. 
 
The cumulative in vitro releases of CPt from 50:50SF and 50:50MS of three size fractions, 
namely; 90-75 µm, 75-53 µm, 53-38 µm over a period of twenty days are shown in Figure 
8.2. The drug release profiles of 50:50 PLGA samples are fundamentally described as 
biphasic; Phase 1 is the initial faster drug release during the first day and a slower drug 
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release, and thereafter Phase 2. It will be shown later that the Phase 2 release is affected by 
different mechanisms that arise from the degrading PLGA devices. Phase 1 is associated 
with a rapid drug release known as the “burst release” and is common in PLGA 
microspheres. It has been reported that an instant cumulative CPt release as high as 20% 
(Itoi et al., 1996) and 25% (Fujiyama et al., 2003) occurred in PLGA microspheres.  
 
0
20
40
60
80
100
0 5 10 15 20
Incubation Time (Days)
%
 C
P
t 
R
e
le
a
s
e
 (
C
u
m
u
la
ti
v
e
)
50:50MS (53-38 microns)
50:50MS (75-53 microns)
50:50MS (90-75 microns)
50:50SF
 
Figure 8.2: Percentage (%) cumulative release of CPt from 50:50MS with size fractions: 53-38 µm (   ), 
75-53 µm (   ), 90-75 µm (   ) and 50:50SF (   ).  Data represent mean ± standard deviation (n = 5).  
 
The mechanisms contributing to the Phase 1 release are proposed below: 
i. The presence of a large drug concentration gradient between microspheres and 
buffer at the first instant of buffer immersion. The large concentration gradient may 
provide a greater driving force for CPt to diffuse faster into the buffer. 
ii. During polymer solidification, drug diffused towards the periphery of the nascent 
microspheres or solid fibres. This leads to entrapment of CPt in the periphery of the 
microspheres or solid fibres. During immersion in buffer, these samples become 
hydrated and CPt located in these peripheral layers is rapidly released.  
iii. During the production processes, free CPt from leakage adsorbed on the surface of 
the microspheres or solid fibres. These CPt are then rapidly released into the buffer.  
 
Previously in Chapter Seven, it was found that the pore size of 50:50MS (Batch 1) 
underwent hydration during the first few hours of measurement and then increased in size 
from the first to the second day. Pore swelling (Hopfenberg and Hsu, 1978) and buffer 
immersion (Siepmann et al., 2004) shift the physical state of the system to a rubbery state 
X 
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which permits faster medium diffusion (Fan and Singh, 1989). Siepmann et al. (2004) also 
found that this shift was independent of microsphere size. Thus, the swelling susceptibility 
of 50:50MS is thought to be closely related to a rapid drug release. The rapid Phase 1 drug 
release observed in CPt-50:50MS during the first day correlates well to the pore swelling 
profile seen in Figure 7.7 (Section 7.1). 
 
During the Phase 1 release, 50:50MS released 45-65% of their drug contents compared to 
~30% from 50:50SF. Comparing the forms of solid fibres to microspheres, solid fibre is a 
cylindrical device whereas microspheres present as multiple submicron particles. In addition 
to swelling, these spherical devices also offer much higher surface area for drug diffusion. 
As a result, 50:50MS exhibits a higher drug release rate compared to 50:50SF. After 
approximately ten days, the drug release from 50:50SF converged to the drug release from 
50:50MS of intermediate and largest size fractions. Meanwhile, 50:50MS of the smallest 
size fraction has reached to content depletion. The smallest size fraction 50:50MS has the 
largest surface area:volume ratio and it was anticipated that they would exhibit a faster drug 
release rate. See Table 8.3 for estimation of surface area:volume ratio.  
 
Drug release from 50:50SF was slower because of its lower surface area and its dense wall 
structure. The release of drug from PLGA solid fibres is closely related to their skin layers 
formed during the phase inversion process. Figure 8.3A shows the finger-like structure of 
50:50SF extended towards the outer surface of the fibre. The structure is denser towards the 
fibre outer surface (indicated as ‘s2’ in Figure 8.3A) compared to the structure at the fibre 
core (s1). The denser structure near the skin layer offers higher mass transfer resistance and 
limits medium transport compared to macrovoids. From previous discussion in Sections 3.5 
and 5.2, this feature of skin layer could reduce drug release rate. This phenomenon is 
reflected in the slower drug release of 50:50SF (Figure 8.2). 
 
    
Figure 8.3: SEM images of (A) the finger structure of undegraded 50:50SF. Region ‘s2’ has a denser 
structure compared to region ‘s1’ with microvoids. (B) and (C)  twenty days degraded 50:50SF.  
A    B – fibre wall core structure C – fibre wall core structure 
Elongated finger structure 
  
s1
 
s2
 
x 700                   x 850               x 1,200 
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Figure 8.4: Percentage (%) cumulative release of CPt from 65:35MS with size fractions: 53-38 µm (   ), 
75-53 µm (   ), 90-75 µm (   ) and 65:35SF (   ).  Data represent mean ± standard deviation (n = 5).  
 
Figure 8.4 shows the cumulative in vitro releases of CPt from 65:35MS of different size 
fractions; 90-75 µm, 75-53 µm, 53-38 µm, and 65:35SF over a period of twenty days. 
65:35MS of the smallest size fraction clearly exhibits the fastest drug release rate compared 
to other size fractions and 65:35SF. For example, 65:35MS of the smallest size fraction 
released up to 40% of its drug content during the first day whereas 65:35SF did not reach to 
40% drug release until Day 3. 65:35SF with its larger and dense fibre wall structures possess 
higher resistance to drug diffusion. These features of solid fibre caused CPt to require longer 
time to diffuse to the surface. Thus, drug release from 65:35SF is delayed and slower. After 
two weeks, the drug release from 65:35MS of all size fractions and 65:35SF tend to 
converge and proceed at the same rate towards the end.  
 
The overall slower CPt release from CPt-65:35MS compared to CPt-50:50MS, can be 
related to a tendency of gradual pore swelling in 65:35MS (Figure 7.5, Section 7.1) over a 
period of approximately three weeks. The corresponding fractions of imbibed water were 
observed to be increasing over this period. This hydration profile obtained from PFG-NMR 
experiments mimics the CPt release from 65:35MS seen in Figure 8.4. The gradual 
hydration within 65:35MS provides medium for drug transport such that drug can be 
released into the buffer. 
 
For CPt-loaded PLGA solid fibres, SEM images following the degradation of PLGA solid 
fibres in Section 6.6 showed that 50:50SF (Figure 6.26) degraded faster than 65:35SF 
X 
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(Figure 6.27). For the degrading 50:50SF and 65:35SF, large cavities were formed at the 
centre of the fibres. Comparing their surfaces conditions, pores formation started after ten 
days and thereafter, the surface pores of 50:50SF increased in numbers and sizes faster than 
those of 65:35SF. The larger pores developed on the 50:50SF after twenty days in buffer 
may be the reason why a full drug release is observed after approximately eighteen days in 
Figure 8.2. The pores on the surface of 65:35SF were size-consistent and this may have led 
to near zero-order drug release while preventing uncontrollable release of the remaining CPt.  
 
According to Fick’s Law of diffusion, the driving force for drug diffusion is due to the 
presence of a concentration gradient between two points of measurement (Coulson and 
Richardson, 1999). In this case, the concentration of drug in buffer is lower than in the 
microsphere/solid fibre. Table 8.11 shows that the estimate surface area:volume ratio of 
smaller microspheres are higher than those larger ones. In comparison, Table 8.3 shows that 
the much larger solid fibre has much smaller surface area:volume ratio. See Appendix VI.I 
for sample calculations. Microsphere of larger size would exhibit a lower rate of drug 
release because of the longer diffusion path length across the larger microsphere. Vice versa, 
smaller microsphere will shorter path length would have a higher drug release rate.  
 
Table 8.3: Estimate surface area:volume ratio of 15 % (w/w) PLGA microspheres in a 0.2 g sample. 
 
Table 8.4: Estimate surface area:volume ratio of 20 % (w/w) PLGA solid fibres. 
PLGA 
Size 
Fraction 
Diameter 
(10
-6
 m) 
Number of 
microspheres 
(10
7
) 
Surface area of 
one microsphere 
(10
-5
 cm
2
) 
Volume of one 
microsphere 
(10
-9
 cm
3
) 
Total Surface 
Area:Volume 
ratio 
D [v, 0.1] 6 114.93 0.11 0.11 100.00 
D [v, 0.5] 26 1.41 2.12 9.20 23.08 50:50MS 
D [v, 0.9] 84 0.04 22.17 310.38 7.14 
D [v, 0.1] 8 48.49 0.20 0.27 75.00 
D [v, 0.5] 45 0.27 6.33 47.71 13.33 65:35MS 
D [v, 0.9] 90 0.03 25.45 381.75 6.67 
D [v, 0.1] 5 239.10 0.07 0.05 127.66 
D [v, 0.5] 53 0.17 8.83 77.96 11.32 75:25MS 
D [v, 0.9] 107 0.02 35.97 641.51 5.61 
PLGA 
Diameter  
(10
-6
 m) 
Number 
of fibres 
Surface area of one fibre 
(10
-5
 cm
2
) 
Volume of one fibre 
(10
-9
 cm
3
) 
Total Surface 
Area:Volume ratio 
50:50SF 670 10 16.84 2.82 5.97 
65:35SF 720 10 18.10 3.26 5.56 
75:25SF 760 10 19.11 3.63 5.26 
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The CPt release profiles of 50:50 and 65:35 PLGA shown on Figures 8.2 and 8.4 indicate 
agreement to Fick’s Law. In some cases, the microspheres of intermediate and largest size 
fractions exhibited similar release rates. The reasons causing the deviation from the Fick’s 
law of diffusion are such as: (1) a spatial heterogeneous distribution of the entrapped agent 
in PLGA microsphere was shown in Section 6.1.3. Drug located in the outermost periphery 
of the microspheres are expected to be rapidly released, (2) the different local concentration 
of the drug within a microsphere which can influence the drug release pattern (Matsumoto et 
al., 2005), (3) while hindering a homogeneous drug distribution, the different amorphous 
regions in PLGA also affect the freedom of drug diffusion within the matrix, in addition to 
contributing to a rapid drug release (Sastre et al., 2004).  
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Figure 8.5: Percentage (%) cumulative release of CPt from 75:25MS with size fractions: 53-38 µm (   ), 
75-53 µm (   ), 90-75 µm (   ) and 75:25SF (   ).  Data represent mean ± standard deviation (n = 5).  
 
Figure 8.5 shows the cumulative in vitro releases of CPt from 75:25MS of different size 
fractions; 90-75 µm, 75-53 µm, 53-38 µm, and 65:35SF over a period of twenty days. 
75:25MS exhibits a higher overall release rate while the drug release from 75:25SF remains 
the lowest throughout the twenty days period. The 75:25MS of the smallest size fraction 
exhibits the highest release rate during the first week and followed by a slower release 
towards the end. In this case, CPt may be entrapped deeper in the matrix and longer time 
was required for these drugs to diffuse to the surface. After a week, 75:25MS of the 
intermediate size fraction exhibits a fast release and approaches to content depletion. In this 
case, most of the CPt may be located in the peripheral layer of the microsphere and a faster 
X 
CHAPTER 8: IN VITRO CISPLATIN RELEASE PROFILES 
THE DEVELOPMENT OF CONTROLLED-CHEMOTHERAPY DRUG DELIVERY SYSTEM 138 
continual drug release is observed. For 75:25SF, its degradation resistance restricted the 
surface pore formation (Section 6.6, Figure 6.28) which produces a slower drug release 
compared to 50:50SF and 65:35SF.  
 
The overall time taken to reach to content depletion exhibited by 75:25 PLGA samples is 
longer compared to 65:35 and 50:50 PLGA. This could be attributed to the higher 
degradation resistance of 75:25 PLGA. The burst release is also more prominent in 50:50MS 
compared to 65:35MS and 75:25MS.  
 
Findings in Section 7.1 showed that PLGA microspheres underwent swelling. During 
swelling of a microsphere, its glass transition temperature is lowered and the system shifts to 
a rubbery state. 50:50MS was found the most susceptible to swelling compared to 65:35MS 
and 75:25MS. The pore expansion in 50:50MS would promote medium transport and lead to 
an increase in drug diffusion. As a result, 50:50MS exhibits a faster drug release as oppose 
to 75:25MS which restricts pore swelling. The interior tortuosity of 75:25MS was also found 
to be constant (Figure 12.3, Appendix V.B). This constancy may have contributed to the 
near zero order release in the later stage of Phase 2 drug release. 
 
Findings from Section 6.1.2 indicated the porous interior of PLGA microspheres used in this 
work while degradation changes their surface morphologies (Section 6.2). While the 
diffusion pathway for the entrapped drug may not be of forward channels, the tortuosity of 
these channels also changes over time (Section 7.1). Based on these results, it is thought that 
the diffusion of entrapped CPt and subsequent drug release are affected by the changing 
interior of the microspheres due to degradation and swelling effects. Local autocatalytic 
degradation will also alter the interior porosity of the device however its effect is 
theoretically difficult to be accounted for in drug release (Siepmann et al., 2004).  
 
As the degradation progresses, disintegration of the polymeric structure continues to disrupt 
the finger structure (Section 6.6). The degraded solid fibre with increased structural porosity 
would eventually leads to a faster drug release. Results from PFG-NMR experiments 
showed that the tortuosity of PLGA microspheres changes over a period of thirty days 
(Figure 12.3, Appendix V.B). This characteristic is attributable to the evolutionary swelling 
and shrinking in the PLGA microspheres, due to hydration and water transport in the porous 
interior. Likewise, the similar polymeric solid fibres made of PLGA were also anticipated to 
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experience changes in their interior tortuosities, due to both swelling/shrinking and 
degradation effects.  
 
Spenlehauer et al. (1988) presented a study on the effects of process conditions on the 
distribution CPt crystal in PLGA microsphere. The drug distribution system by Spenlehaeur 
et al. (1988) is suitable to be adopted because of the similarity in working polymer (PLGA), 
solvent (DCM), emulsifier (PVA), and single emulsion method.  Spenlehauer et al. (1988) 
proposed five types of CPt distribution as illustrated in Figure 8.6. The characteristic of 
these distribution patterns are summarised in Table 8.5.  
 
 
 
 
 
Figure 8.6: Different distribution patterns of cisplatin crystal within a microsphere. Black triangle 
represents cisplatin (Spenlehauer et al., 1988). 
 
Table 8.5: The distribution patterns of cisplatin in PLGA microsphere (Spenlehauer et al., 1988). 
 Type Characteristic of Distribution Pattern 
I Cisplatin are distributed in the polymer matrix with no contact between each other. 
II Large amounts of cisplatin present in the matrix. Some are in contact with each other and formed 
a network, which connects the cisplatin at the inner part of the microsphere to those nearer to the 
surface.  
III Similar to type II but no isolated cisplatin. All cisplatin are in contact with each other forming a 
dense network.  
IV Cisplatin are in contact with each other but they tend to locate at the surface layer of the 
microsphere. 
V Similar to Type II, but the cisplatin-network is located at the centre of the microspheres with not 
cisplatin at the surface layer. For example, no direct connection between the inner drug-network 
and the surface of the microsphere. Also depicted as a layer of polymer enveloping an inner drug 
network. 
 
For the developed CPt-loaded microspheres herein, Type IV is an appropriate pattern to be 
adapted because Spenlehauer et al. (1988) suggested that centrifugation promoted this type 
of distribution. While a Type IV drug distribution pattern can be assumed initially, this 
distribution pattern would likely to change, and different distribution patterns could be 
assumed at different stages as drug release proceeded.  
 
Type I          Type II                           Type III                      Type IV                      Type V 
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From the CPt release profiles of 50:50MS and 50:50SF shown in Figure 8.2, their Phase 1 
releases are likely to associate with a Type IV drug distribution pattern resulted from a 
centrifugation effect. After that, the faster CPt release rate observed on 50:50MS may be 
characterised by a Type I distribution pattern because the drug loading was relatively lower 
in 50:50MS. The lesser amount of drug entrapped in the microsphere is unlikely to give rise 
to a dense crystal network. During buffer immersion, the medium transport promoted 
random diffusion and redistribution of CPt. With a fast degradation rate, CPt in 50:50MS 
had less chance to alter between drug distribution patterns as drug release was fast. 
 
For 65:35MS, the CPt distribution may initially assume a Type IV distribution pattern and 
later changed to a Type II and/or Type I. After Phase 1 release, the CPt released from 
65:35MS was slower compared to 50:50MS. A Type II distribution might have produced 
this slower release. Following this, with a higher resistance in degradation compared to 
50:50MS, the drug distribution pattern changed to Type I. At this later stage, the drug 
diffusion continued and drugs entrapped deeper in the matrix were slowly released. 
 
For 75:25MS, after Phase 1 release, a Type V of drug distribution may be used to 
characterise the system. The reason being that the highly degradation-resistant 75:25MS 
would have an intact interior which is more capable of entrapping the remaining CPt. 
Although 75:25MS was least affected by hydrolytic degradation, but medium transport 
continued to allow the outflow of drug. Apart from predicting the different drug distribution 
pattern, a hypothetical model of the drug release in parallel with a bulk degrading PLGA 
microsphere is illustrated in Figure 8.7.  
 
 
 
 
 
 
Figure 8.7: A hypothetical model of drug release from microspheres with a Type IV drug distribution. 
 
The sequence of the drug release is envisaged as below: 
i. Initially, Type IV drug distribution is assumed in the microsphere.  
ii. The release of drug crystals located at the outermost peripheral of the microsphere. 
Since the microsphere has a porous interior, immersion in PBS enables buffer 
Hydrolytic Degradation Progresses 
Microsphere Immersion in buffer 
i  ii    iii      iv      v                 vi 
Drug crystals 
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penetration. This will initiate internal hydrolytic degradation. The presence of 
porous structure and buffer enable drug transport inside the microsphere. 
iii. With bulk degradation, internal degradation will lead to changes in tortuosity. New 
microchannels will be formed and collapsed as a result of degradation.  
iv - vii.  Degradation progresses and this increases the size of the microchannels which then 
offer higher freedom for medium and drug transports. Structural disintegration 
continues and the remaining drugs are released into the buffer.  
 
Siepmann et al. (2004) followed the in vitro degradation of PLGA microspheres by 
measuring their molecular weights and showed that the size of microsphere did not affect the 
rate of degradation. Chapter Six concluded that the lactide:glycolide ratio was more 
prominent in governing the degradation rate of microsphere. Sections 6.2 showed that 
75:25MS exhibits high degradation resistance. Hence, the effect of degradation on the 
release of CPt from 75:25MS is thought to be lesser compared to 50:50MS and 65:35MS. 
 
A bulk degradation pattern for both PLGA hollow and solid fibres were also determined in 
Chapter Six. The core matrixes of these fibres are observed to degrade faster than their outer 
surface. This effect is thought to be promoted by the skin layers surrounding these fibres and 
also their much larger structure. Similar to PLGA microspheres, the hypothetical model 
described in Figure 8.7 could be used to predict the drug release from the bulk degrading 
fibres. The major difference is that the larger structure of the fibre is thought to offer a 
longer diffusion pathway and thus, slower drug release could be expected.  
 
As described earlier, the drug release during the first day can be termed as Phase 1 and drug 
release thereafter as Phase 2. In preliminarily fittings, partitioning the in vitro drug release 
profiles into Phase 1 and Phase 2 show better models fittings using Equations 8.1 to 8.3. The 
Higuchi model, Qt = kH.t
0.5
  (Equation 8.1) fits well to the experimental data for both 
microspheres and solid fibres during the Phase 1 drug release and examples of results are 
shown in Figure 8.8. The estimated Higuchi constants, kH are presented in Table 12.4 
(Appendix VI.C). 
 
Based on these results, it could be suggested that the drug release from PLGA solid fibres 
and microspheres during the first day are diffusional-controlled and is proportional to the 
square root of time. The nature of bulk degrading PLGA where water diffusion into the 
device is fast, supports a possible diffusional drug release phase in PLGA depots. The 
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diffusional release during Phase 1 is thought to be associated with the ‘burst effect’ 
discussed earlier. Factors such as surface-adsorbed drugs, drugs located at/near surface, 
centrifugation effect that caused drugs to locate in the peripheral layer of the microsphere, 
and the swelling susceptibility of polymeric devices especially those made of 50:50 PLGA 
are thought to contribute to Phase 1 release.  
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Figure 8.8: Fittings of Higuchi model to drug releases from (A) 50:50 and (B) 75:25 PLGA microspheres 
and solid fibres during Phase 1.  Size fractions: S = 53-38 µm, M = 75-53 µm and L = 90-75 µm. 
 
During Phase 1 drug release, microspheres of the smallest size fraction tend to exhibit the 
fastest drug release compared to microspheres of larger size fractions. This trend agrees to a 
Fickian’s diffusion where smaller particles is associated with higher surface area:volume 
ratio, which offer higher surface area for drug diffusion. Similar observation is also applied 
for the slower drug release comparing solid fibre to microsphere. 
 
Equations 8.1 to 8.3 were also fitted to the Phase 2 drug release and results are shown in 
Appendix VI.C. The Phase 2 drug releases of PLGA samples indicate partial similarities to 
Equations 8.1 to 8.3 with respect to different stages during the release period. This similarity 
may due to the existing conditions of the PLGA devices that fulfilled the assumptions of 
[                     ] Experimental Data 
[                     ] Higuchi Model 
 
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
 
[                    ] Experimental Data 
[                    ] Higuchi Model 
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these models described in Table 8.1. The structural evolution of these PLGA devices causes 
the system to deviate from the assumptions and therefore model Equations 8.1 to 8.3 were 
not longer valid in the new condition. Based on studies findings in Chapters Six and Seven, 
the deviations from the models are suggested to be caused by: 
i. Degradation leads to the formation of surface pores on microspheres and 
hollow/solid fibres. The development of these pores, the bulk and heterogeneous 
degradations influenced the drug release rate as the diffusion passages for drug are 
altered over time. 
ii. The pore swelling and shrinking in PLGA microspheres alter the interior tortuosity. 
These mechanisms will affect drug diffusion in the pore network, the rubbery state 
or amorphous regions in the matrix. Thus, the drug diffusion pathway is altered. 
iii. In addition to (i) and (ii), the spatial heterogeneous distribution of the entrapped drug 
within a microsphere, subsequent drug release and the redistribution of the entrapped 
drug due to medium transport and subsequent drug release. 
iv. Cryoporometry experiments in Section 7.2 showed that the pores in PLGA 
microspheres are made of ink-bottle geometry. The connecting necks were also 
found to undergo swelling and shrinking. It is also hypothesised the transformation 
of an expanding neck to a pore-like cavity, and the formation of new and smaller 
necks. In part to (iii) above, the random swelling/shrinking of necks could have 
effect of releasing the drug entrapped in the main pores.  
 
Results show that CPt release from PLGA microspheres and solid fibres cannot be fully 
characterised by empirical models (Equations 8.1 to 8.3) with single parameters. It has been 
reported in the literature that PLGA microparticles can yield non-square root relation drug 
release profile (Le Corre et al., 1997 and Fujiyama et al., 2003). Simple empirical models 
such as averages or straight lines are useful for generalising trends in a system, but do not 
account for physical condition such as degradation effect of the PLGA drug releasing 
depots. Preliminary model fittings show that CPt release profiles of PLGA microspheres and 
solid fibres are at least biphasic. A biphasic drug release model for microsphere drug 
delivery is common in the literatures. Examples are such as the one developed by Batycky et 
al. (1997) which considers a burst release phase followed by a drug diffusion phase which 
occurs via interconnected pores.  
 
More comprehensive model developed by Grassi et al. (2000) accounted the factors such as 
the sizes of the particles, the physical state and distribution of the entrapped drug within the 
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device including the dissolution and diffusion of the drug. Jalil and Nixon (1990a and 
1990b) proposed a number of relevant mechanisms such as surface-drug desorption, drug 
diffusion through particle pores and various regions in the polymer matrix. It is common for 
a model to have specific components that are mechanism- and time-dependent during the 
release period (Liu et al., 2006 and Duarte et al., 2006). Sometimes, the contribution of 
these mechanisms could be difficult to be quantified (Polakovič et al., 1999).  
 
Empirical models derived from the first order models are appropriate for use to study drug 
release from depots. A semi-mechanistic model is an empirical model which can be used to 
relate the parameters of the rate equation to physical condition of the depots. When a solid 
matrix containing a water soluble drug is introduced into an aqueous environment the drug 
will leach into the aqueous phase. The more that drug leaves the matrix means that the 
amount remaining for subsequent released is reduced. It can be assumed that the driving 
force for mass transfer is proportional to the difference between the outer surface 
concentration and the concentration of solute in a solute-rich region (Glueckauf and Coates, 
1947).  
 
                               
 
 
Figure 8.9: A two compartmental model showing the relationship between Qo and Q1. 
 
Figure 8.9 shows a two compartmental model of drug release, where Qo is the amount of 
drug remained in the depot after Q1, the amount of drug is released in solution, which is 
dependent on the release constant, ko. Qo(∞) is amount of drug in the depot which will be 
released after a long time. The equation which predicts release of drug from a depot device 
(i.e. PLGA microsphere or fibre) can be derived from the rate equations using Laplace 
transformations (Mayersohn and Gibaldi, 1970). Here, drug released in the solution is 
related to the drug remained in the depot by: 
oo Qk
dt
dQ
.1 =        (8.5) 
where Qo is the amount of drug remaining in the depot. Q1 is the amount of drug released in 
solution from the depot. ko is the rate of drug release. From Figure 8.9, it can be seen that he 
concentration of drug remaining in the depot, Qo decreases at a rate: 
oo
o Qk
dt
dQ
.−=        (8.6) 
Qo 
Qo(∞) 
 
Q1 
ko 
    Depot            Solution 
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Transforming the differential Equations 8.5 and 8.6 using Laplace transformation gives: 
oo QkQQs .)0(. 11 =−       (8.7) 
oooo QkQQs .)0(. −=−       (8.8) 
 
1Q and oQ  are Q1 and Qo in Laplace space. Applying the initial conditions when t = 0 are: 
Q1(0) = 0 and Qo(0) = Qo(∞). Rearranging Equation 8.8 gives: 
)(
)(
o
o
o
ks
Q
Q
+
∞
=        (8.9) 
 
Substituting Equation 8.9 into Equation 8.7 gives; 
)(
)(.
1
o
oo
kss
Qk
Q
+
∞
=        (8.10) 
 
An anti-Laplace transformation of Equation 8.10 gives: 
)1).((1
tk
o
oeQQ
−
−∞=       (8.11) 
 
A single exponential, also known as the linear driving force (LDF) model (Sircar and 
Hufton, 2000), is simple to implement and so is widely used (Messaritaki et al., 2005 and 
Machida et al., 2000). For some PLGA devices the initial burst of drug release can occur to 
a greater extent than predicted by a single exponential or mono-exponential equation. 
Evidence of this is indicated in preliminary fittings of Equations 8.1 to 8.3. More examples 
of these results are shown in Appendix VI.C. As the apparent rate of release changes the 
previous model is no longer applicable. As a result, a single exponential (Equation 8.11) 
shows poor fit to experimental data and examples are shown in Figure 8.11. Such an effect 
could be caused by redistribution of the drug within the depot, the decreasing amount of the 
remaining drug, or the structural changes in the degrading devices.  
 
To attempt to improve the fit of model Equation 8.11, a second exponential term can be 
added to the model based on an approach of using a three compartmental model, as 
illustrated in Figure 8.10. The model now contains a releasing depot with two pools. 
Physically it means that a fraction of drug is released faster from a pool where the readily 
released drugs are located near/at the surface of the depot, while the second pool represents 
subsequent drug release preferably from those entrapped deeper in the matrix.  
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Figure 8.10: A three compartmental model showing the drug release from a two pools-releasing depot.  
 
The amount of drug release in solution, Q1 is related to Q2 and Q3 by:  
3322
1 .. QkQk
dt
dQ
+=       (8.12)  
Where Q2 and Q3 are the remaining drug in the depot after drug of amount Q1 is released 
into the solution. Q2(∞) and Q3(∞) are the amount of drugs remaining in Pools A and B, 
which will be released after a long time. k2 and k3 are the release rate constants of Pools A 
and B respectively. Using the same treatment applied in Equations 8.5 to 8.10; integrating 
and transforming the individual components of Q1, Q2 and Q3, the final three 
compartmental-model describing the relationships between the amount of drug release and 
the remaining drug in a two pools-releasing depot is given by:  
Q1 = [ )1).(( 22
tkeQ −−∞ ] + [ )1).(( 33
tk
eQ
−
−∞ ]    (8.13) 
 
For details of derivation, see Appendix VI.D. Both Equations 8.11 and 8.13 were fitted to 
the CPt release profiles and examples of results are shown in Figure 8.11. The full set of 
result is presented in Appendix VI.F. The amount of remaining drugs; Q2 and Q3, rate 
release constants; k2 and k3 of model Equation 8.13 were estimated from fitting the model to 
CPt release profiles. Results are plotted in Figure 8.12. Summary of goodness of fit is 
presented in Table 8.6 and was compared based on the Akaike’s Information Criterion (AIC) 
(Akaike, 1974) factor. 
 
Adding parameters should always reduce the residual error of the model; a more complex 
model cannot be justified unless the improvement in predicting power justifies the reduction 
in degrees of freedom. The complete set of results of model Equations 8.11 and 8.13 fittings 
can be found in Appendix VI.F with examples of residual error plots in Appendix VI.G. A 
summary is tabulated in Table 8.6. In all cases, the AIC values of model Equation 8.13 are 
lower compared to those of Equation 8.11. The distribution of residual plots also shows 
random distribution between the zero-axis. These results validate the addition of a second 
exponential term. 
Q2 
Q2(∞) 
 
Q1 
k2 
Depot 
Q3 
Q3(∞) Solution 
k3 
Pool A 
 
 
Pool B 
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Figure 8.11: Examples of model Equations 8.11 and 8.13 fittings to CPt release profiles of PLGA solid 
fibres and microspheres of the intermediate size fraction (75-53 µm). (A) CPt-50:50MS, (B) CPt-50:50SF, 
(C) CPt-65:35MS, (D) CPt-65:35SF, (E) CPt-75:25MS (F) CPt-75:25SF. Solid lines represent 
biexponential Equation 8.13 and dashed lines represent monoexponential Equation 8.11.  
 
 
 
(A) CPt-50:50MS (75-53 µm)              (B) CPt-50:50SF  
 
 
(C) CPt-65:35MS (75-53 µm)                 (D) CPt-65:35SF 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
(E) CPt-75:25MS (75-53 µm)              (F) CPt-75:25SF 
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Table 8.6: Summary of goodness of fit of model Equations 8.11 and 8.13 to CPt release profiles. 
CPt-Loaded Device 
Bi-exponential - Equation 8.13 
Mono-exponential - Equation 8.11 
AIC Degrees of Freedom 
Bi-exponential 32.2835 15 
53-38 µm 
Mono-exponential 69.4570 17 
Bi-exponential 39.9778 17 
75-53 µm 
Mono-exponential 103.254 19 
Bi-exponential 27.1519 16 
CPt-
50:50MS 
90-53 µm 
Mono-exponential 97.9456 18 
Bi-exponential 27.1519 16 
CPt-50:50SF 
Mono-exponential 80.7240 20 
Bi-exponential 32.4188 16 
53-38 µm 
Mono-exponential 95.6021 18 
Bi-exponential 33.2682 17 
75-53 µm 
Mono-exponential 103.0168 19 
Bi-exponential 52.4364 14 
CPt-
65:35MS 
90-53 µm 
Mono-exponential 7.323e-06 16 
Bi-exponential 2.204e-06 18 
CPt-65:35SF 
Mono-exponential 36.3515 16 
Bi-exponential 99.1854 18 
53-38 µm 
Mono-exponential 51.6827 15 
Bi-exponential 82.2888 17 
75-53 µm 
Mono-exponential 35.4511 16 
Bi-exponential 81.077 18 
CPt-
75:25MS 
90-53 µm 
Mono-exponential 42.7116 17 
Bi-exponential 50.5924 20 
CPt-75:25SF 
Mono-exponential 112.9819 22 
 
 
Based on results above, the bi-exponential Equation 8.13 is suggested to be more suitable to 
fit to the CPt release profiles compared to a mono-exponential model. This also implies that 
the developed PLGA solid fibres and microspheres can be described as a depot having two 
pools; the first pool contains a fraction of readily release drug is which located near/at the 
surface, and subsequent drug release is from the second pool with drug entrapped deeper in 
the depot. The parameters of Equation 8.13 are plotted in Figure 8.12. 
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Figure 8.12: Estimate parameters of biexponential model Equation 8.13. k2 and k3 are the rate constants 
associated to Pools A and B respectively. Q2(∞) and Q3(∞) are the amount of drug in Pools A and B which 
will be released after a long time respectively. 
 
Small Medium Large SF 
(A) 50:50 PLGA 
(B) 65:35 PLGA 
(C) 75:25 PLGA 
Small Medium Large SF 
Small Medium Large SF Small Medium Large SF 
Small Medium Large SF Small Medium Large SF 
Symbols: 
= k2   SF = solid fibre  
  = k3  Microsphere size fractions: Small = 53-38 µm   
= Q2(∞)     Medium = 75-53 µm 
= Q3(∞)     Large = 90-75 µm 
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Model Equation 8.13 is based on a condition of two pools being present in the depot. This is 
based on the observation of a faster initial drug release from “Pool A” which can be 
characterised using a Higuchi diffusional model. Subsequently, drug remaining drug in 
“Pool B” in the depot will be released. Hence, k2 and k3 are the rate constants of drugs 
release from Pools A and B respectively. Figure 8.12A shows that the k2 values of CPt-
50:50-MS and –SF are of similar magnitudes and likewise, for their k3 values. The same 
observation can be made for CPt-65:35MS and -SF (Figure 8.12B).  
 
In terms of the amount of remaining drugs in CPt-50:50MS/SF and CPt-65:35MS/SF; i.e. 
Q2(∞) in Pool A and Q3(∞) in Pool B, Q2(∞) tends to increase with a decrease in surface 
area:volume ratio. On the other hand, Q3(∞) tends to decrease with a decrease in surface 
area:volume ratio. As previously shown in Tables 8.3 and 8.4, larger structure is associated 
with smaller surface area:volume ratio. This result indicates that a larger structure holds 
more drugs in its fast release pool. The amount of drug in the fast releasing Pool A also 
tends to be higher than those in Pool B.  
  
CPt-75:25MS and -SF exhibit different behaviour then CPt-50:50MS/SF and CPt-
65:35MS/SF. The clear decreasing trend of k2 is observed to be correlated to a clear 
increasing trend of Q2(∞). This relationship can be translated to a condition where a larger 
structure could hold more drug in its fast release pool (i.e. Pool A) and its smaller surface 
area:volume ratio decreases the rate of drug release from this pool. 
  
An observation can also be made where the sample with the largest surface area:volume 
ratio tends to have equal amount of drug in its separate pools, whereas the differences in 
amount of drug between the pools increases with decrease in surface area:volume ratio. 
 
Figure 8.12 shows that CPt-loaded devices tend to hold the similar amount of drug in their 
Pools B. The amount of drug in Pool A is also observed to increase with increase in 
lactide:glycolide acids ratio.  
 
In order to compare the competence of the in vitro cisplatin release profile to the real drug 
dosage used in chemotherapy treatment, the drug release profiles were reproduced as the 
amount of cisplatin released in buffer as a function of measured time. Example is shown in 
Figure 8.13 using the drug release profiles of PLGA solid fibres and microspheres of the 
smallest size fractions (53-38 µm). For clarity, error bars are omitted. The intravenous (IV) 
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cisplatin regimen previously discussed in Section 2.2.1 suggested a drug dosage of 170 mg 
cisplatin/cycle.  
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Figure 8.13: Cumulative drug release from 50:50, 65:35, 75:25 PLGA solid fibres and microspheres of 
the smallest size fraction (53-38 µm). Inset: Drug release during the first half day.  
 
Table 8.7: Final cumulative (%) drug release on Day-20 of PLGA solid fibres and microspheres of the 
smallest size fraction (53-38 µm). 
% Cumulative Release at Day-20 
Estimate amount of sample required to 
deliver a 170 mg CPt (g) 
PLGA 
MS (53-38µm) SF MS (53-38 µm) SF 
50:50 99.58 ± 7.45 98.33 ± 6.03 2.2 1.2 
65:35 95.69 ± 6.54 93.04 ± 5.29 1.4 1.1 
75:25 87.81 ± 5.29 78.48 ± 5.28 1.2 0.9 
 
Table 8.7 tabulates the percentages of cumulative release from PLGA samples at Day 20. 
Microsphere and solid fibres made of 50:50 PLGA reached to complete drug release faster 
than those made of 65:35 and 75:25 PLGA. In the case of 50:50SF, complete drug release is 
observed just before twenty days whereas complete drug release from 50:50MS is observed 
after approximately ten days. CPt-loaded 65:35 and 75:35 PLGA clearly exhibit a prolonged 
drug release characteristic for up to three weeks. In the case of 50:50 PLGA devices, they 
are more suitable for a two weeks treatment schedule. These products offer the options of 
two or three weeks CPt delivery while they can also serve as sequential treatment or follow-
up chemotherapy treatment. The chemotherapy treatment cycle is usually three weeks as 
time allowance is required for the patients to recover from tissue damage caused by previous 
chemotherapy treatment.  
50:50MS (53-38 µm) 
50:50SF 
65:35MS (53-38 µm) 
65:25SF 
75:25MS (53-38 µm) 
75:25SF 
Symbols: 
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The initial rapid release is advantageous because a higher dose is useful to penetrate the 
tumour cells. This causes higher cancerous cell death rate at the surface of the tumour and 
induces apoptosis. Subsequent effect would be the creation of passages to drugs to penetrate 
into the tumour.  CPt-loaded microsphere can also be injected into the IP cavity at desired 
time should their initial “burst effect” is required. Larger amount of microspheres would not 
be a problem because IP delivery usually involves up to two litres of saline solution to be 
transfused into the peritoneal cavity (Gilby, 2008). The submicron devices are designed for 
the purpose of increasing the exposure of the cancer cells to the drug. The distribution of 
larger amount of microspheres in the IP cavity is likely to increase the local therapeutic 
effect of the cytotoxic drug.  
 
The amount of 1 g of solid fibre is most likely to constitute > 50 fibres of 8 cm in length. 
This amount provides a practical amount of material for fabrication of a fibre-patch. 
Preliminary experiments have shown the viability of producing a fibre patch. The rational of 
developing a CPt-loaded fibre patch is to attach the product to the peritoneum cavity after 
debulking in order to kill residual cancerous materials (Gilby, 2008). The flexibility of these 
polymeric fibres can easily adapt to the curvature the of the peritoneum cavity.  
 
 
8.4 Conclusion 
 
1. Cisplatin was successfully encapsulated into PLGA microspheres and solid fibres. 
Drug loadings tend to be higher in 75:25 PLGA devices compared to 50:50 PLGA. 
This is because of the higher lactic acid ratio and the higher viscosity of 75:25 
PLGA. Lactic acid is less amorphous than glycolide acid and therefore offers a 
lower freedom for medium transport. Thus, drug diffusion is lower and drug leakage 
is minimised during the solidification process.  
 
2. Solid fibre tend to have higher drug loadings compared to microsphere because the 
former system has lower surface area which reduces the diffusion area for drug 
leakage. The formation of skin layer during the phase inversion is also thought to 
have beneficial effect against drug loss. 
 
3. Overall the drug releases from PLGA solid fibres was slower than from PLGA 
microspheres. The main reason is because the solid fibres offer much lower surface 
area:volume ratio for drug diffusion. Likewise, their hydrolytic degradation rates are 
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also lower compared to microspheres. The skin layer of solid fibre is also thought to 
offer high mass transfer resistance thereby reducing the drug release rate.  
 
4. In the approach to characterise CPt release profiles, a biphasic release pattern is 
used. Drug release during the first day is described as Phase 1 and is associated with 
a “burst release”. This burst release is attributed to the release of CPt located at the 
surface of the microspheres or solid fibres. This condition caused by the tendency of 
drug leakage during the production process. Upon solidification, the drug is 
entrapped in the peripheral layer of the microspheres or solid fibres. Hydration in 
microspheres or solid fibres then permits the release of drugs located in this layer. 
 
5. The drug release in Phase 1 can be characterised using the Higuchi-diffusional 
model for both PLGA microspheres and solid fibres. The drug release is proportional 
to the square root of time. Reasons contributing to this initial diffusional drug release 
are described in (4) above. Furthermore, the swelling susceptibility of the developed 
PLGA microsphere also contributes to an initial rapid release.  
 
6. The burst effect during Phase 1 release is more prominent in CPt-50:50MS 
compared to 65:35MS and 75:25MS. Findings in Section 7.1 showed that PLGA 
microspheres underwent hydration and led to swelling. Swelling leads to pore 
expansion and shifts the system to rubbery state. These conditions permitted higher 
degree of medium transport and drug diffusion is higher. Hence, drug release is 
faster. The pores in 50:50MS were found to be more susceptible to swelling 
compared to 65:35MS and 75:25MS. This tendency of 50:50MS can lead to faster 
medium diffusion and transport. As a result, more rapid drug diffusion into the 
buffer is observed. In contrast, 75:25MS restricted pore swelling and therefore burst 
release is not as rapid as in 50:50MS. 
 
7. The deviations of Phase 2 drug release profiles from empirical models; Higuchi 
model (Qt = kH.t
0.5), first order kinetic ( ln Qt = ln Qo + kF.t) and zero order kinetic (Qt 
= Qo + kz.t) are mainly attributable to: (1) the influence of PLGA degradation, (2) 
inhomogeneities in drug distribution and (3) the evolutionary swelling and shrinking 
of the polymeric devices. The empirical models expressed in Equations 8.1 to 8.3 
did not account for all these factors.  
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8. Equation 8.13; i.e. [ ] [ ])1).(()1).(( 21 321 tktk eQeQQ −− −∞+−∞=  was found to better fit 
CPt release profiles without partitioning the release profiles. This model suggests 
that there are a fraction of drug in the device will be readily release and thereafter 
the release of the remaining drug. Those readily release drug are likely to be located 
at or near the surface of the device whereas the remaining would be entrapped 
deeper in the device. 
 
9. Results show that the copolymer ratio of PLGA is more prominent in influencing the 
drug release rate regardless of the sizes of the microspheres. Comparing the overall 
drug release profiles of CPt-50:50MS, CPt-65:35MS and CPt-75:25MS, CPt-
50:50MS released its CPt content the fastest. This trend is attributable to the fast 
degradation rate of 50:50 PLGA and its highest affinity for medium transport. 
 
10. Other factors influencing the drug release rates are proposed below: 
i. The different availability of the entrapped different regions in the microsphere. 
The amorphous structure of PLGA hinders a homogeneous drug distribution 
which promoted spatial heterogeneous distribution of the entrapped drug.  
ii. The bulk and autocatalytic degradations occurring in microsphere changes the 
morphology and structure of the device. As a result, both interior porosity and 
tortuosity are altered. This consequently changes the diffusion passage of drug. 
iii. Similar to microsphere, the distribution of CPt in solid fibre may not be 
homogeneous. Given the length of solid fibre, the amount of CPt entrapped in 
across the fibre will be less homogenous. Similarly for the heterogeneous 
degradation across the solid fibre due to bulk and autocatalytic degradations. 
iv. The presence of inhomogeneities in batch-to-batch samples. 
 
11. Results of in vitro CPt release show that CPt-50:50SF can provide a prolong drug 
release for more than two weeks. Devices made of 65:35 and 75:25 PLGA have 
higher drug loadings and degradation resistances than 50:50 PLGA devices. 
Therefore they are more competent to deliver an IV or IP dose for a period three 
weeks or longer.  
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CHAPTER 9: IN  VITRO  LIDOCAINE  RELEASE  PROFILES 
 
9.1 Lidocaine-Loaded PLGA Microspheres and Hollow Fibres 
Lidocaine (LID) was selected as the model drug in this work for the application of pain 
relief. This is because of the abdominal pain issues associated with intraperitoneal route of 
administration. The objectives of this chapter were two-fold; firstly, to study the effects of 
both drug and polymer concentrations on drug loading. Secondly, to compare the in vitro 
drug releases from microspheres and hollow fibres. For ease, LID-loaded 50:50 PLGA 
microsphere will be abbreviated as LID-50:50MS and LID-loaded 50:50 PLGA hollow fibre 
as LID-50:50HF henceforth. Similarly for devices made of 65:35 and 75:25 PLGA. 
 
 
9.2 Production of LID-Loaded PLGA Microspheres and Hollow Fibres 
LID-loaded 50:50, 65:35 and 75:25 PLGA microspheres were produced using the method 
described in Section 4.1.3. Briefly, 10 g of polymer/drug solution was homogenised in 100 
ml PVA solution (0.5 % w/w). Then the nascent microspheres were transferred to magnetic 
stirring before they were harvested. Only the concentration of the polymer and the ratio of 
drug-to-polymer were varied. Table 9.1 shows the experimental conditions and variables.  
  
Table 9.1: Production conditions for LID-loaded 50:50, 65:35 and 75:25 PLGA microspheres. 
PLGA (% w/w) LID-to-PLGA Ratio Homogenisations Speed & Time 
1:1 
1:2 8 
1:3 
6500 rpm, 15 min 
1:1 
1:2 10 
1:3 
6500 rpm, 15 min 
1:1 
1:2 15 
1:3 
6500 rpm, 15 min 
1:1 
1:2 20 
1:3 
6500 rpm, 15 min 
 
LID-loaded PLGA hollow fibres were produced using the method described in Section 4.2.3. 
A drug-to-polymer ratio of 1:1 was used with LID powder premixed to the polymer solution 
prior to spinning. Typically, a 50 g of polymer/drug solution was used to spin a batch of 
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hollow fibre using 20 % (w/w) 50:50, 65:35 and 75:25 PLGA. For lumen-filling experiment, 
lidocaine-hydrochloride solution (20 mg/ml) was injected into the lumen of the LID-loaded 
hollow fibres using a syringe with a 19G needle. Each fibre was estimated to accommodate 
approximately 30 µl of drug solution. With a free flow of solution through its lumen, one end 
of the fibre was sealed with Epoxy® resin and left to dry at room condition overnight. The 
other end of the fibre was sealed in a similar way.  
 
The similar procedure was carried out to fill the lumen of LID-loaded hollow fibres with 
LID-loaded microspheres. In this case, the lumen was filled with approximately 30 µl of 
buffer solution containing LID-loaded microspheres. The latter suspension was freshly 
prepared prior to each experiment by immersing 0.2 g of microspheres in 1 ml of PBS. Table 
9.2 tabulates the abbreviations representing the hollow fibres with different lumen fillings. 
 
Table 9.2: Abbreviations for PLGA hollow fibres with lumen filled with drug-solution or microsphere. 
Sample Condition 
Abbreviation 
Hollow Fibre Lumen Content 
LID-50:50HF LID-loaded 50:50 PLGA hollow fibre Blank 
LID-50:50HFso LID-loaded 50:50 PLGA hollow fibre Filled with LID-hydrochloride solution 
LID-50:50HFms LID-loaded 50:50 PLGA hollow fibre Filled with LID-50:50MS 
LID-65:35HF LID-loaded 65:35 PLGA hollow fibre Blank  
LID-65:35HFso LID-loaded 65:35 PLGA hollow fibre Filled with LID- hydrochloride solution 
LID-65:35HFms LID-loaded 65:35 PLGA hollow fibre Filled with LID-65:35MS 
LID-75:25HF LID-loaded 75:25 PLGA hollow fibre Blank 
LID-75:25HFso LID-loaded 75:25 PLGA hollow fibre Filled with LID- hydrochloride solution 
LID-75:25HFms LID-loaded 75:25 PLGA hollow fibre Filled with LID-75:25MS 
 
Five preweighed samples were prepared from each PLGA microsphere and hollow fibre 
for in vitro drug release analyses. LID concentration and drug loading were determined using 
methods described in Sections 4.3.1 and 4.4 respectively. In vitro drug release analysis was 
carried out by incubating the sample in a shaking water bath maintained at 37oC. More 
details of incubation condition can be found in Section 4.5.  
 
 
9.3 Results and Discussion 
The effects of the drug-to-polymer ratio and polymer concentration on drug loading are 
shown in Figure 9.1. Figure 9.1A shows that the drug loading are higher towards higher 
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concentration of 50:50 PLGA. Section 5.1.1 showed that a higher polymer concentration 
tended to produce larger microsphere. This leads to an increase in diameter and a decrease in 
the overall surface area, which reduces the possibility drug loss by diffusion towards the 
aqueous phase during the production process (Görner et al., 1999 and Polakovič et al., 1999). 
The same reason is applied for the higher drug loadings with increased 65:35 and 75:25 
PLGA concentrations.  
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Figure 9.1: The effects of polymer concentration and LID-to-PLGA ratio on drug loading for (A) 50:50, 
(B) 65:35 and (C) 75:25 PLGA. 
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Figure 9.1 indicates that the drug loadings in LID-65:35MS and LID-75:25MS tend to be 
higher than in LID-50:50MS. This trend is attributed to the higher viscosities of both 65:35 
and 75:25 PLGA compared to 50:50 PLGA. The amount of drug encapsulated in polymeric 
device depends on the degree of the partition of the drug in the aqueous phase during the 
production process. Hydrophilic drug such as lidocaine with high partition degree will tend 
to diffuse into the aqueous phase while its concentration in the polymeric droplets decreases. 
This drug loss can be minimised by having a more viscous polymer solution, such as 75:25 
PLGA, which offers higher resistance for medium diffusion and promotes a faster rate of 
solidification (Matsumoto et al., 2005). The as-reported viscosity presented in Table 5.1 
shows that PLGA with higher lactic acid ratio tends to have higher viscosity and it has been 
confirmed by previous a researcher (Shearer, 2007).  
 
Figure 9.1 also indicates that higher LID-to-PLGA ratio tends to yield higher drug loading. 
This is generally due to the presence of more drug in the system that improves the frequency 
of drug entrapment. However, at a 1:1 LID-to-PLGA ratio, there exists a critical point where 
further increase in polymer concentration will not further increase the drug loading (Ghaderi 
et al., 1996). This is due to the increased viscosity in the system (Yan et al., 1994). At a 
constant homogenisation speed, the shear force is no longer sufficient to emulsify the organic 
phase. This deficiency can lead to the formation of microspheres with non-uniform 
morphology. Evidence can be found in Section 5.1 where various homogenisation effects 
were investigated.  
 
Sandrap and Moës (1993) showed that improved drug loading was associated with 
microspheres system with constant sizes and narrow size distribution. The deficiency in 
achieving a stable emulsion in an increased viscosity system may have also led to deficiency 
in drug loading even when 1:1 drug-to-polymer ratio is used. For PLGA microsphere system, 
Yan et al. (1994) showed that there was no obvious relationship between drug loading and 
PLGA concentration once the polymer concentration was ≥ 15%.  
 
For material and cost effectiveness, a polymer concentration of 15 % (w/w) and a 1:1 drug-
to-polymer ratio were employed for in vitro drug release studies. The cumulative release of 
LID from 50:50 PLGA devices is shown in Figure 9.2. The drug release of 50:50 PLGA 
devices exhibit biphasic profiles which can be termed as Phase 1 and Phase 2, as previously 
described in Chapter Eight. Phase 1 release is associated with a burst release and other 
factors that can affect burst release are such as the dimensions within the microparticles; the 
polymer matrix density and the particle porosity.  
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Burst release can be defined as the quantity of drug that escapes from microparticles prior to 
the onset of polymer erosion-mediated drug release (Allison, 2008b). Burst release may be an 
inherent property of diffusion-controlled drug delivery devices and this will be shown later 
by fitting the Higuchi model to LID release profiles. Hydrophilic lidocaine has a tendency 
to diffuse towards the aqueous phase during production (Perez et al., 2000). This leads to an 
increased drug concentration near the surface of the device due to convective solvent flow. 
Upon hydration, these drugs are easily released into the solution. The termination of burst 
release may be explained by structural relaxation due to increased particle density and 
surface pore closure (Allison, 2008a). 
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Figure 9.2: The percentage (%) LID cumulative release from LID-50:50MS (  ), LID-50:50HF (  ), LID-
50:50HFso (  ) and LID-50:50HFms (  ). [LID-50:50HFso = lidocaine-loaded 50:50 PLGA hollow fibre 
with its lumen filled with lidocaine hydrochloride solution; LID-50:50HFms = lidocaine-loaded 50:50 
PLGA hollow fibre with its lumen filled with lidocaine-loaded 50:50 PLGA microsphere.] 
 
From Section 6.2 (Figure 6.11), degradation was visible for 50:50MS after ten days and 
polymeric disruption was evident after twenty days. This situation may be accounted for the 
drug release from LID-50:50MS after two weeks. The degradation and swelling effects are 
thought to have changed the morphology of 50:50MS by increasing its porosity forming 
more passages for drug diffusion. Hence, drug release rate is increased and complete drug 
release is achieved after two weeks. This result suggests that 50:50MS can offer a LID 
release of less than three weeks.  
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For 50:50HF, degradation effect led to micropores formation on the fibre surface after ten 
days in buffer (Section 6.4, Figure 6.20). As degradation progresses, disintegration of the 
50:50HF structure increases and this decreases the diffusion resistance of 50:50HF. These 
conditions are thought to account for the drug release from LID-50:50HF during the first ten 
days. After approximately two weeks, from the disintegration of its polymeric structure and 
when the onset of mass loss was observed (Section 6.4, Figure 6.23), the degrading 50:50HF 
release its remaining drug into the buffer. The LID-50:50HF exhibits a higher drug release 
rate during the first four days compared to LID-50:50HFms and LID-50:50HFso. This may 
due to the higher medium influx rate through its unsealed lumen. The open-ends LID-
50:50HF permit buffer penetration into the structure and subsequently promotes drugs 
diffusion and release. 
 
For LID-50:50HFso, its drug release rate is higher than LID-50:50HF. This is attributed to 
addition of LID solution in its lumen which enhances the drug diffusion across the fibre wall. 
The drug solution may have also promoted hydrolytic degradation in the fibre lumen. 
Degradation on 50:50HF led to the pore formation on the lumen surface after ten days in 
buffer. In this case, these pores would promote drug solution transport into the fibre wall. 
Consequently, this drug solution would enhance the diffusion of LID entrapped in the fibre 
and leads to the release of LID.  
 
For LID-50:50HFms, its drug release during the first week is the lowest compared to other 
samples. This may be due to the retardant barrier formed by the dense structures within the 
fibre wall, which limit the drug release. Discussions in Sections 3.5 and 6.5 suggested that 
the unique structures in the fibre wall offer better control of drug release due to their higher 
mass transfer resistances. Meanwhile, with their sealed-fibre ends, the degradation products 
from the microsphere may be trapped within the lumen.  
 
The accumulation of the acidic products in the fibre lumen may have caused autocatalytic 
reaction thereby increasing the hydrolytic degradation in the lumen. This condition can 
consequently promote heterogeneous degradation across the hollow fibre. Thus, disruption of 
the amorphous regions might be greater in the case of LID-50:50HFms, and produces a faster 
drug release compared to LID-50:50MS and -HF. On the other hand, the drug release from 
LID-50:50HFms is slower than LID-50:50HFso because in the latter, medium diffusion 
across the fibre wall is enhanced by the additional drug solution. 
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Overall, the drug release from LID-50:50MS completes drug release faster compared to LID-
50:50HF samples. Comparing the forms of hollow fibre and microsphere, hollow fibre is a 
cylindrical device whereas the microspheres present as multiple submicron particles. Table 
9.3 shows the comparisons of estimate surface area:volume ratios of microspheres and 
hollow fibres. Sample calculations are shown in Appendix VI.I. Because of their much 
higher surface area:volume ratios, microspheres show the tendency to exhibit faster drug 
release compared to hollow fibre. 
 
Table 9.3: Estimate surface area:volume ratios of 20 % (w/w) PLGA hollow fibres, and 15 % (w/w) PLGA 
microspheres based on their median sizes.  
PLGA Device 
Diameter 
(10-6 m) 
Number of 
sample  
Surface Area 
of one sample 
(10-5 cm2) 
Total Volume 
of one sample 
(10-9 cm3) 
Total Surface 
Area:Volume 
Ratio 
50:50MS 26 1.41  x 10
7
 2.12 9.20 23.08 
65:35MS 45 2.72  x 10
6
 6.36 47.72 13.33 
75:25MS 53 1.67 x 10
6
 8.83 77.96 11.32 
50:50HF 690 10 16.84 2.99 5.80 
65:35HF 750 10 18.10 3.53 5.33 
75:25HF 850 10 19.10 4.54 4.71 
 
An example of ten days degraded LID-65:35HF is shown in Figure 9.3 in order to correlate 
drug release to structural changes due to degradation in PLGA hollow fibres. It was found 
that the hydrolytic degradation on PLGA hollow fibres will alter the integrity of the fibre 
wall structure such as increased porosity. This increment is likely offer higher freedom of 
medium transport therefore increases drug release rate.  
 
    
Figure 9.3: The ten days degraded 65:35HF with increased porosity in fibre wall structure. (A) Skin layer 
near lumen. (B) Cross section of fibre wall. (C) Skin layer near outer surface. (D) Fibre wall.  
 
The nature of asymmetric hollow fibre derives from its different skin layers and fibre wall. 
Both the skin layers at the lumen (Figure 9.3A) and outer surface (Figure 9.3C) have finger-
like cavities adjacent to them. Macrovoids constitute the core layer between these skin layers 
in the fibre wall (Figure 9.3D). The microvoids offer higher freedom for drug transport as 
oppose to the denser structures near the skin layers. The latter offers higher resistance to drug 
(A) Skin layer – inner       (B) Cross section             (C) Skin layer – outer       (D) Fibre wall 
 
 
 
    Micro- 
          Dense                           voids 
          Structure                  
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diffusion and decreases drug release. In this regard, the hollow fibre acts as a retardant 
barrier against rapid drug release. The above phenomenon is attributable to one of the 
reasons why the drug release from hollow fibre is slower than microsphere. 
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Figure 9.4: The percentage (%) LID cumulative release from LID-65:35MS (  ), LID-65:35HF (  ), LID-
65:35HFso (  ) and LID-65:35HFms (  ). [LID-65:35HFso = lidocaine-loaded 65:35 PLGA hollow fibre 
with its lumen filled with lidocaine hydrochloride solution; LID-65:35HFms = lidocaine-loaded 65:35 
PLGA hollow fibre with its lumen filled with lidocaine-loaded 65:35 PLGA microsphere.] 
 
Figure 9.4 shows the cumulative release of LID from 65:35 PLGA samples. As expected, the 
higher surface area available for drug diffusion offered by 65:35MS would result in the 
fastest drug release compared to the other samples. After the initial rapid release, buffer 
influx provides a medium for drug diffusion and coupled with drug located at the surface of 
the microspheres, LID is released into the buffer during the first two weeks. After that, drug 
release is probably from the drug entrapped deeper in the structure. While 65:35MS 
experiencing swelling effect, the drug slowly diffused towards the surface of the 
microsphere. These two phenomena and coupled with a better degradation resistance, a slow 
drug release towards the end of the twenty days period is observed.  
 
The Phase 1 release of LID-65:35HF is attributable to a rapid release of drugs located at or 
near the surface of the fibre, thereafter followed by drug release from those entrapped in the 
fibre structure. The entrapment of these drugs and the time required for buffer influx, may 
have delayed the drug release while these drugs diffused from the inner structure to the 
surface. The skin layers of the hollow fibre also increase the residence time of drug diffusion. 
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These conditions could be accounted for the slower drug release throughout the twenty days 
period. SEM images in Section 6.4 (Figure 6.21) indicated that surface micropores of the 
degrading 65:35HF were not as prominent as those observed on 50:50HF. The delay in 
surface micropores formation is attributed to the degradation resistance of 65:35 PLGA. As a 
result, the drug release is slower. After approximately fifteen days, buffer influx through 
lumen surface and degradation eventually disrupted the structure of 65:35HF, resulting in a 
faster drug release towards the end of twenty days. 
  
The initial rapid drug release from LID-65:35HFso is thought to cause by enhanced drug 
diffusion through the fibre wall promoted by the drug solution in its lumen. The drug 
solution diffuses into the fibre through the lumen surface and provides additional medium for 
drug release. This condition provides a near zero order release from Day 5 onwards.   
 
For LID-65:35HFms, there is an increase in drug release after approximately ten days. This 
may have caused by an autocatalytic degradation inside 65:35HF. Due to the sealed ends of 
LID-65:35HFms, the accumulated of degradation products from the microsphere in the fibre 
lumen may have promoted heterogeneous degradation across the fibre. This may have 
consequently disrupted the fibre interior structure and given rise to more diffusion passages. 
When prominent effect sets it, together with the increased medium transport, a faster drug 
release is observed after ten days.  
 
The cumulative release of LID from 75:25 PLGA samples is shown Figure 9.5. For LID-
75:25MS, its drug release rate tends to parallel to that of LID-75:25HFso during the first four 
days. The drug release rate of LID-75:25HF is also observed to be similar to that of LID-
75:25HFms during the first week. Previous SEM images showed that 75:25MS (Section 6.2, 
Figure 6.11) and 75:25HF (Section 6.4, Figure 6.22) experienced minimal degradation effect 
after twenty days in buffer. The slow drug releases observed in Figure 9.5 during the first 
two weeks are attributable to the high degradation resistance of 75:25 PLGA. With its least 
amorphous property that limits the freedom of drug transport within the device, drug release 
rates are reduced. 
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Figure 9.5: The percentage (%) LID cumulative release from LID-75:25MS (  ), LID-75:25HF (  ), LID-
75:25HFso (  ) and LID-75:25HFms (  ). [LID-75:25HFso = lidocaine-loaded 75:25 PLGA hollow fibre 
with its lumen filled with lidocaine hydrochloride solution; LID-75:25HFms = lidocaine-loaded 75:25 
PLGA hollow fibre with its lumen filled with lidocaine-loaded 75:25 PLGA microsphere.] 
 
After Phase 1 drug release, medium influx enables the entrapped drug to diffuse to the 
surface of 75:25HF. This effect is reflected on its increased drug release after approximately 
a week. Meanwhile, the open-ends of LID-75:25HF permit buffer penetration and as a result, 
drug release continued due to more medium to transport the drug in the fibre.  
 
The higher drug release from LID-75:25HFso compared to LID-75:25-HF and -HFms, is 
likely to cause by the presence of drug solution in its lumen which promotes faster drug 
diffusion across the fibre wall. The drug release from LID-75:25HF, LID-75:25HFso and 
LID-75:25HFms tend to coincide after approximately eighteen days. This may due to the 
structural collapse in 75:25HF which was seen earlier in Figure 6.22 (Section 6.4). As a 
result, the reduction in diffusion passage produces a retardant effect on drug release. The 
increased crystallinity by the remaining lactide acid as glycolide acid is removed from the 
chain also reduces the amorphous regions in the fibre. Hence, drug release becomes slower. 
 
When PLGA undergoes random polymer chain scission, its average molecular weight 
decreases (Mohr et al., 1999). This reduces the length of the polymer chain which in turns 
reduces the entanglement of the chain. Consequently, the mobility of the molecules is 
increased and this flexibility permits more amorphous regions for diffusion. Hence, drug 
diffusion within the device is increased and an increase in subsequent drug release can be 
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observed. These phenomena help to explain the tendencies of LID-50:50-MS and -HF to 
exhibit faster drug release because of their faster degradation rate. The swelling susceptibility 
of 50:50 PLGA that shifts the polymeric devices into rubbery states also permitted higher 
drug diffusion. The opposite observations are assumed for 75:25 PLGA samples. 
 
The penetration of residual PVA from the production process can introduce plasticising 
effect on the mobility of PLGA chain. However, Bouissou et al., (2006) reported that the 
total amount of PVA remaining on/in the microspheres only increases water uptake at high 
relative humidities and residual PVA seemed to only weakly influence the molecular 
mobility or free volume of PLGA particles.  
 
Similar approach applied in Chapter Eight in terms of model fittings were applied for LID 
release profiles. The three models expressed in Equation 8.1 to 8.3; Higuchi Model (Qt = 
kH.t
0.5), first order kinetic (ln Qt = ln Qi + kF.t) and zero order kinetic (Qt = Qi + kz.t) were 
fundamentally used to fit to Phase 1 and Phase 2 drug release profiles. Phase 1 represents the 
drug release during the first day and thereafter, Phase 2. The Higuchi model shows good fit 
to the Phase 1 LID release and examples are shown in Figure 9.6. Full set of result can be 
found in Appendix VII.D and VII.E. 
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Figure 9.6: The fittings of Higuchi Model (Qt = kH.t
0.5
) to drug releases from (A) 50:50 and (B) 75:25 
PLGA microsphere and hollow fibre samples during Phase 1.  Symbols (×,    ,    ,   ) represent experimental 
data and lines (       ,        ,        ,       ) represent Higuchi model.  
 
Similar to previous findings in Chapter Eight, Equations 8.1 to 8.3 were unable to provide 
good fit to LID release profiles. Hence, the mono- and biexponential model Equations 8.11 
and 8.13; i.e. )1).((1
tk
o
oeQQ
−
−∞=  and )]1).(([)]1).(([ 32 321
tktk
eQeQQ
−−
−∞+−∞=  respectively 
were also used to fit to LID release profiles. Examples of results are shown in Figure 9.7.  
(A)        (B) 
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Figure 9.7: Results of model Equations 8.11 and 8.13 fittings to LID release profiles of (A) LID-50:50MS, 
(B) LID-50:50HF, (C) LID-65:35MS, (D) LID-65:35HF, (E) LID-75:25MS (F) LID-75:25HF. Solid lines 
represent Equation 8.13 and dashed lines represent Equation 8.11.  
 
A summary of AIC and degrees of freedom generated based on fittings of Equations 8.11 and 
8.13 are shown in Table 9.4. Equation 8.13 was found to better fit the LID release profiles 
based on the lower values of AIC and degrees of freedom. This suggests that the 
biexponential model is more suitable to describe LID release from the developed PLGA 
(A) LID-50:50MS              (B) LID-50:50HF 
 
 
(C) LID-65:35MS                                   (D) LID-65:35HF 
(E) LID-75:25MS                 (F) LID-75:25HF 
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microspheres and hollow fibres. This model is based on two pools present in the depot; one 
pool represents a fraction of drug which is readily released and another pool represents the 
remaining drug entrapped deeper in the depot. 
 
Table 9.4: Summary of goodness of fit of model Equations 8.11 and 8.13 to LID release profiles. 
LID-Loaded Device 
Bi-exponential - Equation 8.13 
Mono-exponential - Equation 8.11 
AIC Degrees of Freedom 
Bi-exponential 58.1083 20 
LID-50:50MS 
Mono-exponential 86.0025 22 
Bi-exponential 21.4055 22 
LID-50:50HF 
Mono-exponential 85.0514 24 
Bi-exponential 4.3099 23 
LID-50:50HFso 
Mono-exponential 60.1035 25 
Bi-exponential 8.0958 20 
LID-50:50HFms 
Mono-exponential 39.1433 22 
Bi-exponential 68.3661 23 
LID-65:35MS 
Mono-exponential 102.0084 25 
Bi-exponential 9.0574 23 
LID-65:35HF 
Mono-exponential 68.0395 25 
Bi-exponential 50.7528 21 
LID-65:35HFso 
Mono-exponential 95.8173 23 
Bi-exponential 24.9815 19 
LID-65:35HFms 
Mono-exponential 94.2173 23 
Bi-exponential 57.4923 23 
LID-75:25MS 
Mono-exponential 73.7451 25 
Bi-exponential 56.6755 21 
LID-75:25HF 
Mono-exponential 66.1725 24 
Bi-exponential 28.1547 22 
LID-75:25HFso 
Mono-exponential 76.4795 24 
Bi-exponential 45.1416 22 
LID75:25HFms 
Mono-exponential 77.4150 24 
 
 
The parameters of the biexponential model Equation 8.13; i.e. Q2(∞) (mg) and Q3(∞) (mg), 
the amount of drugs remaining in two separate pools which will be released after a long time, 
k1 (day
-1) and k2 (day
-1), the drug release rate constants of the two pools are plotted in Figure 
9.8. The complete set of results can be found in Appendix VII.A and VII.B. 
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Figure 9.8: Estimated parameters of biexponential model Equation 8.13. k2 and k3 are the rate constants 
associated to Pools A and B respectively. Q2(∞) and Q3(∞) are the amount of drug in Pools A and B  which 
will be released after a long time respectively. [HFso = hollow fibre with lumen filled with lidocaine 
hydrochloride solution; HFms = hollow fibre with lumen filled with lidocaine-loaded microsphere.] 
 
MS HF HFso HFms 
(A) 50:50 PLGA 
(B) 65:35 PLGA 
(C) 75:25 PLGA 
Symbols: 
= k2   SF = solid fibre  
  = k3  Microsphere size fractions: Small = 53-38 µm   
= Q2(∞)     Medium = 75-53 µm 
= Q3(∞)     Large = 90-75 µm 
MS HF HFso HFms 
MS HF HFso HFms 
MS  HF HFso HFms 
MS  HF HFso HFms 
MS  HF HFso HFms 
CHAPTER 9: IN VITRO LIDOCAINE RELEASE PROFILES 
THE DEVELOPMENT OF A CONTROLLED-CHEMOTHERAPY DRUG DELIVERY SYSTEM 169 
The biexponential Equation 8.13 with two pools is thought to be not appropriate to predict 
the systems of hollow fibres with additional loading in their lumens. This is because of the 
altered physics of the systems where the combinations of hollow fibre with drug-solution or 
drug-microsphere essentially form a new system comprises two depots and four pools. This 
helps to explain the random trends in results shown in Figure 9.8 for the samples of HFms 
and HFso.  
 
Figure 9.8 indicates that “Pool A” of all the PLGA samples have similar rates of drug release 
where k1 values were of similar magnitudes; i.e. ≤ 0.1 day
-1 while k2 values tend to be more 
random. LID-50:50MS, -65:35MS and -75:25MS also tend to have higher amount of drugs in 
both their Pools A and B compared to LID-50:50HF, -65:35HF and -75:25HF. This may be 
attributed to the higher drug loadings in microspheres.  
 
In the cases of drug release profiles of devices made of 65:35 PLGA (Figure 9.4) and 75:25 
PLGA (Figure 9.5), these systems tend to require more than twenty drugs for complete drug 
release. The conditions may have contributed to the inappropriateness of biexponential 
Equation 8.13 to be applied on these profiles. 
 
For the developed LID-loaded hollow fibres (blank lumens), the estimate parameters indicate 
that LID-50:50HF, -65:35HF and -75:25HF have higher amount of drug in their fast 
releasing Pool A than in Pool B. For LID-50:50HF, -65:35HF and -75:25HF, preliminary 
fittings using a first order kinetic model, results indicate that the second phase (i.e. Phase 2) 
is highly first-ordered. Examples of plot can be found in Appendix VII.E. Based on these 
observations, it is suggested that partitioning the drug release profiles to Phase 1 and Phase 2, 
would ease the prediction of LID releases from hollow fibre samples. Phase 1 can be 
characterised using a Higuchi Model while Phase 2, a first order kinetics model would be a 
better fit for the drug release profiles.  
 
Results above indicate that the semi-mechanistic Equation 8.13 can be improved further. The 
presences of additional drug loadings in the lumens were anticipated to further cause 
deviation from the model. Siepmann et al. (1998) has reported consideration in geometry and 
dimension of drug release devices in their drug release modelling. As discussed earlier, the 
degradation within these lumen-filled fibres would be different from lumen-blank fibres. The 
effect of degradation in PLGA depots has been considered Göpferich and Langer (1995) and 
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Göpferich (1997) where factors such as pH, polymer composition, water uptake by polymer, 
surface and bulk degradation are important in drug release modelling.  
 
Ehtezazi and Washington (2000), and Messaritake et al. (2005) proposed percolation theory 
which relates drug release to morphology and transports property of the drug-loaded 
microspheres. This approach takes into account of the pore network tortuosity. Drug release 
from PLGA microspheres during later stages when permanent degradation effect had set it, 
the erosion-mediated release can produced non-Fickian release and percolation theory should 
be incorporated to describe the drug release kinetic. Other approaches in drug modelling can 
include simultaneous consideration of polymer degradation and drug diffusion (Charlier et 
al., 2000), triphasic model that includes burst release, degradative drug release and 
diffusional release (Lao et al., 2008).  
 
Findings from Section 6.1.3 indicated the heterogeneity in spatial distribution of entrapped 
agent in 75:25MS. This further suggests that the drug release will not be purely a diffusive 
process. Drugs that are thermodynamically compatible with the encapsulating polymer tend 
to be uniformly dissolved in the polymer matrix, while incompatible drugs are dispersed as a 
separate phase within the microparticle (Allison, 2008a). Drug releases from dissolved and 
dispersed systems are treated by distinct mathematical models (Arifin et al., 2006). 
 
Discussion is presented below to explore the possible LID release from PLGA hollow fibres. 
For hollow fibre, buffer penetration through its lumen increases the contact areas between 
fibres and buffer. This leads to an enhance hydration effect and medium transport will be 
greater producing greater freedom for drug diffusion in the fibre matrix. Assuming that 
initially the fibre matrix is not completely saturated with the buffer, times may be required 
for buffer influx and later, outflow of drug. This in turn will create a lag phase where the rate 
of drug release is slow. An important factor which can increase the outflow of drug is the 
formation of micropores on the fibre surface which depends on the polymer degradation rate.  
 
The main external component, the medium or water plays active roles such as excipient for 
drug and species to cause hydrolysis on the polymer (Schmitt et al., 1994). During buffer 
immersion, buffer influx provides a medium for drug transport within the device. Studies in 
Chapters Six and Seven suggested that drug can travel between cavities through 
interconnecting channels in microsphere. This transport is likely to be random and drug will 
be displaced over time. Consequently, drug redistribution within the depot will and drug 
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distribution is usually accounted for the release rate of entrapped drug (Matsumoto et al., 
2005). Polakovič et al. (1999) had suggested that the diffusional distance between the initial 
and final drug locations inside the microspheres can affect drug release rate. 
 
In the case of hollow fibres with lumens filled with drug-solution or –microspheres, these 
conditions raised the complexness in the prediction of drug release. Assuming a perfect 
sealing with no leakage on the ends of these fibres, the effect of buffer penetration through 
their lumens is removed. The presence of drug solution in the fibre lumen is thought to 
enhance the drug diffusion across the fibre wall and therefore leads to a faster drug release. 
In the case of lumen filled-microspheres, the degradation of products from the microsphere 
was anticipated to cause interior autocatalytic degradation in the lumen. Comparing hollow 
fibre to microspheres, larger sample tends to undergo bimodal degradation (Grizzi et al., 
1995).  Dunne et al. (2000) showed that the molecular weight of larger particles decreased 
faster than smaller particles. They attributed the trend to autocatalytic degradation. 
                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.9: Hypothetical drug release profile of hollow fibres.  
 
A hypothetical profile of drug release from hollow fibre is illustrated in Figure 9.9. The 
degradation susceptibility of the polymer may alter the onset or the duration of different drug 
release stages. Owing to the tendency of the hydrophilic lidocaine to diffuse into the aqueous 
phase during the solidification process, the drug could be located in the peripheral of the 
device. During the Phase 1 release, drug release is from the drugs located near or at the fibre 
surface. Meanwhile, the buffer influx takes place through both the outer and lumen surfaces. 
The degradation effect increases the drug diffusion and drug release rate increases at ‘tn1’. 
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Following this release, drug release continues from the drug entrapped deeper in the fibre 
matrix. The formation of surface microspores sets in and degradation continues. At stage 
‘tn2’, morphological changes are prominent and the device eventually loses its integrity, i.e. 
collapse and the remaining drug are released. 
 
Figure 9.9 is an approach with partitioning between drug release stages but the presence of 
overlapping and random mechanisms such as, structural swelling/shrinking or restriction 
exerted by certain structures can be anticipated. These mechanisms would change the interior 
tortuosity and consequently affect drug diffusion within the matrix. Attempts to model LID 
release from the developed PLGA devices show the inadequacy of simple empirical model to 
account for the mass transport mechanisms and chemical processes that occur in these 
disparate systems. Further modelling work should consider the rate-controlling mechanisms 
such as diffusion-, swelling- and erosion-controlled drug release as reviewed by Kanjickal 
and Lopina (2004). 
 
By comparing the cumulative drug release of the PLGA devices, complete drug release is 
observed on LID-50:50MS after fifteen days and twenty days for LID-50:50HF samples. 
LID-65:35 PLGA samples can probably provide sustain release of just after three weeks, and 
most likely few days longer for the case of 75:25 PLGA samples. Table 9.5 shows the total 
amount of LID encapsulated in the PLGA samples produced in this study.  
 
Table 9.5: Estimated total drug content in the PLGA microspheres and hollow fibres samples used in in 
vitro drug releases analyses. Data represent average ± standard deviation (n = 5). HFso = hollow fibre with 
lumen filled with drug solution; HFms = hollow fibre with lumen filled with drug-loaded microsphere. 
Estimated Total Drug content in a 0.2 g sample (mg) 
PLGA 
MS HF HFso HFms 
50:50 
27.24 ± 5.72 
(DL = 12.40 ± 2.87 %) 
11.12 ± 3.21 
(DL = 5.60 ± 2.54 %) 
14.60 ± 2.84 13.17 ± 3.64  
65:35 
34.04 ± 4.69 
(DL = 18.69 ± 4.77 %) 
12.22 ± 2.87 
(DL = 6.73 ± 2.17 %) 
15.11 ± 3.26 14.64 ± 3.50 
75:25 
38.92 ± 3.77 
(DL = 20.40 ± 3.67 %) 
18.34 ± 2.87 
(DL = 8.76 ± 2.45 %) 
21.94 ± 4.64 20.28 ± 4.32 
 
Figures in brackets represent drug loading (DL) of microsphere and hollow fibre calculated using method 
described in Section 4.4. 
 
Devices made of 50:50 PLGA tend to have the lowest drug loadings and coupled with its fast 
degradation nature, complete drug release is reached within the measured period. The higher 
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lactide acid ratio in the copolymer shows higher drug loading. Both higher drug loading and 
degradation resistance in 75:25 PLGA may have lead to a longer drug release compared to 
50:50 PLGA. The drug loadings of microspheres and hollow fibres made of the same PLGA 
were significantly different (t-test, p < 0.05). Comparing drug loadings among PLGA 
microspheres, only LID-50:50MS and LID-75:25MS show significant difference in drug 
loadings. Likewise, for the drug loadings between LID-50:50HF and LID-75:25HF 
(ANOVA-single factor). 
 
Local anaesthetic such as lidocaine are usually given to patient at a dose of 10-20 ml of 2 % 
drug solution (20 g/l) prior to intraperitoneal surgery (Willemse and de Vries, 2003, and Ye 
et al., 2004). This equals a dose of 100-200 mg of anaesthetic drug. Example of cumulative 
lidocaine release (mg) from 50:50 PLGA samples is shown in Figure 9.10. The plot shows 
that a 0.2 g sample of LID-50:50MS could deliver up to 25 mg of lidocaine over a period of 
three weeks. 
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Figure 9.10: Plot showing the cumulative release of LID in 10 ml of PBS.  
 
In order to achieve an anaesthetic dose of 20 ml 2% drug solution, approximately 3.5 g of 
LID-50:50MS is required. This amount of microsphere may be an advantage where they 
could spread over a larger area in the peritoneum for better local anaesthetic effect. The dose 
of local anaesthetic could vary depending on the physical health condition of the patient. 
LID-microspheres could be given in conjunction with IV local anaesthetic or the prolong 
drug release from LID-microsphere/hollow fibre can be applied for minor surgery with 
persisted surgical pain. The additional drugs in the lumen of hollow fibres enhanced the drug 
release and their lower dose is also suitable for minor surgery.   
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The rational of developing LID-hollow fibre is the additional drug loading in its lumen. It has 
been shown that the drug release from HFms or HFso were higher than hollow fibre alone. 
The higher drug loading offered by 65:35 and 75:25 PLGA can deliver higher dose of 
lidocaine. Figures 9.2, 9.4 and 9.5 show that each PLGA exhibit prolong lidocaine release of 
at least two weeks and higher lactide:glycolide acid ratio tends to exhibited longer drug 
release period. The combination of microsphere and hollow fibre made of different PLGA 
can potentially diversify the duration of drug release. 
 
 
9.4 Conclusion 
 
1. LID was encapsulated into PLGA microspheres and hollow fibres produced using the 
single emulsion and wet-spinning methods respectively. The estimated drug loadings 
for PLGA microspheres ranged from 10-20% whereas for hollow fibres, it was 5-8%. 
The drug loading of hollow fibres can be increased by the addition of drug-loaded 
microsphere or drug solution into the lumen.  
 
2. Preliminary model fittings using Equations 8.1 to 8.3 to Phase 1 drug release suggest 
that LID-loaded PLGA devices can exhibit diffusional-controlled drug release based 
on the Higuchi model. Reasons are due to the tendency of hydrophilic lidocaine to 
diffuse to the aqueous phase during the solidification process. Thus, drug tended to 
accumulated at the peripheral layer of the device. Hydration effect on the device then 
permits the rapid release of the drug located in this layer. Other factors are such as 
those previously concluded in Section 8.4, no. (3) and (4).  
 
3. The Phase 2 release could not be fully characterised using the Higuchi , first and zero 
order kinetics models. The main reasons are the systems used herein are degrading 
and the degradation process affects the internal structures of both microspheres and 
hollow fibres. This effect alters the internal porosity of the polymeric devices while 
changing the freedom of drug diffusion within the matrix and out into the buffer. 
Other factors are such as those previously concluded in Section 8.4, no. (10). 
 
4. For the hollow fibres with sealed ends, the local autocatalytic effect is expected to be 
greater than opened-end hollow fibres due to lesser passages for degradation products 
transport. The accumulation of the degradation products from microspheres in the 
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fibre lumens is likely to enhance autocatalytic effect. On the other hand, the lumen 
impregnation with drug solution is thought to enhance drug diffusion within and out 
from the fibre matrix.  
 
5. The combination of microspheres and hollow fibres have complicated the prediction 
of drug release profiles but from a therapeutic point’s of view, the combination of the 
duo can offer higher drug dosage. Hollow fibre can offer a “retardant” barrier against 
burst release exhibited by microspheres.   
 
6. Devices made of 50:50 PLGA tended to show a faster release rate reaching to content 
depletion due to its fast degradation property, which is in contrast to the high 
degradation resistance of 75:25 PLGA.  
 
7. The three compartmental model expressed in Equation 8.13 was found to better fit 
the LID release profiles of the developed PLGA microspheres. This condition 
suggests the presence of two fractions of drug in the device, a fraction of this drug is 
readily release while the remaining entrapped drug will be subsequently released into 
the solution. For PLGA hollow fibres, their Phase 2 drug releases highly resemble 
first order release kinetic.  
 
8. The hypothetical model of different drug release phases illustrated in Figure 9.9 is 
preliminary used to describe the release of drug from hollow fibre. This system 
differs from microsphere system based on the larger matrix and the lumen of the 
hollow fibre that offers a channel for medium transport.  
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CHAPTER  10: CONCLUSIONS AND FURTHER WORK   
 
10.1 Overall Conclusions 
 
The aim of this thesis was to develop drug-loaded PLGA devices which are suitable to be 
used for IP treatment of advanced ovarian cancer. PLGA was selected as the model polymer 
because of its proven history, versatility and approval by the FDA. An effective cytotoxic 
drug used to treat ovarian cancer, cisplatin (CPt), was selected as the model chemotherapy 
drug. Lidocaine (LID) was also used as a model drug for the reason of IP treatment-
associated pain issue. Different copolymer ratios of 50:50, 65:35 and 75:25 PLGA were used 
to produce drugs-loaded PLGA microspheres, novel hollow and solid fibres. This selection 
of copolymers enabled the studies and comparisons of their drug loadings, degradation and 
drug release profiles. 
 
This thesis has made several contributions to the field of controlled-drug delivery particularly 
for the IP treatment of advanced ovarian cancer by: (1) developing CPt-loaded PLGA 
microspheres and solid fibres, and (2) LID-loaded PLGA microspheres and hollow fibres. 
The development of these systems required multidisciplinary approach. One of the major 
novelties of this thesis is combining the concepts of biodegradable-controlled drug delivery 
system with membrane technology (hollow fibre), along with detailed characterisation work 
to understand the behaviours of the developed systems. This novelty also enabled the 
evaluations of in vitro drug release profiles of the developed microspheres, hollow and solid 
fibres to be presented in a single thesis for the first time. 
 
Drug-loaded microspheres systems were successfully produced through investigations into 
the effects of both PLGA and PVA concentrations, homogenisations speed and time. A 
standard production condition was established as: 100 ml of 0.5 % (w/w) PVA, 
homogenisations time and speed of 15 minutes and 6500 rpm respectively to process 10 g of 
polymer/drug solution. The drug loadings of CPt-loaded PLGA microspheres vary with 
different size fractions and copolymer ratios. Maximum drug loading for microsphere was 
approximately 10% and 15% for solid fibre. CPt-loaded microspheres exhibited different 
release rates and this condition show the flexibility of the developed systems to be used for a 
two weeks (CPt-50:50MS) or three weeks (CPt-75:25MS) chemotherapy delivery.  
 
To the best knowledge of the author, limited literature concerning the development of CPt-
loaded PLGA solid fibre has been reported. New system taking the form of CPt-loaded 
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PLGA solid fibres was successfully produced and this work showed that this system can 
offer higher drug loading than microspheres. PLGA solid fibres were found to degrade 
slower in comparison to PLGA microspheres, benefited from their small surface area:volume 
ratios, and skin layers which is associated with high mass transfer resistance. The latter 
fulfilled the rationale of using phase inversion membrane to provide better control of drug 
release. Results showed that CPt-65:35SF and CPt-75:25SF can potentially offer a 
chemotherapy delivery of longer than three weeks.  
 
The in vitro release of CPt from microspheres and solid fibres demonstrated good 
competence in mimicking an IP or IV dose for chemotherapy regimen. For example, 
approximately 2 g of CPt-50:50MS with the smallest size fraction (53-38 µm) and 1 g of 
CPt-50:50SF will be required to deliver a CPt dose of 170 mg. For ovarian cancer treatment, 
chemotherapy is used to treat residual cancerous materials after primary surgery. For this 
reason, the CPt-loaded solid fibre could ultimately fabricate into a drug delivery patch and 
can be attached to the IP cavity to kill residual cancerous cells. The flexibility of the fibre 
could also provide good adaptation to the curvature of the peritoneal cavity. 
 
The CPt release profiles are fundamentally characterised as a biphasic release. Phase 1 
release is the drug release during the first day and thereafter, Phase 2. Phase 1 is associated 
with a “burst” release and drug release in this phase was found to closely resemble a Higuchi 
diffusional-controlled release for both PLGA solid fibres and microspheres. Simple empirical 
models were found inadequate to describe the overall CPt release profiles. A biexponential 
equation was found to better fit the CPt release profiles. This model suggests that there are 
two fractions of drug present in the device. A fraction of this drug is located near or at the 
surface which are readily release into the buffer. The remaining drug fraction is thought to be 
entrapped deeper in the device and will be subsequently released into the solution. 
 
Similar to the case of CPt-loaded PLGA solid fibre, limited literature concerning the 
development of LID-loaded hollow fibre system has been reported. LID-loaded hollow fibres 
were successfully developed in this work and their behaviours were evaluated in terms of 
their degradation and drug release profiles. The phase inversion technique was studied 
closely and applied to spin both hollow and solid fibres. A standard spinning condition was 
established as: air gap of 10 cm, starting bore liquid flowrate of 2.5 ± 0.5 ml/min, starting 
polymer solution extrusion rate of 2.0 ± 0.5 ml/min and 7 ± 2 rpm as the starting speed for the 
collection motor. Additional drug loadings were highly feasible in this case where drug 
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solution and drug-loaded microsphere were post-filled into the lumen of the hollow fibres. 
For future application, these combinations could offer co-delivery of therapeutic agents.  
 
The Phase 1 LID release was also found to follow a Higuchi-diffusional release model for 
both microspheres and solid fibres. A biexponential model was also used to fit to the LID 
release profiles. Results indicated that an assumption of a system consists of a depot with two 
pools is suitable to describe the drug release kinetics. However, Phase 2 LID release profiles 
also indicate a first order release kinetic. The presence of additional drug loadings in the fibre 
lumen is though to alter the mass transport property of the system. Therefore, the 
biexponential model could no longer adequately characterise the drug release profiles. 
 
Studies of the diffusion of imbibe water showed that polymeric PLGA microspheres 
underwent pore swelling and shrinking. 50:50MS was found most susceptible to pore 
swelling possibly due to the higher amorphous region in its polymer matrix. In the case of 
75:25MS, copolymer with higher lactide acid ratio has higher crystallinity therefore 
restricted pore swelling. Pore swelling and immersion in buffer may shift the system from a 
glassy state to a rubbery state. Medium diffusion is thought to be faster in the latter state. The 
findings in PFG-NMR experiments help to explain the initial faster drug release in PLGA 
devices. However, burst release may also associate to structural relaxation due to a condition 
where the glassy devices are attempting to reach thermodynamic equilibrium.   
   
A bulk degradation pathway is used to describe the degradation characteristics of the 
developed PLGA systems. Results showed agreement to the trends reported in the literature 
whereby copolymer PLGA with higher lactide:glycolide acids ratio shows better resistance 
against hydrolytic degradation. Studies following the degradation of PLGA hollow and solid 
fibres also highly suggested the presence of autocatalytic degradation. This is attributable to 
the accumulation of acidic degradation products. Devices of larger structure are also thought 
to be more susceptible to biomodal or heterogeneous degradation.  
 
 
10.2 Suggestion for Further Work 
 
1. Chapters Five and Six study the morphologies of the developed PLGA devices and 
their degradations. The chemistry of polymer often involves the studies of glass 
transition temperature and crystallinity of the polymer. PLA (semi-crystalline) and 
PLGA (amorphous) polymers rapidly undergo chain alterations or structural relaxation 
CHAPTER 10: CONCLUSION AND FURTHER WORK 
THE DEVELOPMENT OF CONTROLLED-CHEMOTHERAPY DRUG DELIVERY SYSTEM  179 
due to plasticiser effect from absorbed moistures or water ions, or the 
thermodynamically unstable nature of the polymer chain.  
 
In order to fully comprehend the degradation profiles of the developed PLGA depots, 
differential scanning calorimetry (DSC) can be used to follow the time-dependent 
physical and morphological changes within the hydrated or dried microparticles. This 
can help to determine the effect of the absorbed water, and to detect the penetration of 
buffer ions into the particle bulk. The main affect of absorbed water is thought to 
contribute to the polymer chain mobility, which can alter the physical properties, such 
as Tg of the polymer. Information of this sort can then be correlated to the 
morphological changes within the particles. In general, the polymer below its Tg 
behaves as a glassy material and gradually shifts to rubbery state as the temperature 
approaches and exceeds the Tg. 
 
X-ray diffraction (XRD) or small-angle x-ray scattering (SAXS) techniques are 
commonly used to study the crystallinity of a polymer. The latter technique is used to 
study polymer with smaller matrixes. The data generated from these techniques are 
often presented as the scattered intensity as a function of wave-number. Using Bragg’s 
Law, the interplanar distance between the polymer matrixes can be determined. This 
information can then be translated to give the crystallinity profile of the polymer. 
Hence, the evolution of crystallinity or amorphous regions of the degrading PLGA 
depots can be studied in details.  
 
2. Characterisation of PLGA microspheres: 
Atomic force microscopy (AFM) can resolve the issue of heat sensitivity of PLGA 
encountered in SEM imaging. Preliminarily analysis using AFM generated useful 
information showing the porous nature of the surface of 75:25MS (Figure 10.1).  
 
             
Figure 10.1: AFM images showing the surface conditions of PLGA microspheres. 
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Result shows that single-emulsion 75:25MS has surface pores of nano-scale. This is 
indicated by the indentation and denser colour density observed in the AFM images 
shown in Figure 10.1. This result can further agree with the freezing of interior pores 
by the ingress of ice through surface pores suggested in Chapter Seven. For future 
work, AFM imaging should be applied for better characterisation of the morphology of 
PLGA microspheres or correlate with NMR studies in pore structural information.  
 
3. Drug-loaded Microsphere System: 
Burst effect is common in microparticulate system and future effort should be given to 
circumvent this rapid release. A direct solution is to prewash or prerelease the drug-
loaded microspheres. However, this would not be economical. It has been shown by 
Tamura et al. (200l) and Matsumoto et al. (2005) that double-layered microspheres 
could reduce the burst release. Additional layers or coatings serve the purpose of 
introducing higher diffusion resistance at the surface to attenuate rapid drug release.  
 
Confocal laser scanning microscopy has generated useful information regarding the 
distribution of the entrapped component. This method can be calibrated to relate the 
intensity of the fluorescence to the concentration of the entrapped component. Analysis 
of this sort can provide information of local drug population in the microspheres, and 
can be further related to drug release characteristic. 
 
4. Drug-loaded Hollow Fibre System: 
A circular spinneret was used in this work and there are spinnerets which produce 
hexagonal or pentagonal shaped hollow fibres. These new systems will require new 
approach and the increased dimension of these non-circular hollow fibres can offer 
greater surface area for drug diffusion. Hence, they have the potential to revolutionise 
the current circular hollow fibres in relation to drug release kinetic. Double or triple 
layered hollow fibres can also be produced using specially designed spinnerets. An 
example of double-layered hollow fibre is shown in Figure 10.2A. These extra layers 
not only could help to reduce both the burst release and drug release rate, but co-
encapsulation of other drugs can also be formulated into these layers.  
 
There are alternative methods to incorporate drug into hollow fibres. The macrovoids 
in the core matrix are suitable to contain drug solution. Drug solution can be post-
loaded into the hollow fibre matrix by applying a vacuum at one end (open) of the fibre, 
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Vacuum 
with its other end sealed. The sealed end is then immersed in the desired drug solution. 
Through a vacuum effect, the drug solution will be drawn into the fibre matrix. 
Preliminary experiment has shown the viability of this approach and the apparatus 
setup is shown in Figure 10.2B. 
 
 
 
 
 
 
 
 
Figure 10.2: (A) Cross section of a double layered polyethersulfone hollow fibre. (B) A vacuum 
system for the loading of drug solution into hollow fibres.  
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APPENDIX  I  
 
A. Sample Calculation for Drug Concentration Determination  
 
Lidocaine concentration determination: 
Absorbance measured at 266 nm using UV-spectrometer = 1.95 
From calibration curve (Figure 4.5), y = 1.8829 x + 0.0811 
Concentration of lidocaine in 10 ml PBS, x = 1.95 – 0.0811 / 1.8829 = 0.9925 mg/ml 
Total lidocaine in 10 ml PBS = 0.9925 x 10 = 9.925 mg 
 
Cisplatin concentration determination: 
Absorbance measured at 265.9 nm using AAS = 0.45 
From calibration curve (Figure 4.6), y = 0.6077 x + 0.0181 
Concentration of cisplatin in 10 ml PBS, x = 0.45 – 0.0181 / 0.6077 = 0.7107 mg/ml 
Total cisplatin in 10 ml PBS = 0.7107 x 10 = 7.107 mg 
 
Drug loading determination: 
0.2 g CPt-50:50MS acid-digested and redissolved in 10 ml 0.1M HCl, absorbance measured at 
265.9 nm using AAS = 0.85, concentration of cisplatin = 1.3689 mg/ml 
Total cisplatin in 10 ml 0.1M HCl = 13.689 
 
Drug loading (%)  =      Total Drug Encapsulated (mg) x  100%     
   Total Sample Used (mg)                 (Equation 4.1) 
 
Drug loading   = [13.689 / 200]  x 100 % = 6.84 % 
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APPENDIX  II 
 
A. Sample Calculation for Gas Permeation Analysis 
 
Membrane surface area, A (m
2
): 
A=2.pi.r.L  pi = Pi (3.142) 
r = Hollow fibre radius (3.0 x 10
-4
 m)  
L = Hollow fibre length (10 x 10
-2
 m) 
A = 2 * 3.142 * 3.0 x 10
-4 
* 10 x 10
-2
 = 1.88 x 10
-4
 m
2
 
 
Mean pressure across hollow fibre, P (Pa): 
P = (Pin + Pout)/2 Pin = Pressure inside fibre (2.0 x 10
5
 Pa) 
   Pout = Pressure outside fibre / atmospheric (1.01 x 10
5
 Pa) 
P = [(2 + 1) x 10
5
 ] / 2 = 1.5 x 10
5
 Pa 
 
Volumetric gas flow rate, Q (m
3
/s): 
Q = V / t   V = Volume of gas timed (5 x 10
-5
 m
3
) 
   t = Time taken (average 10 s) 
Q = 5 x 10
-5 
/ 10 = 5 x 10
-6
 m
3
/s 
 
Molar gas flow rate, N (mol/s): 
N = Q.Pout / R.T Q = Volumetric gas flow rate (m
3
/s) 
   Pout = Pressure outside fibre / atmospheric (1.01 x 10
5
 Pa) 
   R = Molar gas constant (8.31 J/mol.K) 
   T = Atmospheric temperature (298 K) 
N = (5 x 10
-6
 * 1.01 x 10
5
) / (8.31 * 298) = 2.02 x 10
-4
 mol/s 
 
Gas permeation flux, J (mol/s.Pa.m
2
): 
J = N / A.Pin  Molar gas flow rate, N (mol/s) 
   Membrane surface area, A (m
2
) 
   Pin = Pressure inside fibre (Pa) 
J = 2.02 x 10
-4
 / (1.88 x 10
-4
 * 2.0 x 10
5
) = 5.37 x 10
-6
 mol/s.Pa.m
2
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APPENDIX III 
 
A. Cumulative release profiles of 5Fu from double emulsion PLGA microspheres (Section 5.1.2) 
 
A number of PLGA microspheres loaded with fluorouracil (5Fu) were produced using double 
emulsion methods adapted from the literatures. Details of procedures, discussion and SEM 
images of the resultant microspheres were presented in Section 5.1.2. Figure 12.1 shows their 
corresponding 5Fu release (cumulative) measured over a period of one week. The concentration 
of 5Fu was measured using a uv-spectrometer with wavelength of 262 nm. 
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Figure 12.1: In vitro cumulative release of fluorouracil (5Fu) from microspheres produced in Section 5.1.2 
using w/o/w emulsion methods.  
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APPENDIX IV 
 
Modified Cryo-Fractioning Procedures for PLGA microspheres: 
 
1. Sample preparation: Treat sample in liquid nitrogen and then freeze-dry overnight at -600C 
and 10
-2
 torr. 
2. Mix an appropriate amount of Spurr Resin. 
3. Place in capsules and allow the mixture to set (forming cylindrical blocks). 
4. Trim one end of the hardened resin with razor blades until flat. 
5. Mix an appropriate amount of araldite. 
6. Using a cocktail stick, add a thin coat of araldite to the flat end of each block. 
7. When araldite is still tacky, sprinkle on PLGA beads. 
8. Leave block upright until Araldite® has solidified. 
9. Blow off any excess beads with an air duster. 
10. Place the samples on the resin blocks in suitable microtome chucks. Carefully ensure 
samples are as level as possible. 
11. Cut down with razors the top of each block to give a central 1 mm x 1 mm square 
(retaining the original surface on the raised area). 
12. Make a fresh glass knife for each sample. 
13. Place a knife in the ultra microtome.  
14. Place one of the chucks (with a sample) in the microtome. 
15. Align each sample very carefully parallel with a sharp part of the knife. 
16. Approach the knife to the sample using manual control.  
17. If necessary, stop, realign sample to knife and approach again. 
18. When close, use 3 mm/sec and 0.5 µm automated semi cuts until knife cuts the sample. 
19. Stop and change microtome to 75 nm cuts and take two to five cuts. 
20. Remove the block from its chuck. 
21. Remove central cut area from block (the block can be reused). 
22. Mount the cut area using aluminium dish and carbon double sided tape. 
23. Gold coating for 4-5 minutes. 
24. SEM imaging examination. 
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APPENDIX V 
 
A. Results of water r.m.s displacement and pore diameter of PLGA Microspheres  
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Figure 12.2: The r.m.s displacement and pore diameter of (A) 50:50MS, (B) 65:35MS and (C) 75:25MS 
from Batches 1, 2 and 3 (B1, B2 and B3). Symbols: Circle = pore size diameter; Triangle = r.m.s 
displacement 
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B. Results of tortuosity factor of PLGA Microspheres  
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Figure 12.3: The results of tortuosity (D1/D2) calculated using the estimated diffusion coefficients of 
imbibed water (D2) and free water (D1) of (A) 50:50MS, (B) 65:35MS and (C) 75:25MS from Batches 1, 2 
and 3. 
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C. Results of freezing cycles conducted on 50:50MS and 65:35MS 
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Figure 12.4: IT curves for the F-cycles of 50:50MS after immersion in water for 8 hours, 18 hours, 15, 17 
and 19 days. Inset: A refocus on the lower scale of I/Io. 
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Figure 12.5: IT curves for the F-cycles of 65:35MS after immersion in water for 10, 20 and 30 days. Inset: 
A refocus on the lower scale of I/Io. 
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Figure 12.6: IT curves for F/M/F cycles of 75:25MS after 10 days immersion in water. 
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Figure 12.7: IT curves for F/M/F cycles of 75:25MS after 20 days immersion in water. 
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Figure 12.8: IT curves for F/M/F cycles of 75:25MS after 30 days immersion in water. 
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D. Results of pore size distributions of 50:50MS and 65:35MS 
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Figure 12.9: The measurement of dV/dx as a function of pore size distribution for 50:50MS immersed in 
water for 8 hours, 18 hours, 15, 17 and 19 days. Inset: Refocus on the lower scale of pore size distribution. 
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Figure 12.10: The measurement of dV/dx as a function of pore size distribution for 65:35MS immersed in 
water for 10, 20 and 30 days. Inset: Refocus on the lower scale of pore size distribution. 
 
 
E. Samples calculation for r.m.s water displacement and pore size 
D and Do are the measured diffusion coefficient of imbibed water (e.g. 0.8 x 10
-9
 cm
2
/s), ∆ is the 
diffusion time (0.05s) and δ is the length of the gradient pulse (0.002s). From Equation 7.1;  
Root mean square displacement of water, 
2r  = 6 Do∆ 
= 6 * 0.8 x 10
-9
 cm
2
/s * 0.05s  
= 2.4 x 10
-10
 cm
2
 
r  = (1.55 x 10-5 cm)0.5 
= 15.5 µm 
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From Equation 7.4; pore radius, 





−∆=
3
5
δ
DR 





−×= −
3
002.0
05.0108.0*5
9  = 1.40 x 10
-5
 cm 
 
Pore diameter = 2R = 2 * 1.40 x 10
-5
 cm = 2.80 x 10
-5
 cm = 28 µm 
 
 
G. Hourly PFG-NMR measurements of Batch 1 50:50MS, 65:35MS and 75:25MS.  
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Figure 12.11: (A) The diffusion coefficient of imbibed water, D2 of 50:50MS (  ), 65:35MS (  ) and 
75:25MS (   ). (B) The fraction of imbibed water (1 – p) in 50:50MS (   ), 65:35MS (   ) and 75:25MS (   ). × × 
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APPENDIX VI 
 
A. Summary of cumulative cisplatin release (%) from PLGA microspheres and solid fibres 
  
Table 12.1: Different stages of cumulative CPt release rates estimated from 50:50SF and 50:50MS of 
different size fractions. Figures in brackets represent average release rate over the noted period. 
Rate of % Cumulative Release 
Sample 
Phase 1 Cumulative 
Release 
Complete Cumulative 
 Release  Slowest Fastest 
  Size 
  53-38 µm 
65 ± 4% 
100 % Release  
Day 10 
Day 6-10, 
95% - 100% 
(1.25% / day) 
Day 1-6, 
65% - 95% 
(7% / day) 
  Size 
  75-53 µm 
36 ± 4% 
94 % Release 
Day 20 
Day 8-19, 
91% - 93% 
(0.18% / day) 
Day 1-8, 
36% - 75% 
(7.9% / day) 
50:50
MS 
  Size 
  90-75 µm 
46 ± 3% 
100 % Release  
Day 19 
Day 8-20, 
75% -99% 
(0.75% / day) 
Day 1-8, 
48% -95% 
(6.7% / day) 
50:50SF 30 ± 4% 
93 % Release 
Day 20 
Day 10-19 
87% - 94% 
(0.88% / day) 
Day 1-7 
33% - 75% 
(7% / day) 
 
 
Table 12.2: Different stages of cumulative CPt release rates estimated from 65:35SF and 65:35MS of 
different size fractions. Figures in brackets represent average release rate over the noted period. 
Rate of % Cumulative Release 
Sample 
Phase 1 
Cumulative Release 
100% Cumulative 
Release Slowest Fastest 
Size 
53-38 
µm 
50 ± 4% Day 19 
Day 2-17, 
76% - 75% 
(0.93% / day) 
Day 1-2, 
68% - 73% 
(5% / day) 
Size 
75-53 
µm 
32 ± 2 % Day 20 
Day 6-12, 
67% - 82% 
(2.5% / day) 
Day 1-5, 
40% - 68% 
(5% / day) 
65:35
MS 
Size 
90-75 
µm 
26 ± 3 % Day 20 
Day 7-13, 
73% -80% 
(1.17% / day) 
Day 1-4, 
48% -73% 
(8.3% / day) 
65:35SF 24 ± 3 % Day 19 
Day 10-18 
74% - 89% 
(1.88% / day) 
Day 1-10 
28% - 82% 
(6% / day) 
 
Table 12.3: Different stages of cumulative CPt release rates estimated from 75:25SF and 75:25MS of 
different size fractions. Figures in brackets represent average release rate over the noted period. 
Rate of % Cumulative Release 
Sample 
Phase 1  
Cumulative Release  
% Cumulative 
Release on Day 20 Slowest Fastest 
Size 
53-38 µm 
58± 4% ~85% 
Day 4-14, 
72% - 80% 
(0.8% / day) 
Day 1-3, 
48% - 71% 
(11.5% / day) 
Size 
75-53 µm 
32 ± 4% ~100% 
Day 9-19, 
86% - 92% 
(0.6% / day) 
Day 1-10, 
32% - 85% 
(5.89% / day) 
75:25
MS 
Size 
90-75 µm 
21± 3% ~80% 
Day 10-18, 
71% -79% 
(1% / day) 
Day 1-10, 
21% -71% 
(5.56% / day) 
75:25SF 16 ± 4% ~80% 
Day 4-11 
45% - 60% 
(2.14% / day) 
Day 14-20 
60% - 80% 
(3.33% / day) 
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B. Fittings of Higuchi Model to Phase 1 cisplatin release from 65:35-MS and -SF.  
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Figure 12.12: The fitting of Higuchi Model (Qt = kH.t
0.5
) to in vitro Phase 1 cisplatin release from 
65:35 PLGA microspheres and solid fibres.    
 
 
C. Fittings of Higuchi, first and zero order kinetics models to Phase 2 cisplatin release.  
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Figure 12.13: The fittings of Higuchi, first and zero order kinetics models to Phase 2 cisplatin release from 
50:50MS and 50:50SF. 
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[                     ] Burst Release Model 
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Figure 12.14: The fittings of Higuchi, first and zero order kinetics models to Phase 2 cisplatin release from 
65:35MS and 65:35SF. 
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Figure 12.15: The fitting of Higuchi, first and zero order kinetics models to Phase 2 cisplatin release from 
75:25MS and 75:25SF. 
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Table 12.4: Summary of the goodness of fit of Equations 8.1 to 8.3 to Phase 2 drug release from PLGA 
samples. The Higuchi constant, kH was estimated for Phase 1 drug release.  denotes poor fitting; 
additional notes no. (i) to (vii), see text for discussion. 
Phase 1 Phase 2 – Goodness of fit of models 
CPt-loaded  
PLGA Devices kH 
Higuchi  
Model 
First Order 
Kinetic 
Zero Order 
Kinetic 
Note 
5050MS (53-38 µm) 61.42    - 
5050MS (75-53 µm) 51.85    - 
5050MS (90-75 µm) 50.25    - 
5050SF 27.52 Possible fit   (i) 
6535MS (53-38 µm) 58.30   Possible fit (ii) 
6535MS (75-53 µm) 35.20 Possible fit  Possible fit (iii) 
6535MS (90-75 µm) 29.25    - 
6535SF 28.67 Good  Possible fit (iv) 
7525MS (53-38 µm) 44.13  Possible fit Possible fit (v) 
7525MS (75-53 µm) 30.33    - 
7525MS (90-75 µm) 23.80 Possible fit   (vi) 
7525SF 21.43 Possible fit  Possible fit (vii) 
 
 
For the Phase 2 drug release, 65:35 and 75:25 PLGA devices exhibited varied degree of 
similarities to the Higuchi, first and zero order kinetics models at different stages. The overall 
poor fitting of the three models in 50:50 PLGA devices may due to the fast degrading nature of 
50:50 PLGA. The additional notes no. (i) to (viii) are discussed below:  
(i)  CPt-50:50SF exhibits partial similarity to the Higuchi model. 
(ii)  The zero order kinetic provides good fit to the drug release from CPt-65:35MS after day-
five and thereafter.  
(iii)  The drug release profile of CPt-65:35MS with size fraction (75-53 µm) closely resembles 
the Higuchi model, and the zero order kinetic also fits well to the profile from day-four 
and thereafter. 
(iv)  The Higuchi model provides good fit to the drug release profile of CPt-65:35SF, and the 
zero order kinetic also fits well to the profile from day-four and thereafter. 
(v)  The first and zero order kinetics provide good fits to the drug release from CPt-75:25MS 
of size fraction (53-38 µm) after day-four and thereafter.  
(vi) The Higuchi model provides good fit to the drug release profile of CPt-75:25MS of size 
fraction (90-75 µm) after day-one until the end of week-two. 
(vii) The Higuchi model provides good fit to the profile of CPt-75:25SF. The profile also 
scatters closely to the zero order kinetic. 
 
 
D. Derivation of three compartmental model, Equation 8.13 
The pharmacokinetics of cisplatin release profiles can be derived from the rate equations using 
Laplace transformations (Mayersohn and Gibaldi, 1970). Converting a function into Laplace 
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space allows operations to be performed on the expressions more easily than in regular space. 
The Laplace transform (Equation 12.1) is widely used in science and engineering for solving 
integrals. 
{ } dttftstfL ∫
∞
−=
0
)().exp()(       (12.1) 
 
Table 8.5: Common Laplace transformation of functions: 
Function: f(t) Laplace: f(s) 
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Figure 12.16 (a reproduce of Figure 8.11) shows the scheme of drug release, where Q2 and Q3 are 
the amount of drug remained in two separate pools of the depot after the amount of drug, Q1 has 
been released into solution. Q2(∞) and Q3(∞) are the amount of drug in the depot which will be 
released after a long time. k2 and k3 are the release rate constants of Pools A and B  respectively. 
 
 
 
 
 
 
Figure 12.16: A three compartmental model showing the drug release from a two pools-releasing depot. 
 
For the solution compartment:  3222
1 .. QkQk
dt
dQ
+=     (12.2) 
 
Q2 decrease with:   22
2 .Qk
dt
dQ
−=                  (12.3) 
Q3 decrease with:   33
3 .Qk
dt
dQ
−=                  (12.4) 
 
Transforming the differential Equations 12.2, 12.3 and 12.4 using Laplace transformation gives: 
)0(. 11 QQs − 22.Qk= 33.Qk+      (12.5) 
Q2 
Q2(∞) 
 
Q1 
k2 
Depot 
Q3 
Q3(∞) Solution 
k3 
Pool A 
Pool B 
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2222 .)0(. QkQQs −=−       (12.6) 
3333 .)0(. QkQQs −=−       (12.7) 
2Q and 3Q  are Q2 and Q3 in Laplace space. With the initial conditions, t = 0; Q1(0) = 0,  Q2(0) = 
Q2 (∞) and Q3(0) = Q3(∞). Rearranging Equations 12.6 and 12.7 give: 
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Substituting Equations 12.8 and 12.9 into Equation 12.5 gives: 
 
3
3
3
2
2
21
)()(
.
ks
Q
k
ks
Q
ksQ
+
∞
+
+
∞
=  or,  
 
))(.(
))((.))((.
32
233322
1
kskss
ksQkksQk
Q
++
+∞++∞
=                         (12.10) 
 
The general partial fraction theorem states that the function P(s)/Q(s) can be expressed as a sum 
of partial fractions, where P(s) is a polynomial with a lower degree in s than another polynomial, 
Q(s). General partial fraction theorem can be used to solve first order rate equations. This method 
(Equation 12.11), described as the fingerprint method (Bourne and Strauss, 1995). 
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The inverse Laplace transformation of a quotient of two polynomials of the form P(s)/Q(s) can be 
expressed as the sum of the expression with each root substituted in turn. This is true provided 
that Q(s) has a higher degree in s and contains the factor (s – λi) which is not repeated. P (λi) is 
the value of the numerator for each s term. Qi (λi) is the value of the denominator when λi is 
substituted for s terms apart from the term containing λi which is excluded.  
 
Equation 12.10 can be solved using the fingerprint method. The degree in s of the polynomial in 
the denominator of Equation 12.10 is higher than the polynomial in the numerator and there are 
no repeating terms so the fingerprint method may be applied. The roots are found by letting each 
factor of the denominator be zero so s = 0, -k2 and –k3. To transform this into an expression in 
real space each root is substituted for s in turn (excluding the polynomial term) and then 
multiplied by the exponential of the product of time and the root, exp(λit). The sum of these three 
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values is the integrated function Q1. By anti-Laplace transformation and solving Equation 12.10 
for Q1 will yield: 
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[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞= ,  as expressed in Equation 8.12 
 
 
 
E. Fittings of two and three compartmental models to cisplatin release profiles.  
 
       
       
(A) CPt-50:50MS (53-38 µm)      (B) CPt-50:50MS (90-75 µm) 
 
(C) CPt-65:35MS (53-38 µm)                      (D) CPt-65:35MS (90-75 µm) 
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Figure 12.17: Fittings of a two compartmental model, Equation 8.11 (dashed lines) and a three 
compartmental model, Equation 8.13 (solid lines) to cisplatin release profiles of (A) CPt-50:50MS (53-38 
µm), (B) CPt-50:50MS (90-75 µm), (C) CPt-65:35MS (53-38 µm), (D) CPt-65:35MS (90-75 µm), (E) CPt-
75:25MS (53-38 µm) and (F) CPt-75:25MS (90-75 µm). 
 
 
F. Statistics of model fittings using a two compartmental model (Equation 8.11) and a three 
compartmental model (Equation 8.13) to cisplatin release profiles.  
 
CPt-50:50MS (53-38 µm) 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=   
Estimate  Std. Error  t value   Pr(>|t|)      
Q2(∞)  8.35005    0.72329   11.545   7.32e-09 *** 
Q3(∞)  8.79112    0.90312    9.734   7.11e-08 *** 
k1  0.20653     0.04765    4.334   0.00059 *** 
k2  3.07252     0.46977    6.541   9.35e-06 *** 
 
Residual standard error:    0.4895 on 15 degrees of freedom 
Number of iterations to convergence:  9  
Achieved convergence tolerance:   1.707e-06  
AIC:     32.28352  
 
)1).((01
tkoeQQ
−−∞=     
Estimate  Std. Error  t value   Pr(>|t|)     
Q0(∞) 15.1578    0.4103    36.944    < 2e-16 *** 
ko    1.2815      0.1881     6.814   3.02e-06 *** 
 
Residual standard error:    1.359 on 17 degrees of freedom 
Number of iterations to convergence:  15  
Achieved convergence tolerance:   8.28e-06  
AIC:     69.45698 
Significance codes: ***=0 ; **=0.001; *=0.01 ; .=0.5 
 
 
CPt-50:50MS (75-53 µm) 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate  Std. Error  t value   Pr(>|t|)     
Q2(∞) 16.52474   0.57272   28.853   7.00e-16 *** 
Q3(∞)  7.76413    0.61203   12.686   4.28e-10 *** 
k1  0.24569     0.01956   12.561   4.98e-10 *** 
(E) CPt-75:25MS (53-38 µm)           (F) CPt-75:25MS (90-75 µm) 
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k2  8.20045     1.47863    5.546   3.56e-05 *** 
 
Residual standard error:    0.5491 on 17 degrees of freedom 
Number of iterations to convergence:  9  
Achieved convergence tolerance:   3.869e-06  
AIC:     39.97783  
 
)1).((01
tkoeQQ
−−∞=     
Estimate  Std. Error  t value   Pr(>|t|)     
Q0(∞)  22.3528    0.8036    27.814    < 2e-16 *** 
ko    0.6722      0.1328     5.062   6.93e-05 *** 
 
Residual standard error:    2.577 on 19 degrees of freedom 
Number of iterations to convergence:  15  
Achieved convergence tolerance:   9.408e-06  
AIC:     103.2542 
Significance codes: ***=0 ; **=0.001; *=0.01 ; .=0.5 
 
 
CPt-50:50MS (90-75 µm) 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate  Std. Error  t value   Pr(>|t|)     
Q2(∞) 15.39650   0.43822   35.134    < 2e-16 *** 
Q3(∞)  8.04881    0.47105   17.087   1.07e-11 *** 
k1  0.14412     0.01377   10.469   1.45e-08 *** 
k2  4.90482     0.60077    8.164   4.26e-07 *** 
 
Residual standard error:    0.4154 on 16 degrees of freedom 
Number of iterations to convergence:  8  
Achieved convergence tolerance:   1.167e-06  
AIC:     27.15193  
 
)1).((01
tkoeQQ
−−∞=     
Estimate  Std. Error  t value   Pr(>|t|)     
Q0(∞) 20.21224   0.90969   2.219   1.55e-14 *** 
ko   0.48730     0.09921    4.912   0.000112 *** 
 
Residual standard error:    2.541 on 18 degrees of freedom 
Number of iterations to convergence:  16  
Achieved convergence tolerance:   9.648e-06  
AIC:     97.94559 
Significance codes: ***=0 ; **=0.001; *=0.01 ; .=0.5 
 
 
CPt-50:50SF 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate  Std. Error  t value   Pr(>|t|)     
Q2(∞) 24.7724      0.5057  48.982    < 2e-16 *** 
Q3(∞) 4.2862      0.5960    7.192   1.08e-06 *** 
k1 0.1599     0.0096   16.605   2.32e-12 *** 
k2 4.0296       1.0661    3.779    0.0014 **   
 
Q0(∞) 27.4082      0.7202    38.05    < 2e-16 *** 
ko   0.2274       0.0189    12.04   1.29e-10 *** 80.7240 
 
Residual standard error:    0.4154 on 16 degrees of freedom 
Number of iterations to convergence:  8  
Achieved convergence tolerance:   1.167e-06  
AIC:     27.15193  
 
)1).((01
tkoeQQ
−−∞=     
Estimate  Std. Error  t value   Pr(>|t|)     
Q0(∞) 27.40817  0.72022    38.05    < 2e-16 *** 
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k0   0.22739     0.01889    12.04   1.29e-10 *** 
Residual standard error:    1.387 on 20 degrees of freedom 
Number of iterations to convergence:  8  
Achieved convergence tolerance:   2.792e-06  
AIC:      80.72395 
Significance codes: ***=0 ; **=0.001; *=0.01 ; .=0.5 
 
 
 
CPt-65:35MS (53-38 µm) 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate  Std. Error  t value   Pr(>|t|)     
Q2(∞) 12.19541    0.43336   28.141   4.69e-15 *** 
Q3(∞)  9.01762    0.46339   19.460   1.46e-12 *** 
k1  0.19257     0.01928    9.990   2.79e-08 *** 
k2  7.81159     1.06592    7.329   1.70e-06 *** 
 
Residual standard error:    0.4738 on 16 degrees of freedom 
Number of iterations to convergence:  18  
Achieved convergence tolerance:   5.379e-06  
AIC:    32.41882 
 
)1).((01
tkoeQQ
−−∞=     
Estimate  Std. Error  t value   Pr(>|t|)     
Q0(∞)  18.6035    0.6641    28.012   2.69e-16 *** 
ko    1.3568      0.2965     4.577   0.000234 *** 
 
Residual standard error:    2.396 on 18 degrees of freedom 
Number of iterations to convergence:  23  
Achieved convergence tolerance:   9.785e-06  
AIC:      95.60209 
Significance codes: ***=0 ; **=0.001; *=0.01 ; .=0.5 
 
 
CPt-65:35MS (75-53 µm) 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate  Std. Error  t value   Pr(>|t|)     
Q2(∞) 26.05405 0.979779   26.592   2.72e-15 *** 
Q3(∞)  7.39633    0.468179   15.798   1.36e-11 *** 
k1  0.085761    0.008593    9.981   1.59e-08 *** 
k2  4.495799    0.653625    6.878   2.68e-06 *** 
 
Residual standard error:    0.468 on 17 degrees of freedom 
Number of iterations to convergence:  5  
Achieved convergence tolerance:   8.527e-07  
AIC:     33.26819  
 
)1).((01
tkoeQQ
−−∞=     
Estimate  Std. Error  t value   Pr(>|t|)     
Q0(∞) 26.8117   1.43159   18.729   1.05e-13 *** 
ko   0.21359     0.03464    6.167   6.32e-06 *** 
 
Residual standard error:    2.563 on 19 degrees of freedom 
Number of iterations to convergence:  10  
Achieved convergence tolerance:   4.737e-06  
AIC:     103.0168 
Significance codes: ***=0 ; **=0.001; *=0.01 ; .=0.5 
 
 
CPt-65:35MS (90-75 µm) 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate  Std. Error  t value   Pr(>|t|)     
Q2(∞) 25.13164   0.65202   38.544    < 2e-16 *** 
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Q3(∞)  3.89737    0.54794    7.113   2.46e-06 *** 
k1  0.17419     0.01304   13.360   4.28e-10 *** 
k2 12.49721     7.10914    1.758     0.0979 .   
 
Residual standard error:    0.7816 on 16 degrees of freedom 
Number of iterations to convergence:  11  
Achieved convergence tolerance:   7.323e-06  
AIC:     52.43635  
 
)1).((01
tkoeQQ
−−∞=     
Estimate  Std. Error  t value   Pr(>|t|)     
Q0(∞) 27.55376   0.96233   28.632    < 2e-16 *** 
ko   0.24053     0.02635    9.128   3.57e-08 *** 
 
Residual standard error:    1.818 on 18 degrees of freedom 
Number of iterations to convergence:  8  
Achieved convergence tolerance:   2.204e-06  
AIC:     84.56192 
 
 
CPt-65:35SF 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate  Std. Error  t value   Pr(>|t|)     
Q2(∞) 33.90212  1.242404   27.288   7.60e-15 *** 
Q3(∞)  5.57445   0.315646   17.660   6.45e-12 *** 
k1  0.082115    0.006239   13.161   5.34e-10 *** 
k2 15.039469    3.467380    4.337   0.000509 *** 
 
Residual standard error:    0.5228 on 16 degrees of freedom 
Number of iterations to convergence:  12  
Achieved convergence tolerance:   5.177e-06  
AIC:     36.35148  
 
)1).((01
tkoeQQ
−−∞=     
Estimate  Std. Error  t value   Pr(>|t|)     
Q0(∞) 32.23218    2.25083   14.320   2.79e-11 *** 
ko   0.15814     0.02675   5.911   1.35e-05 *** 
 
Residual standard error:    2.621 on 18 degrees of freedom 
Number of iterations to convergence:  8  
Achieved convergence tolerance:   4.976e-06  
AIC:     99.18538 
Significance codes: ***=0 ; **=0.001; *=0.01 ; .=0.5 
 
 
CPt-75:25 (53-38 µm) 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate  Std. Error  t value   Pr(>|t|)     
Q2(∞) 13.98408    1.41207    9.903   5.68e-08 *** 
Q3(∞) 10.04156    1.55952    6.439   1.12e-05 *** 
k1  0.23892     0.04307    5.547   5.59e-05 *** 
k2  3.19795     0.77464    4.128   0.000894 *** 
 
Residual standard error:    0.8156 on 15 degrees of freedom 
Number of iterations to convergence:  20  
Achieved convergence tolerance:   5.022e-06  
AIC:      51.6827   
 
)1).((01
tkoeQQ
−−∞=     
Estimate  Std. Error  t value   Pr(>|t|)     
Q0(∞)  22.6096 0.5678     39.82    < 2e-16 *** 
ko    0.7371      0.1049     7.03   2.03e-06 *** 
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Residual standard error:    1.905 on 17 degrees of freedom 
Number of iterations to convergence:  12  
Achieved convergence tolerance:   9.495e-06  
AIC:     82.2888 
Significance codes: ***=0 ; **=0.001; *=0.01 ; .=0.5 
 
 
CPt-75:25 (75-53 µm) 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate  Std. Error  t value   Pr(>|t|)     
Q2(∞) 25.0102  0.409857   61.022    < 2e-16 *** 
Q3(∞)  3.8942   0.404434    9.629   4.64e-08 *** 
k1  0.195255    0.009678   0.176   8.36e-13 *** 
k2 12.347591    4.226931    2.921       0.01 **  
 
Residual standard error:    0.5112 on 16 degrees of freedom 
Number of iterations to convergence:  16  
Achieved convergence tolerance:   4.050e-06  
AIC:     35.45113  
 
)1).((01
tkoeQQ
−−∞=     
Estimate  Std. Error  t value   Pr(>|t|)     
Q0(∞) 27.70841   0.73294    37.80     <2e-16 *** 
ko   0.26951     0.02653    10.16      7e-09 *** 
 
Residual standard error:    1.666 on 18 degrees of freedom 
Number of iterations to convergence:  9  
Achieved convergence tolerance:   1.870e-06  
AIC:      81.07726 
Significance codes: ***=0 ; **=0.001; *=0.01 ; .=0.5 
 
 
CPt-75:25(90-75 µm) 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate  Std. Error  t value   Pr(>|t|)     
Q2(∞) 32.6182 0.520628   62.652    < 2e-16 *** 
Q3(∞)  5.1879   0.321689   16.127   9.75e-12 *** 
k1  0.140962    0.006559   21.491   9.21e-14 *** 
k2 28.486878    9.210367    3.093     0.0066 **  
 
Residual standard error:    0.586 on 17 degrees of freedom 
Number of iterations to convergence:  15  
Achieved convergence tolerance:   4.656e-06  
AIC:      42.71155  
 
)1).((01
tkoeQQ
−−∞=     
Estimate  Std. Error  t value   Pr(>|t|)     
Q0(∞) 35.11144    1.33399   26.321    < 2e-16 *** 
ko   0.20826     0.02511    8.295   9.75e-08 *** 
 
Residual standard error:    2.476 on 19 degrees of freedom 
Number of iterations to convergence:  8  
Achieved convergence tolerance:   2.994e-06  
AIC:     101.5682 
Significance codes: ***=0 ; **=0.001; *=0.01 ; .=0.5 
 
 
CPt-75:25SF 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate  Std. Error  t value   Pr(>|t|)     
Q2(∞) 47.7667 7.448342    6.413   2.96e-06 *** 
Q3(∞)  5.6224 0.400147   14.051   7.98e-12 *** 
k1  0.035098    0.007781    4.511  0.000213 *** 
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k2  9.929343    2.531226   3.923   0.000843 *** 
Residual standard error:    0.6175 on 20 degrees of freedom 
Number of iterations to convergence:  14  
Achieved convergence tolerance:   9.686e-06  
AIC:     50.59237  
 
)1).((01
tkoeQQ
−−∞=     
Estimate  Std. Error  t value   Pr(>|t|)     
Q0(∞) 30.52106 2.61234    11.68   6.63e-11 *** 
Ko   0.11638     0.02151     5.41   1.97e-05 *** 
 
Residual standard error:    2.348 on 22 degrees of freedom 
Number of iterations to convergence:  8  
Achieved convergence tolerance:   2.629e-06  
AIC:      112.9819 
Significance codes: ***=0 ; **=0.001; *=0.01 ; .=0.5 
 
 
 
 
 
 
G. Examples of residual error plots from fittings of model equation 8.13 to CPt release profiles. 
 
     
     
(A) CPt-50:50MS (75-53 µm)      (B) CPt-50:50MS (90-75 µm) 
 
(C) CPt-65:35MS (75-53 µm)                    (D) CPt-65:35MS (90-75 µm) 
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Figure 12.18: Examples of residual error plots from fittings of model Equation 8.13 to cisplatin release 
profiles of (A) CPt-50:50MS (75-53 µm), (B) CPt-50:50MS (90-75 µm), (C) CPt-65:35MS (75-53 µm), 
(D) CPt-65:35MS (90-75 µm), (E) CPt-75:25MS (75-53 µm) and (F) CPt-75:25MS (90-75 µm). 
 
 
H. Akaike’s Information Criterion (AIC) 
 
Akaike’s Information Criterion (AIC) (Akaike, 1974) allows comparison of mathematical models of 
data by trading off the number of parameters used against the residual error. AIC is calculated from 
statistical fitting parameters using Equation 12.12. 
AIC = 2 p − 2.ln(L)         (12.12) 
p is the number of parameters including the sum of squares, L is the likelihood function and 2 is the 
numeric penalty for each parameter. AIC values can be used to compare different models of a dataset. 
The model with the lowest AIC is preferred by this method. AIC can be used in conjunction with 
hypothesis testing methods such as analysis of variance/covariance during model comparison. The 
advantage of AIC is that unlike hypothesis testing there is no concern that the sequence of analysis 
will affect the results. 
 
 
I. Samples calculation of surface area and volume of microspheres, hollow and solid fibres.  
Appendix I Calculation of Diffusivity of Cisplatin in Microspheres using Higuchi Kinetics 
The density of a 200 mg sample was estimated by the displacement of water, with property of 15 
% (w/w) 50:50MS; median size or D[v, 0.5] ≈ 26 µm, radius ≈ 13 µm. 
 
Density  = Mass / Volume 
= 200 mg / 0.130 cm
3
 
= 0.154 mg/cm
3
 
Volume (one microsphere)  = 4/3.pi.(Radius of microspheres)
3
   
= 9.20 x 10
-9
 cm
3
       
Number of microspheres (sample)  = Volume (sample) / Volume (one microsphere) 
= 0.130 cm
3
 / 9.2 x 10
-9
 cm
3
 = 1.41 x 10
7
 
(E) CPt-75:25MS (75-53 µm)       (F) CPt-75:25MS (90-75 µm) 
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Surface area (one microsphere)  = 4.pi.(Radius of microsphere)
2
 
= 2.12 x 10
-5
 cm
2
 
Total Surface area (sample)   = 2.12 x 10
-5
 cm
2
 * 1.41 x 10
7
 
= 299 cm
2  
(radius of 13 µm) 
     = 92.86 cm
2 
(radius of 42 µm, D[v, 0.9] ≈ 84 µm) 
 
The density of a 200 mg sample was estimated by the displacement of water; with property of 20 
% (w/w) 50:50SF; 8 cm in length, OD ≈ 670 µm and radius ≈ 335 µm.  
 
Density (sample) = Mass / Volume 
= 200 mg / 0.65 cm
3
 
= 307 mg/cm
3 
Volume (one fibre)  = pi.(Radius of fibre)
2
.Length of fibre 
= 2.83 x10
-2
 cm
3
 
Surface area (one fibre) = 2.pi.Radius of fibre.Length + 2.pi.(Radius of fibre)
2
 
= 3.24 cm
2 
 
Table 12.6: Estimate surface area:volume ratio of 15 % (w/w) PLGA microspheres in  a 0.2 g sample. 
 
Table 12.7: Estimate surface area:volume ratio of 20 % (w/w) PLGA hollow and solid fibres. 
PLGA 
Size 
Fraction 
Diameter 
(10
-6
 m) 
Number of 
microspheres 
(10
7
) 
Surface area 
(10
-5
 cm
2
) 
Total 
Surface 
Area (cm
2
) 
Volume of one 
microsphere 
(10
-9
 cm
3
) 
Surface 
Area:Volume 
D [v, 0.1] 6 114.9303 0.1131 1300.00 0.1131 100.00 
D [v, 0.5] 26 1.4124 2.1240 300.00 9.2040 23.08 
50:50 
MS 
D [v, 0.9] 84 0.0419 22.1700 92.86 310.3793 7.14 
D [v, 0.1] 8 48.4862 0.2011 975.00 0.2681 75.00 
D [v, 0.5] 45 0.2724 6.3626 173.33 47.7191 13.33 
65:35
MS 
D [v, 0.9] 90 0.0341 25.4502 86.67 381.7530 6.67 
D [v, 0.1] 4.7 239.1084 0.0694 1659.57 0.0544 127.66 
D [v, 0.5] 53 0.1667 8.8259 147.17 77.9619 11.32 
75:25
MS 
D [v, 0.9] 107 0.0203 35.9728 72.90 641.5142 5.61 
PLGA 
Diameter 
(10
-6
 m) 
Number of 
fibres 
Surface area 
(10
-5
 cm
2
) 
Total Surface 
Area (cm
2
) 
Volume of one 
fibre (10
-9
 cm
3
) 
Surface 
Area:Volume 
50:50SF 670 10 16.8432 168.43 2.8209 5.97 
65:35SF 720 10 18.1002 181.00 3.2576 5.56 
75:25SF 760 10 19.1057 191.06 3.6296 5.26 
50:50HF 690 10 17.3460 173.46 2.9918 5.80 
65:35HF 750 10 18.8544 188.54 3.5348 5.33 
75:25HF 850 10 21.3683 213.68 4.5402 4.71 
Lumen 210 10 5.2792 52.29 0.2771 19.05 
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APPENDIX VII 
 
A. Fittings of two and three compartmental models to lidocaine release profiles. 
 
                         
      
      
Figure 12.19: Fittings of a two compartmental model, Equation 8.11 (dashed lines) and a three 
compartmental model, Equation 8.13 (solid lines) to lidocaine release profiles of (A) LID-50:50HFso, (B) 
LID-50:50HFms, (C) LID-65:35HFso, (D) LID-65:35HFms, (E) LID-75:25HFso and (F) LID-75:25HFms. 
 
(A) LID-50:50HFso                         (B) LID-50:50HFms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(C) LID-65:35HFso                               (D) LID-65:35HFms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(E) LID-75:25HFso                                  (F) LID-75:25HFms 
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B. Statistics of model fittings using a two compartmental model (Equation 8.11) and a three 
compartmental model (Equation 8.13) to lidocaine release profiles.  
 
LID-50:50MS 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate   Std. Error  t value   Pr(>|t|)       
Q2(∞) 22.02026     3.17506    6.935   9.83e-07 *** 
Q3(∞) 12.29079     2.82720    4.347   0.000312 *** 
k2  0.07556      0.04218    1.791   0.088363 .   
k3  0.77467      0.19225    4.030   0.000656 *** 
  
Residual standard error:    0.7222 on 20 degrees of freedom  
Number of iterations to convergence:  8  
Achieved convergence tolerance:   1.893e-06  
AIC:     58.10834  
 
)1).(( 001
tk
eQQ
−−∞=  
Estimate   Std. Error  t value   Pr(>|t 
Q0 26.66148      0.58721    45.40    < 2e-16 *** 
ko   0.27268      0.02062    13.22   6.03e-12 *** 
 
Residual standard error:    1.338 on 22 degrees of freedom 
Number of iterations to convergence:  9  
Achieved convergence tolerance:   4.257e-06  
AIC:     86.00245 
Significance codes: ***=0 ; **=0.001; *=0.05 ; .=0.1 
 
 
LID-50:50HF 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate   Std. Error  t value   Pr(>|t 
Q2(∞) 10.9094       0.1892    15.374   2.99e-13 *** 
Q3(∞) 1.2455       0.3818    3.262    0.00357 **  
k2   0.0756       0.5549     5.067   4.49e-05 *** 
k3  -7.4101       0.0132    -7.630   1.29e-07 *** 
 
Residual standard error:    0.3276 on 22 degrees of freedom 
Number of iterations to convergence:  13  
Achieved convergence tolerance:   3.827e-06  
AIC:     21.40553  
 
)1).(( 001
tk
eQQ
−−∞=  
Estimate   Std. Error  t value   Pr(>|t 
Q0 18.33830      8.68559    2.111     0.0453 * 
ko   0.03782      0.02402    1.574     0.1285 . 
 
Residual standard error:    1.174 on 24 degrees of freedom 
Number of iterations to convergence:  11  
Achieved convergence tolerance:   4.36e-06  
AIC:     86.04993 
Significance codes: ***=0 ; **=0.001; *=0.05 ; .=0.1 
 
 
LID-50:50HFso 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate   Std. Error  t value   Pr(>|t|)      
Q2(∞) 8.707023    2.143706    1.567   0.130781     
Q3(∞) 12.120003   1.163884   12.936   4.87e-12 *** 
k2  0.098123     0.005647    1.439   0.163749     
k3  0.2874176     0.923485    4.195   0.000346 *** 
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Residual standard error:    0.2359 on 23 degrees of freedom 
Number of iterations to convergence:  9  
Achieved convergence tolerance:   3.356e-06  
AIC:     4.309898  
 
)1).(( 001
tk
eQQ
−−∞=  
Estimate   Std. Error  t value   Pr(>|t 
Q0 18.94823      2.12056   8.935   2.95e-09 *** 
ko   0.06422      0.01156    5.557   8.88e-06 *** 
 
Residual standard error:    0.7933 on 25 degrees of freedom 
Number of iterations to convergence:  6  
Achieved convergence tolerance:   3.661e-06  
AIC:     60.1035 
Significance codes: ***=0 ; **=0.001; *=0.05 ; .=0.1 
 
 
LID-50:50HFms 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate   Std. Error  t value   Pr(>|t 
Q2(∞) 12.051739   2.763448    3.530    0.00210 **  
Q3(∞) 0.21886     0.021540    9.771   4.67e-09 *** 
k2  0.0799924     0.003278    3.028    0.00665 **  
k3  2.767558     0.811771    3.402    0.00283 **  
 
Residual standard error:    0.1818 on 20 degrees of freedom 
Number of iterations to convergence:  18  
Achieved convergence tolerance:   4.391e-06  
AIC:      8.095792  
 
)1).(( 001
tk
eQQ
−−∞=  
Estimate   Std. Error  t value   Pr(>|t 
Q0 19.092299     2.191163    8.713   1.39e-08 *** 
ko   0.034749     0.005872    5.918   5.91e-06 *** 
 
Residual standard error: 0.5041 on 22 degrees of freedom 
Number of iterations to convergence:  6  
Achieved convergence tolerance:   3.177e-06  
AIC:      39.14331 
Significance codes: ***=0 ; **=0.001; *=0.05 ; .=0.1 
 
 
 
LID-65:35MS 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate   Std. Error  t value   Pr(>|t|)      
Q2(∞) 31.783322    0.573098   55.459    < 2e-16 *** 
Q3(∞) 2.984791     0.408576    7.305   1.96e-07 *** 
k2  0.144029     0.008001   18.000   4.74e-15 *** 
k3  6.602064    25.005155    1.464      0.157     
 
Residual standard error:    0.7727 on 23 degrees of freedom 
Number of iterations to convergence:  18  
Achieved convergence tolerance:   1.260e-06  
AIC:     68.36618  
 
)1).(( 001
tk
eQQ
−−∞=  
Estimate   Std. Error  t value   Pr(>|t 
Q0 33.27496      0.79488    41.86    < 2e-16 *** 
ko   0.18006      0.01272    14.16   1.92e-13 *** 
 
Residual standard error:    1.49 on 25 degrees of freedom 
Number of iterations to convergence:  6  
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Achieved convergence tolerance:   8.995e-06  
AIC:     102.0084 
 
LID-65:35HF  
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate   Std. Error  t value   Pr(>|t|)      
Q2(∞) 9.285845     1.177237    7.255   2.88e-07 *** 
Q3(∞) 2.696044     0.193290   -4.773   9.13e-05 *** 
k2  0.05629     0.0051826    2.564     0.0177 *   
k3 -2.60709     0.006985   -8.052   5.30e-08 *** 
 
Residual standard error:    0.59873 on 23 degrees of freedom 
Number of iterations to convergence:  31  
Achieved convergence tolerance:   8.786e-06  
AIC:     9.057404  
 
)1).(( 001
tk
eQQ
−−∞=  
Estimate   Std. Error  t value   Pr(>|t 
Q0 18.94823      2.12056    8.935   2.95e-09 *** 
ko   0.06422      0.01156    5.557   8.88e-06 *** 
 
Residual standard error:    0.7933 on 25 degrees of freedom 
Number of iterations to convergence:  6  
Achieved convergence tolerance:   3.661e-06  
AIC:     68.03946 
Significance codes: ***=0 ; **=0.001; *=0.05 ; .=0.1 
 
 
 
LID-65:35HFso 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate   Std. Error  t value   Pr(>|t|)      
Q2(∞) 15.10920     3.49559   12.327   4.43e-11 *** 
Q3(∞) 13.07159     2.68636   -1.561   0.133409     
k2  0.04387      0.02167    4.817   9.25e-05 *** 
k3 4.46216      2.27811   -4.029   0.000606 *** 
 
Residual standard error:    0.5965 on 21 degrees of freedom 
Number of iterations to convergence:  34  
Achieved convergence tolerance:   9.358e-06  
AIC:     50.75284  
 
)1).(( 001
tk
eQQ
−−∞=  
Estimate   Std. Error  t value   Pr(>|t 
Q0 13.46539      1.27793   10.537   2.82e-10 *** 
ko   0.12958      0.02953    4.388   0.000214 *** 
 
Residual standard error:    1.521 on 23 degrees of freedom 
Number of iterations to convergence:  9  
Achieved convergence tolerance:   5.249e-06  
AIC:     95.81732 
Significance codes: ***=0 ; **=0.001; *=0.05 ; .=0.1 
    
 
LID-65:35HFms 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate   Sd. Error  t value   Pr(>|t|)      
Q2(∞) 13.0230       0.2086    14.490   1.01e-11 *** 
Q3(∞) 1.3233       0.3407    3.885   0.000997 *** 
k2   0.07671       1.2393     3.147   0.005307 **  
k3  -0.15108       0.0114    -9.721   8.28e-09 *** 
 
Residual standard error:    0.3687 on 19 degrees of freedom 
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Number of iterations to convergence:  16  
Achieved convergence tolerance:   6.75e-06  
AIC:      24.98150  
)1).(( 001
tk
eQQ
−−∞=  
Estimate   Std. Error  t value   Pr(>|t 
Q0 13.46539      1.27793   10.537   2.82e-10 *** 
ko   0.12958      0.02953    4.388   0.000214 *** 
 
Residual standard error:    1.521 on 23 degrees of freedom 
Number of iterations to convergence:  9  
Achieved convergence tolerance:   5.249e-06  
AIC:     94.217332 
Significance codes: ***=0 ; **=0.001; *=0.05 ; .=0.1 
 
 
 
LID-75:25MS 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate   Std. Error  t value   Pr(>|t|)      
Q2(∞) 32.611974    1.886674   22.056    < 2e-16 *** 
Q3(∞) 13.050198    0.597512    3.431    0.00228 **  
k2  0.076667     0.006925    9.627   1.56e-09 *** 
k3  0.154683     0.880979    1.309    0.20334     
 
Residual standard error:    0.6317 on 23 degrees of freedom 
Number of iterations to convergence:  16  
Achieved convergence tolerance:   7.98e-06  
AIC:     57.49235  
 
)1).(( 001
tk
eQQ
−−∞=  
Estimate   Std. Error  t value   Pr(>|t 
Q0 38.922223     1.369952    28.41    < 2e-16 *** 
ko   0.087583     0.005659    15.48   2.58e-14 *** 
 
Residual standard error:    0.8817 on 25 degrees of freedom 
Number of iterations to convergence:  6  
Achieved convergence tolerance:   3.897e-07  
AIC:     73.74509 
Significance codes: ***=0 ; **=0.001; *=0.05 ; .=0.1 
 
 
LID-75:25HF 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate   Std. Error  t value   Pr(>|t|)       
Q2(∞) 5.250921     0.906609   -5.792   9.49e-06 *** 
Q3(∞) 0.954253     0.109974    8.677   2.19e-08 *** 
k2 0.051714     0.005512   -9.382   5.85e-09 *** 
k3  5.9882     2.403051    2.492     0.0211 *   
 
Residual standard error:    0.1792 on 21 degrees of freedom 
Number of iterations to convergence:  18  
Achieved convergence tolerance:   9.621e-06 
AIC:     56.67551  
 
)1).(( 001
tk
eQQ
−−∞=  
Estimate   Std. Error  t value   Pr(>|t 
Q0 7.13025      1.62075    4.536   8.05e-07 ** 
ko   0.1065      0.03139    2.016   0.00219 *** 
 
Residual standard error:    0.9767 on 24 degrees of freedom 
Number of iterations to convergence:  9  
Achieved convergence tolerance:   5.84e-06  
AIC:     76.47952 
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Significance codes: ***=0 ; **=0.001; *=0.05 ; .=0.1 
LID-75:25HFso 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate   Std. Error  t value   Pr(>|t|)      
Q2(∞) 1.784686     26.06097   1.207    0.24023     
Q3(∞) 12.65089     0.26338   10.065   1.07e-09 *** 
k2  -0.081471      0.01051   -1.400    0.17544     
k3   0.71748      0.82194    3.306    0.00321  
 
Residual standard error:    0.373 on 22 degrees of freedom 
Number of iterations to convergence:  19  
Achieved convergence tolerance:   1.421e-06  
AIC:     28.15474  
 
)1).(( 001
tk
eQQ
−−∞=  
Estimate   Std. Error  t value   Pr(>|t|)      
Q0 15.15432      4.20675    3.236   3.5e-05 ** 
ko   0.076565      0.01639    4.006   0.000519 *** 
 
Residual standard error:    0.9767 on 24 degrees of freedom 
Number of iterations to convergence:  9  
Achieved convergence tolerance:   5.84e-06  
AIC:      76.47952 
Significance codes: ***=0 ; **=0.001; *=0.05 ; .=0.1 
 
 
LID-75:25HFms 
[ ] [ ])1).(()1).(( 32 321 tktk eQeQQ −− −∞+−∞=  
Estimate   Std. Error  t value   Pr(>|t|)      
Q2(∞) 4.82709      1.32170   3.652    0.00140 **  
Q3(∞) 13.19786      0.21355    5.609   1.22e-05 *** 
k2 -0.06511      0.01019   -6.390   1.98e-06 *** 
k3 2.18657     27.46614    0.808    0.42787    
 
Residual standard error:    0.5171 on 22 degrees of freedom 
Number of iterations to convergence:  29  
Achieved convergence tolerance:   6.654e-06   
AIC:     45.14155   
 
)1).(( 001
tk
eQQ
−−∞=  
Estimate   Std. Error  t value   Pr(>|t 
Q0 17.13025      2.62075    6.536   9.25e-07 * 
ko   0.06565      0.01639    4.006   0.000519 *** 
 
Residual standard error:    0.9767 on 24 degrees of freedom 
Number of iterations to convergence:  9  
Achieved convergence tolerance:   5.84e-06  
AIC:     77.41502 
Significance codes: ***=0 ; **=0.001; *=0.05 ; .=0.1 
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C. Examples of residual error plots from fittings of model equation 8.13 to LID release profiles. 
 
     
       
          
Figure 12.20: Examples of residual error plots from fittings of model Equation 8.13 to lidocaine release 
profiles of (A) LID-50:50MS, (B) LID-50:50HFso, (C) LID-65:35MS, (D) LID-65:35HFso, (E) LID-
75:25MS and (F) LID-75:25HFso. 
 
(A) LID-50:50MS            (B) LID-50:50HFso 
 
(C) LID-65:35MS                          (D) LID-65:35HFso 
(E) LID-75:25MS             (F) LID-75:25HFso 
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D. Fittings of Higuchi Model to Phase 1 lidocaine release from 65:35-MS and -SF.  
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Figure 12.21: The fitting of Higuchi Model (Qt = kH.t
0.5
) to in vitro Phase 1 lidocaine release from 65:35 
PLGA microspheres and hollow fibres.    
 
 
 
E. Fittings of Higuchi, first and zero order kinetics models to Phase 2 lidocaine release.  
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Figure 12.22: The fitting of Higuchi, first and zero order kinetics models in Phase 2 drug release from 
50:50MS (   ), 50:50HF (   ), 50:50HFso (   ) and 50:50HFms (   ). 
[         ]  Experimental Data 
[         ]  Higuchi Model 
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Figure 12.23: The fitting of Higuchi, first and zero order kinetics models in Phase 2 drug release from 
65:35MS (   ), 65:35HF (   ), 65:35HFso (   ) and 65:35HFms (   ).   
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Figure 12.24: The fitting of Higuchi, first and zero order kinetics models in Phase 2 drug release from 
75:25MS (   ), 75:25HF (   ), 75:25HFso (   ) and 75:25HFms (   ). 
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Table 12.8: Summary of the goodness of fit of Equations 8.1 to 8.3 to Phase 2 drug release from PLGA 
samples. The Higuchi constant, kH was obtained from Phase 1 drug release.  denotes poor fitting; 
additional notes no. (i) to (vii) see text for discussion. 
 
Phase 1 Phase 2 – Goodness of fit of models 
LID-loaded 
PLGA Devices Higuchi Model 
kH (mg/s
0.5
) 
Higuchi  
Model 
First Order 
Kinetic 
Zero Order 
Kinetic 
50:50MS 26.52   Possible fit 
50:50HF  32.61  Good  
50:50HFso 19.37 Possible fit   
50:50HFms 11.27   Good 
65:35MS 32.51    
65:35HF 21.49  Good  
65:35HFso 45.83    
65:35HFms 17.76 Possible fit  Possible fit 
75:25MS 11.68  Possible fit   
75:25HF 11.22  Good  
75:25HFso 17.92 Possible fit  Possible fit 
75:25HFms 21.96   
 
 
Comparing the Phase 1 release, the kH’s of 50:50MS and 65:35MS are larger than the kH of 
75:25MS. This is attributed to the least amorphous region in 75:25 PLGA which limits drug 
diffusion. 65:35HFso and 75:25HFso tend to have larger kH than those of 65:35HF and 75:25HF, 
and this is due to the enhanced drug diffusion by the drug solution in their lumens.  
 
75:25HFms has a larger kH than 75:25HF/HFso and this is attributed to the presence of an 
osmotic gradient in the system caused by the burst effect from the microspheres in their lumens. 
This osmotic effect is not observed in 50:50HFms and 65:35HFms and the reasons are their more 
amorphous properties permitted easier drugs diffusion and release. The consistency in kH of LID-
75:25-MS and HF indicates the structural integrity of this copolymer ratio against rapid drug 
release.  
 
For LID-65:35MS, its kH is larger than the kH of LID-65:35HF. This is attributed to the higher 
surface area:volume ratio of the microspheres. In the case of 50:50MS and 50:50HF, the latter 
has a larger kH. In the production of LID-50:50HF, the spinning process involved massive 
aqueous volume and a hydrophilic lidocaine was used, with 50:50 PLGA having the most 
amorphous region, the drug tended to diffuse towards the aqueous phase and thus concentrated at 
the fibre surface layer. During buffer immersion, the channel through the lumen of 50:50HF 
permitted greater medium influx rate and increased drug transport. As a result, a more rapid 
initial release is observed.  
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APPENDIX VIII 
 
A. Production of 75:25HF-Stent 
20 % (w/w) 75:25 PLGA was used to produce hollow fibres (Section 4.2.3) and was manually 
woven into a “patch” (Figure 12.25A). A monofilament absorbable suture, PDS II from Ethicon 
(Johnson & Johnson Care), made of polydioxanone was used as the warp (lengthwise fibre). 
Briefly, a number of sutures were held vertically with equal space apart. Hollow fibres were then 
inserted horizontally across these sutures with alternate position. Each fibre was pushed gently 
close to the adjacent ones. The edges of the patch were then sealed with epoxy resin and left air-
dried overnight for the resin to solidify. The patch was then incubated in 30 ml of PBS and 
maintained at 37 
o
C with a back-and-forth shaking of 100 rpm. 
 
   
Figure 12.25: (A) A fibre-patch fabricated using 20% (w/w) 75:25HF and absorbable suture from Ethicon.  
(C) After 5 hours of incubation, fibres started to bend and separate between fibres. 
      
   
Figure 12.26: After 30 days incubation. The breakages continued until a big number of fibres had 
displaced, departed from their original parallel structure due to the failure of the suture material to provide 
a structure to hold these fibres in place as themselves, had also underwent displacement.  
 
At the end of the incubation after thirty days, the patch was observed to be distorted in 
comparison to its original flat and horizontal form (Figure 12.26). Fibres were degraded and 
disintegrated into short lengths while the sealing at the patch’s ends were displaced. Due to the 
fact only the site ends were sealed with adhesive and not between parallel fibres, the fibres were 
able to move freely caused the fibre-patch to deform. One of the important findings is that these 
fibres should be securely held in place in parallel to each others. Collagen could be a candidate to 
“glue” these fibres together as it has been safely applied in medial purposes. 
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